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Abstract 
III Abstract 
As a result of the high cost of drug discovery, it is imperative that promising targets with strong 
disease association are identified and validated before embarking on costly molecule discovery 
and development phases. Chemical inhibitors provide an excellent tool for target validation. This 
project was initiated with the aim of designing and characterising tool inhibitors of proteins 
involved in the DNA damage response, to enable detailed mechanistic biological investigation, 
disease validation and initiation of translational drug discovery projects. 
The SMC complexes are critically important in coordinating chromosome condensation, sister 
chromatid cohesion, DNA repair, homologous recombination and transcriptional regulation. 
They represent interesting oncology targets and are compelling targets for tool inhibitor 
development. The core SMC proteins and NSE subunits of SMC5/6 and cohesin SMC1 and SMC3 
were modelled and their druggabilities assessed, with an aim to advance to inhibitor 
development for any of the proteins that proved druggable. Unfortunately, the SMC5/6 and 
cohesin complexes were established as not druggable. 
BAF180 represents a major clear cell renal cell carcinoma (ccRCC) cancer gene, exhibiting 
truncating mutations in 41% of samples in a series of primary ccRCCs.1 It has therefore been 
highlighted as a promising opportunity to target ccRCC using a synthetic lethal therapeutic 
approach.2 Hopkins et al. utilised a novel screening technique to identify several genes that are 
synthetic lethal with BAF180.3 In this work, the druggabilities of three of these genes were 
assessed, and KAT2A was identified as a promising target for tool inhibitor development. 
Druggable pockets were identified at the KAT2A histone acetyltransferase (HAT) domain and 
bromodomain. The catalytically active HAT domain was prioritised as the preferred target. 
Potential KAT2A HAT domain inhibitors were available from a high-throughput screen (HTS), 
which utilised a fluorescence based activity assay.4,5 Unfortunately, this assay format proved 
prohibitively unreliable, and moreover, after discounting the hits from the HTS as likely false 
positives, the inventory of KAT2A inhibitors was quickly exhausted and the target abandoned. 
Focus turned to the KAT2A bromodomain. Available X-ray crystal structures were utilised in a 
computational drug design effort, and Tm shift, TR-FRET, ITC and X-ray crystallography 
techniques were optimised and established in-house to enable characterisation of prospective 
KAT2A tool inhibitors. Over 3000 small molecules and fragments were screened, and an 
assortment of novel KAT2A bromodomain binders were identified. The optimised assays, novel 
chemical matter and ligand-bound crystal structures afford an exciting opportunity to develop 
potent and selective KAT2A bromodomain tool inhibitors. 
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Chapter 1 
1 Introduction 
The discovery of new drugs is labour-intensive and expensive. It is estimated that the fully 
capitalised cost of development of a new approved drug is more than $2.5 billion6, and takes 
approximately 13.5 years7, Figure 1.1. The incredibly high cost is due in large part to poor clinical 
success rates, with only ~12% of drugs which enter phase I ultimately being approved.6 The 
majority of drugs fail in the clinic for one of two reasons; either they do not work, often due to 
poor target identification and inadequate validation, or they are not safe.8 In addition, once in 
the marketplace, many drugs fall short of recovering their development costs and others must 
ultimately be withdrawn.9 As a result, despite significant scientific, technological and managerial 
advances, the productivity of research and development (R&D) is decreasing. Since 1950, the 
number of new US Food and Drug Administration (FDA)-approved drugs per billion US dollars 
spent has halved every nine years.10 This fall in productivity has been specifically attributed to 
four factors. Firstly, as the catalogue of approved medicines expands there are increasingly high 
demands on new drugs. This is an extension of the ‘low-hanging fruit’ problem11, whereby 
therapeutics for easy-to-treat disease targets have been identified and this reduces the 
efficiency of further research on this disease due to raised requirements of any new drugs. This 
serves to deter R&D in these areas and encourage researchers towards harder-to-treat diseases. 
Secondly, authorities such as the FDA are progressively wary of drug safety and this lower 
tolerance of risk understandably increases the cost of R&D. Thirdly, there has been a tendency 
to add resources and increase spending on R&D, likely driven by precedented good returns on 
investment and competition to launch first. Finally, there has been a tendency to overtrust basic 
research and progress quickly to ‘brute force’ high-throughput screening (HTS) methods rather 
than adopting an iterative approach. Without thorough target validation or proof-of-concept 
trials many drugs fail in clinic due to poor efficacy, and while HTS is effective in many cases and 
offers rapid results, it is expensive and often yields hits with high molecular weight, poor ligand 
efficiency (LE) and limited potential for optimisation.10,12,13  
 
Figure 1.1. Model of Research and Development. R&D timeline with associated costs to launch one new drug.6 
Clearly drug safety matters and it would be irresponsible to suggest that regulations should be 
relaxed for the comparatively trivial purpose of improving R&D productivity. As such, it seems 
efficiency must be improved by adopting a more disciplined approach to drug discovery, in early 
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development in particular.14 Resources and spending should be tightly managed, the ‘high-
hanging fruit’ should be targeted by taking advantage of appropriate technological advances, 
targets should be carefully selected and well validated and the physicochemical properties of 
candidate compounds should be assessed prior to clinical development in an attempt to 
anticipate safety issues.13 Fundamentally, costly drug discovery programmes should only be 
undertaken when there is good confidence that regulation of the target protein will result in the 
desired therapeutic effect. Target identification and validation are therefore critically important. 
Drug discovery begins with a hypothesis derived from basic research predicting that regulating 
a particular protein will afford a therapeutic effect for a disease state. This protein is then 
assessed as a potential drug target. As well as evoking the desired biological response, a good 
target should be ‘druggable’. This requires that it is accessible to a conceivable drug molecule 
and binding of such a molecule should induce a measureable response. If the protein is deemed 
a viable target it must be scrutinised to validate the legitimacy of the therapeutic effect. A range 
of validation techniques are available and typically a multi-validation approach is favourable. 
Particularly popular approaches utilise antisense technology, small interfering RNA (siRNA), 
transgenic animals, monoclonal antibodies or small bioactive molecules as tool inhibitors.8 
1.1 The DNA Damage Response 
R&D productivity varies between different disease areas. Fortunately, basic oncology research 
appears to be delivering new and improved targets for which effects observed in the lab 
correlate better with efficacy in humans. Furthermore, authorities are more tolerant of risk on 
the understanding that it is outweighed by benefits, and the current catalogue of approved 
cancer therapeutics leaves considerable scope for improvement.10 As DNA repair plays such a 
prominent role in tumourigenesis and tumour response to therapy, the DNA damage response 
network has been identified as a promising target for improved medicines. 
Every cell in the human body acquires tens of thousands of DNA lesions each day15, capable, if 
not correctly repaired, of blocking genome replication and transcription or leading to mutations 
and aberrations that threaten cell viability.16 Thankfully cells have developed mechanisms to 
combat the threats posed by DNA damage. They are able to detect DNA lesions, signal their 
presence and promote their repair, and arrest cell cycle progression while this is achieved.17,18 
These mechanisms are collectively referred to as the DNA-damage response (DDR).16 
1.1.1 DNA Damage Detection 
The DDR kinase signalling pathway comprises of a protein kinase cascade with mediator proteins 
which facilitate phosphorylation events, Figure 1.2.18 In mammalian cells the most upstream 
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DDR kinases are the ATM (ataxia-telangiectasia mutated), ATR (ATM- and Rad3-related) and 
DNA-PKcs (DNA-dependent protein kinase catalytic subunit). These large serine/threonine 
kinases are members of the phosphatidylinositol-3 kinase-related kinase (PIKK) family.19 As is 
currently understood, DNA-PKcs and ATM are primarily involved in repairing double-stranded 
breaks (DSBs), whereas ATR can respond to a wider range of DNA lesions.20 
 
Figure 1.2. Framework of the DDR Kinase Signalling Pathway. The DDR pathway is comprised of sensor proteins that 
recognise damaged DNA, transducer proteins that relay and amplify the signal and effector proteins that control DNA 
repair, cell cycle progression and cell death. Figure adapted from Maréchal & Zou, 2013 and Falck et al., 2005.18,21 
PIKKs all have similar domain organisations; their kinase domains are located near the carboxyl 
termini, flanked by FAT (FRAP-ATM-TRRAP) and FATC (FAT carboxy-terminal) domains, and the 
amino terminal and internal regions are composed of numerous HEAT (Huntington-elongation 
factor 3-protein phosphatase 2A-TOR1) repeats, Figure 1.3.22 It is suggested that the HEAT 
repeats serve to interact with DNA23 and mediate protein-protein interactions important for the 
function and regulation of the kinases. For example ATM interacts with Nbs1 (Nijmegen 
breakage syndrome protein 1), a component of the MRN (Mre11-Rad50-Nbs1) complex, via 
specific internal HEAT repeats21,24, and ATR with ATRIP (ATR interacting protein) via amino 
terminal repeats.25 The FAT and FATC domains act as regulatory domains. In human cells in the 
absence of DNA damage the ATM FAT and kinase domains interact, inhibiting kinase activity. 
When DNA is damaged, ATM Ser1981 is autophosphorylated. This disrupts the interaction and 
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alleviates inhibition of ATM.26 Analogously, in response to DNA damage the ATR FAT domain is 
phosphorylated at Thr1989 to promote the stimulation of ATR by TopBP1 (Topoisomerase 2-
binding protein 1).27 The FATC domains are similarly responsible for kinase activity.28 
 
Figure 1.3. PIKK Domain Organisation. Generalised schematic of functional domains of PIKKs, annotated to show 
approximate number of amino acids. Figure adapted from Maréchal & Zou, 2013.18 
DSBs are the most perilous form of DNA damage as they can enable genome rearrangements, 
and unrepaired DSBs are typically lethal.29 When a DSB occurs one of the first factors recruited 
is the MRN complex. It appears that MRN recognises blunt double-stranded DNA (dsDNA) ends 
or dsDNA ends with short single-stranded DNA (ssDNA) overhangs, i.e. dsDNA/ssDNA junctions, 
characteristic of DSBs, and recruits and activates ATM.30 The activation of ATM results in 
phosphorylation of as many as 700 substrates such as p53, CHK2, BRCA1 (breast cancer type 1 
susceptibility protein) and H2AX, which mediate a multitude of effects, for example on cell cycle 
arrest, DNA repair, chromatin restructuring, protein synthesis or even apoptosis.31 
DNA-PKcs is also recruited to DSBs, here by the Ku70-Ku80 heterodimer, to form the active DNA-
PK complex.32 Interestingly the C-terminal region of Ku80, which is thought to be necessary for 
interaction with DNA-PKcs, is homologous to the conserved region in the C-terminus of Nbs1 
that serves to recruit ATM.21 It seems that DNA-PKcs functions chiefly in nonhomologous end-
joining and regulates only a small number of targets, compared to the hundreds of proteins 
phosphorylated in an ATM- or ATR-dependent manner.33 
ATR is recruited to sites of DNA damage by association with its binding partner ATRIP. The ATR-
ATRIP complex is localised to stalled forks via a direct interaction between ATRIP and replication 
protein A (RPA)-coated ssDNA34, which is generated during DNA replication when there is a loss 
of coordination between the helicase and DNA polymerase such that the polymerase stalls but 
the helicase does not.35 This ATRIP-mediated ATR localisation is necessary but not sufficient for 
activation of the ATR kinase. In addition, a second complex forms on the RPA-coated ssDNA, 
independent of ATR and ATRIP, at ssDNA/dsDNA junctions. This complex comprises of the ring-
shaped Rad9-Rad1-Hus1 (911) clamp, which interacts with the dsDNA; Rad17-replication factor 
C (RFC), the clamp loader; and TopBP1, which interacts with the ssDNA.18,35,36 As the complex is 
assembled, the TopBP1 ATR activation domain is revealed, which enables interaction with the 
ATR-ATRIP complex and activates the kinase.37,38 ATR activation results in phosphorylation of a 
plethora of substrates including CHK1 and RPA3239, which again mediate an array of effects. 
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1.1.2 DNA Damage Signalling 
As discussed, the PIKKs regulate many hundreds of downstream repair proteins. The kinases 
control DNA repair by three dominant mechanisms. Firstly, they directly regulate the activity of 
DNA repair enzymes via post-translational modifications. Secondly, they initiate modification of 
the chromatin near a DNA lesion, which creates a local environment permissive for repair and 
serves as a scaffold to localise additional repair effectors. Finally, the kinases act at a global level 
to establish a cellular environment conducive to repair. This may include regulating the cell 
cycle, chromosome mobility or deoxynucleotide triphosphate (dNTP) levels.20 One example of 
each of these control mechanisms is discussed below.  
ATR kinase has a critical function in initiating interstrand crosslink (ICL) repair in eukaryotic cells. 
ICLs are highly damaging because they prevent separation of the two DNA strands, which causes 
DNA replication and transcription to halt. Unfortunately, they are also perhaps the most difficult 
lesions to repair, requiring specialised repair mechanisms governed by the FANCs (Fanconi 
anaemia proteins), in addition to input from nucleotide excision repair and DSB repair.20 
Understanding of how DNA ICLs are removed has been greatly enhanced by the study of patients 
with Fanconi anaemia (FA), a rare genetic disorder that leads to ICL sensitivity.40 ICLs are initially 
recognised by FANCM, a DNA translocase, which associates with FAAP24 (Fanconi anaemia core 
complex-associated protein 24) and two histone-like factors, MHF-1 and -2 (FANCM-associated 
histone fold proteins 1 and 2), to form the FA anchor complex. FANCM then recruits the FA core 
complex, a nine-membered E3 ubiquitin ligase. FANCI and FANCD2 are also recruited to the DNA 
damage site, binding directly to the DNA, and are mono-ubiquitinated by this FA core complex. 
The mono-ubiquitinated FANCI-FANCD2 complex serves as a scaffold for the recruitment of 
further ICL repair proteins including nucleases such as FAN1 (Fanconi-associated nuclease 1), 
XPF (Xeroderma pigmentosum, complementation protein group F) and SLX4, and polymerases 
such as Polν.40,41 ATR controls many of the events in the FA pathway. For example, it is 
responsible for phosphorylation of several FA proteins including FANCM, FANCA and FANCG, 
found in the FA core complex, and FANCI and FANCD2.20 The phosphorylation of FANCI appears 
especially critical for FA pathway activation as it is required for mono-ubiquitination and 
localisation of FANCD2.42 In this way, ATR directly regulates the activity of these DNA repair 
enzymes via post-translational modification. 
DDR kinases induce several chromatin changes that promote a local environment conducive to 
repair. These include creating a platform for recruiting effectors, enabling access to the DNA and 
inhibiting nearby transcription, which could interfere with repair. Subsequent to its initial 
activation at DNA ends, ATM triggers a host of events on the chromatin flanking a DSB. Pivotal 
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to these is phosphorylation of histone variant H2AX on serine 139 in the C-terminal tail to form 
γH2AX.43 MDC1 (mediator of DNA damage checkpoint protein 1) recognises and binds to the 
phosphorylated H2AX and Nbs1 as well as ATM. The complex of γH2AX, MDC1 and MRN thereby 
serves to recruit additional ATM to chromatin flanking the DSB. This results in propagation of 
the γH2AX mark to a domain incorporating over 500 kb of chromatin termed γH2AX foci.18 The 
γH2AX-MDC1 forms a scaffold for recruitment of further signalling and effector proteins. For 
example, RING (Really Interesting New Gene) ubiquitin ligases RNF8 (RING finger protein 8) and 
RNF168 (RING finger protein 168) are recruited, which trigger a ubiquitination cascade.44 
Downstream this ubiquitination regulates the recruitment of BRCA1 and 53BP1 (p53-binding 
protein 1), which are believed to regulate the repair choice between nonhomologous end-
joining and homologous recombination.45 Phosphorylation of H2AX also induces changes to 
chromatin structure by recruiting chromatin remodelling complexes such as SWI/SNF 
(SWItch/Sucrose Non-Fermentable). SWI/SNF chromatin remodelling activity is targeted to DSBs 
by H3 acetylation by GCN5 (General Control Non-depressible protein 5)46 and by interaction with 
BRIT1 (BRCT-repeat inhibitor of hTERT expression), which binds γH2AX after damage.47 
Relaxation of the chromatin near the break by SWI/SNF improves access for DNA repair proteins 
to the site of damage.20 
Finally, the PIKKs also facilitate repair at a more global level by establishing a conducive cellular 
environment. For example, the replication stress checkpoint is mediated by ATR. When DNA 
damage is detected ATR phosphorylates and activates CHK1 (checkpoint kinase 1), which inhibits 
cell cycle progression to allow time to repair the damage prior to replication or mitosis.20,48 
1.1.3 DNA Damage Repair 
There are five major classes of DNA repair pathways: base excision repair (BER), nucleotide 
excision repair (NER) and mismatch repair (MMR), which act on damage present on single 
strands; and nonhomologous end-joining (NHEJ) and homologous recombination (HR), which 
act at DSBs, Figure 1.4.29 These pathways can act independently at specific DNA lesions but in 
reality often function in complex networks. For example, if repair by one pathway is 
unsuccessful, a lesion may be passed to a second pathway, or if DNA repair by one pathway 
causes successive damage, this might require repair by another. These repair networks 
constitute a robust system for maintaining genomic stability.29 
Base Excision Repair 
BER describes a collection of mechanisms for the repair of base lesions that cause little distortion 
to the DNA helix structure. DNA damage from oxidation, deamination and alkylation causes 
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these non-bulky lesions such as ring-opened bases and small adducts such as oxidised bases. 
The lesions are recognised by one of at least 11 distinct DNA glycosylases and the damaged base 
is removed, leaving an abasic site (AP-site).49 Apurinic-apyrimidinic endonuclease 1 (APE1), aided 
by Poly [ADP-ribose] polymerase 1 (PARP1), cleaves the DNA at the AP-site to generate a 3’ OH 
and 5’ deoxyribose phosphate (dRP) terminus. Then a deoxyribophosphodiesterase (dRPase) 
cleaves the dRP residue to generate a 5’ phosphate at the single-stranded break (SSB). Finally, 
DNA polymerase and DNA ligase seal the nick in the DNA.49–51 
 
Figure 1.4. DNA Repair Pathways. (a) Repair of non-bulky base lesion by base excision repair (BER). (b) Repair of 
bulky, helix-distorting lesions by nucleotide excision repair (NER). (c) Replacement of mismatched bases by mismatch 
repair (MMR). (d) Repair of DSBs by more accurate classical nonhomologous end-joining (cNHEJ) with minimum loss 
of DNA or backup pathway alternative nonhomologous end-joining (aNHEJ) with significant DNA loss. (e) DSB repair 
by precise RAD51-catalysed homologous recombination (HR) or error-prone single-strand annealing (SSA), which 
results in significant loss of DNA. Figure adapted from Nickoloff, 2015.29 
 
23 
Chapter 1 
Nucleotide Excision Repair 
NER is responsible for removing bulky, helix-distorting lesions such as pyrimidine dimers and 
large DNA adducts, which may be induced, for example by UV light. Lesion recognition proteins 
are responsible for surveying the DNA for lesions and recruiting effector proteins. The unwinding 
of DNA around a lesion and stabilising of the resulting ssDNA requires a multitude of proteins 
including the transcription factor II H (TFIIH) complex, the Cdk-activating-kinase (CAK) complex, 
and XPs (Xeroderma pigmentosum, complementation proteins) named XPG and XPA. As the 
ssDNA is produced it is coated with RPA which activates XPG and a second endonuclease, 
excision repair cross-complementing rodent repair deficiency, complementation group 1 
(ERCC1)-XPF, which create SSBs approximately 15 nucleotides either side of the lesion. A 
helicase then removes the oligonucleotide containing the lesion before finally DNA polymerase 
fills the single-strand gap and the ends are ligated by DNA ligase 3 (LIG3), XRCC1 (X-ray repair 
cross-complementing protein 1) and DNA ligase 1 (LIG1).52 
Mismatch Repair 
In MMR there is no damage to the nucleotides but by some means mismatched bases exist on 
otherwise complementary DNA strands. Such mismatches can arise due to replication errors, 
strand exchange during HR or deamination of 5’-methyl cytosine to produce thymidine, which 
forms a G-T mismatch. MMR can also be utilised to remove loops that arise when bases are 
inserted or deleted, which again can arise due to replication errors or during HR. MMR features 
two families of proteins; heterodimeric homologues of bacterial MutS, MSH (MutS homologue), 
and MutL, MLH (MutL homologue). Repair is initiated by mismatch recognition by heterodimers 
MutSα (MSH2-MSH6) or MutSβ (MSH2-MSH3). These search for and interact with MutLα 
(MLH1-PMS2), PCNA (proliferating cell nuclear antigen) and RFC, to activate the endonuclease 
activity of PMS2 (post-meiotic segregation protein 2), which introduces a SSB. This generates an 
entry point for exonuclease 1 (EXO1) which removes the mismatch by single-strand excision. The 
DNA gap is then filled by DNA polymerases δ or ε (Polδ or Polε) and ligated by LIG1.29,53 
BER, NER and MMR are reasonably accurate repair mechanisms as they are able to utilise the 
intact complementary DNA strand to direct repair of the lesion. Despite this, as the DNA is 
repaired it is vulnerable to localised mutagenesis. Repair polymerases are typically less accurate 
than replicative polymerases and the abasic intermediate produced during BER is susceptible to 
translesion DNA synthesis by Y-family polymerases, which are error-prone.29,54 However, these 
challenges rather pale into insignificance compared to those posed by repair of DSBs. 
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Nonhomologous End-Joining 
NHEJ is composed of two subpathways, classical NHEJ (cNHEJ) and alternative NHEJ (aNHEJ). Of 
these two pathways, cNHEJ is the more accurate and, fortunately, the DSB repair pathway 
predominantly utilised in mammalian cells. It appears that aNHEJ is a backup pathway, generally 
used only where cells are defective in cNHEJ.55 cNHEJ requires little to no end-resection. It is 
initiated by Ku70-Ku80 binding to dsDNA ends and recruiting and activating DNA-PKcs. Together 
Artemis, a nuclease responsible for processing of broken ends56, and Metnase, a nuclease and 
protein methylase that recruits other NHEJ factors57, promote association of the broken ends 
despite poor base pairing. At this stage DNA-PKcs dissociates from the DNA ends, which are then 
ligated by DNA ligase 4 (LIG4) with the aid of accessory factors XRCC4 (X-ray repair cross-
complementing protein 4) and XLF (XRCC4-like factor).29,55 In contrast, moderate end-resection 
is key to aNHEJ. aNHEJ is initiated by PARP1 binding to the DNA ends and recruiting MRN and 
CtIP (C-terminal-binding protein), which are responsible for exposing and aligning 
microhomologies at least five bases in length. The ends are then ligated by LIG3 and XRCC1 and 
the flaps trimmed by flap endonuclease 1 (FEN1).55,58  
Homologous Recombination 
HR is also comprised of two pathways, one relatively precise pathway mediated by RAD51, and 
one more error-prone, RAD51-independent pathway, known as single-strand annealing (SSA). 
Both of these subpathways require extensive end-resection of hundreds or even thousands of 
bases. Perhaps it is understandable then that, as previously mentioned, the choice between DSB 
repair pathways seems to be regulated by proteins which control resection, such as 53BP1 and 
BRCA1.45 The end-resection is conducted initially by MRN and CtIP, as in aNHEJ, and then by BLM 
helicase, DNA2 (DNA replication ATP-dependent helicase/nuclease) and EXO1 (Exonuclease 1).59 
This produces long 3’ ssDNA tails coated with RPA, which, in the RAD51-dependent pathway, is 
exchanged for RAD51 by mediator proteins such as BRCA2 (breast cancer type 2 susceptibility 
protein) and RAD52. The RAD51-coated ssDNA searches for and invades homologous sequences 
and, once in position, is extended by DNA polymerase before release and capture by the DNA 
end on the opposite side of the DSB.29 Where only one end invades, in synthesis-dependent 
strand annealing (SDSA), there is little chance of deleterious crossovers occurring. However, in 
some cases both ends invade, creating a double Holliday junction that must be resolved without 
occurring crossovers.60 Such crossovers can result in loss of heterozygosity (LOH), known as gene 
conversion. To reduce the likelihood that crossovers cause large-scale genome rearrangements 
RAD51-dependent HR is typically restricted to S and G2 phases when sister chromatids, the most 
accurate repair templates, are in close proximity.29 The SSA pathway is independent of RAD51 
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activity and is believed to depend instead on RAD52.60 Extensive end-resection is utilised to 
expose complementary sequences in direct repeats. When uncovered these sequences are 
annealed to form a deletion product which lacks one of the repeats and any intervening 
sequence. SSA is an efficient method of repair for regions containing closely spaced repeats but 
otherwise results in significant loss of DNA.29 
Accurately repairing DSBs is more challenging than SSBs. NHEJ is frequently inaccurate, 
generating short deletion or insertion mutations of up to 20 nucleotides. In addition, if two DSBs 
occur simultaneously on different chromosomes NHEJ can enable translocations. HR, 
particularly SDSA, is typically more accurate, but because any two homologous sequences can 
be engaged, it is associated with a significant risk of genome rearrangements. This might include 
deletions, inversions, amplifications, LOH or translocations.29 
1.2 DNA Repair Dysregulation in Cancer 
DNA damage is ubiquitous and clearly DDR plays a critical role in the accurate transmission of 
genetic information to daughter cells. However, as seen, DNA repair is primarily engineered to 
restore the chemical integrity of DNA with little regard for genetic integrity. As a result, DNA 
damage can generate mutations, which can range wildly in extent from point mutations, 
trinucleotide repeat expansions and contractions, gene duplications, deletions and inversions, 
to large-scale chromosomal rearrangements. This plays an important role in development of the 
immune system and evolution but can also be detrimental and ultimately lead to cancers and 
other genetic diseases.29 
1.2.1 Hallmarks of Cancer 
Hanahan and Weinberg describe eight hallmarks of cancer cells which govern the 
transformation of normal cells into malignant cancers; six well established and two recently 
emerging.61,62 It is suggested that normal cells evolve progressively to become tumourigenic and 
ultimately malignant by successive acquisition of these hallmark capabilities. The proposed 
capabilities include both traits of the cancer cells and contributions from the tumour 
microenvironment. They include: sustaining proliferative signalling, evading growth 
suppressors, avoiding immune destruction, enabling replicative immortality, activating invasion 
and metastasis, inducing angiogenesis, resisting cell death and deregulating cellular energetics, 
Figure 1.5.62 
Sustaining Proliferative Signalling 
Arguably the principal trait of cancer cells is their aptitude for sustained proliferation. In healthy 
tissues, cell growth and division is carefully regulated by production and release of growth 
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promoting signals. These maintain a constant cell number and preserve normal tissue 
architecture and function.63 In cancer cells, these signals are deregulated in a number of ways 
such that they are able to grow and divide more frequently. Firstly, the cells may themselves 
produce growth factor ligands to which they can respond, affording autocrine stimulation of 
proliferation. Alternatively the cells may signal to the normal cells in the tumour-associated 
stroma, which respond by supplying growth factors.64 Some cancer cells display an increased 
number of receptor proteins at their cell surface making them hyperresponsive to any small 
amount of growth factor ligand, and others bear receptor molecules which are structurally 
altered so as to facilitate ligand-independent firing.62 Furthermore, constitutive activation of 
signalling pathway components downstream of these receptors can relieve the necessity for any 
activation of the receptors. Approximately 40% of human melanomas harbour mutated BRAF. 
The most common mutation, occurring in 89% of cases, is the V600E substitution, which 
increases the catalytic activity of BRAF. This affords constitutive signalling to the mitogen-
activated protein kinase (MAPK) pathway, which should otherwise only be triggered by activated 
growth factor receptors.65 Finally defects can exist in feedback mechanisms that would normally 
dampen signalling to ensure homeostasis. One example involves PTEN (phosphatase and tensin 
homologue) phosphatase, which typically counteracts the activity of PI3K (phosphatidylinositol 
3‐kinase) by degrading its product. Loss-of-function mutations in PTEN therefore result in 
amplification of PI3K signalling and promote tumourigenesis.66  
Evading Growth Suppressors 
As well as continually inducing growth, cancer cells must evade those programs designed to 
suppress it. These programs are typically dependent on tumour suppressor genes such as RB 
(Retinoblastoma-associated) and p53.67 RB is responsible for transducing primarily extracellular 
signals and decides whether a cell should proceed to growth and division. Cancer cells with 
defects in RB pathway function are permitted to proliferate continuously. P53 is responsible for 
halting cell cycle progression if the genome has suffered excessive damage or if levels of glucose, 
oxygenation, nucleotide pools or growth-promoting signals are abnormal. If irreparable damage 
has been sustained it can also induce apoptosis. In the absence of competent p53, cancer cells 
are again able to proliferate persistently. In addition, normal cells are prevented from excessive 
proliferation by ‘contact inhibition’, whereby the cell-to-cell contacts formed in dense 
populations suppress further proliferation. Moesin-ezrin-radixin-like protein (Merlin), the 
Neurofibromin-2 (NF2) gene product, coordinates contact inhibition, by coupling cell-surface 
adhesion molecules to transmembrane receptor tyrosine kinases. This stabilises the junctions 
and restrains kinase activity, and sequesters growth factor receptors. In this way Merlin limits 
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the cells ability to emit mitogenic signals.68 Loss of Merlin has been shown to trigger 
neurofibromatosis.62 
 
Figure 1.5. The Hallmarks of Cancer. Illustration of the eight proposed hallmark capabilities of cancer cells. Six are 
well established but the deregulation of cellular energetics and avoidance of immune destruction are more recently 
emerging. Figure adapted from Hanahan & Weinberg, 2011.62 
Resisting Cell Death 
It is well established that programmed cell death acts as a natural barrier to cancer 
development. Apoptosis is initiated in response to many of the physiological stresses which 
cancer cells experience in tumourigenesis or during treatment, such as signalling imbalances, or 
DNA damage due to rapid proliferation. Perhaps it is therefore unsurprising that apoptosis is 
attenuated in tumours which progress to malignancy.69 The apoptotic regulators can be divided 
into two circuits, the extrinsic and intrinsic apoptotic programs. The extrinsic pathway involves 
cell-surface ‘death receptors’ such as FAS and TNFR (tumour necrosis factor receptor). When 
ligated these form ‘death-inducing signalling complexes’, which activate caspase-8 and thereby 
initiate a proteolysis cascade that results in apoptosis. The intrinsic pathway is the primary 
programme responsive to survival factor signals, cell stress and injury and is therefore more 
extensively implicated in deterring cancer pathogenesis.62 The central locus is the 
mitochondrion, which stores pro-apoptotic effectors in its intermembrane space. The 
permeability of the mitochondrion is determined by the balance between pro- and anti-
apoptotic members of the Bcl-2 (B-cell lymphoma-2) protein family. Bcl-2 and its closest relatives 
inhibit apoptosis by binding to and suppressing Bax (Bcl-2 Associated X) and Bak (Bcl-2 
homologous antagonist/killer) at the outer mitochondrial membrane. Damage signals are 
transduced by BH3-only proteins (Bcl-2 family members with a single Bcl-2 homology-3 domain) 
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which interact with Bcl-2 and the other pro-survival proteins. This alleviates inhibition of Bax 
and Bak and initiates release of pro-apoptotic signalling proteins from the mitochondrion. One 
such factor is cytochrome c which triggers activation of caspase-9 and initiates the proteolysis 
cascade that results in apoptosis.70 P53 induces apoptosis in response to severe DNA damage 
and chromosomal abnormalities by upregulating expression of BH3-only proteins.71 Tumour 
cells can limit or escape apoptosis by a variety of strategies including loss of function of p53, 
increased expression of anti-apoptotic regulators or decreased expression of pro-apoptotic 
regulators. 
Not all cell death is by apoptosis however. In contrast to apoptotic cells, which contract and are 
consumed, necrotic cells become bloated and explode, releasing their contents into the 
surrounding tissue. This releases proinflammatory signals and recruits inflammatory cells, which 
can be tumour promoting as they can enable angiogenesis, proliferation and invasiveness. 
Consequently, metastatic tumours may benefit from tolerating some necrotic cell death so as to 
recruit these inflammatory cells.62,72 
Enabling Replicative Immortality 
Normal cells are only able to journey through a limited number of cell growth-and-division cycles 
before induction of senescence or cell death. Cancer cells however exhibit unlimited replicative 
potential, termed immortality. It is understood that this ability to replicate indefinitely is 
associated with telomeres. Telomeres are composed of tandem TTAGGG repeats, which cap the 
ends of chromosomes to protect the DNA from recombination and degradation and maintain 
cell viability. They are progressively shortened at each cell division due to incomplete replication 
of linear chromosomes, the ‘end-replication problem’, and thereby act as a molecular clock, 
which underlies ageing. Telomerase, the DNA polymerase responsible for extension of 
telomeres, is virtually absent in normal cells but is upregulated to functionally significant levels 
in approximately 90% of immortalised cells. The extension of telomeric DNA counteracts the 
progressive erosion and is correlated with resistance to senescence and apoptosis.73 
Furthermore, tumour cells must pass through a significant number of successive telomere-
shortening cell divisions prior to successful upregulation of telomerase. This delayed acquisition 
of telomerase function is conducive to generation of tumour-promoting mutations.74 
Inducing Angiogenesis 
Like any tissue, tumours need to receive nutrients and oxygen and expel metabolic waste and 
carbon dioxide. To achieve this they induce angiogenesis to develop neovasculature. In normal 
tissues vasculature is largely quiescent after embryogenesis. However, during tumour 
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progression angiogenesis is almost permanently activated, causing vasculature to grow new 
capillaries that help to sustain the growth.75 Angiogenesis is induced early in the development 
of invasive cancers, substantiating its status as a hallmark of cancer.62 It is understood that, like 
apoptosis, activation of angiogenesis is regulated by a balance of pro- and anti-angiogenic 
factors. For example, VEGF-A (Vascular Endothelial Growth Factor-A) is a pro-angiogenic gene 
that encodes ligands for tyrosine kinase receptors (VEGFRs), which orchestrate the growth of 
new blood vessels.76 Contrastingly, thrombospondin-1 (TSP1) inhibits angiogenesis via direct 
effects on endothelial cell migration and survival and by sequestering and restricting the 
movement of VEGF. Upregulation of pro-angiogenic genes or downregulation of anti-angiogenic 
genes can induce angiogenesis.77 Finally, as eluded to earlier, it appears that inflammatory cells 
of the innate immune system are recruited to developing tumours to help to initiate and sustain 
angiogenesis.78 The extent of variation of neovascularisation in different tumours is illustrative 
of the complexity of control. Interestingly some oncogenes that drive proliferative signalling can 
also induce angiogenesis, highlighting the potential that hallmark capabilities can be 
coregulated.62 
Activating Invasion & Metastasis 
Fundamental also to malignant cancers is their ability to invade and metastasise. To complete 
these processes the tumour cells must be able to detach, migrate, gain access to and from the 
blood or lymphatic vessels, micrometastasise at a new location and finally colonise to form a 
macroscopic tumour. Three distinct modes of cancer cell invasion have so far been identified; 
mesenchymal, collective invasion and amoeboid. Of these the best understood is mesenchymal 
invasion, which is regulated by the epithelial-mesenchymal transition (EMT) program.62 In EMT 
a subset of tumour cells switch off epithelial markers such as E-cadherin, a key cell-to-cell 
adhesion molecule, and switch on mesenchymal markers such as vimentim. This leads to loss of 
cell polarity, cytoskeleton reorganisation, loss of adherens junctions, expression of matrix 
degrading enzymes, increased motility and heightened resistance to apoptosis.79 The primary 
regulator of EMT is transforming growth factor-β (TGF-β).80 TGF-β functions through a collection 
of transcription factors including Snail, Slug, Twist and Zinc finger E-box-binding homeobox 1/2 
(ZEB1/2), which coordinate the EMT and migratory processes required during embryogenesis 
and have been found to be expressed in various combinations in malignant tumours.81 There is 
increasing evidence that the acquired capability for invasive growth originates from the tumour-
associated stromal cells neighbouring the cancer cells.82,83 Interestingly, if this proves true it is 
plausible that tumours could metastasise without the requirement for mutations other than 
those for primary tumour formation.62 The process of colonisation is highly complex, varying in 
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different tissue types, and it is unclear when and where tumour cells develop the ability to 
colonise foreign tissues. The capability may arise fortuitously during primary tumour formation 
or may develop only in response to selective pressures at the new site. Either way it is highly 
likely that colonisation requires the establishment of a permissive tumour environment 
including stromal support cells.62 
Deregulating Cellular Energetics 
The perpetual cell proliferation associated with cancer cells must be fuelled by adjusted energy 
metabolism. In aerobic conditions normal cells harvest ATP by processing glucose first to 
pyruvate by glycolysis and then to carbon dioxide by oxidative phosphorylation in the 
mitochondria. In anaerobic conditions little pyruvate can be processed by the mitochondria so 
energy metabolism is limited largely to glycolysis. As first observed by Warburg84, cancer cells 
often reprogram their glucose metabolism to utilise glycolysis almost exclusively, independent 
of the presence of oxygen. Considering that ‘aerobic glycolysis’ is an inefficient way to generate 
ATP this is somewhat surprising. However, it is suggested that the abundance of glycolytic 
intermediates produced can be utilised in generating biomass including nucleosides, amino acids 
or lipids, which enables the biosynthesis of macromolecules and organelles required to produce 
a new cell.85,86 This increased reliance on glycolysis is associated with activated oncogenes and 
downregulated tumour suppressors as well as being accentuated in some tumours by hypoxic 
conditions.87 As deregulation of cellular energetics seems to be as prevalent as other hallmarks 
of cancer it has been designated as an emerging hallmark.62 
Avoiding Immune Destruction 
It is believed that the immune system acts as a barrier to tumour formation and progression. 
Increased tumour growth has been observed in immunodeficient mice, for example with 
deficiencies in development or functioning of natural killer (NK) cells, compared to 
immunocompetent controls.88 Transplantation experiments have also shown that cancer cells 
that originally developed in immunodeficient mice are unable to establish tumours in 
immunocompetent mice, whereas cells from the immunocompetent mice can initiate tumour 
growth in any new host.88 There is increasing support for the existence of a similar 
immunosurveillance mechanism in human cancers.89 It is suggested that cancer cells may avoid 
immune destruction by disabling components of the immune system destined to eliminate 
them.62 The cancer cells may for example secrete TGF-β or other immunosuppressive factors.90 
In light of this research, avoiding immune destruction is identified as a second emerging hallmark 
of cancer.62 
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Concordantly, over the past decade there has been a surge of interest in the field of cancer 
immunotherapy, which aims to treat cancer by generating or augmenting an immune response. 
In clinical trials immunotherapies have consistently improved the overall survival of patients 
with advanced-stage cancers and three immune-checkpoint-blocking monoclonal antibodies 
have already been approved for treatment of several cancer types in the USA.91 
1.2.2 Genome Instability 
The DDR operates very effectively, and despite the very high occurrence of DNA lesions, 
mutation rates in normal mammalian cells are low, at approximately 10-10 per base per cell 
generation, or 10-6-10-8 per gene per cell generation.92 It is estimated that converting a normal 
cell to a metastatic cancer cell requires 3-10 mutations in key growth cells and tissue regulatory 
genes.29 If mutations arise independently, the chance of accumulating five in a single cell is 
phenomenally small, 10-30-10-40. However, unfortunately mutations do not always arise 
independently. 
Early insights into the role of the genome in cancer development emerged in the late nineteenth 
and early twentieth centuries when David von Hansemann and Theodor Boveri observed 
chromosomal aberrations in dividing cancer cells.93,94 As discussed above, cancers arise when 
cells obtain hallmarks such as altered cell growth properties, immortality and defective 
programmed cell death pathways. Progression to the more aggressive metastatic state requires 
enhancements such as angiogenesis, tissue invasion and adaptability to new environments.29 
Despite it having been well established that cancer is linked with genome instability, it was 
difficult to ascertain whether this was causative or a secondary manifestation.95 There are now 
several studies however in which it has been definitively shown that genome instability precedes 
cancer.96,97 Although the genetic changes responsible for initiating tumourigenesis and 
promoting tumour progression differ in different cancer types, the early acquisition of defects 
in DNA repair is common.  Such DNA repair defects cause genetic instability which considerably 
increase the rate at which mutations are acquired, including gain-of-function mutations in proto-
oncogenes and loss-of-function mutations in tumour suppressor genes.29 
As well as initiating tumourigenesis, the increased mutagenesis afforded by acquisition of a DNA 
repair defect enables evolution of the cancer cells to promote tumour progression. The fitness 
of tumour cells is determined by the balance of the beneficial effects of mutational variation, 
which facilitate adaptation to changing environmental pressures, and any detrimental effects of 
mutation. The limit of the cellular capacity to tolerate further mutagenesis is termed the ‘error 
catastrophe’ limit.98 Providing that mutation rates remain below this limit, the tumour cells are 
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able to experiment with successive mutations that may afford an improved response to 
environmental stresses or resistance to therapy. This has two interesting repercussions. Firstly, 
the majority of the tens of thousands of mutations present in every cancer genome are not 
believed to have been selected for or be causally linked to the pathogenesis of the cancer and 
are instead ‘passenger mutations’.98,99 Secondly, some mutations acquired late in the evolution 
of the cancer cell may only be advantageous or even tolerated because of a preceding mutation, 
establishing oncogene ‘addiction’.100 Most cancer patients are treated with chemotherapeutics 
or ionising radiation that induce DNA damage. These approaches were developed to exploit the 
high proliferation rate of tumour cells compared to healthy human cells, as cells actively 
replicating DNA are more susceptible to the cytotoxic effects of DNA damage.101 However, 
perhaps their anticancer effects may also be attributed in part to inducing increased mutational 
load on the cancer cells which pushes them over the error catastrophe limit.98 
Unfortunately, tumour cells can exhibit resistance to traditional therapies. In some cases this 
may reflect a poor tailoring of treatment to the specific DNA defect, whereby the selected 
therapeutic induces DNA damage repaired by pathways still functional in that particular tumour. 
However, resistance may also reflect upregulation of other DNA repair pathways or defects in 
apoptosis and other programmed cell death. For example, approximately 50% of tumours carry 
defects in p53.29 Furthermore, the rapid evolution of tumour cells afforded by genome instability 
allows them to adapt and acquire resistance to therapies. Traditional therapies are effective in 
killing tumour cells in bulk but the DNA damage they induce can spawn and ultimately select for 
cancer cells that are resistant to therapy and potentially more aggressive, which can result in 
tumour recurrence and progression to a metastatic state.29 As such, despite short-term benefits, 
the therapies do not necessarily increase long-term patient survival. It seems that current 
therapeutic strategies require re-evaluation. To improve patient survival, new therapeutics must 
be able to destroy the entire population of tumour cells. This is not easily achieved alongside 
minimising the effects on normal tissue. Traditional cancer therapies also cause many serious 
side effects including neurological and gastrointestinal problems, fatigue, fever and liver and 
kidney failure, and additional late effects including cardiac disease, infertility, hearing loss and 
secondary tumours.29,102 It is hoped that therapeutics designed to selectively target tumour 
weaknesses could eradicate tumour cells while being less harmful to normal cells. 
1.3 Targeted Cancer Therapy 
The predominant obstacle in developing cancer therapeutics is not finding chemicals that are 
able to kill cancer cells but identifying those which are capable of doing so at concentrations 
that spare normal tissue. Indeed, most available chemotherapeutic agents have surprisingly low 
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therapeutic indices, defined as the dose at which toxic effects are observed divided by the dose 
required for the therapeutic effect.100,103 This can result from a number of contributing factors 
relating to both the on- and off-target effects of the drugs, including the selectivity profile of the 
drug or the distribution and function of the protein target.100 The tolerance level of normal 
tissues thereby limits the dose at which the drug can be delivered and increases the likelihood 
that some tumour cells will survive after treatment.29 One particular challenge in developing 
chemotherapeutics is identifying a suitable target that affords the opportunity to preferentially 
target cancer cells over normal cells with any considerable degree of selectivity. 
Two avenues can be explored in attempt to improve the therapeutic index of drugs. The first, 
the target-driven therapeutic index, requires identification of a target that is specific to the 
diseased tissue. Antibacterial agents, for example, are invariably safe because they target 
proteins present only in the invading organism and not in normal human cells.100 This is not 
impossible for cancer therapeutics, especially as the number of oncogenes described in the 
literature continues to grow.104 For example, Imatinib (Gleevec) and later generation tyrosine 
kinase inhibitors have been used to good effect to treat chronic myelogenous leukaemia by 
inhibition of tumour-specific BCR-ABL (breakpoint cluster region-Abelson murine leukaemia viral 
oncogene homologue).105 However, this approach is not always applicable. Suitable targets are 
limited as many of the genetic alterations frequently observed in tumours, particularly those of 
DDR proteins, are loss-of-function mutations; also it can be difficult to develop drugs that 
specifically inhibit oncoproteins without affecting their normal counterparts, as these often only 
result from point mutations.100 Additionally, such highly specific therapies may not be effective 
in targeting genetically heterogeneous tumours.29 The second, context-driven therapeutic index, 
is dependent on an enhanced requirement for the target protein in the diseased tissue 
compared to normal tissue.103 This approach is more broadly applicable as it enables targeting 
of cancer cells with loss-of-function mutations, which are traditionally harder to treat, because 
it is technically difficult to recapitulate tumour suppressor function. It is clear that these 
contextual differences are therapeutically exploitable from the wealth of effective anticancer 
drugs already in use that target proteins common to normal and cancer cells.100 However, it 
must be acknowledged that this approach will generate drugs vulnerable not just to toxicity via 
off-target effects but also potentially deleterious on-target effects. 
1.3.1 Synthetic Lethality 
One key approach in developing deletion-guided chemotherapies is to exploit synthetic lethal 
interactions. The concept of synthetic lethality was first defined by Dobzhansky in relation to 
drosophila genetics. He identified genes which separately were not lethal to homozygotes but 
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became lethal when combined by crossing over.106 Correspondingly, two mutations are now 
termed ‘synthetic lethal’ if neither alone affects the viability of the cell but in combination they 
result in cell death, Figure 1.6. Mutations are termed ‘synthetic sick’ if they impair cellular fitness 
more in combination than individually, but this impairment is non-lethal. It has now been 20 
years since it was first suggested that synthetic lethality could be utilised in anticancer drug 
discovery.107 Protein products of genes which are synthetic lethal with mutations commonly 
observed in cancers should represent promising targets for chemotherapeutics, provided that 
they are amenable to pharmacological regulation. Ideally, if genes A and B are synthetic lethal, 
inhibition of B should kill cancers cells with mutant A with no effect on normal cells. However, 
in practice it is more common that inhibitors of B either exhibit some toxicity in normal cells, or 
are non-lethal in cancer cells, because A and B fall short of being truly synthetic lethal.108 This 
will limit the specificity of therapeutics targeting B, but it is hoped that these inhibitors could 
still afford a significant therapeutic index.100 
 
Figure 1.6. Synthetic Lethal Interactions for Two Genes. Two genes, A and B, are said to be synthetic lethal if mutation 
of neither alone affects the viability of the cell but simultaneous mutation of both genes results in cell death. Lower 
case letters denote mutants. 
The best renowned example of a synthetic lethal interaction in human cancer is that of BRCA1 
or BRCA2 with PARP1. In 2005, the Helleday and Ashworth labs independently showed that 
BRCA1- or BRCA2-defective breast cancers were sensitive to PARP1 inhibitors.109,110 Mutations 
in either BRCA1 or BRCA2 are associated with a predisposition to breast and ovarian cancers.111 
As discussed earlier, these genes are important in double-stranded break repair by homologous 
recombination. PARP1 is also involved in DNA repair, particularly the repair of single-stranded 
breaks. It appears that loss of function of PARP1 results in a hyper-recombination phenotype 
and collapse of replication forks. Loss of PARP1 correlates with increased levels of RAD51 foci, 
where RAD51 is gathered at sites of DNA damage, and sister chromatid exchange, in which sister 
chromatids exchange DNA by breaking and rejoining with each other.112 This suggests that the 
loss of PARP1 serves to increase the formation of DNA lesions to be repaired by HR. It was 
hypothesised and shown that inhibition of PARP1 in BRCA1- or BRCA2-defective cells, which are 
defective in HR, results in irreparable DNA lesions which cause chromatid aberrations and loss 
of viability.109,110 These findings sparked great excitement. PARP1 inhibitors were capable of 
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eradicating BRCA-defective tumours in mice models. Furthermore, BRCA-defective cells showed 
incredible sensitivity to PARP1 inhibition in comparison to wild type cells, displaying a 50- to 
1000-fold enhanced effect.110 The PARP1 inhibitors were unique among cancer therapies 
exploiting DNA damage sensitivity in tumour cells as they displayed an impressive therapeutic 
index without the need to apply exogenous DNA damaging agents. The BRCA-PARP1 interaction 
is truly synthetic lethal and not synthetic sick, or synthetic sensitive.29 It is uncertain how 
common such strong genetic interactions will prove to be in human cells.108  
Clinical trials were quickly initiated for several PARP inhibitors, including Sanofi’s iniparib and 
AstraZeneca’s olaparib, Figure 1.7. Unfortunately this very promising class of compounds 
suffered a near-fatal blow when both iniparib and olaparib failed to demonstrate good efficacy 
in trials in patients with triple-negative breast cancer.113 However, it seems that these failures 
were alarmingly easily explained. Despite PARP inhibitors having been clearly shown to confer 
synthetic lethality in cancers with BRCA1 and BRCA2 mutations, the trials utilised a larger, 
heterogeneous population including patients with intact BRCA genes as long as they displayed 
other homologous recombination defects. It later emerged that iniparib is also not a bona fide 
PARP inhibitor.113 This illustrates the immense importance of good communication in drug 
development and regrettably delayed the approval of drugs.114 Despite these setbacks, by 2016, 
13 PARP inhibitors had been or were being tested in the clinic for cancer therapy and, after 
restarting of phase III clinical trials in 2003, olaparib was finally approved for the treatment of 
advanced ovarian cancer in patients with BRCA mutations by the European Union and the FDA 
in 2014.115 Very recently another PARP inhibitor, simmiparib also entered clinical trials.116 
Unfortunately the battle is not yet won. Examples are emerging of BRCA-defective tumours 
which are gaining resistance to PARP inhibitors by mechanisms such as loss of PARP1 or 
reactivation of HR.117 
 
Figure 1.7. Chemical Structures of Proposed PARP Inhibitors. Iniparib, eventually proven not to be a functional PARP 
inhibitor, olaparib and simmiparib.115,116 
Synthetic lethality can result both from two mutations having additive negative effects on a 
single essential biological pathway or, as just discussed, inactivating different but functionally 
overlapping pathways.107 As a result, the web of synthetic lethal relationships is complicated and 
chaotic, with perhaps ten interactions per gene.100 Consequently, despite the wealth of genetic 
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and epigenetic data available about cancers, molecular networks are not sufficiently well 
understood to enable accurate prediction of synthetic lethal relationships. For this reason 
screens have been developed, utilising chemical or genetic methodologies, to expose the 
synthetic lethal relationships of cancer-relevant mutations, with the hope of identifying 
opportunities for future therapeutics. Chemical and genetic synthetic lethal screens are likely to 
afford distinct but complementary results as the effect of drug-induced inhibition of enzymatic 
function may differ significantly from complete loss of expression of the protein.118 For example, 
a drug might interfere with only one function of a multifunctional protein, may upregulate or 
downregulate protein function or may exert an effect via multiple protein targets.119 
1.3.2 Chemical Synthetic Lethal Screens 
Chemical-based screens aim to directly identify molecules which induce a synthetic lethal 
response with cancer-relevant mutations in cell-based phenotypic assays. This screening 
technique benefits from preserving the cellular context of the protein function, averting any 
problematic disparities between the effect of a drug compared to complete loss of gene 
expression, and can provide a shortcut to utilise drugs already in clinical use. The opportunity 
and applications for such screens were highlighted in 1997 by Hartwell and Friend107, who 
quickly followed this with a screen of FDA-approved anticancer drug sensitivities in yeast 
deletion mutants defective in DNA repair or cell cycle checkpoint functions.120 
 
Figure 1.8. Fluorescence Based Synthetic Lethal Assay. Isogenic cell-line pairs with and without KRAS mutations and 
expressing blue and yellow fluorescent protein respectively are grown in multiwell plates with drugs administered. A 
‘hit’ is identified as a chemical which selectively kills the cells with mutant KRAS, creating a yellow well.121 Figure 
adapted from Kaelin, 2005.100 
The concept can be extended to human cells to identify compounds able to selectively inhibit 
cells with DDR deficiencies utilising isogenic human cell-line pairs grown in multiwell plates. This 
has been used to good effect in identifying compounds which afford selective killing of KRAS 
mutant cancer cells. Torrance et al. co-cultured colon cancer cells with mutant KRAS, which they 
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had engineered to express blue fluorescent protein, and wild type cells with the mutant KRAS 
deleted, engineered to express yellow fluorescent protein. A different compound was added to 
each well and differential killing was monitored using the ratios of blue to yellow fluorescence, 
Figure 1.8.121 Several novel compounds including triphenyl tetrazolium and a cytidine nucleoside 
were identified which selectively killed the KRAS mutant cell line. In a more recent example, in 
2011, Shaw et al. screened over 50,000 compounds using an ATP-based cell viability assay.122 
Two compounds showed potent and selective activity against the mouse embryonic fibroblasts 
expressing oncogenic KRAS compared to wild type controls. Of these, tolperisone was selected 
as the subject for further study and ultimately the derivative lanperisone was selected as their 
most potent hit, with an IC50 of 4 μM, Figure 1.9. It was ascertained that lanperisone induces its 
cytotoxic effect by triggering oxidative stress; however, the precise target of the compound 
remains unclear. Indeed successful target identification can often be a problem related to 
chemical-based synthetic lethality screening.100 
 
Figure 1.9. Chemical Structures of Tolperisone and Lanperisone.122 
Such screens are particularly powerful and unique in their ability to correctly prioritise hits. It is 
not uncommon in HTS for approximately 1% of the compounds in a chemical library to inhibit 
the growth of cancer cells, which, from a screen of 105-106 compounds, results in thousands of 
hits. In the absence of an appropriate filter, such as this specific killing of cells with cancer-
relevant mutations, these hits are prioritised based on features such as potency, ease of 
synthesis, issues of intellectual property and ADME (absorption, distribution, metabolism and 
excretion) properties, which although are important, do not pertain to selectivity. This can 
potentially cause compounds which would offer selectivity to be missed.100 
As alluded to, the frustration in chemical-based screens is that the precise protein targets and 
mechanism of action of the molecules responsible for the observed phenotype are unknown.123 
Successful target identification can often be difficult, especially if the drugs screened have broad 
activity profiles.100 Three distinct and complementary approaches are typically utilised. Firstly, 
direct biochemical methods, employing biochemical affinity purification to find those target 
proteins which bind to the small molecules of interest. Secondly, genetic interaction and 
genomics methods, in which target hypotheses are generated based on knowledge and 
understanding of genetic interactions and modifiers (enhancers or suppressors) and tested using 
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gene knockout organisms, RNAi (RNA interference) or other small molecule modulators. Finally, 
computational inference methods, which rely on small molecule phenotypic profiling, ligand-
based methods or structure-based methods.123 Each of these approaches has strengths and 
limitations and typically labs will make the decision on which to employ based on their technical 
expertise. There are examples where the methods have been successfully implemented to 
determine the mechanism of action of a small molecule. An integrative chemical genomic and 
proteomic approach was employed to determine that K252a, a natural-product, potentiates 
neuregulin-1-dependent neuritogenesis by interaction with AAK1 (adaptor-associated kinase 1). 
Active and inactive analogues of the small molecule probe were utilised in stable isotope 
labelling by amino acids in cell culture (SILAC)-based affinity enrichment, and the resulting 
candidate targets were tested by RNAi-mediated gene silencing.124 
There are however many instances in which the mechanisms of action have never been 
successfully unveiled. Additionally, the scope of chemical synthetic lethal screens is limited as 
only those targets for which there is already a tool inhibitor available can be investigated, which 
could result in superior targets being overlooked. Essentially therefore, complementary genetic 
synthetic lethal screens have also been developed. 
1.3.3 Genetic Synthetic Lethal Screens 
Genetic screens serve to identify genes which are synthetic lethal with the mutation of interest. 
In contrast to chemical screens, which are more diverse, in that the drugs employed can have a 
range of effects on their target protein or proteins, genetic screens can typically only be used to 
investigate downregulation of gene expression. However, they are invariably applicable and 
allow a broader scope to investigate genes whether or not there is an existing tool inhibitor.100  
Traditionally genetic screens for synthetic lethal interactors were conducted in model organisms 
amenable to forward-genetic approaches, such as yeast and drosophila. Screens in yeast have 
been key in developing understanding of the fundamentals of synthetic lethal interactions, but 
they are limited, as many human cancer genes have no yeast orthologue. Forward-genetic 
screens in drosophila are more laborious but afford the advantage that their genomes contain 
orthologues of most human oncogenes and tumour-suppressor genes.100 For example, 
inactivating mutations in the retinoblastoma (Rb) pathway are common in human tumours, so 
in 2005, Edgar et al. performed a clonal screen in the eyes of drosophila to identify mutations 
which selectively eliminate Rb mutant cells. Peptidyl prolyl isomerase was identified as synthetic 
lethal with Rb.125  
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Reverse-genetic approaches are now overtaking forward approaches. RNAi is an endogenous 
cellular process that enables targeted gene silencing. It was first observed in 1998 in 
Caenorhabditis elegans where double-stranded RNA (dsRNA) was uncovered as the potent 
trigger of gene silencing.126 It is thought to have evolved to protect hosts from transposable 
elements and viruses that utilise dsRNA to propagate.127 RNAi was quickly adopted as a research 
tool in invertebrate model systems where it facilitated functional genomic analysis.128,129 
Unfortunately the methodologies were limited in scope because in mammalian cells dsRNA 
tended to induce an antiviral interferon response which resulted in global shutdown of protein 
synthesis and therefore cell death.130 Thankfully though, this obstacle was overcome when it 
was observed that during RNAi dsRNA is cleaved into smaller siRNA fragments and these are 
capable of triggering RNAi in mammalian cells without activating the antiviral response.131 
RNAi is now known to be a widespread phenomenon, occurring in fungi, plants and animals, in 
all of which it is triggered by long dsRNAs.132 All protein-encoding genes are transcribed in the 
nucleus by RNA polymerase II. The primary RNA transcript is processed by splicing to produce 
mature messenger RNA (mRNA), which is then exported from the nucleus into the cytoplasm. 
Here ribosomes catalyse translation of the mRNA to form proteins.133 This is where RNAi exerts 
its silencing effect, Figure 1.10. RNAi is initiated by the interaction of long dsRNAs with DICER, 
an endoribonuclease that cuts the RNA into short segments, approximately 21 nucleotides long, 
to create siRNAs with 3’ overhangs and 5’ phosphate groups. Dicer can process linear dsRNAs 
and hairpin-RNA substrates.132 The resulting siRNA binds to argonaute-2 (AGO2) and assembles 
into RNA-induced silencing complex (RISC).134 The two strands of the siRNA are sense and 
antisense with respect to the target mRNA. The antisense ‘guide’ strand acts as a template for 
the sequence-specific gene silencing. The sense strand is a ‘passenger’ and is degraded upon 
RISC assembly. The guide-strand-containing RISC binds to the target mRNA and silences gene 
expression by RNA cleavage and degradation. Only when there is perfect complementarity 
between the guide and target strands will the mRNA be cleaved. Therefore, RNAi affords 
reasonable specificity in silencing genes.132 Gene silencing can also be provoked by endogenous, 
small non-coding RNAs called microRNAs (miRNAs). miRNAs are transcribed in the nucleus by 
RNA polymerase II to form primary miRNA transcripts, which are cropped to 70-nucleotide pre-
miRNAs by the DROSHA-DGCR8 (DiGeorge syndrome critical region 8) complex.135 These pre-
miRNAs are moved to the cytoplasm by nuclear transport receptor complex, exportin-5-
RanGTP136, where they are then processed by DICER to mature miRNAs. The miRNAs are 
subsequently loaded on to RISCs by AGO2 and guide gene silencing. Usually only part of the 
miRNA, known as the seed, pairs with the target mRNA. This imprecise matching allows miRNAs 
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to target hundreds of endogenous mRNAs. Without a perfect match between the miRNA and 
mRNA the target does not undergo cleavage and degradation but translation is repressed.132 
Researchers have now been harnessing RNAi as a tool for sequence-specific gene silencing for 
over 15 years. siRNAs, designed for endogenous mRNA transcripts, are introduced to cells or 
whole organisms to afford targeted gene silencing. The siRNAs can be introduced either directly 
as synthetic siRNAs or siRNA precursors, such as short hairpin RNAs (shRNAs) and long dsRNAs, 
or by addition of plasmids expressing RNA, Figure 1.10.  
 
Figure 1.10. Mechanisms of RNAi. RNAi is triggered by long dsRNA, siRNA, shRNA or miRNA. Pre-miRNA, dsRNA and 
shRNA require processing by DICER to form shorter siRNA duplexes approximately 21 nucleotides long. Processed 
siRNAs or miRNAs assemble with a collection of proteins including AGO2 to form RISC. During RISC assembly the sense 
‘passenger’ strand of the RNA is degraded. The other antisense ‘guide’ strand is retained to produce activated RISC, 
which triggers sequence-specific mRNA degradation or translational repression depending on the extent of 
complementarity. Figure adapted from De Paula et al., 2007.137 
Ten years ago, experiments using individual RNAi reagents were being widely used in examining 
the functional roles of specific proteins and genes. For example the defining roles of KRAS, 
AURORA B kinase and plasminogen activator inhibitor 1 (PAI1) in tumourigenesis. Such 
approaches highlighted the huge potential for RNAi in drug discovery efforts and it was 
suggested that the development of genome-wide RNAi approaches could significantly reduce 
the cost and time involved in target identification and validation.138 The development of 
genome-wide RNAi libraries, by academic and commercial groups, has made it possible to 
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conduct high-throughput genome-wide loss-of-function screens.139 These libraries can be 
comprised of one or more types of RNAi reagents. Fundamentally, the library formats are 
divided into two types: collections of siRNA reagents, synthesised chemically or generated from 
complementary DNA (cDNA) by ribonuclease III digestion, or libraries of shRNA expression 
vectors, which can be viral or non-viral (plasmid). The siRNA libraries are typically employed in 
those situations where short-term gene silencing is sufficient. The siRNAs are not replicated by 
the mammalian cells and therefore become progressively diluted as the cells divide. The shRNA 
vector libraries provide long-term, stable gene silencing, as the vectors integrate into the 
genomic DNA and are therefore copied at cell division.138 UP-TORR is an online tool which aims 
to curate accurate and up-to-date annotations of the available cell-based and in vivo RNAi 
reagents, to offer researchers an informed decision as to which are most appropriate for their 
experiments.140 
Ideally, RNAi screening combines the powers of genetic screens and phenotypic assays. It can 
be adapted to identify genes or gene networks involved in a huge variety of biological processes 
by integration of appropriate assays, such as for signal transduction, cell viability, cell or 
organelle morphology, organelle or protein localisation and/or function, drug resistance or 
cellular response to pathogens.139 Broadly speaking there are two typical formats for RNAi 
screening. The first, arrayed screening, aims to determine the effect of loss-of-function of 
individual genes on a phenotype of interest. This is achieved by transfecting with libraries of 
RNAi reagents separated one into each well of multiwell plates. Any suitable readout can be 
employed. Perhaps the simplest and most common is cell viability. The second approach utilises 
pooled shRNA vectors. Groups of library-derived vectors are introduced to cells and those cells 
are selected for a resulting phenotype of interest.138 The target gene in these select cells is 
identified either by PCR (polymerase chain reaction) amplification and sequencing or by an 
approach known as barcode screening.141 
Hundreds of large-scale cell-based and in vivo RNAi screens have now been carried out, which 
promise improved understanding of many complex cellular networks and processes.139 
However, this technology has proved to have a number of associated pitfalls, which have 
resulted in few of the genes identified in these screens being successfully validated. Chiefly, off-
target effects have been linked to virtually every type of RNAi reagent.142 This difficulty is 
exacerbated when scoring for inhibition of a complex phenotype regulated by many genes, such 
as cellular proliferation or viability.143 Consequently, RNAi screening is afflicted with inter-screen 
hit discordance and poor reproducibility. In 2013, Bhinder and Djaballah conducted a systematic 
comparative analysis of screening data from 30 representative lethality-based studies.144 They 
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noted a distinct lack of overlap between the studies, particularly those employing different RNAi 
technologies, with no genes common across the board. In addition, 80% of the genes identified 
by shRNA screening were found to be exclusive to the pooled format, raising doubt as to the 
merits of this approach.144 It is suggested that gold standards and greater prudence in analysis 
of RNAi screening data are essential in improving the reproducibility of data.143,144  
RNAi screening methodologies can be adapted to screen for synthetic lethal interactions. 
Theoretically, RNAis that exacerbate the mutant phenotype of tumour cells, or cells otherwise 
mutated in one particular gene, without affecting wild type cells, would be indicative of a 
synthetic lethal or synthetic sick interaction. This comparative approach may incidentally help 
to reduce false positives in screening that result from non-specific impairment to cellular fitness. 
Combinatorial screens, in which two genes are simultaneously silenced, can be used to uncover 
synthetic lethal relationships between genes. For example, the Boone lab developed a screening 
method in Saccharomyces cerevisiae termed synthetic genetic array (SGA), which enabled them 
to cross a ‘query’ strain bearing one viable gene mutation with an array of ~5000 viable deletion 
mutants, select the resulting double mutants and score these for growth and fitness defects.145 
Those double mutants that exhibited greater impairment of fitness than expected from the 
combination of the corresponding individual mutations were indicative of synthetic lethal 
interactions. The same method was later employed in generating and screening ~110,000 yeast 
double mutants to identify sensitivities to genotoxins. The yeast fitness was determined by 
comparing colony size in untreated conditions and in the presence of three chemical agents that 
induce DNA damage: DNA alkylating agent methyl methanesulfonate, topoisomerase I inhibitor 
camptothecin and DNA intercalating agent zeocin.146 One potentially interesting advantage of 
the SGA system is that compelling double mutants could be back-crossed with further deletion 
mutants to generate triple mutants, which can be screened to investigate whether the lethal or 
drug-sensitive phenotype can be supressed by a third mutation. By identifying potential 
suppressors of the synthetic lethal or synthetic sensitive phenotype it may be possible to 
anticipate and thereby prevent resistant tumours from developing.29 
The alternative approach to combinatorial screening utilises RNAi, small molecules or genetic 
alterations to develop a sensitised cell background, which is submitted to large-scale RNAi 
screening. Any differences in response of isogenic cell lines to gene silencing are indicative of a 
synthetic genetic relationship, be that negative (synthetic lethal) or positive (suppression). For 
example, large-scale loss-of-function screens have been used to identify genes required by KRAS 
mutant colorectal cancer cells but not wild type cells lacking the oncogene. KRAS-transformed 
cancer cells showed synthetic lethality with proteasome and topoisomerase components147, and 
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CDK1 (cyclin-dependent kinase 1).148 It is hoped that the datasets established from these screens 
will reveal new drug targets for use in deletion-guided cancer therapies. 
Although synthetic lethality screening is now widely acknowledged as a valuable tool in 
identifying cancer vulnerabilities, a limited number of synthetic interactions have progressed 
from basic research. It is likely that the screening assays typically employed are limited by 
sensitivity and selectivity. In 2016, Hopkins et al. presented a novel method for synthetic 
lethality screening.3 They explain that the majority of screens to date utilise pooled RNAi 
reagents, containing tens of thousands of RNA sequences. As such, the individual transfection 
frequency is low, resulting in poor sensitivity, inherent variability and poor reproducibility, as 
discussed previously, which could mean more modest synthetic interactions are overlooked. 
Accordingly they designed a screening system based on shRNA and siRNA double knockdown, in 
which isogenic cell lines expressing experimental or control shRNA with individual fluorescent 
tags were co-cultured and siRNA arrayed screening was used to diagnose synthetic lethal 
interactors, Figure 1.11. The system is intended for general use, but in this instance was 
developed to identify genes which are synthetic lethal with tumour suppressor BAF180 (BRG1-
associated factor 180). Mutations in BAF180 are frequently observed in a variety of human 
cancers and in particular, it is a major ccRCC (clear cell Renal Cell Carcinoma) cancer gene, 
exhibiting truncating mutations in 41% of primary samples.1 As such, it has been highlighted as 
a promising opportunity to target ccRCC using a synthetic lethal therapeutic approach.2 A 
synthetic lethal interaction was discovered between BAF180 and histone acetyltransferase 
TIP60 (Tat-interactive protein, 60 kDa). Further data derived using this novel screening method 
is discussed in Chapter 4. 
 
Figure 1.11. Schematic of the Syngeneic Co-culturing System. Two syngeneic cell lines, expressing shRNA for the gene 
of interest or control shRNA and labelled with GFP or mCherry respectively, were mixed together for use in an siRNA 
screen. Imaging and analysis of the GFP:mCherry ratio upon experimental siRNA treatment versus non-targeting 
control enabled validation of synthetic lethal pairs. Figure adapted from Hopkins et al., 2016.3 
44 
Chapter 1 
The RNAi based technologies discussed have widely dominated research applications involving 
experimental modulation of gene expression over the past decade. However, recently a new 
gene editing technology, clustered regularly interspaced short palindromic repeat (CRISPR)-
CRISPR-associated protein 9 (Cas9), has generated excitement. While RNAi regulates gene 
expression at the post-transcriptional level, the CRISPR-Cas9 system is used to introduce 
precision insertions and deletions directly to the genome. Due to the potential capabilities of 
the CRISPR-Cas9 system it has rapidly been accepted by the scientific community for use in a 
variety of genetic applications. It is likely that this technology will soon occupy many of the roles 
currently served by RNAi.149  
1.4 Target Identification 
Target identification is arguably the most crucial step in modern drug discovery. As discussed 
previously, drugs typically fail in clinic either because they do not work or they are not safe, and 
this can often be attributed to poor target selection.8 
1.4.1 Exploratory Research 
Drug discovery projects are typically initiated to address unmet clinical need. Suitable targets 
can be identified using a systems approach, a molecular approach, or often these in 
combination. The systems approach utilises whole organism studies in target discovery. 
Historically it was the main strategy for target identification and it remains so in diseases in 
which the relevant phenotype is only detectable at the organismal level. The molecular 
approach relies on establishing understanding of the cellular mechanisms underlying disease 
phenotypes to identify new targets. The approach therefore employs disease-relevant cells.150 
Outstanding advancements in molecular biology have caused a significant shift towards 
molecular approaches over the past two decades.151 ‘Target’ is a broad term, encompassing an 
assortment of biological moieties, including molecular entities, proteins, genes or RNA, or 
disease biomarkers or biological pathways. A good target, as well as satisfying the unmet clinical 
need, must be efficacious, safe and druggable, i.e. accessible to a conceivable drug molecule.8 It 
is well established that some target classes are more amenable to small molecule drug 
discovery, for example enzymes and G-protein-coupled receptors (GPCRs)152, but there is a 
necessity to explore more challenging targets in pursuit of improved therapeutics. 
In initial research, data is generated to develop hypotheses that inhibition or activation of a 
particular protein or pathway will afford a desirable therapeutic effect. For instance, in the 
example above, TIP60 was identified as synthetic lethal with BAF180, which is frequently 
mutated in ccRCC cancer cells.3 This suggests that BAF180-deficient tumours should be 
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selectively sensitive to TIP60-targeted therapeutics. The aforementioned rapid advances in 
biomolecular research combined with information from genome sequencing, gene expression, 
molecular interaction experiments, association studies and phenotypic screening have resulted 
in an explosion of such available data. As such, the challenge of prioritising targets for further 
experimentation is not trivial. For the best results, bioinformatics approaches should be adopted 
in data mining the available biomedical data, to identify, prioritise and ultimately select suitable 
targets.153 
During the course of this project, attention has moved between a number of different biological 
targets, which form the basis for the thesis chapters. Consequently, the specific therapeutic 
relevance, regarding the efficacy and safety of each target is discussed in the chapter 
introductions. Common to all however is the way in which proteins are assessed for viability as 
druggable candidate targets. 
1.4.2 Target Viability Data 
Advances in crystallographic methods, computational power, molecular biology and 
recombinant protein expression systems have resulted in much improved accessibility of three-
dimensional (3D) structural information on a wide variety of proteins. This structural 
information can streamline many aspects of drug discovery such as target identification, the 
discovery of novel molecular scaffolds to form the basis for potential drugs, and lead 
optimisation. Accordingly, structure-guided drug design has been used to good effect in multiple 
therapeutic areas.9 Most interesting in this instance is the use of structural information early in 
drug discovery to evaluate the viability of a protein as a drug target. Given the aim in drug 
discovery to design bioactive molecules, which selectively target a protein implicated in a 
diseased state without causing adverse effects, there is a requirement for the development of 
molecules with a controlled interaction profile against a variety of proteins. During target 
identification, validation and early lead discovery the focus is typically on the main target, but 
this shifts to include related and similar proteins as the drug discovery program progresses to 
lead optimisation.154 Structure-based methods can be used to identify binding pockets in the 
target protein which might have suitable properties to accommodate a small molecule inhibitor 
and later to establish means to adequately discriminate between any related proteins to avoid 
undesirable off-target binding.9 
Data accessibility is vitally important in the success of drug discovery projects. With such 
tremendous numbers of organic molecules, biological sequences and three-dimensional 
structures reported each year in scientific literature, there is a crucial need for it to be collected 
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and organised into databases.155 Usefully, thousands of biological databases are detailed in the 
Nucleic Acids Research (NAR) online Molecular Biology Database Collection.156 Some of these 
databases have been found to be of particular value in this work in druggability analysis. The 
Universal Protein Resource (UniProt) protein sequence database157 is a comprehensive and 
freely accessible database of protein sequence and functional information. The UniProt 
Knowledgebase (UniProtKB) is comprised of the manually annotated UniProtKB/Swiss-Prot 
section and the automatically annotated UniProtKB/TrEMBL. The Protein Data Bank (PDB; 
www.rcsb.org)158 is the single worldwide archive of three-dimensional structural data of 
biological macromolecules. ChEMBL159 is a manually curated chemical database of drug-like 
molecules, which contains compound bioactivity data against drug targets. canSAR160 is an 
integrated cancer research and drug discovery resource developed to improve data accessibility 
by gathering together publicly available biological annotation, information from screening, 
expression and amplification experiments and 3D structural data. Finally, STRING v9.1 
(http://string-db.org)161 is a database of known and predicted protein interactions, including 
physical and functional associations. 
1.4.3 Structure-Based Druggability Assessment 
With growing numbers of available X-ray crystal structures and enhanced computational power, 
structure-based druggability assessment is often employed in target identification. Early 
assessment of druggability at target identification focuses efforts on targets more susceptible to 
therapeutic intervention by exposing potential target liabilities. This reduces drug discovery 
attrition, preventing unnecessary investment of time or money.9,162 Target druggability analysis 
assesses the likelihood that a target is amenable to functional regulation by interaction with a 
drug-like molecule.162 There are many computational methods that enable rapid and robust 
evaluation of druggability. 
All drugs must not only interact with their molecular target but also be able to reach their site 
of action. Oral drugs, which must be absorbed from the gastrointestinal tract, typically therefore 
share specific physicochemical properties, as described by Lipinski’s Rule of 5 (Ro5). Molecules 
should contain fewer than 5 H-bond donors, between 3 and 10 H-bond acceptors, have 
molecular weight less than 500 and have CLogP less than 5.163 Most existing drugs engage their 
target proteins at predefined ligand binding sites, suggesting that compounds similar to the 
endogenous ligand should possess biological activity.152 Furthermore, for the vast majority of 
these targets the substrate, product or allosteric effector is Ro5 compliant. However, this may 
be due to ease of design and the absence of a Ro5 ligand does not guarantee that a target is not 
druggable.162 This is fortunate as most endogenous ligands are not drug-like, with less than a 
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third of the proteins annotated with ligands in the Human Metabolome Database164 associated 
with a Ro5 compliant ligand.162  
Methods of structure-based assessment of target druggability are typically assembled of three 
elements; a mechanism to detect potential binding sites, a mechanism to evaluate these sites 
based on their physicochemical properties, and a set of reference targets used to validate and 
refine the assessment.162 Pocket-finding algorithms, used in predicting the ligand-binding sites, 
can rely purely on geometry or include physicochemical considerations. Fpocket, which is used 
in this work, utilises a geometry-only method to predict binding sites then goes on to score these 
based on the physicochemical properties of the surrounding atoms.165 
Fpocket is an open source package which employs Voronoi tessellation and alpha spheres in 
pocket detection.165 Voronoi tessellation is a method of dividing space with regard to a set of 
predefined points. In this instance qvoronoi from the qhull package166 is utilised to produce a 
set of Voronoi vertices and the radii of alpha spheres centred at these positions is measured. An 
alpha sphere is a sphere which contacts four atoms at its boundary and contains no internal 
atoms. The four atoms will be, by definition, equidistant to the centre of the alpha sphere, the 
sphere radius. The radius of an alpha sphere is therefore dependent on the local curvature of 
the protein, as described by the four atoms. Very small spheres exist at the interior of proteins 
and very large spheres at the exterior, while clefts or cavities result in alpha spheres of 
intermediate radii, allowing them to be detected. By identifying clusters of such alpha spheres 
of intermediate radii, fpocket is able to discern structural pockets. Following this the spheres are 
categorised depending on the four surrounding atoms to enable filtering of the clusters with 
respect to their physicochemical properties, e.g. by hydrophobicity.165 
It is good practice to validate structure-based target druggability methods against a set of 
reference targets of known tractability. Huang and Schroeder compiled a standard test set of 48 
protein targets for which bound and apo crystal structures were available and utilised these to 
validate pocket-finding methods.167 The average success rate of correct prediction of the true 
ligand binding site as the top scoring pocket was 60% for the apo structures and 67% for the 
bound structures. Fpocket in comparison achieved 69% for the apo structures and 83% for the 
bound structures.165 Fpocket is also one of the few target druggability methods that is validated 
against a set of reference targets with known degrees of druggability. It can therefore be used 
to quantitatively assess druggability. This approach was spearheaded by Hajduk et al. who 
designed a simple model to assign the pockets a druggability score.168 They included terms for 
polar and apolar surface area, surface complexity and pocket dimensions. The scores were 
tailored to conform with hit rates from nuclear magnetic resonance (NMR)-based fragment 
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screening, as an index of binding site druggability. The resulting algorithm was validated against 
a test set of 23 proteins with 57 pockets, which were not used in the training set, and correctly 
classified 94%. This reliable algorithm enables a quantitative assessment of the capacity of a 
given pocket to bind small compounds with high affinity and specificity. Cheng et al. developed 
a different but complementary approach two years later.169 They utilised a biophysical binding-
free-energy model, predominantly dependent on the curvature and hydrophobic surface area 
of the binding pocket, to devise the maximal affinity predicted for a passively absorbed oral drug 
(MAPPOD) for the target. A test set of 27 pharmaceutical targets was compiled with 17 classified 
as druggable, 6 as difficult and 4 as undruggable. They found that a 100 nM threshold for MAPPOD 
score clearly separated those that are druggable from those which are difficult or undruggable, 
affording a mechanism to quantitatively assess druggability in other targets. Their manually 
curated dataset is now considered the benchmark for developing and validating new 
algorithms.162 The validation set utilised in training fpocket is notable as it was compiled via an 
open collaborative platform (http://fpocket.sourceforge.net/dcd) and is the largest publicly 
available.170 It combines targets from the two aforementioned studies with others manually 
annotated from the PDB.158 The fpocket logistic model was trained from this dataset employing 
local hydrophobic density, hydrophobicity and normalised polarity as pocket descriptors.162,165  
In the preceding studies, druggability is assessed solely on the properties of the protein. 
Alternatively, or additionally, the energetics of protein-ligand binding can be calculated via 
docking or molecular simulation. Molecular docking facilitates prediction of the binding modes 
and associated affinities of ligands at putative binding sites on the protein. Huang and Jacobsen 
virtually screened ~11,000 diverse fragments against 152 binding sites using docking to calculate 
computational hit rates for each site, indicative of druggability.171 They showed that these hit 
rates correlated with those previously published from NMR-based screening.168 However, this 
evolving technology still faces significant challenges that affect the accuracy of results, 
particularly in sampling approaches and scoring functions.172 Due to the flexibility of the proteins 
and ligands, there are too many potential binding conformations to sample every one and 
although flexible docking is prevalent, it is computationally expensive. The scoring function is a 
prediction of ligand binding affinity. Current scoring algorithms underestimate the contributions 
of entropy and structural water and surrounding ions.173 Seco et al. apply a decidedly different 
technique utilising molecular dynamics (MD) simulations of the interaction of the protein with 
isopropyl alcohol.174 Analysis of the simulations enables deduction of the interaction free 
energies between the protein and probe molecule, which are used to detect binding sites and 
predict the maximal affinity of drug-like molecules at these positions. 
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MD simulations are now increasingly often being used in druggability assessment. Proteins are 
dynamic but a single X-ray crystal structure typically embodies only one of many possible 
conformations, although the B-factor provides a measure of the displacement of atoms from 
their mean position. The alternative conformations are not well evaluated using standard 
structure-based target druggability assessment. Structural variability can be scrutinised either 
by assessing multiple crystal structures of one target or by evaluating MD trajectories. 
Somewhat surprisingly, the druggabilities calculated from different crystal structures of the 
same protein can vary a great deal. Often this might be attributable to structural perturbation, 
such as mutant or missing residues, but in many cases it is the result of protein flexibility. A 
computationally expensive but thorough approach involves scoring the druggability of a series 
of structures along MD trajectories.162 This highlights any plausible conformational changes that 
could occur under conditions of temperature, pressure, solvation and pH, simulating those in 
vivo, which may affect the druggability of the target.173  
1.4.4 Modelling Three-Dimensional Protein Structure 
As discussed, thanks to the advances in crystallographic methods, there is now a vast amount of 
protein structural data available. However, the number of known protein sequences remains 
significantly higher than the number of solved structures. This is known as the sequence-
structure gap.154 Fortunately, for many of the proteins for which there are no published 3D 
structures, it might be possible to use protein structure prediction to enable structural analysis. 
Indeed, modelling techniques have now matured to a point of routine use in complementing 
experimental techniques.175 
Computational methods for protein structure modelling are widely used in the pharmaceutical 
industry and a great deal of time and effort has been devoted to expanding the scope and 
improving the accuracy of the models. Current methods can be categorised as one or a 
combination of three approaches.176 Firstly, homology or ‘comparative’ modelling; in which a 
model of the target protein of interest is generated based on protein sequence alignment with 
a homologous protein for which an experimental structure is available as a template. This 
technique is derived from the work of Šali and Blundell.177 It relies on the observation that 
evolutionarily related sequences typically adopt similar 3D structures as they retain folds 
characterised by core structures that are robust against sequence modifications. It is therefore 
most effective when the structure of a closely related protein family member is available.154 
Secondly, where no structures of proteins with significant sequence similarity are available, fold 
recognition or ‘threading’ methods can be utilised. In threading, the target protein sequence is 
systematically aligned to a library of proteins of known structure and the fit is assessed by 
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energetics. The best match, producing the most reliable model, is identified as that with the 
lowest quasi-energy score, which represents the structural similarity of the target and template 
proteins. This approach is reliant on the hypothesis that because there are more known proteins 
than folds; the folds of a protein with unknown structure are likely to resemble known folds.176 
Thirdly, when neither comparative modelling nor threading can be utilised due to a lack of 
available templates, de novo methods can be employed. De novo methods are used to predict 
the protein structure directly from the primary sequence using the physical principles of protein 
folding. Information from determined structures may be incorporated but without assumption 
of any evolutionary relationships. Whilst versatile, this process is hugely computationally 
demanding and therefore successes tend to be limited to predicting folding of short peptides.176 
Of these approaches, homology modelling is considered the most accurate and is therefore the 
most commonly employed in drug discovery research.178 
Template-based protein structure prediction is founded on two assumptions: that similar 
protein sequences will adopt similar folds, and that individual regions of a protein will exhibit 
the same folds already observed in the PDB. The process of homology modelling involves several 
phases: template selection, target-template sequence alignment, model building, model 
refinement and model quality estimation, Figure 1.12.154 These stages are amenable to 
implementation of automated pipeline workflows, in which the user inputs the target protein 
sequence and the pipeline outputs a predicted structure.176 For example, the SWISS-MODEL 
server (http://swissmodel.expasy.org)179 enables automated comparative modelling of 3D 
structures. 
In template selection, the experimental structure most appropriate for modelling is identified. 
Generally this is the 3D structure of the most closely related protein available, however there 
are additional criteria that might be considered. Single experimental structures and, by virtue of 
this, models only represent one conformation of the large range exhibited by proteins, which, 
as discussed, are intrinsically highly dynamic. Given that proteins can undergo a substantial 
rearrangement in order to accommodate a ligand, in some cases it can therefore be favourable 
to use an experimental structure depicting the protein in a ligand-bound state.154 In addition, 
the quality of the template structure should be taken into account. Crystal structures with poor 
resolution or which are missing critical residues or loops may not provide adequate structural 
information to build a reliable model. In practice, programs such as NCBI BLAST (Basic Local 
Alignment Search Tool)180 are used to search the PDB for suitable templates using the protein 
sequence of the target, and the most appropriate is selected. 
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Figure 1.12. Homology Modelling Pipeline. A typical homology modelling workflow of template selection, target-
template sequence alignment, model building, model refinement and model quality estimation, annotated with 
suggested software for each step. 
Target-template sequence alignment is performed by programs such as EMBL-EBI Clustal 
Omega.181,182 The sequence identity of the target-template alignment is good indication of the 
quality of the resulting model. Models where the target-template sequence identity is above 
50% are regarded as highly accurate and can be employed in drug discovery research. The 
protein core is typically modelled with high accuracy due to good evolutionary conservation in 
this domain and any flaws will likely only be observed in the packing of side chains or loop 
regions. Models based on less than 30% sequence identity are considered low accuracy models. 
Ambiguous alignment becomes a severe problem and it is possible that an entirely incorrect fold 
can be predicted.176 In attempt to prevent this, more sensitive methods can be employed in 
homologue detection, such as DELTA-BLAST (Domain Enhanced Lookup Time Accelerated 
BLAST).183 However, threading methods may provide better results in these instances. 
Model building can be accomplished by two approaches. The first, rigid fragment assembly, was 
first implemented in 1987 by the Blundell lab.184 The core of the model is constructed first from 
the best structurally conserved regions of one or more templates. Any inserts or deletions in the 
target-template alignment, such as loops, are then incorporated as fragments, each individually 
modelled on a template of close resemblance.185 The SWISS-MODEL server employs a rigid 
fragment assembly modelling procedure.179 The second is satisfaction of spatial restraints. Here 
spatial restraints are derived from a range of sources, including the target-template alignment, 
other known protein structures and molecular mechanics force fields. The target protein is then 
folded into the conformation which best satisfies these restraints. The most widely adopted 
approach that uses satisfaction of spatial restraints, which is also the industry standard in 
homology modelling, is MODELLER (https://salilab.org/modeller/).177 
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Following generation of primary protein models, refinement is required to optimise geometry 
and stereochemistry and remove any unfavourable contacts. This typically involves energy 
minimisation utilising a molecular mechanics force field, which may be followed by molecular 
dynamics to improve side chain contacts and rotamer states, and Monte Carlo sampling to 
improve accuracy of backbone conformations and core side chains.176 Model building software 
often incorporates model refinement and evaluation capabilities. For further optimisation, drug 
discovery software such as Discovery Studio186 and MOE (Molecular Operating Environment)187 
offer automated preparation functions to prepare and minimise models. 
Model quality estimation is important as models can be produced with significant 
inaccuracies.154 The geometrical accuracy and completeness of the model is evaluated and it is 
determined whether the proposed structure is energetically reasonable. Models can be 
assessed as to whether they possess the correct folds, which can aid in detecting errors in 
template selection, fold recognition and target-template alignment.188 A scoring system, such as 
the DOPE (Discrete Optimised Protein Energy) score incorporated into MODELLER189, can be 
used to identify the best of a series of models. The quality of model required is highly dependent 
on its intended use, and in some instances, even if it is low resolution, ‘any level of physical 
characterisation of a protein, as opposed to its absence, is valuable’.190 Lower accuracy models 
can be sufficient in designing mutagenesis experiments or in preliminary target validation, 
whereas greater accuracy is required for structure-based virtual screening applications.191  
Homology modelling capabilities are constantly improving but there are a few challenges that 
remain to be overcome. The accuracy of template-based modelling is limited by the availability 
of appropriate template structures and even at high sequence identity, although overall protein 
folds are well conserved, substrate specificity and mechanisms of catalysis vary greatly, 
indicating structural divergence. Approaches that specifically scrutinise and refine local 
structure could be used to complement homology-based modelling in these instances. There 
are also prevailing difficulties in refining models away from the template and toward the target 
structure, especially at low target-template sequence identity where significant rearrangement 
can be necessary.176 
1.5 Target Validation 
Once a suitable target has been identified, it should be investigated thoroughly to establish its 
clinical relevance before investment in costly drug discovery programmes. Such target validation 
should reduce attrition rates in the clinic and thereby help to improve R&D productivity. A large 
range of validation techniques are available, from in vitro tools, to mouse models, to patient 
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screening, which all have unique strengths and limitations. There is a strong temptation for 
groups to use only the approach most compatible with their technical expertise. However, while 
individual results are persuasive, a multi-validation approach is necessary to establish 
confidence in the target, Figure 1.13.8  
 
Figure 1.13. Overview of the Techniques Utilised in Target Validation. mRNA expression can be modulated either 
directly by RNAi or antisense technology, or genetically in transgenic animals or xenograft models, by conventional 
transgenesis, HR or targeted nucleases. Target protein function can be modulated by monoclonal antibodies or 
chemical probes. Figure adapted from Lindsay, 2003.150 
1.5.1. Genetic Modulation 
Transgenic and knockout animals are a useful validation tool, which enable elucidation of the 
functional consequence of gene manipulation.8 Additionally, it is important to include an in vivo 
validation step in the early stage of drug discovery to verify that modulating the target retains 
an antitumourigenic effect in this setting, and to reduce the risk of missing targets that cannot 
be effectively assessed in vitro. Mouse models are the primary model of choice in cancer 
research. The models can be tailored for use in target validation, to assess whether a target is 
therapeutically relevant and loss of its function will be beneficial, and whether suppressing the 
target can inhibit the disease without causing systemic toxicity. The target is modulated by 
genetic means, either by directly manipulating the mouse germ line to produce genetically 
engineered mouse models (GEMMs), or by genetically manipulating human cancer cell lines, 
which are then transplanted into immunodeficient mice, termed xenograft models.192 
There are two techniques used to produce GEMMs. The first is conventional transgenesis, in 
which plasmid DNA or bacterial artificial chromosome (BAC) DNA is injected into the pronucleus 
of fertilised oocytes, and these microinjected embryos are implanted into the oviducts of foster 
mother mice. Some of the resulting newborns will exhibit exogenous DNA randomly integrated 
into their genomes. These transgenic founder mice can be bred with wild-type mice to establish 
a selection of transgenic mouse lines. This method is typically used to insert new genetic 
information into the genome, to overexpress or knock down genes.192 The first transgenic mouse 
lines were recorded by Constantini and Lacy in 1981.193 The second is modification of the 
genomes of embryonic stem (ES) cells by homologous recombination. Targeted genome 
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modification is achieved with carefully designed DNA constructs. Cells in which the exogenous 
DNA sequence and genomic DNA have been successfully recombined are introduced into a 
developing mouse embryo, which is then implanted into the foster mother. The resulting 
newborn will be a chimeric mouse. The GEMM is produced when the genetic modification is 
transmitted to the offspring. This approach is typically used to manipulate single genes by 
knockout, knockin or point mutation.192 The first targeted knockout mouse was achieved in 
1989.194 In gene knockins, an endogenous protein is replaced with a non-enzymatically 
functional protein. These animals may exhibit a different phenotype to the knockouts, 
particularly when the protein has structural functions as well as enzymatic.195 Theoretically, gene 
knockin should better mimic the effect of drug treatment, as the protein is still present but not 
functional.8 
The HR technology in particular has revolutionised mouse modelling and as testament to its 
huge scientific impact it was awarded the Nobel Prize for Medicine in 2007.192 Mouse genomes 
can be precisely altered, for example to generate ‘oncomice’ in which to investigate gene 
alterations associated with cancer progression. Crossbreeding of these oncomouse GEMMs with 
appropriate tool GEMMs enables interrogation of proposed oncology targets in vivo, with the 
added genetic modification mimicking the therapeutic effect of a target inhibitor. For example, 
GEMMs were used in ascertaining that Cdk4 is synthetic lethal with KRAS196, and that Cdk 
inhibition is therapeutically beneficial in KRAS-driven non-small cell lung cancer.197 This strategy 
also exposes any possible mechanism-based toxicity in vivo. Tool GEMMs are therefore 
profoundly enabling in biomedical discovery. Accordingly, the Knockout Mouse Project (KOMP) 
was initiated in 2004 as an international effort to produce and phenotype knockouts for all 
mouse genes and deliver them to the public domain.198 This effort is ongoing and in 2016 the 
National Institutes of Health (NIH) awarded the University of California, Davis, over $29 million 
for the next five years of related research.199   
As research progressed, there was increasing demand for tissue restricted or inducible knockout 
mice, termed conditional GEMMs. Sometimes constitutive loss of function of a gene lead to 
embryonic lethality, preventing characterisation of the adult mice.138 In addition, chronic 
absence of gene function could induce genetic adaptation by compensatory mechanisms and 
developmental phenotypes.8 Temporally or spatially restricted gene expression is achieved by 
crossbreeding two GEMMs to merge the genetic modifications into one mouse. One allele 
consists of a silent mutation, which is stimulated only when an inductor is expressed or 
activated. For example, one widely used system is the Cre-LoxP system derived from 
bacteriophage P1.200 The Cre recombinase specifically recognises 34 base pair loxP (locus of X-
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over P1) sites. Mice are generated to harbour a gene of interest (GOI) flanked by loxP. These so 
called ‘floxed’ DNA sequences will be deleted wherever Cre is present. For spatial control, either 
the mice can be crossbred with transgenic mice expressing Cre in a cell or tissue specific manner, 
or Cre can be sporadically expressed at sites of interest via a viral vector. For temporal control, 
they can be crossed with mice expressing CreERT2 fusion protein, in which Cre is fused to an 
oestrogen receptor variant (ERT2). CreERT2 is ligand-dependent and inactive in the absence of 
ligand 4-hydroxytamoxifen, which affords inducible control of Cre activity and therefore target 
gene function. The ligand is delivered when desired, topically, systemically or via drinking 
water.192  
Although GEMMs are extremely useful in enabling biological studies and target identification 
and validation, they are expensive and time-consuming to produce. As such, attention has been 
drawn to the potential uses of non-germ-line GEMMs, human xenograft mouse models, 
generated by transplanting human cancer cells that have undergone ex vivo genetic engineering, 
into immunodeficient mice. These have the advantage over GEMMs that they are of human 
origin and therefore reproduce the genetic complexity of human tumours. To interrogate and 
validate proposed oncology targets, the cancer cells are genetically modified in such a way as to 
mimic the effect of inhibiting the target, and the resulting effect is analysed in vivo.192 Advancing 
technologies facilitate the introduction of appropriate targeted mutations into the cancer cell 
DNA. Targeted nucleases enable the rapid and economical manipulation of genomic sequences 
in a broad spectrum of cell types and organisms. Zinc-finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs) and CRISPR-Cas9 are designed to recognise specific 
sequences in the genome. The nucleases generate DSBs at these specific locations and stimulate 
DNA damage repair mechanisms, which can be harnessed to achieve precisely targeted genomic 
edits.201 Genome editing with engineered nucleases was awarded Method of the Year in 2011.202   
1.5.2. mRNA Modulation 
The modulation of target genes in cancer cells for xenograft models can also be achieved by 
knocking down the expression of the GOI by RNAi, using either siRNA or shRNA. Generally it is 
preferable to use shRNA due to the challenges in delivery, stability and transient knockdown 
associated with siRNA. shRNA is delivered by transfecting or transducing cells with plasmids or 
viral vectors respectively, and is designed such that it is stably integrated into the genome, 
expressed under either a constitutive or inducible promoter. The cells are transplanted into 
immunocompromised mice to enable evaluation of the effect of downregulating the target in 
vivo. Again, inducible expression offers a number of advantages, including the prevention of 
undesired effects on cell growth and the opportunity for time-dependent regulation.203 
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Proposed targets are validated by genetic modification of the cells to imitate therapeutic 
intervention. Targets such as Ran (Ras-related Nuclear protein)204, receptor tyrosine kinase HER3 
(Human Epidermal Growth Factor Receptor 3)205 and PLCγ1 (phospholipase Cγ1)206 have been 
validated by this approach. 
RNAi-based gene knockdown has also evolved into an alternative approach to classic gene 
knockdown in mouse models. As in cultured cells, siRNA can be used to transiently induce gene 
silencing in somatic tissues and is frequently employed in experiments requiring only short term 
knockdown of gene function.207 Local delivery of siRNAs is also proving valuable in therapeutics 
and there has been a resurgence in clinical trials employing RNAi technology.208 Permanent gene 
silencing is achieved by integration of shRNAs into the mice genomes. Transgenesis of the shRNA 
occurs as discussed above, by pronucleus injection, viral embryo infection or targeted knockin 
by homologous recombination to ES cell genomes. The shRNA expression vectors are inserted 
by recombinase-mediated cassette exchange (RMCE) into the ubiquitously active Rosa26 locus 
of the ES cells, and these are developed into GEMMs. This targeted insertion ensures ubiquitous 
and reproducible expression of the shRNA, which affords constitutive gene silencing by mRNA 
degradation. Spatially- or temporally-specific silencing can again be achieved utilising the Cre-
LoxP system. A loxP-STOP cassette, which disrupts function, is inserted at a restriction site in the 
shRNA loop region. The dsRNA structure of the shRNA is formed from carefully designed single-
stranded RNA, comprising of a 19-22 base pair sense siRNA sequence linked to the 
complementary anti-sense sequence by a loop region of 8 bases. After transcription the 
complementary RNA sequences hybridise to form the dsRNA which is exported from the nucleus 
and processed by DICER to produce siRNA, Figure 1.10.207 Despite significant developments in 
RNAi technologies, development of GEMMs nonetheless remains a costly and time-consuming 
endeavour. In vitro screening and target validation using RNAi has also highlighted many 
promising drug targets, however, in vivo validation is desirable before investing in a full drug 
discovery program.  
Similarly to RNAi, antisense technology can be used to silence genes by transcriptional 
regulation. RNA-like oligonucleotides are designed which are complementary to a region of the 
target mRNA.8 The antisense oligonucleotides (ASOs) enter the cell, exploiting either natural 
processes or facilitators, and interact with the target mRNA. Formation of the ASO-mRNA duplex 
activates RNase H, which cleaves the mRNA, thereby impeding protein synthesis. Like siRNA, 
ASOs represent a promising opportunity in therapeutics and have been tested in more than 100 
clinical trials.209 Antisense technology can also be used in target validation. For example, 
antisense probes for the P2X3 receptor induce reduced pain sensitivity in the Complete Freund’s 
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Adjuvant (CFA) model, validating the role of the receptor in chronic inflammation.210 Unlike gene 
knockout and shRNA approaches, antisense technology is reversible and after administration is 
discontinued, target function will be restored.8 A number of challenges of ASOs remain to be 
addressed, including issues with delivery, targeting and off-target effects.209 
1.5.3. Protein Modulation 
With the specific exception of gene knockin, all of the approaches described above result in the 
complete elimination of the target protein from the cell. This however may not be the best 
approach to validate that a target is amenable to regulation by small molecule drug compounds. 
A small molecule will likely inactivate the enzymatic function of a protein but not destroy it, or 
cause major structural disruption. Any structural functions of the protein, for example regarding 
complex formation, may therefore remain viable, despite inhibition of the enzymatic function.8 
In target validation, it is therefore prudent to include an effort in protein modulation. 
Monoclonal antibodies (mAbs) are a useful tool in target validation. They interact with a large 
region of the target molecular surface, affording good selectivity and high affinity.8 HER3 plays 
an essential role as a cell surface receptor for neuregulins.  In contrast to other HER receptors 
HER3 lacks intrinsic kinase activity. As such, mAbs, which are able to prevent the receptor from 
interacting with ligands or other proteins, are the most suitable tool for HER3 target validation 
and therapeutics. Over a dozen anti-HER3 mAbs are in clinical development and clinical 
observations strongly validate HER3 as a cancer drug target.211 While monoclonal antibodies 
provide high affinity and good discrimination between targets and therefore show little non-
mechanistic toxicity, they are unable to cross cell membranes and as such the target class is 
restricted mainly to cell surface and secreted proteins.8 
In many cases it is therefore necessary to design and prepare small bioactive molecules, which 
are able to functionally modulate the target protein.8 It is important to note the clear distinction 
between molecules destined to become drug candidates and these chemical probes, which are 
used primarily to explore protein function and validate efficacious and druggable targets. It is 
often acceptable that probes exhibit less good pharmacokinetic properties, which offers a wider 
scope to incorporate diverse chemical groups212, but the probes must be highly selective. In fact, 
selectivity is often more important for chemical probes than it is for drug compounds, which 
may benefit from off-target activity via polypharmacology. It is necessary that the probes exhibit 
very few if any off-target effects, to enable clear and reliable interpretation of subsequent 
experimental data.213 Unfortunately, there are many widely used chemical probes that do not 
comply with acceptable potency and selection criteria, and so afford unreliable biological data. 
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Bunnage et al. suggest four ‘pillars of target validation’, which increase the likelihood that drug 
programs succeed in the clinic.214 They propose that by applying these principles to development 
and use of chemical probes, target perturbation can be more confidently linked to disease-
relevant pharmacological regulation. Pillar one is sufficient exposure at the site of action, which 
requires that the probe exhibits good cellular permeability. As Lipinski’s Ro5 establishes criteria 
important in drug absorption163, there are also criteria acknowledged to improve cellular 
penetration, for example regarding lipophilicity.215 By validating probe accessibility it is possible 
to rule out false negatives, where the lack of cellular response is the result of poor cellular 
penetration. Moreover, it may be necessary to determine the precise concentration of the probe 
inside cells, to accurately evaluate dose response and structure-activity relationship (SAR), or to 
ensure that the probe is maintained at a concentration within its selectivity window. Liquid 
chromatography-mass spectrometry (LC-MS) or microscopic imaging could be utilised in this 
endeavour.214 Pillar two is proof of target engagement and selectivity. A thorough understanding 
of the performance of the probe in whole-cell and in vivo is vital, including both the true on- and 
off-targets. In-depth molecular mode-of-action studies and selectivity profiling help to increase 
confidence in the target and probe. An inactive analogue is highly useful as a negative control. 
Activity-based proteomics techniques enable quantification of target engagement. When a 
probe is developed, a bespoke chemical proteomics probe can be designed, founded on the 
structure of this tool compound. The proteomics probe should consist of the binding group (from 
the tool compound), which imparts selectivity, a protein-reactive warhead, to stabilise the 
protein-probe interaction, and a tag, which could be a reporter, such as a fluorophore, or an 
affinity label, such as biotin or an alkyne or azide for use in click chemistry. Application of the 
proteomics probe, followed by cell lysis and experimental interpretation, can confirm the 
cellular target or targets of the probe.214 Pillar three is expression of functional pharmacology, 
i.e. the probe should affect the biochemical function of the target. An assay appropriate to the 
target must be selected with which to measure the affinity or IC50s of the candidate probes. 
Patient-derived cells can be particularly helpful as they often endure pathophysiological 
modifications that simpler model cell lines lack. Finally, pillar four is expression of a disease-
relevant phenotype. As previously highlighted, often biomarkers can be disease-related but non-
causal. Unearthing these early in preclinical research confers a substantial saving of time and 
money. Mammalian models are often prohibitively expensive and time-consuming, but more 
primitive organisms such as zebrafish can be employed in phenotypic screening.214 Together 
these pillars help to determine the desirable characteristics of small molecule probes. 
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Workman and Collins define a series of ‘fitness factors’ as guidelines for consideration when 
assessing the quality of chemical probes, with an aim to avoid generation of poor quality and 
misleading data, while retaining the freedom for creative and innovative research.215 These 
factors are separated into four categories, Figure 1.14. (1) Chemical properties. It is paramount 
that the probe is well-characterised and pure, and that reliable and reproducible preparative 
methods are available. It should be stable in relevant media and free from non-specific chemical 
reactivity. Solubility and membrane permeability are also of great importance if the probe is to 
be used in cell-, tissue- or whole organism-based research. It should be sufficiently soluble in 
aqueous media, not prone to aggregation in assay conditions and have proven passive 
membrane permeability or defined active transport mechanisms. (2) Biological potency. The 
potency of the probe should be appropriate for the intended use, with approximate guidelines 
of <100 nM in in vitro biochemical assays and 1-10 μM in cell-based assays. Established SAR and 
good correlation between biochemical and cellular data improves confidence in the targeted 
mechanism of action of the probe. Finally, to be useful in in vivo studies, the phobe must have 
suitable pharmacokinetic properties to achieve levels in target tissues that are relevant to the 
cellular potency. (3) Biological selectivity. A good chemical probe should exhibit >10-100 fold 
selectively over other related targets, and analogues with no measurable biochemical activity 
should also exhibit no activity in cells. Ideally there should be multiple probes with different 
chemotypes available, which exhibit similar activity, to improve confidence in data reliability, 
and any chemical activities of the probe should be well understood. (4) Context of use. In 
addition to the intrinsic properties of the compound, the use governs the suitability of a probe. 
It is favourable to have access to RNAi or mouse models of the target for complementary 
experiments. The cellular context of the target and any linked activities should be considered, 
as well as the fitness of the probe to test the specific biological hypothesis. Finally, the probe 
should be available or accessible in quantities that enable follow up studies (15-20 mg).215  
Good quality chemical tools provide an excellent mechanism to test therapeutic hypotheses 
with a molecule close to the profile of a clinical candidate. Demonstration of a non-toxic 
therapeutic phenotype in cellular or in vivo models in response to the probe affords a significant 
boost in confidence and is fundamental in target validation.216 Use of such chemical probes 
remains disadvantaged by the need to interact with conserved sites on the protein and the 
resulting high propensity for non-mechanistic toxicity.8 However, careful target selection and 
thorough counter-screening efforts assist in relieving this difficulty, and inhibitor development 
is certainly a worthwhile venture. Chemical probes are remarkably powerful in unveiling and 
accessing novel biology and potential targets.214 For example, the discovery of selective BET 
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(bromodomain and extra-terminal domain) inhibitors in 2010217,218, has resulted in an explosion 
of research in BET bromodomain biology, the therapeutic potential of BET inhibition and the 
role of other bromodomains. 
 
Figure 1.14. Criteria for Designing and Creating Effective Chemical Probes. Fitness factors grouped into four areas: 
chemical properties, biological potency, selectivity, and context of use, which enable evaluation of the suitability of a 
chemical probe in exploratory biology. Figure adapted from Workman & Collins, 2010.215 
1.6 Project Aim 
The aim of this project was to design and characterise tool inhibitors of proteins involved in DNA 
damage response, primarily focusing on the structural maintenance of chromosomes (SMC) 
proteins and lysine acetyltransferase 2-A (KAT2A). It is hoped that these probes will emulate the 
success of others in enabling detailed mechanistic biological investigation, disease validation 
and ultimately initiation of translational drug discovery projects. 
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2 Materials and Methods 
2.1 Bioinformatics  
2.1.1 Data Procurement 
Information on proteins of interest was collected from online resources and databases; protein 
descriptions and domain information from canSAR 2.0160, protein association networks from 
STRING v9.1161, phylogenetic trees from the Structural Genomics Consortium website219 and 
information regarding known small molecule inhibitors or binders from ChEMBL159. 
The complete amino acid sequences of targets were retrieved, in FASTA format, from the 
UniProt protein sequence database.157  
2.1.2 Homology Searches 
Utilising the amino acid sequences of targets, the NCBI BLAST180 program was used to search 
for: 
 Human homologues (Database: UniProtKB/Swiss-Prot, Organism: Homo sapiens (taxid: 9606)) 
 Orthologues (Database: UniProtKB/Swiss-Prot) 
 Relevant crystal structures available in the PDB (Database: Protein Data Bank) 
Commonly, BlastP is used to compare the protein query to a protein sequence database. In this 
work however, DELTA-BLAST was used, which searches a database of pre-constructed PSSMs 
(Position Specific Scoring Matrices) before searching the protein database, in order to yield 
better homology detection.183 The complete FASTA sequences of selected hits were downloaded 
from the DELTA-BLAST search results. 
2.1.3 Sequence Alignments 
EMBL-EBI Clustal Omega181,182 was used to compile pairwise and multiple sequence alignments 
of protein sequences, utilising amino acid sequences downloaded from UniProt protein 
sequence database.157  
2.1.4 Conservation Scoring 
The Scorecons server220 was used to rate the conservation at each amino acid site in pairwise 
and multiple sequence alignments of: 
 Human SMC proteins and Rad50   
 KAT2A and KAT2B HAT domains 
 GNAT and MYST HAT domains 
 KAT2A and KAT2B bromodomains 
 Type I and type II bromodomains 
 All human bromodomains 
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Scorecons provides a measure of the site-specific conservation, using a sum-of-pairs scoring 
system to assign scores ranging from 0 to 1, which depend on the amino-acid frequency and 
relative stereochemical properties of substituted amino acids.220 
2.2 Homology Modelling 
2.2.1 Model Building 
Modelling was performed using homology modelling programs, SWISS-MODEL179 and 
MODELLER 9.12177, which rely on protein sequence alignment, and PHYRE 2.0 (Protein 
Homology/analogy Recognition Engine)221 which uses a protein threading software. 
SWISS-MODEL179 was used to build one model, Table 2.1. 
Table 2.1. Models of Target Homo Sapiens Protein Domains Constructed Using SWISS-MODEL.179 
Target 
Template 
Organism Protein & Domain PDB ID Resolution 
SMC5/6 hinge Thermotoga maritima SMC hinge 1GXJ222 2.00 Å 
 
MODELLER 9.12177 was used to build seven models, Table 2.2. 
Table 2.2. Models of Target Homo Sapiens Proteins or Protein Domains Constructed Using MODELLER 9.12.177 
Target 
Template 
Organism Protein & Domain PDB ID Resolution 
SMC5/6 hinge Schizosaccharomyces pombe SMC5/6 hinge 5MG8223 2.75 Å 
SMC5/6 head Pyrococcus furiosus SMC ATPase 1XEX224 2.50 Å 
NSE1 Homo sapiens NSE1 3NW0 A225 2.92 Å 
NSE2 Saccharomyces cerevisiae Mms21 3HTK C226 2.31 Å 
NSE3 Homo sapiens MAGEA4 2WA0227 2.30 Å 
SMC1/3 hinge Mus musculus SMC1/3 hinge 2WD5228 2.70 Å 
SMC1/3 head Pyrococcus furiosus SMC ATPase 1XEX224 2.50 Å 
 
Models were constructed by the satisfaction of spatial restraints, using the ‘automodel’ class. 
Five similar models were generated using the python script command, additionally assessing the 
DOPE score189 and GA341 score, and the ‘best’ selected as that with the lowest DOPE score, i.e. 
that with the lowest associated energy. Table 2.3 to Table 2.9 show the log file summaries for 
all the models built. The ‘best’ model, which was further analysed, is highlighted. 
Table 2.3. MODELLER 9.12177 Log File Summary for SMC5-SMC6 Hinge Models. 
Filename molpdf DOPE Score GA341 Score 
HSMCAB_hinge.001.pdb 4286.1 -38403.9 1.000 
HSMCAB_hinge.002.pdb 4023.1 -38437.8 1.000 
HSMCAB_hinge.003.pdb 4131.2 -38639.1 1.000 
HSMCAB_hinge.004.pdb 4217.1 -38916.5 1.000 
HSMCAB_hinge.005.pdb 4008.4 -38514.0 1.000 
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Table 2.4. MODELLER 9.12177 Log File Summary for SMC5-SMC6 Head Models. 
Filename molpdf DOPE Score GA341 Score 
HSMC56_head.001.pdb 4875.5 -66034.6 0.921 
HSMC56_head.002.pdb 4729.7 -66159.1 0.904 
HSMC56_head.003.pdb 5003.4 -65486.4 0.850 
HSMC56_head.004.pdb 5396.0 -64320.7 0.769 
HSMC56_head.005.pdb 4935.7 -65919.4 0.917 
   
Table 2.5. MODELLER 9.12177 Log File Summary for NSE1 Models. 
Filename molpdf DOPE Score GA341 Score 
HNSE1.B99990001.pdb 1584.1 -27186.2 1.000 
HNSE1.B99990002.pdb 1488.4 -27065.1 1.000 
HNSE1.B99990003.pdb 1408.9 -27149.6 1.000 
HNSE1.B99990004.pdb 1430.3 -27134.1 1.000 
HNSE1.B99990005.pdb 1529.6 -27031.7 1.000     
Table 2.6. MODELLER 9.12177 Log File Summary for NSE2 Models. 
Filename molpdf DOPE Score GA341 Score 
HNSE2.B99990001.pdb 1360.3 -16265.0 0.448 
HNSE2.B99990002.pdb 1470.3 -16566.1 0.845 
HNSE2.B99990003.pdb 1371.4 -16093.6 0.522 
HNSE2.B99990004.pdb 1315.5 -16638.1 0.462 
HNSE2.B99990005.pdb 1401.7 -16193.6 0.485 
   
Table 2.7. MODELLER 9.12177 Log File Summary for NSE3 Models. 
Filename molpdf DOPE Score GA341 Score 
HNSE3.B99990001.pdb 1596.2 -26809.6 1.000 
HNSE3.B99990002.pdb 1503.4 -26783.0 1.000 
HNSE3.B99990003.pdb 1569.1 -26738.9 1.000 
HNSE3.B99990004.pdb 1565.5 -26527.8 1.000 
HNSE3.B99990005.pdb 1589.6 -26791.4 1.000 
   
Table 2.8. MODELLER 9.12177 Log File Summary for SMC1-SMC3 Hinge Models. 
Filename molpdf DOPE Score GA341 Score 
HSMCAB_hinge.B99990001.pdb 2628.6 -43777.5 1.000 
HSMCAB_hinge.B99990002.pdb 2564.9 -44103.1 1.000 
HSMCAB_hinge.B99990003.pdb 2606.3 -43488.2 1.000 
HSMCAB_hinge.B99990004.pdb 2658.5 -43959.9 1.000 
HSMCAB_hinge.B99990005.pdb 2583.3 -43485.1 1.000 
   
Table 2.9. MODELLER 9.12177 Log File Summary for SMC1-SMC3 Head Models. 
Filename molpdf DOPE Score GA341 Score 
HSMC13_head.B99990001.pdb 4302.1 -77329.9 0.997 
HSMC13_head.B99990002.pdb 4004.0 -77646.0 1.000 
HSMC13_head.B99990003.pdb 4277.9 -78393.1 1.000 
HSMC13_head.B99990004.pdb 4326.0 -77139.1 0.999 
HSMC13_head.B99990005.pdb 4146.5 -77750.7 0.987 
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Phyre 2.0221 was used to build one model, Table 2.10. A model confidence of 100% was quoted. 
Table 2.10. Models of Target Homo Sapiens Protein Domains Constructed Using Phyre 2.0.221 
Target 
Template 
Organism Protein & Domain PDB ID Resolution 
SMC5 head Deinococcus radiodurans RecN 4AD8229 4.00 Å 
 
2.2.2 Model Preparation and Minimisation 
Preparation and minimisation of protein models was performed using Discovery Studio 4.0.186 
The Automatic Preparation function was used to prepare, clean and protonate the model, which 
was then minimised using the default parameters. Table 2.11 displays CHARMM (Chemistry at 
HARvard Macromolecular Mechanics) energies calculated for each model at minimisation.230,231 
Table 2.11. CHARMM Energies Calculated by Discovery Studio 4.0186 at Model Minimisation. 
Model Filename Modelling Software CHARMM Energy 
HSMCAB_hinge.004.pdb MODELLER -23880.0 
HSMC56_head.001.pdb MODELLER -40835.0 
HSMC56_head.002.pdb MODELLER -41080.4 
HSMC56_head.003.pdb MODELLER -40831.4 
HSMC56_head.004.pdb MODELLER -40564.7 
HSMC56_head.005.pdb MODELLER -40858.1 
HSMC5ab_head_4AD8.pdb PHYRE 2.0 -18068.4 
HNSE1.B99990001.pdb MODELLER -16412.2 
HNSE2.B99990004.pdb MODELLER -15264.1 
HNSE3.B99990001.pdb MODELLER -16664.6 
HSMCAB_hinge.B99990002.pdb MODELLER -29243.0 
HSMC13_head.B99990003.pdb MODELLER -46803.4 
   
2.3 Structural Alignment and Visualisation 
Table 2.12. Structural Alignments Between Targets and Templates Prepared Using PyMOL.232 
Target Template 
Organism 
Protein & 
Domain 
PDB ID Organism 
Protein & 
Domain 
PDB ID 
Homo sapiens SMC5 head Model 
Pyrococcus 
furiosus 
SMC ATPase 1XEX224 
Homo sapiens NSE3 Model Homo sapiens NSE1-MAGEG1 3NW0 B225 
Homo sapiens SMC1/3 head Model 
Saccharomyces 
cerevisiae 
SMC1-SCC1 1W1W A233 
Rattus 
norvegicus 
RNF4 3NG2 B234 Homo sapiens RNF4 2XEU235 
Homo sapiens ASF1A 2IO5 A236 Homo sapiens ASF1A-HIRA 2I32237 
Homo sapiens GCN5 BRD 3D7C238 
Saccharomyces 
cerevisiae 
GCN5 BRD-H4 1E6I239 
Homo sapiens PCAF BRD 5FE8240 
Saccharomyces 
cerevisiae 
GCN5 BRD-H4 1E6I239 
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PyMOL 1.6232 was used as standard to produce 3D representations of proteins and models and 
to prepare structural alignments utilising the action_align_to molecule functionality, Table 2.12. 
2.4 Pocket Prediction and Scoring 
Binding pockets were defined using both Discovery Studio 4.0186 and Fpocket 2.0165, Table 2.13. 
In both programs the binding pockets were defined from receptor cavities using the default 
parameters. The structure-based target druggability prediction score coupled to Fpocket 2.0 was 
utilised in assessing sites.170 
Table 2.13. Targets of Pocket Prediction Using Discovery Studio186 and Fpocket165. 
Target Prediction Software 
Organism 
Protein & 
Domain 
PDB ID 
Discovery 
Studio186 
Fpocket165 
Homo sapiens SMC5/6 hinge Model Y  
Homo sapiens SMC5/6 head Model Y Y 
Pyrococcus furiosus SMC ATPase 1XEX224 Y Y 
Homo sapiens SMC5 head Model Y Y 
Homo sapiens NSE1 Model Y Y 
Homo sapiens NSE2 Model Y Y 
Homo sapiens NSE3 Model Y Y 
Homo sapiens SMC1/3 hinge Model Y Y 
Homo sapiens SMC1/3 head Model Y Y 
Saccharomyces cerevisiae SMC1-SCC1 1W1W A233  Y 
Rattus norvegicus RNF4 3NG2 B234  Y 
Homo sapiens ASF1A 2IO5 A236  Y 
Homo sapiens GCN5 HAT 1Z4R241  Y 
Homo sapiens GCN5 BRD 3D7C238  Y 
 
2.5 Data Handling - KNIME 
KNIME (Konstanz Information Miner)242 is a modular environment that enables visual assembly 
and execution of data pipelines. Nodes are assembled into workflows for data processing. 
2.5.1 Filter Results of HTS and Hit Confirmation Assay 
A KNIME242 workflow was created to filter the results of hit confirmation assay, PubChem 
BioAssay AID: 5883475, completed by the NIH Chemical Genomics Center (NCGC), to identify 
compounds from the set that were defined as ‘active’, had acceptable curve descriptions, 
discarding any with efficacy >150 calculated from a partial curve, and were available from 
preferred suppliers. 
Of the 145 compounds screened, 82 were available from preferred suppliers, identified using 
workflow prepared by Dr Ben Wahab (Sussex Drug Discovery Centre, University of Sussex). This 
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filter output an SDF file detailing the structures of the available compounds. Meta Node 
ExtractInfoForSubset was used to reintroduce information from the assay summary, regarding 
the activity profile and curve descriptors. A row filter was utilised to select entries with 
PUBCHEM_ACTIVITY_OUTCOME ‘Active’, and Meta Node GoodCurveDescription was used to 
remove entries with unreasonable curve descriptors, where efficacy >150 was calculated from 
partial curves. Finally, Meta Node DiversityCluster was employed in attempt to cluster the 
compounds into series of similar structures and the data was output to an interactive table. 
 
Figure 2.1. Overview of KNIME242 workflow used to filter results of hit confirmation assay. 
ExtractInfoForSubset 
In Meta Node ExtractInfoForSubset, tautomers were generated of the compounds from both 
the original hit confirmation assay and the SDF file of those available for purchase. To the former 
an Orig_number column was introduced using RowID to enable later identification of origin and 
to the latter, a constant value column to infer availability. The two datasets were then 
concatenated, grouped by Unique_SMILES, filtered on availability from preferred suppliers, and 
grouped back by Orig_number to give individual entries for each compound input. Finally, these 
individual entries were recombined with the non-structural information from the assay 
summary by concatenating the datasets and again grouping by Orig_number and filtering on 
availability from preferred suppliers. 
 
Figure 2.2. Outline of KNIME242 ExtractInfoForSubset Meta Node. 
GoodCurveDescription 
In Meta Node GoodCurveDescription those entries with Curve_Description ‘Partial curve; high 
efficacy’ were selected and filtered to retain only those with Efficacy lower than 150, before 
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recombining with entries with Curve_Descriptions ‘Complete curve; high efficacy’, ‘Complete 
curve; partial efficacy’ and ‘Partial curve; partial efficacy’. 
 
Figure 2.3. Outline of KNIME242 GoodCurveDescription Meta Node. 
DiversityCluster 
In Meta Node DiversityCluster, initially the RDKit Diversity Picker was used to select a diverse set 
from the data. A loop was initiated in which the fingerprints of the diverse molecules were 
compared to those of the complete dataset to calculate the Tanimoto similarity coefficient, the 
coefficients were sorted into descending order and entries with coefficients below 0.5 were 
removed. To collect only results which had been successfully clustered, the number of results of 
each iteration were counted and those with two or more associated results were selected. A 
second loop was then used to recollect the compounds that were identified in those iterations. 
 
Figure 2.4. Outline of KNIME242 DiversityCluster Meta Node. 
2.5.2 Retrieve and React Isothiazolones 
Compounds identified by a ChEMBL159 search against KAT2B were filtered manually and only 
those with reasonable reported activity against the KAT2B HAT domain (< 150 μM) were 
retained. A KNIME242 workflow was used to select and sort the isothiazolones from this list and 
then convert them to the mercaptoacrylamide species, as required for docking. 
Of the 110 compounds input, 65 were selected as isothiazolones. These were separated using 
the Rule-based Row Splitter into those with and without reported IC50 values. For both subsets 
the String To Number functionality was used to convert the ChEMBL ID to a number and 
duplicates then removed using GroupBy ChEMBL ID. Following this, the Affinity was renamed 
either as IC50 or as % inhibition, before concatenating to afford one table. This table was then: 
saved as an SDF file, sorted by IC50 and saved as a PDF file for printing, and passed to Meta Node 
ReactToMercaptoacrylamide for conversion of the isothiazolone motif, as required for docking. 
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Figure 2.5. Overview of KNIME242 workflow used to retrieve and react isothiazolones. 
ReactToMercaptoacrylamide 
In Meta Node ReactToMercaptoacrylamide the JChem reactor node, JChem 6.1.0, 2013, 
ChemAxon (http://www.chemaxon.com) was used to convert the isothiazolones to the 
mercaptoacrylamide species, before converting and saving to SDF.  
 
Figure 2.6. Outline of KNIME242 ReactToMercaptoacrylamide Meta Node. 
2.5.3 Generate Conformers 
A KNIME242 workflow was designed to generate six conformers of each compound from a library 
saved in SDF format, give each a unique identifier and output another SDF file.  
The list of structures was imported from the SDF file. It was then necessary to convert the 
structures to a format recognised by the RDKit Add Conformers node. A loop was utilised to 
generate six conformers for each compound in turn and assign each a unique identifying 
number. Outside the loop this number was incorporated into the compound reference number, 
to generate a single unique identifier for each conformer, before saving to SDF. 
 
Figure 2.7. Outline of KNIME242 Workflow Used to Generate Conformers. 
2.5.4 Select Highest Scoring Docking Pose and Retrieve Top 40% of Compounds 
A KNIME242 workflow was designed to group conformers with multiple poses generated by 
docking, retaining only the highest scoring pose for each compound, sort these by an associated 
docking score, retrieve the top scoring 40% and output to an SDF file.  
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The list of docked structures was imported from an SDF file. The conformers were grouped, 
retaining the first (best) docking pose and associated score. The resulting data table was joined 
with that from a compound catalogue, to retrieve the associated catalogue numbers. The data 
was sorted by ascending docking score and a ranking column was inserted, dependent on the 
row index. The rows were filtered to retrieve those where RANK/0.4 < ROWCOUNT, i.e. the 40% 
with the best docking scores. The results were written to an SDF file. 
 
Figure 2.8. Outline of KNIME242 Workflow Used to Select Highest Scoring Docked Pose and Retrieve Top 40% of 
Compounds by Docking Score. 
2.5.5 Generate Final List of Docked Hit Compounds 
A KNIME242 workflow was designed to first split a list of docked compounds according to two 
columns detailing whether they were interesting because they made new interactions with the 
protein, or should be ignored because the pose was unreasonable. Those compounds that 
instigated new interactions were then combined with the top 20% of compounds, by docking 
score, which did not instigate new interactions but were not unreasonable. 
The list of docked structures was imported from an SDF file. The compounds were split 
depending on whether they formed new interactions. Those that did not form new interactions 
were split again to remove any marked to be ignored. Those not marked to be ignored were 
ranked by ascending docking score, dependent on the row index, and the rows were filtered to 
retrieve those where RANK/0.2 < ROWCOUNT, i.e. the 20% with the best docking scores. The 
top scoring 20% were combined with the compounds that formed new interactions to generate 
a final hit list, which was sorted by ascending docking score and saved to SDF. 
 
Figure 2.9. Outline of KNIME242 Workflow Used to Split List of Compounds According to Two Columns and Partially 
Recombine to Generate Final List of Hits. 
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2.6 Data Analysis and Visualisation 
Instant JChem was used for structure database management and searching, JChem 6.1.0, 2013, 
ChemAxon (http://www.chemaxon.com). 
Unless otherwise specified, numerical data was analysed using Microsoft Office Excel (2013) and 
GraphPad Prism version 7.02243 for Windows, GraphPad Software, La Jolla California USA, 
www.graphpad.com, in combination. 
2D representations of chemical structures and reactions were generated using ChemDraw® 
Prime version 15.1, PerkinElmer, Waltham, Massachusetts USA, www.perkinelmer.co.uk. 
2.7 Molecular Docking 
Ligand:Receptor docking and protein visualisation was performed using MOE.187 Forcefield 
Amber10:EHT and Solvation R-Field were employed as standard. The Structure Preparation 
function was used to prepare, correct and protonate protein structures, which were then Energy 
Minimised. The Site Finder functionality was used to detect structural pockets available for 
ligand binding, dummies were created at the alpha sphere centres, and a molecular surface was 
generated within 4.5 Å of these dummy atoms using the Surfaces and Maps functionality, to 
enable visualisation of the pocket. 
Ligand databases, stored in SDF format, were imported and converted to MDB. The compounds 
were Energy Minimised using the Calculate Partial Charges, Add Hydrogens and Preserve 
Existing Chirality options. Pharmacophores were generated using the Pharmacophore Editor. 
2.7.1 KAT2A HAT Domain 
The isothiazolones and corresponding mercaptoacrylamides were docked into the structure of 
the Homo sapiens KAT2A HAT domain (PDB ID: 1Z4R)241 using the following options: 
 Protocol: Induced Fit 
 Receptor: Receptor+Solvent 
 Site: Dummy Atoms 
Pharmacophore: PH4 File 
Ligand: MDB File 
Placement: Alpha Triangle 
Rescoring 1: London dG 
Retain: 30 
Refinement: Forcefield 
Rescoring 2: GBVI/WSA dG 
Retain: 30 
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2.7.2 KAT2B Bromodomain 
The amides and sulphonamides were docked into the structure of the Homo sapiens PCAF BRD 
(PDB ID: 5FE8)240 using the following options: 
 Protocol: Rigid Receptor 
 Receptor: Receptor+Solvent 
 Site: Dummy Atoms 
Pharmacophore: PH4 File 
Template: Selected Atoms 
Ligand: MDB File 
Placement: Template Forcing 
Rescoring 1: London dG 
Retain: 30 
Refinement: Forcefield 
Rescoring 2: GBVI/WSA dG 
Retain: 30 
2.8 Protein Techniques 
2.8.1 Transformation and Expression 
SMC5 Head Domain Protein 
N-terminal His6-tagged SMC5 head domain protein was derived from construct AA5, comprised 
of the N- and C-terminal regions of SMC5 joined by a short linker. 
Harvested cells expressing His6-SMC5 head domain protein were generously provided by Dr 
Aaron Alt (Genome Damage and Stability Centre, University of Sussex). 
KAT2A BRD Protein 
His6-tagged KAT2A BRD construct was generously provided by Dr Antony Oliver (Genome 
Damage and Stability Centre, University of Sussex). 
Expressed 
Sequence 
MHHHHHHSSGVDLGTENLYFQSMELKDPDQLYTTLKNLLAQIKSHPSAWPFMEPVKKSEAPDYYE
VIRFPIDLKTMTERLRSRYYVTRKLFVADLQRVIANCREYNPPDSEYCRCASALEKFFYFKLKEGGLIDK 
 
The construct was transformed into competent BL21(DE3) cells (New England Biolabs Inc., 
Massachusetts, USA). 1 μL plasmid was added to 50 μL competent cells and they were incubated 
for 30 min on ice. The cells were transferred to a heating block for 45 s at 42 °C and returned to 
ice. 200 μL SOC medium (69319) (Novagen, Merck KGaA, Darmstadt, Germany) was added and 
the cells were incubated for 1 h at 37 °C, then spread on to Luria-Bertani Agar (10 g/L tryptone, 
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5 g/L yeast extract, 10 g/L NaCl, 15 g/L agar, pH 7.5) supplemented with ampicillin and incubated 
overnight at 37 °C. 
The transformed cells were grown in 50 mL of Turbo Broth™ (Molecular Dimensions Ltd, 
Newmarket, UK) supplemented with ampicillin, for ~4 h at 37 °C until OD600 nm > 1.0. This 
culture was used to inoculate 4 x 1 L of Turbo Broth™ supplemented with ampicillin, and the 
cells were grown at 37 °C with 220 rpm shaking. Protein expression was induced overnight with 
0.2 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 20 °C at OD600 nm > 1.5. Cultures were 
harvested by centrifugation (8,100 x g for 15 min at 4 °C) on a Beckman Coulter Avanti J-26 XP 
Centrifuge (California, USA), and then frozen and stored at -20 °C until later use. 
2.8.2 Protein Purification 
SMC5 Head Domain Protein 
Cells from 6 L of culture were thawed and re-suspended in 50 mL lysis buffer (50 mM HEPES pH 
7.5, 250 mM NaCl, 10 mM imidazole and 0.5 mM TCEP, supplemented with cOmplete protease 
inhibitor tablets (Roche Diagnostics Ltd, Burgess Hill, UK) and 10 μL benzonase), filtered using a 
Millex-GP syringe-driven filter unit, 0.22 μm pore size (Millipore Corporation, MA, USA). Cells 
were lysed by sonicating for 5 min, using a VCX Vibra-Cell™ ultrasonic processor (Sonics & 
Materials Inc., Connecticut, USA). The lysate was cleared by centrifugation (37,000 x g for 1 h at 
4 °C) on a Beckman Coulter Allegra™ 64R Centrifuge (California, USA). The supernatant was 
incubated with Talon® His-Tag Purification Resin (TaKaRa Bio, Saint-Germain-en-Laye, France), 
pre-equilibrated with lysis buffer, for 30 min at 4 °C, before washing with six column volumes of 
lysis buffer. The His6-tagged protein was eluted from the column using lysis buffer with 300 mM 
imidazole. Fractions were collected and monitored by SDS-PAGE using TruPAGE™ Precast Gels 
(Sigma-Aldrich Company Ltd., Dorset, UK) using gel run conditions of 200 V, 40 min, in TruPAGE™ 
Tris-MOPS SDS Express Running Buffer (Sigma-Aldrich Company Ltd., Dorset, UK). The 
appropriate fractions were recombined and the protein was concentrated to a volume of 10 mL 
using Vivaspin® 20 (10 kDa MWCO) centrifugal concentrators (Generon, Slough, UK). The His6-
tagged protein was further purified by size exclusion chromatography on a Superdex 200 size 
exclusion column (GE Healthcare, Illinois, USA), using a storage buffer of 20 mM HEPES pH 7.5, 
250 mM NaCl and 0.5 mM TCEP. The fractions were examined by SDS-PAGE and recombined 
appropriately. Finally, the protein was re-concentrated to 12 mg/mL, flash frozen in liquid 
nitrogen and stored at -80 °C until later use. Protein concentration was estimated using a 
NanoDrop™ 2000c Spectrophotometer (Thermo Fisher Scientific, Hertfordshire, UK). 
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KAT2A BRD Protein 
Cells from 4 L of culture were thawed and re-suspended in 50 mL lysis buffer (see Table 2.14, 
supplemented with cOmplete protease inhibitor tablets (Roche Diagnostics Ltd, Burgess Hill, 
UK)), filtered using a Steritop™ Filter Unit, 0.22 μm pore size (Merck KGaA, Darmstadt, 
Germany). Cells were lysed by sonicating for 5 min, using a VCX Vibra-Cell™ ultrasonic processor 
(Sonics & Materials Inc., Connecticut, USA). The lysate was cleared by centrifugation (40,000 x g 
for 1 h at 4 °C) on a Beckman Coulter Allegra™ 64R Centrifuge (California, USA). The supernatant 
was filtered using a Minisart® syringe-driven filter unit, 5 μm pore size (Sartorius Stedim Biotech, 
Aubagne, France), and incubated with Talon® His-Tag Purification Resin (TaKaRa Bio, Saint-
Germain-en-Laye, France), pre-equilibrated with lysis buffer, for 30 min at 4 °C, before washing 
with twenty column volumes of lysis buffer. The His6-tagged protein was eluted from the 
column using lysis buffer with 300 mM imidazole. Fractions were collected and monitored by 
SDS-PAGE using TruPAGE™ Precast Gels (Sigma-Aldrich Company Ltd., Dorset, UK) using gel run 
conditions of 200 V, 40 min, in TruPAGE™ Tris-MOPS SDS Express Running Buffer (Sigma-Aldrich 
Company Ltd., Dorset, UK). The appropriate fractions were recombined and if necessary the 
protein was treated overnight at 4 °C with TEV protease to remove the hexa-histidine expression 
tag, Table 2.14. The protein was concentrated to a volume of 10 mL using Vivaspin® 20 (5 kDa 
MWCO) centrifugal concentrators (Generon, Slough, UK) and further purified by size exclusion 
chromatography on a Superdex 75 size exclusion column (GE Healthcare, Illinois, USA), using 
storage buffer, see Table 2.14. The fractions were examined by SDS-PAGE and recombined 
appropriately. Finally, the protein was re-concentrated to ~10 mg/mL and stored at -80 °C until 
later use. Protein concentration was estimated using a NanoDrop™ 2000c Spectrophotometer 
(Thermo Fisher Scientific, Hertfordshire, UK). 
Table 2.14. Purification Details for KAT2A BRD Protein. 
Purpose Lysis Buffer Storage Buffer 
His6-Tag 
Cleaved 
Tm Shift 
50 mM HEPES pH 7.5, 250 mM NaCl, 
10 mM imidazole and 0.5 mM TCEP 
20 mM HEPES pH 7.5, 250 mM 
NaCl and 0.5 mM TCEP 
N 
NMR 
50 mM Sodium Phosphate pH 7.5, 
500 mM NaCl, 10 mM imidazole and 
0.5 mM TCEP 
20 mM Sodium Phosphate pH 
7.5, 500 mM NaCl, and 0.5 mM 
TCEP 
Y 
ITC 
50 mM HEPES pH 7.5, 500 mM NaCl, 
10 mM imidazole and 0.5 mM TCEP 
20 mM HEPES pH 7.5, 500 mM 
NaCl and 0.5 mM TCEP 
Y 
 
2.9 Screening Compounds 
Unless otherwise specified, small molecule compounds and fragments were prepared by 
colleagues in the Sussex Drug Discovery Centre (University of Sussex), or obtained from in-house 
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libraries, as solid samples or dissolved in DMSO at 10 mM (compounds) or 100 mM (fragments). 
The in-house fragment library is comprised of the Maybridge Ro3 2500 Diversity Fragment 
Library (Maybridge, Altrincham, UK) and the Life Chemicals 3D Fragments Library (Life Chemicals 
Inc., Niagara-on-the-Lake, Canada). Additionally, a library of quinolinone amides and 
sulphonamides was prepared by David Pearce (Automated High-Throughput Medicinal 
Chemistry and Synthesis Lab, University of Sussex). Other chemicals were of analytical grade and 
obtained from Sigma-Aldrich Company Ltd. (Dorset, UK). 
2.10 Isothermal Titration Calorimetry 
2.10.1 SMC5 Head Domain Protein 
Purified SMC5 head domain protein, stored at -80 °C, was thawed rapidly and dialysed into a 
buffer of 20 mM HEPES pH 7.5, 150 mM NaCl and 5 mM MgCl, using dialyzer tubes, D-Tube™ 
Dialyzer Midi, MWCO 3.5 kDa (Novagen, Merck KGaA, Darmstadt, Germany) and the protein 
concentration measured using a NanoDrop™ 2000c Spectrophotometer (Thermo Fisher 
Scientific, Hertfordshire, UK). 
ITC experiments were carried out on a MicroCal ITC200 (GE Healthcare, Illinois, USA), with a cell 
volume of 200 μL, and were performed at 30 °C in 20 mM HEPES pH 7.5, 150 mM NaCl and 5 mM 
MgCl, with the pH of the compound solutions adjusted by addition of Tris HCl pH 9.5 or HEPES 
pH 8.0. All titrations were conducted using an initial injection of 0.9 μL followed by ten identical 
injections of 3.8 μL at 240 s intervals. The dilution heats were measured in separate experiments 
and were subtracted from the titration data. The data was analysed using the MicroCal PEAQ-
ITC Analysis Software. The compound and protein concentrations employed are quoted 
alongside the resulting data. 
2.10.2 KAT2A BRD Protein 
Purified KAT2A bromodomain protein, stored at -80 °C, was thawed rapidly and dialysed into a 
buffer of 20 mM HEPES pH 7.5 and 150 mM NaCl, using BioDesignDialysis Tubing™, MWCO 
3.5 kDa (BioDesign Inc. of New York, USA) or Slide-A-Lyzer™ Dialysis Cassettes, MWCO 3.5 kDa 
(Thermo Fisher Scientific, Hertfordshire, UK), and the protein concentration measured using a 
NanoDrop™ Lite Spectrophotometer (Thermo Fisher Scientific, Hertfordshire, UK). 
ITC experiments were carried out on a MicroCal ITC200 (GE Healthcare, Illinois, USA) or a 
MicroCal PEAQ-ITC (Malvern Instruments, Worcestershire, UK), with cell volumes of 200 μL, and 
were performed at 30 °C (ITC200) or 25 °C (PEAQ-ITC) in 20 mM HEPES pH 7.5 and 150 mM NaCl. 
Titrations were conducted using an initial injection of 0.9 μL followed by ten identical injections 
of 3.8 μL at 240 s intervals (ITC200) or 0.4 μL followed by twelve identical injections of 3.0 μL at 
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150 s intervals (PEAQ-ITC). The dilution heats were measured in separate experiments and were 
subtracted from the titration data. The data was analysed using the MicroCal PEAQ-ITC Analysis 
Software and the single site binding model was employed to determine binding constants. The 
compound and protein concentrations employed are quoted alongside the resulting data. 
2.11 HAT Activity Assays 
2.11.1 Fluorescence Based Activity Assay 
Experiments with KAT2A were performed using the N-terminal GST-tagged form (KAT2A (GCN5), 
Active (K311-381G)) and histone H3 Peptide (1-21) (H12-58-500) from SignalChem (BC, Canada). 
Acetyl coenzyme A sodium salt, Fluorescein diacetate 5-maleimide and ThioGlo-5 were 
purchased from Sigma-Aldrich Company Ltd. (Dorset, UK), and Thiol Fluorescent Probe IV from 
Merck Millipore (Billerica, MA, USA). All other chemicals were of analytical grade and obtained 
from Sigma-Aldrich Company Ltd. (Dorset, UK). 
All experiments were conducted in black FLUOTRAC™ 384 well plates (781076) (Greiner Bio-
One, Kremsmünster, Austria) in a buffer of 50 mM HEPES, 0.1 mM EDTA, 0.01% Tween-20, pH 
7.5, with a final reaction volume of 40 μL. Individual assay components are listed alongside the 
resulting experimental data. Unless otherwise specified, when measuring enzyme activity, the 
reaction was initiated by addition of a mixture of the acetyl coenzyme A, histone H3 peptide and 
fluorescence indicator to the KAT2A. Fluorescence was monitored using a FlexStation® 3 
microplate reader (Molecular Devices, California, USA) with excitation and emission 
wavelengths as specified in Table 2.15. 
Table 2.15. Excitation and Emission Wavelengths for Fluorescence Indicators. 
Fluorescence indicator λex (nm) λem (nm) Cutoff (nm) 
Fluorescein diacetate 5-maleimide 340 540 530 
Thiol Fluorescent Probe IV 400 465 455 
ThioGlo-5 285 515 515 
 
2.11.2 EpiQuik™ Activity Assay 
All experiments were performed using GCN5L2 generously provided by the Structural Genomics 
Consortium (Toronto, Canada). The EpiQuik™ HAT activity assay kit (P-4003) was purchased from 
Epigentek (Farmingdale, NY, USA). All other chemicals were of analytical grade and obtained 
from Sigma-Aldrich Company Ltd. (Dorset, UK). 
HAT activity was measured using the EpiQuik™ calorimetric assay kit and the absorbance was 
read on a PHERAstar® FS plate reader (BMG Labtech, Ortenberg, Germany) at 450 nm. 
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2.12 KAT2A BRD Tm Shift Assay 
Experiments were performed with KAT2A BRD with and without a His6-tag, prepared in-house. 
SYPRO® Orange Protein Gel Stain, 5000x concentrate (S5692), was purchased from Sigma-
Aldrich Company Ltd. (Dorset, UK) and DMSO (D/4120/PB08) from Fisher Chemical (Thermo 
Fisher Scientific, Hertfordshire, UK). All other chemicals were of analytical grade and obtained 
from Sigma-Aldrich Company Ltd. (Dorset, UK). 
All experiments were conducted in white LightCycler® 480 96 well plates (04 729 692 001) 
(Roche Molecular Systems, CA, USA), with a final reaction volume of 20 μL. Buffers are specified 
in Table 2.16. Individual assay components are listed alongside the resulting experimental data. 
Post-optimisation, experiments were conducted at 5x SYPRO® Orange and 2 μM KAT2A BRD. 
SYPRO® Orange was added to a solution of the protein with or without 1 mM test compound 
and 2% DMSO and the plate was sealed using a clear LightCycler® 480 sealing foil (04729757001) 
(Roche Molecular Systems, CA, USA). The plate was equilibrated briefly on ice, before measuring 
the fluorescence whilst raising the temperature from 20 °C to 85 °C, using the LightCycler® 480 
Instrument, 96 well (05 015 278 001) (Roche Molecular Systems, CA, USA) with excitation and 
emission wavelengths 465 nm and 580 nm respectively. The protein melting temperature (Tm) 
was determined using the Roche Protein Melting Analysis Software and Tm shift values 
calculated by comparing the Tm of the protein with and without addition of compound.  
Table 2.16. Buffer Details for KAT2A BRD Tm Shift Assays. 
KAT2A BRD Species Buffer 
His6-KAT2A BRD 10 mM HEPES pH 7.5 and 100-700 mM NaCl 
KAT2A BRD 20 mM Sodium Phosphate pH 7.5 and 200 mM NaCl 
 
2.13 X-Ray Crystallography 
2.13.1 Crystal Growing in Hanging Drops 
His6-KAT2A bromodomain protein was predominantly crystallised in hanging drops, with 0.1 M 
Tris, pH 8.5 and 16% PEG 3350 at 5 mg/mL protein at 4 °C. 24 well VDX™ plates, pre-applied with 
sealant (HR3-170) (Hampton Research, California, USA), were prepared with 1 mL reservoir 
solution of 0.1 M Tris, pH 7.5 or pH 8.5 and 16%-20% PEG 3350. 1 μL protein, stored at -80 °C, 
was transferred to siliconized cover slips, 22 mm round (MD4-04) (Molecular Dimensions Ltd, 
Newmarket, UK) and 1 μL reservoir solution was added. The cover slips were inverted and 
pressed on to the wells to form a seal. The plates were incubated at 4 °C and crystal growth was 
monitored using a Leica M165 C microscope (Leica Microsystems, Wetzlar, Germany). 
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2.13.2 Crystal Soaking 
Ligand-bound structures were obtained predominantly via crystal soaking. Suitable crystals, 
selected dependent on their size and morphology, were soaked for 1 h at 4 °C in a 10 μL drop of 
reservoir solution supplemented with test compound, Table 2.17.  
Table 2.17. Crystal Soaking Conditions. Soaking conditions used to obtain ligand-bound structures of KAT2A BRD. 
Compound Compound Soaking Conditions 
UOS-21430 10 mM with 10% DMSO 
UOS-18715 100 mM with 20% Methanol 
UOS-28438 10 mM with 10% DMSO 
UOS-28625 10 mM with 10% DMSO 
UOS-28734 10 mM with 10% DMSO 
UOS-27986 100 mM with 20% DMSO 
UOS-31388 10 mM with 10% DMSO 
 
2.13.3 Co-Crystallisation 
UOS-31181-bound His6-KAT2A BRD was crystallised in sitting drops, with 0.1 M sodium acetate, 
pH 5.0 and 1.5 M ammonium sulphate at 6 mg/mL protein at 20 °C. UOS-31181 was added to 
His6-KAT2A BRD to afford a protein-ligand solution with 10 mM ligand at 33% DMSO 
(D/4120/PB08) (Fisher Chemical, Thermo Fisher Scientific, Hertfordshire, UK). MRC 2 drop well 
96 well crystallization plates, manufactured by Swissci (HR3-107) (Hampton Research, California, 
USA), were prepared using a Crystal Phoenix protein crystallography dispenser (Art Robbins 
Instruments, California, USA). Four 96-condition crystallisation screens were conducted with the 
JCSG-plus™ HT-96 (MD1-40), ProPlex HT-96 (MD1-42), Morpheus™ (MD1-47) and PACT 
premier™ HT-96 (MD1-36) commercial libraries (Molecular Dimensions Ltd, Newmarket, UK). 
50 μL reservoir solution was dispensed into each well and 0.15 μL protein-ligand solution into 
each drop well, to which 0.15 μL reservoir solution was added. Plates were sealed with ClearVue 
Sealing Sheets (MD6-01S) (Molecular Dimensions Ltd, Newmarket, UK) and incubated at 20 °C. 
Crystal growth was monitored using a Leica M165 C microscope (Leica Microsystems, Wetzlar, 
Germany). 
2.13.4 Diffraction Data Collection, Structure Solution and Refinement 
Crystals of suitable size and morphology were cryoprotected by successive soaking in reservoir 
solution supplemented with 10%, 20% and 30% ethylene glycol, mounted on to CrystalCap™ 
SPINE HT CryoLoops (Hampton Research, California, USA), and flash frozen in liquid nitrogen or 
examined immediately. 
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Table 2.18. Data Collection and Refinement Statistics. Statistics from single crystals of apo or ligand-bound KAT2A BRD. Averaged data presented alongside that for highest shell (in parentheses). 
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X-ray diffraction data was generously collected and analysed by Dr Mark Roe (X-Ray 
Crystallography Collaborative Research Facility, University of Sussex). The data was collected on 
the in-house X-ray system, consisting of a Rigaku MicroMax™-007 HF generator, VariMax-HF 
mirrors, Saturn 944+ CCD detector and Oxford Cryosystems 700 cryostream, or using 
synchrotron radiation at the Diamond Light Source on beamline I03. The diffraction images were 
indexed and integrated, the data scaled and averaged and the structures solved and refined. 
Data collection and refinement statistics were provided by Dr Mark Roe, Table 2.18. 
PyMOL 1.6232 was used to produce 3D representations of the protein structures. 
2.14 KAT2A BRD TR-FRET Assay 
Experiments were performed using N-terminal GST-fusion KAT2A bromodomain (RD-11-258), 
from CisBio (Bedford, MA, USA). Ligand-biotin compounds UOS-31490 and UOS-31670 were 
generously synthesised by Dr Lewis Pennicott (Sussex Drug Discovery Centre, University of 
Sussex). DMSO (D/4120/PB08) was purchased from Fisher Chemical (Thermo Fisher Scientific, 
Hertfordshire, UK). All other chemicals were of analytical grade and obtained from Sigma-Aldrich 
Company Ltd. (Dorset, UK). 
All experiments were conducted in white LUMITRAC™ 384 well low volume plates (784075) 
(Greiner Bio-One, Kremsmünster, Austria), at 1% DMSO concentration, with a final reaction 
volume of 20 μL and were incubated at room temperature. Fluorescence was monitored using 
a PHERAstar® FS plate reader (BMG Labtech, Ortenberg, Germany) with an HTRF® appropriate 
optic module, employing a 60 μs integration delay, 400 μs integration time and 300 flashes, with 
excitation wavelength 370 nm and emission wavelengths 620 nm and 665 nm. Results were 
expressed as HTRF® ratios, and negative controls, without GST-KAT2A, were used to assess non-
specific signal, to calculate the assay window and specific signal. 
 HTRF® ratio = (665 nm/620 nm) x 104 
 Assay window = HTRF® ratio positive / HTRF® ratio negative 
 Specific signal, HTRF® Δ ratio = HTRF® positive - HTRF® negative 
The data was analysed using either Microsoft Office Excel (2013) and GraphPad Prism version 
7.02243 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com, or the 
Studies and Vortex packages from Dotmatics Suite version 5.1244, Dotmatics Limited, Bishops 
Stortford UK, www.dotmatics.com. 
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2.14.1 Assay Design 
The EPIgeneous™ Binding Domain Discovery Kit (62BDDPEG) (Cisbio, Bedford, MA, USA) was 
utilised in assay design, to identify a suitable biotinylated ligand and determine the optimal 
combination of donor and acceptor dyes. Titrations of UOS-31490 or UOS-31670 and 
streptavidin -acceptor (SA-d2 or SA-XL665) at a ligand-biotin : SA-acceptor ratio of 8:1 were 
conducted as per the kit instructions, with 5 nM GST-KAT2A BRD and 1x anti-GST-donor cryptate 
(Eu3+ or Tb2+), using Binding Domain Diluent Buffer, Binding Domain Detection Buffer #1 and 
Binding Domain Detection Buffer #2 as appropriate. The plates were incubated for three hours. 
Three detector reagent pairings were assessed, anti-GST-Eu3+ with SA-d2, anti-GST-Eu3+ with SA-
XL665 and anti-GST-Tb2+ with SA-XL665. 
2.14.2 Assay Optimisation and Screening 
In assay optimisation and screening the interaction between GST-KAT2A BRD and ligand-biotin 
compound UOS-31670 was detected using anti-GST-Eu3+ (61GSTKLA) and SA-XL665 (610SAXLA) 
using Binding Domain Diluent Buffer (62DLBDDF) and Binding Domain Detection Buffer #1 
(62DB1FDG), all purchased from Cisbio (Bedford, MA, USA).  
For optimisation, assay conditions are listed alongside the resulting experimental data. In 
screening, 2.5 nM GST-KAT2A BRD, 80 nM UOS-31670, 0.313 ng anti-GST-Eu3+ and 10 nM SA-
XL665 concentrations were used. GST-KAT2A BRD in 4 μL Binding Domain Diluent Buffer was 
added using a Multidrop™ Combi Reagent Dispenser (Thermo Fisher Scientific, Hertfordshire, 
UK), to 2 μL compound in Binding Domain Diluent Buffer with 10% DMSO previously dispensed 
using an XPP-721 Automated Liquid Handler (FluidX, Manchester, UK). After 15 min, 14 μL of a 
solution of 4:5:5 UOS-31670 in Binding Domain Diluent Buffer : anti-GST-Eu3+ in Binding Domain 
Detection Buffer #1 : SA-XL665 in Binding Domain Detection Buffer #1 was added using the 
Multidrop™ Combi Reagent Dispenser. The plates were incubated for two hours before reading. 
Each compound was assayed in at least two independent experiments. 
For single point screens, compounds were tested at 1 mM final assay concentration and 
percentage inhibition was calculated relative to positive and negative controls on a per plate 
basis. For IC50 screens, ten-point dose-response compound titrations were prepared in 
duplicate. Percentage inhibition was calculated relative to the controls and IC50 values were 
determined by fitting the percentage inhibition versus compound concentration, constraining 
the upper and lower limits to 0% and 100%. 
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3 Assessing the SMC Complexes as Potential Targets for Tool 
Inhibitor Development 
The SMC complexes are critically important in regulating chromosome architecture and 
organisation and thereby coordinating chromosome condensation, sister chromatid cohesion, 
DNA repair, homologous recombination and transcriptional regulation. Their biological 
functions and mechanisms are not yet fully understood, but already they represent interesting 
oncology targets, particularly due to their roles in DNA repair. As such, they are compelling 
targets for development of tool inhibitors, which will enable biological investigation and 
potentially initiation of drug discovery projects. 
In this chapter, the druggabilities of the core SMC proteins and NSE subunits of SMC5/6, and 
cohesin SMC1 and SMC3 were assessed, with the aim to advance to design and characterisation 
of tool inhibitors for any of the proteins deemed druggable. However, at the time at which this 
research was completed, the SMC5/6 and cohesin complexes were established as not druggable, 
within the constraints of accessible resources. 
3.1 Introduction 
Every human cell contains approximately four meters of DNA that needs to be meticulously 
packed into the cell nucleus, which has an average diameter of just 6 μm. Moreover, at cell 
division this DNA must be further compacted into mitotic chromosomes. This compaction is 
carefully regulated during the cell cycle, Figure 3.1, and is dependent on an array of facilitator 
proteins, which associate with the DNA to build chromosomes. The structural maintenance of 
chromosomes (SMC) proteins are principal chromosomal constituents that regulate 
chromosome architecture and organisation. By virtue of this, they function in a variety of cellular 
processes including chromosome condensation, sister chromatid cohesion, DNA repair, 
homologous recombination and transcriptional regulation.245  
The first SMC protein reported was Escherichia coli mukB in 1991.246 Niki et al. observed that 
mukB mutants exhibit anucleate cells, and used computational analysis to predict that the 
protein structure comprised of three globular domains interspaced by two α-helical coiled-coil 
regions. They also noted that the amino-terminal domain contained a nucleotide binding 
sequence. Soon after, SMC1 was identified in Saccharomyces cerevisiae247, and SMC2 and SMC4 
in Xenopus laevis248, where it was also recognised that these associate to form a heterodimer. 
SMC6, originally known as RAD18, was first identified in Schizosaccharomyces pombe.249 Genes 
encoding similar SMC proteins have subsequently been found in a wide variety of organisms.245  
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Figure 3.1. Schematic of the Cell Cycle. 
It is now well established that these widely conserved proteins form dimeric structures, which 
in turn associate with regulatory subunits to form large protein complexes. While it seems most 
prokaryotes have just one SMC protein that forms a homodimer, eukaryotes have at least six, 
which interact to form three heterodimers.250,251 SMC1 and SMC3 are the central components 
of the cohesin complex, which mediates sister chromatid cohesion and is required for proper 
chromosome segregation at cell division.252 SMC2 and SMC4 constitute the core of the 
condensin complex that is essential for chromosome condensation during mitosis.253 The third 
heterodimer is composed of SMC5 and SMC6, whose sequences are substantially divergent from 
those of SMC1-4. The SMC5/6 complex has multiple roles in DNA repair254–256 and checkpoint 
signalling.257 Interestingly, while the SMC genes are each essential for eukaryotic life, the three 
heterodimers exhibit partly overlapping roles. For example, cohesin can aid in chromosome 
condensation258 and both cohesin and condensin have roles in DNA repair.259,260 
All SMC proteins share a common architecture. They are composed of about 1,000 amino 
acids251, self-folded by antiparallel coiled-coil interactions to create rod-shaped molecules. The 
long stretches of coiled-coil are flexible, due to discontinuities245, and are connected at one end 
to an ATP-binding cassette (ABC)-like head domain and at the other to a hinge domain250, Figure 
3.2 (a). Nucleotide-binding Walker A and Walker B motifs reside separately in the N- and C-
termini respectively, which together compose the globular ATPase head domain.251 Two SMC 
subunits interact tightly at their hinge domains to produce a V-shaped heterodimer.261 ATP 
binding at the SMC heads then promotes formation of the characteristic ring-shaped dimer. The 
head domains form nucleotide-sandwiched dimers in which two molecules of ATP reside at the 
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interface, each bound via α and β phosphates to the Walker A motif of one SMC subunit and via 
the γ phosphate to the Walker B motif of the second.224 Engagement and disengagement of the 
ATPase heads is controlled by binding and hydrolysis of ATP, which is thought to play a vital role 
in the dynamic interactions of SMC proteins and DNA262, Figure 3.2 (b). 
In addition to the ATP-dependent binding, the SMC heads are held together by ‘kleisin’ 
subunits.245 These kleisins are less well conserved than the SMCs. They make asymmetric 
contacts with the SMC proteins, with the N-terminus forming a helix bundle with the coiled-coil 
adjacent to one SMC head domain, while a winged-helix domain at the C-terminus interacts with 
the bottom surface of the ATPase domain of the other.263,264 Additional non-conserved subunits 
assemble around the kleisin.245 The bridging kleisin can cause the SMC complexes to appear as 
closed ring structures by electron microscopy.265 As might be implied by this shape, according to 
the ‘embrace’ model, these complexes bind DNA by topological embrace. There is evidence that 
the eukaryotic SMC complexes are linked to minichromosomes in vivo and it seems that 
topological entrapment is essential for complex function.266–268 This does not preclude additional 
functions not reliant on topological linking.245 
 
Figure 3.2. Structure of SMC Heterodimers. Each SMC subunit is self-folded by antiparallel coiled-coil interactions to 
create a rod-shaped molecule with a hinge domain at one end and an ATP-binding head domain at the other. (a) Two 
SMC subunits interact tightly at their hinge domains to produce a V-shaped heterodimer. (b) ATP binding at the SMC 
heads drives formation of nucleotide-sandwiched dimers with two molecules of ATP at the interface. Engagement 
and disengagement of the ATPase heads is controlled by binding and hydrolysis of ATP. Figure adapted from Losada 
& Hirano, 2005.250 
Most of the time SMC complexes are in dynamic contact with chromosomes, with the notable 
exception of cohesin on sister chromatids following DNA replication.269 If the complexes function 
by topological binding to DNA, this provokes the question of how the DNA enters and exits the 
ring. In attempt to identify the mechanism of cohesin loading and unloading on DNA, individual 
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subunit interfaces can be sealed by covalent linkage or ligand-induced dimerisation.245 Using this 
approach it was ascertained that DNA loading is dependent only on the SMC hinge domain 
interface, which would suggest that DNA enters via the cohesin hinge.270,271 Contrastingly, 
locking the SMC3-kleisin interface stabilised the cohesin on the chromosome, suggesting a role 
for this interface in DNA exit.271 However, crosslinks and ligand-induce dimerization can affect 
protein function in ways other than the intended interface closures, so these results should be 
interpreted with caution.245 A different model has since been proposed, founded on in vitro 
experiments reconstituting cohesin loading on to DNA in S. pombe.272,273 From these it was 
suggested that loading and unloading follow similar routes, regulated by the tripartite ring 
structure of the SMC complex, which establishes two sequential interlocking gates. Initially, 
DNA-sensing lysine residues on the SMC3 head trigger ATP hydrolysis, which promotes the 
disengagement of the ATPase head, allowing DNA to move through this first barrier. Once the 
ATP is replenished and therefore the head interaction is re-engaged, the kleisin N-terminus 
dissociates from SMC3, allowing the DNA to pass fully into or out of the ring. Importantly this 
model of interlocking gates also explains earlier observations. Covalently linking SMC3 and the 
kleisin is not sufficient to prevent DNA from interacting with the complex because the DNA is 
still able to pass through the ATPase gate and thereby interact with cohesin, however, this will 
impede the exit of any DNA secured within the ring by the kleisin.273 Contrastingly, if the kleisin 
is mutated to inhibit binding with SMC3, the cohesin complex is capable of interacting with 
chromatin but the interaction is unstable, as one of the two gates has been destroyed.274 The 
DNA-sensing lysine residues on SMC3 point into the ring, which is ideal for DNA exit but awkward 
for DNA entry. As DNA is relatively stiff, presumably the flexible cohesin must fold to expose the 
lysines to initiate loading, Figure 3.3.245,273 It is likely that the entry and exit of DNA from the 
other SMC complexes involves similar reactions. Both cohesin and condensin have been 
observed by atomic force microscopy in the folded conformation suggested for DNA entry275,276, 
and in SMC5/6 non-SMC element 5 (NSE5) and NSE6 have been reported to bind to both the 
head and hinge, which is possible only if the two come into close proximity.277,278 This model for 
DNA loading and unloading however remains just that. There are still many unanswered 
questions. For example, recent publications suggest that while head engagement is critical for 
cohesin unloading, ATP hydrolysis is possibly not.279 Perhaps the SMC-kleisin interaction is less 
favourable when the SMC heads are engaged and dissociates simply due to steric effects.280 
SMC complexes appear to concentrate at centromeres and at discrete locations on chromosome 
arms.281–283 In S. cerevisiae it appears that the accumulation of Cdc7-Dbf4 kinase, facilitated by 
the COMA (Ctf19-Okp1-Mcm21-Ame1) complex, serves to enrich centromeric cohesin, by 
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recruitment of the cohesin loader complex.284 Condensin enrichment is promoted by 
centromere protector shugoshin.285 Along the chromosome arms, SMC complex loading occurs 
most frequently at promoters of highly expressed genes.286,287 It is not known what defines these 
sites, although they are often associated with transcription factors.245 However, it has been 
shown that the ‘remodelling the structure of chromatin’ (RSC) complex, which is recruited to 
open reading frames of actively transcribed genes, in turn recruits the cohesin loader 
complex.288 Condensin and cohesin are typically loaded at the same DNA sites.287 Although 
condensin is not known to interact with the cohesin loader it appears that this loader complex 
helps to facilitate its binding282, potentially by maintaining nucleosome-free regions at promoter 
sites.288 Condensin is also known to interact with TFIIIC (transcription factor for polymerase III 
C) and TATA-box binding protein (TBP), which are involved in recruiting RNA polymerase III to 
transcribe small untranslated RNAs289, and with components of the monopolin complex, which 
is responsible for maintaining the integrity of ribosomal DNA (rDNA).290 These interactions can 
target condensin to tRNA (transfer RNA) genes and rDNA. 
After the SMC complexes are loaded it appears that they translocate, retaining topological 
contact, to reside more permanently at sites of convergent transcriptional termination, between 
genes that are transcribed in converging directions.291 Accordingly, in S. pombe, the majority of 
cohesin resides at convergent transcriptional terminators, with a smaller amount coinciding with 
the cohesin loader.292 In human cells, cohesin commonly accumulates at sites of the CCCTC-
binding factor (CTCF)293, the vast majority of which are inter- or intra-genic.294 In humans, it is 
unlikely that cohesin will be able to traverse an entire gene before disengaging from the DNA.245 
However, acetylated cohesin, which enjoys a longer residence time, appears to accumulate at 
downstream regions of genes.295 Analogously, condensin exhibits a bimodal distribution at 
transcription start and end sites296, and appears to translocate from loading sites in a similar 
transcription-dependent fashion, albeit with reduced processivity.282 The distribution of SMC5/6 
also appears to be similar, although uniquely, the complex is particularly highly associated with 
chromosome arms around DNA replication and loading is quantitatively correlated with 
chromosome length.283 It appears therefore that translocation is common to the SMC 
complexes, and it is seems to represent an effective mechanism to implement their structural 
functions without impeding other chromosomal activities.245  
It is clear that further investigation is critical to improve understanding of these mechanisms of 
action, making the SMC complexes compelling targets for tool inhibitor development. 
Considering the data, it is reasonable to expect that a small molecule that interacts with either 
the hinge or head domains will impact complex function and be of significant scientific interest. 
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Figure 3.3. Model for DNA Exit from and Entry to the Cohesin Ring. (a) For DNA exit, lysine residues on the SMC3 
head sense the DNA and trigger ATP hydrolysis to promote disengagement of the ATPase head, allowing DNA to pass 
through. ATP is then replenished, the head interaction is re-engaged and the kleisin dissociates from SMC3, allowing 
the DNA to exit the ring. (b) DNA entry occurs by a similar route but because the lysines point into the ring, this 
requires the cohesin complex to fold around the DNA, so as to expose these DNA-sensing residues. Figure adapted 
from Uhlmann, 2016.245 
3.1.1 Cohesin 
Cohesin is composed of two core SMC proteins, SMC1 and SMC3 and two non-SMC proteins, 
RAD21/SCC1 (sister chromatid cohesion protein 1) and SCC3251, Figure 3.4. Vertebrates have two 
SCC3 paralogues, stromal antigen 1 (SA1) and stromal antigen 2 (SA2). Cohesin-SA1 is specifically 
involved in telomere cohesion, whereas cohesin-SA2 is responsible for cohesion at 
centromeres.297 SCC1 is a member of the kleisin family298, which, as discussed, interacts with the 
head domains of SMC3 and SMC1 via its N- and C-termini respectively to form a tripartite ring.222 
The HEAT repeat protein SCC3 interacts with SCC1, serving to further strengthen the cohesin 
ring structure.251 It is understood that cohesin topologically embraces DNA within this ring.266  
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Although the primary function of cohesin is in regulating sister-chromatid cohesion, during the 
G1 phase it also engages in dynamic interactions between DNA binding sites, assisting in defining 
the spatial conformation of specific loci.299 The complex is loaded on to chromatin by the SCC2-
4 cohesin loader. Recruitment is likely via the SCC4 subunit, which serves as the chromatin 
adapter, to localise the loader to the DNA, while the SCC2 contacts cohesin.300 Cohesin unloading 
is dependent on Wapl (wings apart-like protein homologue), which dissociates the SCC1 N-
terminus from SMC3, thereby opening the kleisin gate.273 In the absence of Wapl, cohesin is 
turned over more slowly, causing chromosomes to compact into wormlike ‘vermicelli’.258  
 
Figure 3.4. Structure of the Cohesin Complex. Structure comprised of core SMC proteins, SMC1 and SMC3 and two 
non-SMC proteins, kleisin SCC1 and HEAT repeat protein SCC3. Figure adapted from Losada & Hirano, 2005.250 
Post-replication cohesin becomes cohesive, topologically embracing sister chromatids within its 
ring to maintain their cohesion.266 This enduring sister chromatid cohesion is established during 
S phase by acetylation of conserved lysine residues on the SMC3 ATPase head by ECO1 
(establishment of cohesion protein 1).301 It appears that this acetylation locks the cohesin ring 
by preventing DNA from triggering ATP hydrolysis and by recruiting sororin to inhibit the 
complex from interacting with Wapl, which in combination would complete the dynamic binding 
and dissociation cycle.302,303 The obvious predicament here is that successful DNA loading 
requires active DNA-sensing lysines. As a result, acetylation must be postponed until both 
chromatids are adequately associated with the cohesin complex. 
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There are two plausible mechanisms that could enable co-entrapping of two sister DNA strands 
by cohesin. One possibility is that replication forks can pass through cohesin rings. In this case, 
acetylation at any time prior to or during fork passage would establish sister-chromatid 
cohesion. The second is that acetyltransferases follow immediately behind replication forks, 
such that as cohesin establishes links between the sister chromatids, which are naturally in close 
proximity, these are stabilised.245 It is likely that both of these mechanisms contribute to 
establishing cohesion. The two human ECO1 paralogues, ESCO1 (establishment of cohesion 1 
homologue 1) and ESCO2 (establishment of cohesion 1 homologue 2), contribute non-
redundantly to sister chromatid cohesion. While ESCO2 interacts with replication machinery and 
therefore likely follows behind a replication fork304, ESCO1 acetylates cohesin as early G1, 
independently of DNA replication.305  
As cells enter mitosis, cohesin must be removed from the chromosomes to enable proper 
chromosome segregation. By necessity this dissociation is tightly regulated and occurs during 
two phases of mitosis.306 The majority of cohesin from the chromosome arms is removed in the 
‘prophase pathway’. Mitotic kinases phosphorylate sororin, to destabilise its interaction with 
cohesin, enabling the complex to be unloaded by Wapl.307,308 The sororin at the centromeres 
however is protected from phosphorylation throughout prophase by shugoshin. Cohesion is 
therefore maintained here until SCC1 is cleaved at the metaphase-anaphase transition by a 
protease named separase.308,309  
Cohesin also has additional cellular roles in DNA damage response. SCC1 was in fact first 
identified because its mutation in S. pombe resulted in cells which were hypersensitive to UV 
and IR radiation.260 It is understood that cohesin has a specific and vital role in repair of DNA 
double stranded breaks via sister chromatid homologous recombination during S and G2 phases 
of the cell cycle.310 HR-mediated DSB repair requires an undamaged DNA template. During the 
mitotic cell cycle, use of the sister chromatid is preferred in order to prevent potential loss of 
heterozygosity. It is likely that sister-chromatid cohesion near to the DSB, which keeps the 
undamaged chromatid in close proximity, should promote strand invasion and therefore DSB 
repair by HR.251 The observed recruitment of cohesin to DSBs supports this suggested role in 
DNA repair.311 Furthermore, a study in S. pombe indicated that use of non-cleavable SCC1 or 
inactivation of separase hindered DNA repair at G2, indicating a necessary requirement for 
cohesin cleavage by separase in DNA repair.312 Further studies have implicated cohesin in DNA 
damage checkpoint activation at S-phase313 and more recently at G2/M.314 
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3.1.2 Condensin 
In vertebrates there are two different condensin complexes, condensins I and II. These 
complexes are composed of five subunits: the core SMC proteins, SMC2 and SMC4, which are 
common to both, and three chromosome-associated proteins (CAPs). Condensin I incorporates 
CAPD2, CAPH and CAPG, while condensin II contains CAPD3, CAPH2 and CAPG2250, Figure 3.5. 
CAPH and CAPH2 are members of the aforementioned kleisin family298, while CAPD2, CAPD3, 
CAPG and CAPG2 contain HEAT repeats, which serve as flexible scaffolding to afford secure 
protein-protein interactions315 and are suggested to elicit DNA binding activity.316 Available data 
suggests that, like SCC1, the kleisins bind across the SMC subunits. The N-terminal half of 
CAPH/H2 links CAPD2/D3 to SMC2 and the C-terminal half links CAPG/G2 to SMC4. There is no 
direct interaction between the HEAT subunits and SMC proteins.317,318 Unlike in cohesin, where 
the SMC coiled-coil arms are spread apart, in condensin they often appear closer together such 
that with the regulatory subunits bound at the head domain the complex resembles a 
tadpole.265,275 However, it seems this rod-like structure opens to a ring upon DNA binding.319 
 
Figure 3.5. Structures of the Condensin Complexes. Structures comprised of core SMC proteins, SMC2 and SMC4 and 
three non-SMC proteins, kleisins CAPH or CAPH2 and HEAT repeat proteins CAPD2 or CAPD3 and CAPG of CAPG2. 
Figure adapted from Losada & Hirano, 2005.250 
The primary role of condensins is in chromosome condensation during mitosis. Although both 
play essential roles in mitotic chromosome architecture and segregation, condensins I and II 
display different behaviours during the cell cycle320 and different roles in condensation. 
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Condensin II is present on DNA throughout interphase and concentrates at prophase 
chromosomes, suggesting that it participates in early stage chromosomal condensation. 
Condensin I however only concentrates on chromosomes after nuclear envelope breakdown 
(NEBD) at prometaphase.321 Until recently it was believed that condensin I is segregated to the 
cytoplasm and therefore only gains access to chromosomes after NEBD, however it is now 
understood that a small pool of condensin I persists in the nucleus during G1, which is gradually 
lost during S and G2.322 During prometaphase the condensins work in tandem to afford well 
resolved sister chromatids by metaphase, which enables them to be successfully separated at 
anaphase.323 Condensin I appears to be responsible for lateral compaction and in its absence the 
mitotic chromosomes become wider and shorter, whereas if cohesin II is removed, a loss of axial 
condensation is evident with longer and less rigid chromosomes.324 
The interaction of condensin with DNA is less well understood than that of cohesin. In 2011 
Cuylen et al. showed that circular minichromosomes linked to condensin disengaged upon either 
proteolytic opening of the condensin or linearization of the DNA, suggesting that condensin 
topologically entraps DNA.267 There is accumulating evidence that ATPase activity is essential for 
condensin binding to DNA. ATP binding mutations at the Walker A or Walker B motifs of SMC2 
or SMC4 prevent condensin loading, while ATP hydrolysis mutations permit loading but disrupt 
condensin localisation and higher order structure.325,326 There is also data to suggest that the 
HEAT subunits316 and the SMC hinge domains327 influence DNA binding.   
The molecular mechanism of action of the condensins is hotly debated. Condensin has two well-
described enzymatic functions: ATPase-dependent positive supercoiling of dsDNA and ATP-
independent DNA reannealing.321 It has been shown that condensin is able to introduce positive 
supercoils in DNA.328 Such large-scale folding of chromatin intensifies torsional stress in the 
DNA329, which must be relieved periodically to allow folding to continue. Topoisomerases such 
as Top2 (topoisomerase II) are therefore essential for hypercompaction of chromosomes.330 
Top2 also serves to decatenate DNA as it is condensed331, to facilitate individualisation and sister 
chromatid resolution. The reannealing activity of condensin is necessary to eliminate unwound 
DNA generated by transcription, which is believed to be essential for successful supercoiling.296 
As a result, classically, an integrated model is speculated323, in which condensin generates 
dsDNA by inducing reannealing276 and introduces supercoils to cause superhelical tension332, 
thereby promoting Top2-mediated decatenation333 and chromosome resolution. Continued 
positive supercoiling could then cause the formation of chiral loops, which could subsequently 
be organised into a solenoidal structure by higher order assembly.334 In support of this model, 
in cross sections of mitotic chromosomes, strands comprised of condensin, topoisomerase II and 
91 
Chapter 3 
KIF4A (kinesin family member 4A) are visible in the central core.335 These strands could represent 
the central scaffold structure associated with higher order assembly. 
The lack of a molecular explanation for how such a central scaffold would form, has led to the 
proposal of alternative models for the condensin mechanism of action. One such model is built 
on the observation of condensin at the intersections of 10 nm fibres.336 This has resulted in the 
proposal that condensin functions by stochastically crosslinking freely diffusing chromatin 
fibres.245 Ab initio simulations of a chromosome constrained by stochastic interactions between 
condensin-binding sites, successfully generate behaviour closely resembling that observed in 
vivo.337 Another popular model for condensin action is the loop extrusion model. This suggests 
that condensin binds at two nearby points on DNA and slides in such a way as to gradually 
generate large loops. Polymer simulations of chromosome dynamics have been used to show 
that condensin could bind to two adjacent loci and slide the contacts in opposite directions to 
create such extruded loops.338  
Like cohesin, condensin has additional roles in DNA damage response. In 2002 an S. pombe 
temperature-sensitive cnd2 (orthologous to human CAPH) mutant was isolated. As well as the 
expected mitotic chromosome condensation defects, the mutant displayed increased sensitivity 
to UV, hydroxyurea and methyl methanesulfonate and a defect in activation of CHK2, a 
checkpoint kinase which is activated in response to DNA damage.259 These results suggest a role 
for condensin in replication checkpoint control and DNA repair. Since this, the human condensin 
complexes have also been implicated in DNA repair. Condensin I appears to be involved in repair 
of DNA single-stranded breaks in association with PARP1 and XRCC1339, whereas condensin II is 
thought to have a role in HR repair of DSBs in association with MCPH1 (microcephalin 1).340 In 
addition to being directly involved in DNA repair to help maintain genome integrity, it has been 
found that in yeast condensin prevents unwanted intrachromosomal HR at the rDNA locus and 
controls rDNA stability.341 Such dysregulation of ribosome biogenesis has been linked to cancers 
and other human diseases.251 
3.1.3 SMC5/6 
The human SMC5/6 complex comprises of two core SMC proteins SMC5 and SMC6, as the name 
suggests, and four non-SMC elements, NSE1, 2, 3 and 4, Figure 3.6.342 SMC5 and SMC6 are 
substantially divergent from SMC1-4. NSE3 and NSE4 independently bind at the head domains 
of SMC5 and SMC6. NSE4 is another member of the kleisin protein family, which binds across 
the SMC head domains.277 NSE3, also known as MAGEG1, belongs to the MAGE (melanoma-
associated antigen) protein class, which are overexpressed in certain cancers. MAGE proteins 
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have suggested functions in cell cycle regulation, apoptosis and neuronal development.343 NSE3 
interacts with NSE1 which contains a RING (really interesting new gene) finger domain that 
confers ubiquitin ligase activity.344 Interestingly, NSE1 and NSE3 are similar in structure to the 
prokaryotic SMC subunits ScpB and MukE, which may suggest functional similarities between 
SMC5/6 and the prokaryotic SMC complex.345 Finally, uniquely, SMC5/6 incorporates a small 
ubiquitin-like modifier (SUMO) ligase, NSE2. NSE2 binds to the SMC5/6 dimer independently of 
NSE1, 3 and 4, through interaction with the SMC5 coiled-coil.346 It promotes the covalent 
attachment of SUMO to proteins. This SUMOylation activity is required in DNA damage 
response, playing a key role in maintaining genomic stability.347 While NSE2 is essential, its 
SUMO ligase activity does not appear to be.226 In humans, NSE2 does not affect the stability of 
the SMC5/6 complex, but the SUMO-ligase activity is executed only within the context of the 
complex.343 
 
Figure 3.6. Structure of the SMC5/6 Complex. Structure comprised of core SMC proteins, SMC5 and SMC6 and four 
non-SMC proteins, kleisin NSE4, SUMO ligase NSE2 and ubiquitin ligase NSE1-NSE3.  
The function of the SMC5/6 complex is less well understood than that of cohesin and condensin. 
It is known to play a prominent role in DNA repair by recombination. SMC6 was first identified 
via a screen for radiation-sensitive mutations in S. pombe348 and further studies have shown that 
mutation of any of the subunits of the SMC5/6 complex induces hypersensitivity to DNA damage 
agents.343,347,349 In particular, SMC5/6 is found to be recruited to DSBs where it promotes repair 
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by sister-chromatid HR, possibly in conjunction with cohesin.255 In addition, the complex has 
been shown to be involved in repair of collapsed replication forks, such that inactivation causes 
accumulation of X-shaped HR intermediates254, and resolution of sister-chromatid linkages 
during mitosis.350 These investigations indicate that the SMC5/6 complex promotes HR-
dependent rescue of stalled replication forks.251 Like condensin, the SMC5/6 complex also has a 
suggested role in maintaining rDNA stability by helping to prevent unwanted HR at the rDNA 
locus, thereby suppressing recombinational loss of rDNA repeats.351 
It is unlikely though that DNA repair is the essential function of SMC5/6, as other recombination 
proteins are dispensable for eukaryotic survival.352 The search for the true essential function of 
the complex is ongoing. A study aimed at examining the function of SMC5/6 throughout the cell 
cycle determined that the complex associates with chromatin during interphase but largely 
dissociates at mitosis. Depletion of SMC5/6 was observed to cause deformation of sister 
chromatids, abnormal Top2 distribution to distal arms rather than centromeres, and defective 
chromosomal segregation. Interestingly, this damage can be substantially alleviated by allowing 
the cells extra time to complete DNA replication before mitosis by subjecting them to G2 arrest. 
This could suggest that SMC5/6 depletion either slows DNA replication or provokes a temporal 
disconnection between replication and chromosome assembly, possibly due to defective 
checkpoint control.353 Congruous with these findings, another recent study revealed that the 
essential functions of SMC5/6 manifest selectively in G2/M. Critical roles of SMC5/6 were 
identified in facilitating replication past replication fork barriers (RFBs), and metabolising DNA 
damage tolerance (DDT) intermediates, formed in response to endogenous replication stress, 
such as the RFBs. This suggests that SMC5/6 expedites replication whilst helping to regulate 
genome integrity.354  
Others have also noted chromosome segregation errors resulting from SMC5/6 depletion. 
Cohesin is the main constituent of chromatid cohesion. However, Farcas et al. have shown that 
cohesin inhibits Top2 from resolving sister chromatid intertwinings (SCIs), suggesting that these 
could also contribute to cohesion.355 SCIs arise behind replication forks when the advancing fork 
occasionally rotates with the turn of the DNA helix. This leaves the sister chromatids entwined 
and if left unresolved will prevent chromosome segregation during mitosis. In 2014, Jeppsson et 
al. showed that cohesin and cohesion motivate the chromosomal association and localization of 
SMC5/6, which interacts at SCIs and facilitates their Top2-independent resolution.283 
Other novel roles of the complex are still being discovered. A genome-wide analysis of the 
replication dynamics of a S. cerevisiae SMC6 mutant has recently been conducted.356 The study 
highlighted roles of SMC5/6, firstly in preventing misincorporation of ribonucleoside 
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monophosphates (rNMPs) into DNA, and secondly ensuring proper DNA repair after incision to 
remove any rNMPs incorporated erroneously. The mutant was observed to incorporate 
ribonucleotides and accumulate ssDNA gaps, capable of producing toxic HR intermediates.356  
How SMC5/6 interacts with DNA and chromosomes also remains elusive. In 2011, Roy et al. 
reported that SMC5 and SMC6 preferentially bind ssDNA357,358, consistent with their roles in DNA 
repair. Concordantly, last year it was demonstrated that the SMC5/6 hinge has significantly 
higher affinity for ssDNA than dsDNA.223 In this publication, Alt et al. determined the X-ray crystal 
structure of the S. pombe SMC5/6 hinge. They identified two features, a ‘molecular latch’ and a 
‘hub’, which are critical for proper SMC5/6 function. The ‘latch’ comprises of 13 amino acids, 
607-619, of SMC5, which compose an extended β-hairpin that makes several interactions with 
the SMC6 hinge. The ‘hub’ is the cluster of interacting SMC6 residues, residing at the junction of 
the SMC6 arm and globular hinge domain. They speculate that the distinctive structure of 
SMC5/6 facilitates dynamic loading and unloading. Interestingly, it was not possible to fit the 
experimental data to a 1:1 binding model. The authors instead suggest that the association and 
dissociation of SMC5/6 is biphasic, with ssDNA making a primary interaction with SMC5-
R609/R615 at the latch, and a secondary interaction with residues at the hub.223 
While it seems SMC5/6 preferentially binds ssDNA, it is also known that the ATPase activity of 
the complex is stimulated chiefly by dsDNA and only to a lesser extent ssDNA.359 In 2015, Kanno 
et al. were able to show that purified SMC5/6 binds dsDNA via a mechanism dependent on ATP 
hydrolysis.268 They observed that the association of SMC5/6 with circular, but not linear, DNA 
was resistant to high salt concentrations, suggestive of a topological interaction. Additionally, 
they established that the interaction promotes Top2 dependent catenation, indicating that the 
complex can tether two DNA molecules. They therefore suggest that SMC5/6 acts to 
interconnect DNA molecules via ATP-regulated topological entrapment, potentially actually 
inducing SCIs behind the fork to facilitate fork rotation and expedite replication.268 In 2016, 
Zabrady et al. described a novel DNA-binding mode of SMC5/6 via its NSE1/3/4 subcomplex.360 
They determined that the NSE3 protein binds to dsDNA via its evolutionarily conserved C-
terminal winged-helix domain. NSE1 and NSE4 may also interact with the DNA. Disruption of the 
DNA-binding ability of NSE3 is lethal in S. pombe, analogous to gene deletion.360 In the 
knowledge that SMC5 and SMC6 preferentially bind ssDNA357,358, but ATP hydrolysis is provoked 
by dsDNA359, the authors suggest that the NSE subunits interact with dsDNA and subsequently 
stimulate ATPase activity at the SMC heads.360  
If any SMC5, SMC6 or NSE mutations prove non-lethal, the SMC5/6 complex may also become 
a plausible target for design of a novel cancer therapeutic utilising a synthetic lethality approach. 
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As discussed in Chapter 1.3, such an approach is reliant on genetic interactions of two mutations 
for which neither mutation alone will kill cells, but that in combination render them inviable. 
This could create an opportunity to selectively kill cancer cells that harbour mutations in genes 
synthetic lethal with SMC5/6 by mimicking the effect of the SMC5/6 mutation using targeted 
drug therapy. 
It is also established that SMC5/6 has a role in the alternative lengthening of telomeres (ALT) 
pathway.361 Telomeres are proteinaceous, repetitive DNA elements, attached at the end of each 
chromosome362, which are shortened at every cell division owing to the end-replication problem 
of the lagging strand.363 Ultimately, shortened telomeres result in cell senescence and as such 
this effectively limits the proliferative potential of the cell.364 As discussed in Chapter 1.2, by 
upregulating telomerase transcription, which is repressed in normal somatic cells, cancer cells 
can overcome this limitation, affording them replicative mortality.365 10-15% of cancer cells 
however rely on the ALT pathway instead of telomerase reactivation.366 Here HR between 
telomeric sequences is used to elongate telomeres.367 One defining feature of ALT cells is that 
telomeres become localised to promyelocytic leukaemia (PML) bodies, named ALT-associated 
PML bodies (APBs).368 It has been shown that SMC5/6 is required for telomere recombination 
and APB formation. In particular NSE2 appears to be responsible for SUMOylation of several 
shelterin subunits.361 The shelterin complex is responsible for protecting telomeres from being 
recognised as DSBs and therefore preventing telomere HR.369 SUMOylation often changes 
protein-protein interactions and it is possible that the stability of the complex could be affected 
and disassemble to leave the telomeres unprotected and exposed for HR. In support of this 
model, Chavez et al. report similar observations in S. cerevisiae.370 Typically, telomerase is 
constitutively expressed in S. cerevisiae and if it is genetically inactivated this causes telomere 
loss and senescence. However, some telomerase-null yeast are able to survive, utilising HR-
dependent telomere maintenance to slow senescence, echoing ALT cancer cells. Furthermore, 
SUMOylation-deficient telomerase-null cells senesce at an elevated rate and NSE2 is identified 
as the key ligase mediating this effect.370 Whatever the mechanism, there is good evidence that 
depletion of SMC5/6 subunits causes inhibition of telomere HR, and should thereby induce 
telomere shortening and cell senescence in the tumour cells. Interestingly, in 2016 it was 
discovered that SMC5/6 is present at telomeres throughout the cell cycle and this association is 
dependent on NSE3.371 Cells mutated in NSE3 are defective in SMC5/6 localisation and have 
shortened telomeres. This is consistent with the prior observation that SMC5/6 interacts with 
DNA via the NSE3 subunit,360 and suggests an additional role for SMC5/6 in telomere 
maintenance, separate from the established role in HR-mediated telomere elongation. 
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3.2 Results 
3.2.1 SMC5 and SMC6 
DELTA-BLAST180,183 searches for human homologues of SMC5 and SMC6 identified the other SMC 
proteins and RAD50, Table 3.1 and Table 3.2. The Max and Total scores are associated with the 
statistics of the database search. The Max score depends on the query-hit alignment length and 
quality of the ‘best’ region of similarity. The Total score is equal to the Max score if only a single 
alignment is present. When multiple aligned regions exist, each individual score contributes to 
the Total score, and therefore this is greater than the Max, as was often observed. The Query 
cover gives the length of the alignment as a percentage of the length of the query sequence. In 
this work, all hits showed Query cover greater than 90%, demonstrating good conservation. The 
E (expectation) value evaluates the likelihood that the hit is significant by calculating the number 
of hits of this calibre expected due to chance alone. This depends on the quality of the alignment 
and the size of the database. A number close to zero indicates a significant hit. For the SMC 
proteins there was high confidence that the hits were not due to chance. Finally, the Ident 
represents the percentage identity between the query and hit by simple sequence alignment.372 
Despite the Query cover showing that the alignments spanned the majority of the length of the 
query sequence, the Ident indicated that the number of identical residues by sequence 
alignment was low. This could predict difficulties with modelling on distant relatives.  
Table 3.1. SMC5 Human Homologues. Results of DELTA-BLAST180,183 search on protein sequence. 
Description Max Score Total Score Query Cover E Value Ident 
SMC5 629 629 100% 0.E+00 100% 
SMC6 228 228 96% 3.E-61 15% 
SMC2 204 204 92% 2.E-53 12% 
SMC3 188 188 92% 2.E-48 13% 
SMC4 180 316 92% 5.E-46 12% 
SMC1b 131 260 92% 1.E-30 10% 
SMC1a 130 252 92% 1.E-30 12% 
RAD50 94 238 91% 3.E-19 10% 
 
EMBL-EBI Clustal Omega181,182 was used to compile a multiple amino acid sequence alignment 
of SMC5, SMC6 and the identified human homologues, Figure Apx.1. The alignment indicated 
relatively good conservation at the ATPase head domain but poor conservation at the hinge. 
A DELTA-BLAST180,183 search was used to identify relevant structural data available in the PDB 
(www.rcsb.org).158 Although there were no structures of human SMC5 and SMC6, potential 
model templates were available. These templates were separated into two categories, 
exhibiting sequence similarity with either the hinge or head domains. 
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Table 3.2. SMC6 Human Homologues. Results of DELTA-BLAST180,183 search on protein sequence. 
Description Max Score Total Score Query Cover E Value Ident 
SMC6 655 655 100% 0.E+00 100% 
SMC4 235 235 94% 2.E-63 12% 
SMC2 231 231 94% 3.E-62 14% 
SMC5 219 219 93% 1.E-58 14% 
SMC3 194 194 93% 3.E-50 12% 
SMC1a 153 348 93% 1.E-37 12% 
SMC1b 142 280 93% 5.E-34 12% 
RAD50 114 195 92% 1.E-25 12% 
 
Computational Assessment of SMC5/6 Hinge Domain 
Despite the multiple amino acid sequence alignment181,182 of SMC5, SMC6 and human 
homologues indicating poor conservation at the hinge domain and the only available template 
PDB structures being non-human paralogues an attempt was made to model the SMC5/6 hinge. 
The SMC5/6 domain was modelled on the X-ray crystal structure of the hinge domain of the 
Thermotoga maritima SMC protein (PDB ID: 1GXJ)222 using SWISS-MODEL.179 This was 
unsuccessful. SMC5 and SMC6 had to be modelled independently on 1GXJ chains A and B 
respectively, which resulted in regions clashing at the interface, Figure 3.7. 
 
Figure 3.7. Model of Human SMC5/6 Hinge Domain by SWISS-MODEL.179 SMC5 shown in blue and SMC6 in green, 
illustrating clashing at interface. 
In contrast, the multiple amino acid sequence alignments of SMC5 and SMC6 with their 
respective orthologues indicated good conservation at the hinge domain, Figure Apx.2 and 
Figure Apx.3. Most notable were the SMC5 Ser-624 and Tyr-626 residues. Recently, in S. pombe 
it was observed that SMC5 mutations at Ser-610 and Tyr-612 disrupt the SMC5/6 hinge 
interaction.223 In this work, these serine and tyrosine residues were found to be conserved in 
humans, as well as all other orthologues compared, Figure 3.8. 
98 
Chapter 3 
 
Figure 3.8. Multiple Sequence Alignment of SMC5 Orthologues. Conserved Ser and Tyr highlighted in orange. 
Given the improved homology of the SMC5/6 orthologues compared to the paralogues, these 
represented more desirable template structures. A crystal structure of the S. pombe SMC5/6 
hinge domain (PDB ID: 5MG8) was identified.223 The SMC5/6 hinge was modelled on this 
structure using MODELLER 9.12177, which unlike SWISS-MODEL179, permitted the two chains to 
be modelled simultaneously. The resulting model was prepared and minimised using Discovery 
Studio 4.0186, Figure 3.9 (a). The SMC5 Ser-624 and Tyr-626 residues are positioned at the 
interface with SMC6 suggesting that mutating these residues in humans would likely cause the 
same disruption of the SMC5/6 hinge as was observed in S. pombe.223 
One criteria for a good drug target is the ability to develop an assay against the protein. This is 
important in enabling screening and drug development. A drug that is designed to mimic the 
SMC5 Ser-624 and Tyr-626, identified as key residues in stabilising the SMC5/6 hinge interaction, 
would target SMC6. Unfortunately, SMC6 had proved unstable, suggesting that assay 
development would be challenging (Alt, A., Genome Damage and Stability Centre, University of 
Sussex, personal communication). As a result, SMC5 was the preferred target. Accordingly, 
Discovery Studio 4.0186 was used to identify potential binding pockets from receptor cavities on 
SMC5. It was hoped that structural pockets would be identified at the SMC5-SMC6 interface, 
which might indicate the potential to target the protein using an SMC6 mimetic, e.g. an α-helical 
mimetic, although, by eye, the protein-protein interaction (PPI) interfaces looked to be 
composed only of β-sheets, which are notoriously difficult to target. Unfortunately, no structural 
pockets were identified at the PPI interfaces by Discovery Studio 4.0186. A subset of the structural 
pockets identified are shown in Figure 3.9 (b). 
At the time this work was completed, the SMC5 hinge domain therefore appeared undruggable. 
The interface is composed only of β-sheets with no discernible structural pockets, affording no 
scope for rational design of a PPI inhibitor. No further structures existed of other proteins or 
small molecules bound at the hinge, which could provide inspiration for other druggable sites or 
the corresponding pharmacophores. In addition, it was assumed that a fragment screening 
approach would be unsuccessful. Due to their small size, the majority of fragments exhibit low 
affinity. It is therefore essential that any screening is carried out against unliganded protein with 
the binding site accessible.373 This would be problematic, as SMC5 is known to be less stable in 
SMC5_YEAST (623-632) - I K Q S A Y G S K Q - Saccharomyces cerevisiae
SMC5_SCHPO (607-616) - V F R S A Y G D R E - Schizosaccharomyces pombe
SMC5_TAKRU (612-621) - L K R S V Y S K M I - Takifugu rubripes
SMC5_CHICK (600-609) - I K V S T Y T K L S - Gallus gallus
SMC5_XENLA (601-610) - T K K S V Y S Q K L - Xenopus laevis
SMC5_HUMAN (621-630) - V K T S F Y S N K V - Homo sapiens
SMC5_MOUSE (621-630) - L K T S V Y S N K V - Mus musculus
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the absence of SMC6, which will hinder assay development (Alt, A., Genome Damage and 
Stability Centre, University of Sussex, personal communication). 
 
Figure 3.9. Model of Human SMC5/6 Hinge. Human SMC5/6 hinge modelled on 5MG8.223 SMC5 shown in blue and 
SMC6 in green. (a) Prominent Ser-624 and Tyr-626 residues highlighted in pink. (b) Structural pockets highlighted in 
image from Discovery studio 4.0.186 
Computational Assessment of SMC5/6 Head Domain 
Unlike at the hinge, the multiple amino acid sequence alignment181,182 of SMC5, SMC6 and other 
identified human homologues indicated good conservation at the head domain, Figure Apx.1, 
suggesting that a good model could be constructed even from a relatively distant relation. In 
addition, the DELTA-BLAST180,183 search identified more reported structures of better sequence 
similarity to the head domains than to the hinge. Many of these crystal structures were of little 
use, describing the structure of the SMC head domain at either the N- or C-terminal regions but 
not the complete structure. Nevertheless, the most suitable available crystal structure was 
identified and the SMC5/6 head was modelled on the Pyrococcus furiosus SMC ATPase (PDB ID: 
1XEX)224, using MODELLER 9.12.177 
 
Figure 3.10. SMC5/6 Head with Structural Pockets Identified. SMC5 N- and C-terminal chains shown in yellow and 
blue respectively and SMC6 in red and green. (a) Model of human SMC5/6 head with first structural pocket identified. 
(b) 1XEX224 SMC5 with structural pocket identified at ATP binding domain. Images produced in Discovery studio 4.0.186 
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Discovery Studio 4.0186 was used to prepare and minimise the model, and to identify potential 
binding pockets from receptor cavities. The first pocket identified is illustrated in Figure 3.10 (a). 
This large pocket was splayed, extending throughout the SMC5/6 model, and appeared to 
comprise of a collection of smaller pockets. These included cavities at both ATP binding sites. 
With an aim to check that it was possible to correctly identify the shallow ATP binding pockets, 
the 1XEX224 template was examined. Gratifyingly, the ATP binding domains were successfully 
identified. Figure 3.10 (b) shows the pocket identified at the SMC5 N-terminus, which 
encompasses the ATP binding site and a second branching pocket. It should be noted that, as 
was true of the hinge domain, the SMC5 head domain protein was more stable than the SMC6 
head domain, and attempts to prepare and purify SMC6 head domain protein had been 
unsuccessful (Alt, A., Genome Damage and Stability Centre, University of Sussex, personal 
communication). Therefore, SMC5 was again the preferred target. 
 
Figure 3.11. Structural Pockets Identified by Fpocket 2.0.165 SMC N- and C-terminal chains shown in yellow and blue 
respectively with pockets highlighted and ATP from 1XEX template in pink. (a) Model of human SMC5 head. (b) 1XEX 
template.224 
Table 3.3. Druggability Prediction Scores from Fpocket 2.0.170 
 Pocket Colour Druggability Score 
Human 
SMC5/6 
Model 
2 Purple 0.046 
10 Orange 0.014 
12 Green 0.012 
31 Red 0.109 
1XEX 
Template 
1 Purple 0.087 
7 Orange 0.016 
15 Green 0.252 
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With an aim to improve understanding of the available structural pockets at and around the 
SMC5 N-terminal ATP binding site, Fpocket 2.0165 was employed. Fpocket 2.0165 is an open 
source, cavity prediction algorithm, which is coupled to a structure-based target druggability 
prediction score.170 32 pockets were identified for the SMC5/6 model and 25 for the 1XEX 
template.224 The pockets at and nearest to the SMC N-terminal ATP binding site are illustrated 
in Figure 3.11 and the associated Fpocket druggability scores170 are listed in Table 3.3. 
Typically, a druggable pocket should exhibit an Fpocket druggability score of higher than 0.5, 
which suggests that the ATP binding site is not druggable. However, the most important 
descriptor in calculating this druggability score is the mean local hydrophobic density of the 
binding site, with the hydrophobicity and normalised polarity scores, referring to the 
physicochemical character of the residues lining the pocket, also taken into account.170 As such, 
solvent exposed cavities are often predicted as undruggable. In addition, ATP binding sites are 
designed to accommodate charged phosphate residues, requiring a polar environment, which is 
likely to negatively impact the druggability scores of neighbouring pockets. In summary, the 
druggability prediction scores generated may not be truly reflective of the druggability of the 
identified pockets. Furthermore, despite the poor druggability scores, Fpocket 2.0165 and 
Discovery Studio 4.0186 concurred in identifying the same adenosine binding site and the same 
second branching pocket. The decision was made to analyse the pockets further using 
computational and experimental approaches in attempt to determine the true viability of the 
SMC5 head domain as a target. 
Having identified the adenosine binding pocket and branching channel as potentially druggable 
sites, further information was required to assess the quality of the target and likely specificity 
that could be achieved. Two questions were proposed: 
1. Is there sufficient confidence that the pockets exist? 
2. Are the pockets conserved in other proteins? 
Improving Confidence in the Pockets 
As a first attempt to improve confidence in the pockets, all five models produced during model 
building in MODELLER 9.12177 were revisited. All of the models were now prepared, minimised 
and binding pockets were identified from receptor cavities using Discovery Studio 4.0.186 The 
five models were then aligned, Figure 3.12 (a). Given the reasonably low sequence identity of 
the SMC5 head domain and 1XEX template224, it is plausible that the models may be inaccurate 
at the atomic level. However, the same adenosine binding pocket and neighbouring channel 
were observed in all the models, helping to improve confidence that they are real. 
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In addition, another model of the SMC5 head was produced using Phyre 2.0221, a protein fold 
recognition (threading) server. A crystal structure of the Deinococcus radiodurans DNA repair 
protein RecN (PDB ID: 4AD8)229 was selected by the server as the template. The model was 
prepared and minimised and binding pockets identified from receptor cavities using both 
Discovery Studio 4.0186 and Fpocket 2.0.165 Fpocket identified 20 pockets in the new SMC5 
model. Those at and nearest to the SMC N-terminal ATP binding site, which was identified by 
alignment of the model with the 1XEX template used previously224, are illustrated in Figure 3.12 
(b). Again, the adenosine binding pocket and neighbouring channel were recognised, further 
improving confidence in their existence.  
 
Figure 3.12. Attempts to Improve Confidence in Structural Pockets. (a) Alignment of five models of human SMC5 
head. ATP from 1XEX template224 in black. (b) Phyre 2.0221 model of human SMC5 head with structural pockets 
identified by Fpocket 2.0.165 SMC N- and C-terminal chains shown in yellow and blue with pockets highlighted and 
ATP from 1XEX template224 in pink. 
Determining Whether the Pockets are Conserved in Other Proteins 
Those amino acids which comprise the ATP binding pocket and neighbouring channel were 
identified, considering both the 1XEX template224 and SMC5/6 model. In Figure 3.13 these amino 
acids are compared with the corresponding residues in other SMC proteins, determined by 
multiple sequence alignment, Figure Apx.4.181,182 The LIGPLOT374 derived schematic diagram of 
protein-ligand interactions in 1XEX224 was retrieved from canSAR v2.0160, Figure 3.14 (a). Those 
residues involved in binding the phosphate or adenosine moieties are specified in Figure 3.13. 
Scorecons (http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/valdar/scorecons_server.pl) 
was used to calculate conservation scores for each position and these were coloured such that 
dark red indicates the poorest conservation and dark green the best.220 Figure 3.14 (b) shows 
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the model with the associated residues highlighted and coloured respectively. Residue 
conservation appears generally poor, with the exception of the phosphate binding residues, 
suggesting that a drug designed to target this region has the potential for reasonable specificity. 
 
Figure 3.13. Conservation of SMCs. Scoring conservation of potential binding site residues in human SMCs and Rad50. 
 
Figure 3.14. Attempts to Determine Pocket Conservation in Other Human SMC Proteins. (a) Schematic Diagram of 
Protein-Ligand Interactions of 1XEX224 generated by LIGPLOT.374 (b) Model of human SMC5 head with residues at 
potential binding pockets coloured by conservation. SMC N- and C-terminal chains shown in yellow and blue and ATP 
from 1XEX template224 in pink. 
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Analysis of whether similar pockets exist in other protein families was not undertaken, due to 
the manner and extent of work required to achieve this. 
Experimental Assessment of SMC5 Head Domain 
As discussed, ATP binding to SMC5 and SMC6 occurs at the interface between the head domains 
of the two proteins to form a nucleotide-sandwiched dimer, in which the two ATP molecules 
each interact with both subunits, as illustrated in Figure 3.15. Consequently, the SMC5 or SMC6 
head domain alone comprises only one half of each of the ATP binding sites. Given that purified 
SMC6 protein is currently unavailable it was necessary to assess the ability of the head domain 
of SMC5 to bind ATP moieties in its absence. 
 
Figure 3.15. Illustration of SMC5/6 Head Domains with ATP Bound.  ATP shown in pink, SMC5 N- and C-terminal 
chains shown in yellow and blue respectively and SMC6 in red and green. 
SMC5 head domain protein, generously expressed by Dr Aaron Alt (Genome Damage and 
Stability Centre, University of Sussex), was purified using immobilised metal affinity 
chromatography (IMAC) and size exclusion chromatography (SEC), from frozen cells, Figure 3.16. 
The construct, AA5, comprised of the N- and C-terminal regions of SMC5 joined by a short linker. 
 
Figure 3.16. SMC5 Head Domain Protein Purification. (a) SDS-PAGE gel showing composition of wash and elute 
fractions from immobilised metal affinity chromatography. (b) SDS-PAGE gel of fractions obtained by size exclusion 
chromatography. Concentrated protein band corresponds to SMC5 head domain protein. 
Isothermal titration calorimetry (ITC) was employed in an attempt to measure the corresponding 
heats of binding of adenosine, AMP, ADP and AMP-PNP, a non-hydrolysable ATP analogue, 
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Figure 3.17. The results of experiments conducted at 1.5 mM compound and 60 μM protein are 
shown in Figure 3.18. On observation of binding you might expect to detect energy changes of 
over 10 kcalmol-1 of injectant. In these experiments however, the measured ‘heat of binding’ 
was comparable with the heat of dilution, indicating that none of the ATP analogues bound with 
the SMC5 head domain protein. No binding curves could be fit to the resulting data. 
 
Figure 3.17. Chemical Structures of ATP Moieties. Adenosine, AMP, ADP and AMP-PNP. 
From these results it appears that the head domain of SMC5 is unable to bind ATP moieties in 
the absence of that of SMC6. As described previously, one feature of a favourable drug target is 
that a robust assay can be developed against the protein, which is important in enabling 
screening and drug development. It was therefore determined that while purified SMC6 protein 
remained unavailable, the head domain of the SMC5/6 complex, like the hinge, did not 
constitute a good drug target. 
3.2.2 Non-SMC Elements 
In addition to the two core SMC proteins, the human SMC5/6 complex contains four non-SMC 
elements, NSE1, 2, 3 and 4.342 In order to obtain a complete picture of the potential druggability 
of the complex, it was important to also assess these. 
DELTA-BLAST180,183 searches identified suitable structures on which to model NSE1, NSE2 and 
NSE3 but no structures were available which showed sufficient sequence similarity to NSE4 to 
enable modelling. In addition an attempt to use PHYRE 2.0221 to build a model of NSE4 was also 
unsuccessful due to the lack of suitable structures available in the PDB. MODELLER 9.12177 was 
used to model NSE1, NSE2 and NSE3 on the most suitable available crystal structures. NSE1 was 
modelled on the Homo sapiens NSE1-MAGEG1 complex (PDB ID: 3NW0, chain A)225, NSE2 was 
modelled on the S. cerevisiae MMS21 (PDB ID: 3HTK, chain C)226, and NSE3 was modelled on the 
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Homo sapiens MAGEA4 (PDB ID: 2WA0)227. The models were prepared and minimised, the 
binding pockets identified from receptor cavities using both Discovery Studio 4.0186 and Fpocket 
2.0165 and the associated Fpocket druggability scores170 calculated. 
 
Figure 3.18. ITC Binding Data for Interaction Between SMC5 Head Domain Protein and ATP Analogues. Isotherms 
of raw titration heat shown above and normalised binding heat shown below. No binding was observed for any of the 
ATP analogues. (a) 1.5 mM adenosine titrated into 60 μM protein. (b) 1.5 mM AMP titrated into 60 μM protein. (c) 
1.5 mM ADP titrated into 60 μM protein. (d) 1.5 mM AMP-PNP titrated into 60 μM protein. 
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In the SMC5/6 complex NSE1 and NSE3 are known to interact with each other.342 PDB entry 
3NW0225 depicts the structure of the two proteins in a bound conformation but unfortunately is 
of poor quality, especially with respect to the NSE3 subunit, so could not be used to model NSE3. 
Instead, while NSE1 was modelled on the 3NW0225, to reasonably good effect, NSE3 was 
modelled on 2WA0.227 The resulting NSE3 model was then aligned to 3NW0, chain B225, in an 
attempt to observe the PPI interface. 10 pockets were identified in each of the NSE1 and NSE3 
models using Fpocket 2.0.165 Those at and nearest to the site of interaction, are illustrated in 
Figure 3.19 (a). On both proteins, cavities were identified at the PPI interface, although the 
associated druggability scores, displayed in Table 3.4, were low. The poor quality of the available 
X-ray crystal structures used in modelling results in a high likelihood of inaccuracy in these 
models, making them unsuitable for use in further analysis. This investigation was therefore 
abandoned, but should be revisited if improved structures become available. 
 
Figure 3.19. Modes of Human NSE1, NSE3 and NSE2, with Structural Pockets from Fpocket 2.0.165 (a) Models of NSE1 
and NSE3 aligned to display site of interaction. NSE1 shown in green and NSE3 in orange with pockets highlighted. (b) 
Model of NSE2 bound to SMC5. NSE2 shown in green and SMC5 arm in orange with pockets highlighted. 
NSE2 binds to the SMC5/6 dimer independently through interaction at the SMC5 coiled-coil 
arm.346 This interaction is depicted in PDB entry 3HTK.226 14 pockets were identified in the NSE2 
model by Fpocket 2.0.165 Those at and nearest to the interface with the SMC5 arm are illustrated 
in Figure 3.19 (b) and the corresponding druggability scores are displayed in Table 3.4. One 
pocket, highlighted in yellow, has an associated druggability score of 0.551, which is higher than 
any seen in the SMC5/6 head domain or other NSEs and might suggest that the cavity would 
make a viable target site. However, given that in humans NSE2 is not thought to be necessary 
for the stability of the SMC5/6 complex343, before further time and resources is committed to a 
drug design effort at this position, it would be necessary to determine whether targeting NSE2 
affords the desired cellular effect. Point mutation experiments could be utilised toward this aim. 
Accordingly, this analysis should also be revisited if more data becomes available. 
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Table 3.4. Druggability Prediction Scores from Fpocket 2.0.170 
 Pocket Colour Druggability Score 
Human NSE1 
Model 
4 Pink 0.076 
8 Yellow 0.014 
10 Blue 0.385 
Human NSE3 
Model 
4 Red 0.016 
8 Cyan 0.009 
Human NSE2 
Model 
1 Pink 0.468 
3 Yellow 0.551 
10 Blue 0.023 
   
3.2.3 Cohesin 
In addition to their primary roles in sister chromatid cohesion and chromosome condensation 
respectively, cohesin and condensin both have established roles in DNA damage response.251 
Consequently, like SMC5/6, these protein complexes represent biologically desirable drug 
targets. Relevant data on cohesin and condensin was collected from a variety of online sources 
and databases and information was gathered on the availability of resources and potential for 
collaboration with other groups. Cohesin was prioritised, owing to a greater amount of available 
information, potential to obtain X-ray crystal structures (Ramón-Maiques, S., Spanish National 
Cancer Research Centre, personal communication) and potential for development of an in-cell 
assay.272 
 
Figure 3.20. Model of Human Cohesin Hinge Domain. SMC1 shown in blue and SMC3 in green with compelling 
structural pocket identified by Fpocket 2.0.165 highlighted in pink. 
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The most suitable available crystal structures were identified using a DELTA-BLAST180,183 search 
against the PDB, and the SMC1/3 hinge and head domains were modelled respectively on the 
Mus musculus SMC1/3 hinge domain (PDB ID: 2WD5)228, and the Pyrococcus furiosus SMC 
ATPase (PDB ID: 1XEX)224 using MODELLER 9.12.177 The models were prepared and minimised, 
the binding pockets identified from receptor cavities using Discovery Studio 4.0186 and Fpocket 
2.0165, and the corresponding Fpocket druggability scores were calculated.170 In general, the 
models were similar to those of the SMC5/6 hinge and head domains. Interestingly though, one 
pocket identified in the SMC3 hinge domain at the SMC1-SMC3 PPI interface corresponds to the 
binding position of a helix in SMC1, as illustrated in Figure 3.20. The Fpocket druggability score 
for this cavity is 0.192 suggesting that the site is not druggable. However, as discussed earlier, 
the druggability prediction scores may not be truly reflective of the druggability of solvent 
exposed cavities such as this at the PPI interface. Use of helix mimetics to target PPI interfaces 
is well documented375 and this may provide a potential starting platform for drug design. 
 
Figure 3.21. Analysis of the SMC1-SCC1 Interaction Interface. (a) S. cerevisiae SMC1-SCC1 interaction interface (PDB 
ID: 1W1W).233 SMC1 shown in cyan and SCC1 in purple. (b) Model of human SMC1 head domain aligned to S. cerevisiae 
SMC1. SMC N- and C-terminal chains shown in yellow and blue with SCC1 in purple. Alignment results in obscuring of 
the helix binding groove. 
As well as 3D structures of the hinge and head domains, there is a published crystal structure of 
the S. cerevisiae SMC1-SCC1 interaction interface (PDB ID: 1W1W).233 Such information was not 
available for SMC5/6 and was interesting as any proteins or small molecules bound to the SMC 
proteins might provide inspiration for potentially druggable sites, along with corresponding 
pharmacophores. Binding pockets were identified from receptor cavities using Fpocket 2.0165 
and the associated Fpocket druggability scores were calculated.170 11 pockets were identified in 
SMC1 (PDB ID: 1W1W, chain A).233 Unfortunately none of these were situated at the SMC1-SCC1 
interface, likely due to the extensive, flat and lipophilic nature of the interaction. Furthermore, 
alignment of the S. cerevisiae SMC1 with the model of the human SMC1/3 heads was 
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unsuccessful. The majority of the helix binding groove became completely obscured, as shown 
in Figure 3.21, probably as a combined result of inaccuracies in modelling and alignment.  
While cohesin looks appealing as a potential future target for development of tool inhibitors, 
any progress will be highly dependent on the level of interest of potential collaborators and 
availability of resources. 
3.3 Discussion 
The roles of the SMC complexes in regulating chromosome architecture and organisation are 
well known, but not entirely well understood. SMC5/6 is particularly mysterious, with both the 
essential function and mechanism of action unexplained, despite considerable investigative 
effort. In addition, SMC5/6 has been shown to play a prominent role in DNA repair254–256 and in 
the ALT pathway361, as well as representing a potential opportunity to design novel cancer 
therapeutics via a synthetic lethality approach. SMC5/6 was therefore identified as a highly 
desirable target for tool inhibitor development. Such chemical probes are anticipated to enable 
enhanced biological investigation and could initiate drug discovery projects. Before commencing 
any chemistry, it is prudent to use druggability assessment methods to determine the viability 
of the protein as a target. This enables promising targets to be prioritised quickly and cheaply 
and goes a small way toward helping improve R&D productivity.14 
In this work, the human SMC5/6 hinge was modelled successfully on the S. pombe SMC5/6 hinge 
domain (PDB ID: 5MG8).223 S. pombe SMC5 residues Ser-610 and Tyr-612, which are necessary 
to stabilise the interaction at the hinge223, were found to be conserved in humans (Ser-624 and 
Tyr-626). Furthermore, these residues were similarly positioned at the interface with SMC6, 
suggesting a key role in preserving the stability of the hinge interaction. Unfortunately, at this 
time the instability of SMC6 prohibited development of an assay against this protein, making it 
impossible to test drugs designed to mimic these SMC5 residues. Instead, it was necessary to 
identify potential binding pockets from receptor cavities on SMC5. However, it was discovered 
that the interface was composed only of β-sheets, with no discernible structural pockets, 
affording little potential for a rationally designed PPI inhibitor. It therefore seemed that the 
SMC5 hinge domain was undruggable. It is advised that if a human crystal structure is 
determined, if proteins or small molecules are identified that bind at the SMC5 hinge, or if stable 
SMC6 can be produced, the SMC5/6 hinge should be reinvestigated as a target. 
With opportunities at the hinge exhausted, focus shifted to the SMC5/6 head domain. The 
human SMC5/6 head was successfully modelled on the Pyrococcus furiosus SMC ATPase (PDB 
ID: 1XEX).224 SMC5 was the preferred target. As experienced at the hinge, the SMC6 head domain 
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was more unstable than the SMC5, and attempts to prepare and purify it had been unsuccessful. 
Potential binding pockets were identified at and near to the SMC5 N-terminal ATP binding site. 
The associated druggability scores170 suggested that these pockets were undruggable. However, 
it was judged that this could be caused by the solvent exposed nature of the pockets, or the 
polar environment required to accommodate the ATP phosphate residues, and therefore was 
potentially not truly reflective of the druggability. In attempt to validate the two pockets 
identified around the adenosine binding site, a second model of the SMC5 head was produced, 
this time using an energetics approach rather than alignment. Equivalent binding sites were 
observed, improving confidence that the pockets exist. A sequence based approach was used to 
compare residues that could potentially comprise a druggable pocket around the SMC5 N-
terminal ATP binding site with the corresponding residues in other human SMC proteins and 
RAD50. Conservation was generally poor, with the exception of the phosphate binding residues. 
This suggested that a drug targeted at this site would have the potential to offer reasonable 
selectivity for SMC5 over other SMC family members. Having identified the potentially druggable 
sites, ITC was used to assess the ability of the SMC5 head to bind ATP derivatives in the absence 
of SMC6. Unfortunately, no binding could be measured between the SMC5 head domain and 
adenosine, AMP, ADP or AMP-PNP. As such, while purified SMC6 head protein remains 
unavailable, the SMC5/6 head domain also appears undruggable. 
Next, investigations advanced to the non-SMC elements. NSE1, 2 and 3 were modelled on the 
Homo sapiens NSE1-MAGEG1 complex (PDB ID: 3NW0, chain A)225, S. cerevisiae MMS21 (PDB ID: 
3HTK, chain C)226, and Homo sapiens MAGEA4 (PDB ID: 2WA0)227 respectively. Although 
potential cavities were identified at the NSE1-NSE3 PPI interface, the poor quality of the 
available X-ray crystal structures resulted in a high likelihood of inaccuracy in the models, making 
them unsuitable for further analysis. This target was abandoned but should be revisited if 
improved crystal structures become available. Potentially druggable pockets were identified at 
the NSE2-SMC5 PPI interface. However, given that in humans NSE2 is not thought to be 
necessary for the stability of the SMC5/6 complex343, it was concluded that before time and 
resources were committed to any drug design effort at this position, point mutation experiments 
should be utilised to determine whether targeting NSE2 generates the desired response. 
Having failed to identify a satisfactory target protein within the SMC5/6 complex, attention was 
redirected to cohesin. Cohesin was selected over condensin due to the abundance of available 
information, and potential to develop an in-cell assay272 and obtain X-ray crystal structures via 
collaboration. The human cohesin hinge and head domains were successfully modelled on the 
Mus musculus SMC1/3 hinge domain (PDB ID: 2WD5)228, and the Pyrococcus furiosus SMC 
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ATPase (PDB ID: 1XEX)224 respectively. A pocket was identified in the SMC3 subunit at the PPI 
interface between the hinge domains, which corresponded to the binding position of a helix in 
the SMC1. Although the Fpocket druggability score170 for this cavity indicated that it was not 
druggable, it seemed that this might not truly reflect the druggability of such a solvent exposed 
pocket. The site could offer the potential for drug design utilising helix mimetics. Analysis of PDB 
entry 1W1W233, which depicts the S. cerevisiae SMC1-SCC1 interaction interface, identified a lack 
of binding sites at this interface, likely due to the extensive, flat and lipophilic nature of the 
interaction. Cohesin could represent a promising future target for development of tool 
inhibitors. However, for this project it was concluded that the necessary collaborations and 
resources could not be assembled. 
In summary, at the time this work was completed, the SMC5/6 and cohesin complexes were 
established as not druggable, within the restraints of accessible resources. In the future, if 
further data and biological resources become available, many of the proteins would be worth 
reinvestigating. However, within the scope of this project it was not considered a wise 
investment to attempt design and characterisation of tool inhibitors. 
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4 Assessing the Druggability of Three Targets that are 
Synthetic Lethal with BAF180 
BAF180, gene name PBRM1, is one of the defining subunits of PBAF, a SWI/SNF complex 
associated with chromatin formation.376 Mutations in PBRM1 have frequently been identified in 
a variety of human cancers.377 Most recently, PBRM1 was identified as a major clear cell renal 
cell carcinoma (ccRCC) cancer gene, exhibiting truncating mutations in 41% of samples of the 
protein coding exome in a series of primary ccRCCs.1 It is therefore the second most frequently 
mutated gene in ccRCC.376 
Unique features of tumours, such as this high frequency of BAF180 mutation, can be exploited 
by targeted therapies using a synthetic lethality approach and therefore highlight suitable 
targets for chemotherapeutic drug development. Hopkins et al. utilised a novel screening 
technique to identify several genes that are synthetic lethal with BAF180.3 In this chapter, the 
druggability of proteins expressed by three of these genes, RNF4, ASF1A and GCN5/KAT2A, was 
assessed using computational techniques. GCN5/KAT2A was determined to be the most 
druggable of the three proteins, resulting in initiation of tool inhibitor development, as 
described in Chapters 5 and 6. 
4.1 Introduction 
4.1.1 Chromatin Remodelling Complexes 
As revealed in Chapter 3.1, higher-level chromosome condensation is not completely 
understood. Opinion is split between hierarchical folding or radial loop models, as well as 
whether protein scaffolds exist at chromosome axes to constrain the structure.378 In contrast, 
the primary level of DNA organisation is well studied and understood, to the extent that the 
structure has been resolved at 1.9 Å resolution (PDB ID: 1KX5).379 
The charged DNA polymer is compacted into nucleosomes, through association with an 
octameric complex of highly basic histone proteins (H2A, H2B, H3 and H4), as shown in Figure 
4.1. These nucleosomes are the fundamental repeating unit of chromatin and generally occur 
every 157-240 base pairs.379 The chromatin is then successively folded by some means to afford 
higher-order and remarkably well condensed structures.380 Although less is known about the 
nature of these more folded structures, it is clear that the degree of compaction directly 
influences the activity of the associated DNA in transcription, replication and recombination.381 
ATP-dependent chromatin remodellers are key components of the cellular machinery required 
for functional DNA packing. They use energy from ATP hydrolysis to remodel nucleosomes and 
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thereby modulate transcription.382 Notably, such genes are among those most frequently 
disrupted in human tumours. Studies show that 19-20% of human malignancies exhibit defects 
in the subunits of two chromatin remodelling complexes, BAF (BRG1- or BRM-associated factor) 
and PBAF (polybromo-associated BAF).383,384 These are the focus of this discussion. 
 
Figure 4.1. DNA Packaging into Nucleosomes. DNA is wrapped around an octameric core of histone proteins. 
The yeast SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin remodeller was discovered 
independently in screens for mutations which hinder mating type switching385, or sucrose 
fermentation activation.386 The genes identified were later shown to be part of the same 
complex.387,388 SWI/SNF complexes function by modifying the position, phasing, stability or 
histone content of nucleosomes.389 Structural remodelling enables the complexes to mobilise 
nucleosomes either by sliding or by catalysing the ejection and insertion of histone octamers, to 
generate sites more accessible to DNA binding factors.390 Cells with mutant SWI/SNF subunits 
exhibit disrupted chromatin structure and impaired gene expression, causing an array of 
phenotypic defects, as well as increased sensitivity to DNA damaging agents.376 This sensitivity 
may derive from the roles of SWI/SNF complexes in nucleotide excision391 and homologous 
recombination392 repair pathways.  
The SWI/SNF complexes comprise a highly related family of multisubunit complexes.382 The 
mammalian analogues are the aforementioned BAF, also known as SWI/SNF-A; and PBAF, also 
known as SWI/SNF-B. These complexes are composed of a central ATPase, either BRG1 or BRM, 
various evolutionarily conserved BAF subunits, and several subunits specific to mammalian 
complexes, including BCL7A/B/C and BCL11A/B. The two complexes differ in that BAF contains 
ARID1A/B, BRD9, BAF45B/C/D and SS18, where PBAF contains ARID2, BRD7, BAF45A and 
PBRM1/BAF180, as presented in Figure 4.2.376 These subunits are thought to contribute to 
specific targeting, assembly and regulation of the complexes.382  
The BAF complex is heavily implicated in mammalian development. It regulates a variety of 
biological processes including self-renewal and pluripotency in embryonic stem cells, cardiac 
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development and neural differentiation393, and is observed to localise at developmental 
enhancers.394 Additionally, its activity is coupled to transcription factor binding.395 PBAF was first 
identified in a screen for proteins that play an essential role in ligand-mediated transcription.396 
This complex accumulates at the kinetochores of mitotic chromosomes, suggesting a role in cell 
division397, and performs in cell differentiation.398 In addition, analogously to SWI/SNF, there is 
evidence that BAF and PBAF function in DNA repair pathways, including nonhomologous end-
joining and homologous recombination repair.399 Correspondingly, it has long been speculated 
that BAF subunits are tumour suppressors, as these core subunits are recurrently absent or 
mutated in immortalised cell lines.400,401 Indeed, BAF and PBAF have now been confirmed as 
legitimate tumour suppressors, and specific inactivating mutations have been frequently 
identified in a number of the subunits in various human cancers.376 
 
Figure 4.2. SWI/SNF Complexes BAF and PBAF. PBRM1 unique to PBAF and SS18 to BAF. Subunits with important 
roles in malignancy labelled in bold. Figure adapted from Hodges et al., 2016 and Kadoch & Crabtree, 2015.376,402  
4.1.2 BAF180 
BAF180, gene name PBRM1 (Protein polybromo-1), is one of the defining subunits of PBAF, and 
is the focus of the synthetic lethality drug development approach investigated in this chapter.376 
It contains six tandem bromodomains, two bromo-adjacent homology (BAH) domains, and a 
high-mobility group (HMG). Bromodomains are roughly 100 amino acids in length and typically 
serve to recognise and selectively bind acetylated lysines from histones, enabling targeting of 
complexes to precise chromatin sites. However, the specific role of these bromodomains in 
targeting PBAF remains unclear.376 The BAH domains are regions of approximately 130 amino 
acids, which act as protein-protein interaction modules, potentially acting to anchor the BAF180 
subunit within the PBAF complex and recruit effector proteins. Finally, the HMG domain, or 
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HMG-box, is roughly 80 amino acids in length and binds into the minor groove of DNA, which is 
likely to alter histone-DNA interactions and thereby control genetic functions. Collectively it 
therefore appears that BAF180 serves as an important PBAF subunit, coordinating several roles 
vital to the function of chromatin remodelling complexes.403 
Mutations in PBRM1 are associated with a variety of human cancers, such as breast cancers377 
and clear cell renal cell carcinoma, with a recent study identifying truncating mutations in 41% 
of primary ccRCC samples1, making it the second most frequently mutated gene in ccRCC.376 In 
the case of ccRCC, inactivation of PBRM1 often coincides with mutation of tumour suppressor 
VHL (von Hippel-Lindau). This is likely principally due to their close proximity on chromosome 
arm 3p, such that focal or arm-level deletions affect both genes simultaneously. However, 
inactivating point mutations of PBRM1 also regularly coincide with VHL mutation, suggesting 
that joint inactivation of these genes may be beneficial to the cancer.404  
Although PBAF primarily regulates transcription, it is unclear if this is what drives tumourigenesis 
in cells deficient in BAF180.405 BAF180 has a number of specifically defined roles in maintaining 
genome stability and preventing tumourigenesis.399 Firstly, it appears to function in repriming 
stalled replication forks at sites of DNA damage.406 Replication past damaged DNA is regulated 
by PCNA ubiquitination. Following damage-inducing UV-irradiation, BAF180 deficient cells 
present reductions in both ubiquitinated PCNA and chromatin-associated unmodified PCNA, as 
well as reduced fork progression. It has therefore been suggested that PBAF, via BAF180, 
promotes repriming of replication downstream of replication forks blocked by damage, by 
recruiting and ubiquitinating PCNA. In the absence of BAF180, replication is therefore slowed.406 
In accordance with this hypothesis, it has recently been shown that the BAF180 BAH domains 
are necessary and sufficient to promote PCNA ubiquitination.407 Secondly, it has been shown 
that BAF180 is necessary for centromeric sister chromatid cohesion, which could help to prevent 
tumourigenesis.405 BAF180 depletion is not associated with misregulated expression of the SMC 
complex cohesin, which seemingly indicates a transcription-independent role for PBAF. This is 
consistent with the observation that PBAF accumulates at the kinetochores of mitotic 
chromosomes.397 As well as bestowing accurate chromosome segregation, cohesion is 
important for DNA damage repair by HR, and mammalian cells with defects in cohesion are 
hypersensitive to DNA-damaging agents.408 The loss of BAF180 similarly sensitises cells and 
therefore it is suggested that in the absence of BAF180, loss of sister chromatid cohesion results 
in impaired HR-dependent DNA repair.405 
Unique mutations that are associated with tumourigenesis can potentially be exploited by 
targeted therapies, and are currently a key focus in cancer research efforts using synthetic 
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lethality approaches. In this instance, the presence of mutated PBRM1 in cancer cells but not in 
normal cells could create an opportunity to selectively kill the tumour cells by mimicking the 
effect of a synthetic lethal mutation with a drug. Indeed, this prominent mutation of the PBRM1 
gene has been highlighted as a promising opportunity to target ccRCC.2 
Hopkins et al. utilised a novel method of screening to identify genes synthetic lethal with 
BAF180.3 The screening technique was based on shRNA and siRNA double knockdown; co-
culturing isogenic cell lines expressing experimental or control shRNA with individual fluorescent 
tags and applying a library of siRNAs to diagnose synthetic lethal interactors, Figure 1.11.3 Three 
of the proteins expressed by genes identified by Hopkins et al. were selected as biologically 
desirable targets for tool inhibitor development. RNF4, ASF1A and GCN5/KAT2A therefore 
became the focus of a computational druggability study to assess their suitability as targets of 
chemotherapeutic agents that exploit the synthetic lethality with BAF180. 
4.1.3 RNF4 
RNF4 (RING finger protein 4), also known as SNURF (small nuclear RING finger protein), is a RING-
domain-containing, SUMO-targeted E3 ubiquitin ligase409, which exists as a homodimer via its 
RING-type zinc finger domain, Figure 4.3.234 RNF4 mediates SUMO-targeted polyubiquitination 
to designate various poly-SUMO-modified proteins for degradation at the proteasome.409 This 
response is exploited in the treatment of acute promyelocytic leukaemia (APL) using arsenic.410 
After exposure of cells to arsenic, the oncogenic PML-RARα (retinoic acid receptor alpha) fusion 
protein, commonly observed in APL, undergoes rapid SUMO modification. Subsequent RNF4-
mediated ubiquitination results in the proteasomal degradation of PML-RARα.410 RNF4 is also 
responsible for ubiquitination and destabilisation of PEA3 (polyomavirus enhancer activator 3), 
promoting transactivation, possibly by inducing recycling411, and of CENPI (centromere protein 
I), to control vertebrate kinetochore assembly.412 Similarly, it is implicated in regulating the 
cellular response to both hypoxia413 and heat shock414 via ubiquitination of SUMO-conjugated 
HIF2α (hypoxia-inducible factor 2 alpha) and PARP1 respectively. Alternatively, RNF4 may have 
a more direct role in transcriptional regulation. For example, it has also been found to interact 
with TRPS1 to negatively regulate its transcriptional repressor activity.415  
It is also well established that protein ubiquitination and SUMOylation are crucial in coordinating 
the cellular response to DSBs.416 RNF4 is recruited to DNA lesions by damage-induced 
SUMOylation.417 Here it facilitates the ubiquitination and dissociation of chromatin-associated 
MDC1 and RPA, thereby promoting NHEJ and HR DSB repair respectively.417 It is believed that 
RNF4 contributes to DSB repair pathway choice in a cell cycle-dependent manner. It has been 
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shown that during S phase the ligase activity of RNF4 is enhanced by CDK2-mediated 
phosphorylation, inducing MDC1 degradation and therefore favouring HR repair.418 Additionally, 
it was recently demonstrated that during G1 phase, RNF4 is degraded, permitting retention of 
DSB-induced phosphorylated Ser824 and SUMOylated TRIM28 (tripartite motif-containing 28), 
which blocks HR repair and promotes NHEJ.419 When cells progress to S and G2, RNF4 
accumulates and provokes pS824-TRIM28 degradation, relieving HR inhibition.419 Further 
research indicates that ataxin-3, a deubiquitination enzyme, counteracts RNF4 activity during 
the DSB repair response, and that these opposing activities establish robust MDC1-dependent 
signalling and DSB repair.416 It is proposed that ataxin-3 prevents MDC1 from being removed 
prematurely from the chromatin, to reinforce DNA damage signalling and properly initiate 
damage repair. Another study demonstrates that RNF4 is responsible for regulating the timely 
degradation of Fanconi anaemia protein complexes, as necessary during interstrand crosslink 
repair420, further attesting to the role of RNF4 in DSB repair. 
 
Figure 4.3. Crystal Structure of RNF4. Crystal structure of Rattus norvegicus RNF4 RING-type zinc finger domain 
homodimer (PDB ID: 3NG2)234, coloured from blue at N-terminus of chain A to red at C-terminus of chain B. 
4.1.4 ASF1A 
ASF1A (anti-silencing function protein 1 homologue A) is an ATP-independent histone chaperone 
with anti-silencing activity421, capable of facilitating histone deposition, exchange and removal 
during nucleosome assembly or disassembly. It is specifically responsible for chaperoning 
histones H3 and H4 and has been characterised in complex with H3.1, and H4, Figure 4.4.236 
The best understood role of ASF1A is in nucleosome assembly. It acts in cooperation with two 
other chaperones, CAF-1 (chromatin assembly factor 1) and HIRA (histone cell cycle regulator 
A), to mediate replication-coupled and replication-independent assembly respectively.422 The 
interactions of ASF1A with the CAF-1 complex423 and HIRA424 are mutually exclusive. Nucleosome 
assembly and disassembly are essential in replication, transcription, and DNA repair processes 
and ASF1A has an extensive interaction network suggesting that it plays a critical role at the 
junction of chromatin and DNA checkpoint pathways.425 
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Figure 4.4. Crystal Structure of ASF1A in Complex with Histones H3.1 and H4. Crystal structure of Homo sapiens 
ASF1A (blue) in complex with histones H3.1 (yellow) and H4 (pink) (PDB ID: 2IO5).236 
Correspondingly, ASF1A is implicated in a diverse array of cellular processes. As cells approach 
senescence, ASF1A and HIRA drive the formation of senescence-associated heterochromatin 
foci, at which proliferation-promoting genes are transcriptionally repressed, which provokes 
senescence-associated cell cycle exit.426 Another interesting role has recently been determined 
in cellular reprogramming. ASF1A is required for H3K56 acetylation, which is associated with 
human embryonic stem cells, and overlaps with the binding of transcription factors key to 
regulating pluripotency, such as OCT4 (octamer-binding protein 4).427 ASF1A is necessary for the 
reprogramming of human adult dermal fibroblasts into induced pluripotent stem cells (iPSCs).428 
Furthermore, another study demonstrated that p53 knockdown and ASF1A overexpression 
promoted the formation of iPSCs from sheep kidney cells.429 ASF1A is also implicated in the DNA 
repair response. It has been shown that both nucleotide excision repair and mismatch repair 
occur during replication-coupled nucleosome assembly by CAF-1 and ASF1A.423,430 
4.1.5 GCN5/KAT2A 
GCN5, or KAT2A (lysine acetyltransferase 2-A), is a histone acetyltransferase (HAT). These 
enzymes are responsible for acetylating conserved lysine residues within the N-terminal tails of 
histones by transferring acetyl groups from acetyl coenzyme A (CoA). Various studies published 
over the past few decades indicate that post-translational histone modifications serve to 
modulate chromatin compaction and consequently gene activity.381 Specifically, actively 
transcribed DNA is often associated with acetylated histone isoforms, suggesting that HAT 
activity is correlated with transcriptional activation. This was first demonstrated by Hebbes et 
al. in 1988.431 Antibodies raised against hyperacetylated histones were employed in chromatin 
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immunoprecipitation assays to illustrate that these histones tend to localise to regions which 
are transcriptionally active.431 Histone acetylation is now established as a hallmark of 
transcriptionally competent chromatin, alongside sensitivity to nuclease digestion.432 It is 
believed that acetylation activates gene expression by loosening the chromatin structure, due 
to charge neutralisation of the basic lysines. This weakens the interaction of the histone with 
the DNA, and establishes docking sites for other proteins and complexes.433 In contrast to that 
of SWI/SNF complexes, this chromatin remodelling function is ATP-independent.434 
Vertebrates have another HAT called PCAF (P300/CREBBP-associated factor), or KAT2B. KAT2A 
and KAT2B have a sequence identity of 70%.435 Neither exist freely in cells. The two homologues 
are integrated mutually exclusively into one of two related complexes, SAGA (Spt-Ada-Gcn5 
acetyltransferase) or ATAC (ADA2A-containing).436 Until relatively recently there were believed 
to be three unique complexes, STAGA (SPT3-TAF9-GCN5 acetyltransferase), TFTC (TBP-free-TAF-
containing) and ATAC. However, it has been concluded that STAGA and TFTC are the same, and 
the original preparations can be separated into SAGA and a series of TAF (TBP-associated factor)-
containing complexes.437 Yeast have a single SAGA complex, which has an assortment of 
functions, such as in transcription initiation and elongation, TBP interactions, mRNA export and 
maintaining DNA integrity. This complex has diverged during evolution to produce the four 
SAGA-like complexes in humans, SAGA and ATAC, each with two variants, incorporating KAT2A 
or KAT2B438, Figure 4.5. SAGA is the larger of the multiprotein complexes, composed of 18 
subunits arranged into HAT, TAF, DUB (deubiquitination) and SPT (suppressor of Ty) modules. 
The physical relationships between the subunits in ATAC are less well defined, but it is clear that 
the HAT module is retained, with ADA2A replacing ADA2B, and the DUB module is not.436 
Interestingly, ATAC incorporates two HAT subunits, GCN5/PCAF and ATAC2.438 
 
Figure 4.5. Schematic of Mammalian SAGA-Like Complexes. Structures of the multiprotein SAGA and ATAC 
complexes, summarising the modules and subunits incorporated. Subunits with HAT activity are labelled in bold. 
Figure adapted from Wang & Dent, 2014.436 
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The enzymatic activity of GCN5 is enhanced by the other subunits within the complexes.435 SAGA 
and ATAC exhibit HAT activity at histones H3 and H4. However, it appears that GCN5 
preferentially acetylates H3K9 and H3K14 residues. Correspondingly, it has been demonstrated 
that RNAi depletion of GCN5 results in a decrease in the acetylation of H3 but not H4.439 It is 
likely that several HATs act redundantly at H4. The specificity of ATAC2 is less well understood, 
but it appears to show some preference for H4K16.440 The HAT activities of both GCN5 and 
ATAC2 contribute to the specificity of ATAC. SAGA also exhibits a second enzymatic role in 
deubiquitination, via the USP22 (ubiquitin-specific protease 22) subunit. The complex has been 
identified as the major H2B deubiquitinase in human cells and this deubiquitination activity is 
required for full activation of SAGA-dependent inducible genes.441  
SAGA and ATAC have a multitude of functions, for example in stress-induced signalling 
pathways, chromatin remodelling and transcription regulation, embryonic development, cell 
cycle progression and DNA repair.438 Principally, SAGA is critical in transcription initiation. By 
acetylating histones at promoter regions and deubiquitinating those within transcribed regions, 
the complex recruits RNA polymerase II and thereby nucleates transcription initiation. It appears 
that SAGA is the cofactor for all RNA polymerase II transcription.442 The ATAC complex is 
particularly crucial for mammalian development. Atac2-null mice display early embryonic 
lethality due to cell cycle defects.443  
Interestingly, in human immunodeficiency virus type 1 (HIV-1) infection, KAT2A is known to 
specifically interact with and acetylate the viral transactivator protein, Tat, which enhances Tat-
dependent transcription of the HIV-1 long terminal repeat.444 It is also responsible for the 
acetylation of HIV-1 integrase, which catalyses the integration of the viral DNA into the host 
genome. KAT2A knockdown cells demonstrate reduced infectivity.445  
KAT2A contains the catalytic HAT domain and a bromodomain, illustrated in Figure 4.6 (a)241 and 
(b)238 respectively. As discussed, HATs acetylate conserved lysine residues in the amino terminal 
domains of the histones, to induce transcriptional activity.381 The HAT domain is the catalytic 
domain responsible for transferring acetyl groups from acetyl-CoA to the lysine residues. 
Bromodomains are able to recognise and selectively bind these acetylated lysine residues. 
Perhaps predictably, these evolutionarily conserved protein modules are found in many 
chromatin-associated proteins and the majority of known nuclear HATs. It is thought that 
bromodomains facilitate highly specific histone acetylation by tethering the HATs to precise 
chromosomal sites. In three-dimensional structure the domain adopts a left-handed four-helix 
bundle, with the two intervening loops at one end packing to form a surface-accessible 
hydrophobic pocket for binding at acetylated lysine.446 
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Figure 4.6. Crystal Structures of GCN5. (a) Crystal structure of Homo sapiens GCN5 acetyltransferase domain with 
acetyl-CoA (grey) bound (PDB ID: 1Z4R).241 (b) Crystal structure of Homo sapiens GCN5 bromodomain (PDB ID: 3D7C, 
chain A).238 Protein chains coloured from blue at N-terminus to red at C-terminus. 
4.2 Results 
Having selected RNF4, ASF1A and GCN5 as biologically desirable drug targets, information and 
data on these proteins was compiled from online resources and databases with an aim to assess 
their druggability. 
 
Figure 4.7. Schematic of Functional Protein Association Networks. Association networks of PBRM1 and RNF4, ASF1A 
and KAT2A, predicted using results from experiments (pink) and databases (blue), determined by STRING 9.1.161 
A diagram of the relevant protein association networks was constructed in STRING 9.1161, using 
results from experiments and databases to predict association and incorporating 15 additional 
white nodes. The resulting schematic is shown in Figure 4.7. While GCN5 homologues, KAT2A 
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and KAT2B appear to interact with an array of proteins, ASF1A was shown only to interact with 
the histones, HIRA, p53 and ASF1B, and no interacting partners of RNF4 had yet been identified. 
This may be indicative of the number of cellular processes the proteins are involved in. 
4.2.1 RNF4 
Due to the small size of RNF4, it was suggested that it should be relatively easy to produce to 
use in assays. Furthermore, the low number of cellular processes in which it is implicated might 
reduce the number of on-target side effects of a targeted therapeutic. From a biological 
viewpoint, RNF4 was therefore an attractive target. 
A DELTA-BLAST180,183 search against the PDB identified a crystal structure of the Rattus 
norvegicus RNF4 (PDB ID: 3NG2)234, which showed 99% identity with the human orthologue at 
the RING finger domain region, and therefore no modelling was required. Binding pockets were 
identified from receptor cavities using Fpocket 2.0165, and the corresponding Fpocket 
druggability scores were calculated.170 Only one pocket was identified, as highlighted in Figure 
4.8 (a), with an associated druggability score of 0.608, which is higher than the threshold of 0.5, 
suggesting that the cavity may be druggable.  
 
Figure 4.8. Analysis of Structural Pocket in RNF4, Identified by Fpocket 2.0.165 (a) Rattus norvegicus RNF4 homodimer 
(PDB ID: 3NG2)234 shown in green with heteroatoms highlighted. Structural pocket depicted in yellow. (b) Homo 
sapiens RNF4 (PDB ID: 2XEU)235 in grey, aligned with that of Rattus norvegicus in green. Structural pocket shown in 
yellow and ubiquitin moiety in cyan. The interaction site of the ubiquitin moiety does not align with the identified 
cavity. 
The PDB158 and Chembl159 were searched to identify small molecules which could bind at this 
site and thus provide inspiration for a pharmacophore. Unfortunately, this search did not yield 
any positive results. A crystal structure of Homo sapiens RNF4 (PDB ID: 2XEU)235 appeared to 
depict a small molecule binding to RNF4. However, upon closer inspection it became apparent 
that the ligand in question was actually the ‘Ile44 hydrophobic patch’ of the larger ubiquitin 
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protein. Furthermore, alignment of 2XEU235 with 3NG2234 confirmed that the site of this 
interaction did not correspond with the position of the cavity identified by Fpocket, Figure 4.8 
(b). In summary, with the information available, RNF4 did not represent a promising drug target. 
4.2.2 ASF1A 
ASF1A is larger than RNF4 and it may therefore be more difficult to produce stable protein, 
however, similarly to RNF4, the low number of cellular processes in which it has been implicated 
might reduce the potential for on-target side effects.  
A DELTA-BLAST180,183 search against the PDB identified the Homo sapiens crystal structure of 
ASF1A complexed with histones H3 and H4 (PDB ID: 2IO5)236, and therefore no modelling was 
necessary. Fpocket 2.0165 analysis identified six receptor cavities, which are displayed in Figure 
4.9, and the associated Fpocket druggability scores170 are shown in Table 4.1. While five were 
very low scoring, one (shown in red) was very interesting, having an associated druggability 
score of 0.963, suggesting a highly druggable cavity. 
 
Figure 4.9. Analysis of Structural Pockets of ASF1A Identified by Fpocket 2.0.165 Rotated views of Homo sapiens 
ASF1A complexed with histones H3 and H4 (PDB ID: 2IO5)236, with ASF1A shown in cyan, histone H3 and H4 in yellow 
and pink respectively and structural pockets highlighted. 
Surprisingly, the high scoring pocket was not located at the PPI interface with histones H3.1 and 
H4, but on the opposite face of ASF1A. Upon investigation, it was found that this pocket was in 
fact the interaction site for HIRA. By comparing 2IO5236 with a crystal structure of the Homo 
sapiens ASF1A-HIRA complex (PDB ID: 2I32)424, Figure 4.10, it was found that the cavity coincided 
with the binding position of a proline residue at the ASF1A-HIRA PPI interface. This ASF1A-HIRA 
complex had been identified during an interesting study which used targeted mutagenesis as a 
means to biochemically characterise the interaction between HIRA and ASF1A.424 
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Table 4.1. Druggability Scores from Fpocket 2.0.170 Druggability scores for the pockets identified in ASF1A. 
Pocket Colour Druggability score 
1 Red 0.963 
2 Green 0.020 
3 Pink 0.062 
4 Orange 0.026 
5 Blue 0.086 
6 Grey 0.011 
  
While this structural cavity may be druggable, this is of little use if such binding does not induce 
the desired biological effect. The protein association network generated in STRING 9.1161 
suggests that PBRM1/BAF180 and ASF1A are likely to be synthetic lethal partners by virtue of 
their mutual interaction with the histones. Consequently, a small molecule which targets the 
ASF1A-HIRA PPI interface may not confer the necessary biological response to result in cell death 
in combination with a mutation in BAF180. Unfortunately, in unpublished work (Hopkins S. and 
Downs J., Genome Damage and Stability Centre, University of Sussex), it was confirmed that 
HIRA and BAF180 are not synthetic lethal, suggesting that a drug targeted at the ASF1A-HIRA PPI 
interface is unlikely to enable selective killing of cancer cells mutated in BAF180. Given the 
absence of other druggable pockets, it was concluded that ASF1A did not represent a worthwhile 
target for tool inhibitor development at this time. 
 
Figure 4.10. Comparing the PPI of ASF1A and HIRA with Structural Pockets Identified by Fpocket 2.0.165 Homo 
sapiens ASF1A (PDB ID: 2IO5)236 aligned with Homo sapiens ASF1A-HIRA complex (PDB ID: 2I32).424 ASF1A is shown in 
cyan and HIRA in cream, with the heteroatoms highlighted. Structural pockets are displayed as spheres. Red pocket 
corresponds to binding position of proline residue. 
4.2.3 GCN5/KAT2A 
KAT2A is a HAT, responsible for promoting transcriptional activation.447 As HATs are well studied, 
many suitable and relatively simple assays already exist which could be utilised in screening. 
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However, unlike RNF4 and ASF1A, the high number of cellular processes in which the protein is 
implicated may increase the potential for adverse effects from targeted therapy. 
A DELTA-BLAST180,183 search against the PDB yielded two discrete classes of matches, showing 
sequence similarity at either the HAT domain or the bromodomain. The crystal structures of the 
Homo sapiens GCN5 Acetyltransferase domain (PDB ID: 1Z4R)241, and the Homo sapiens GCN5 
bromodomain (PDB ID: 3D7C)238, were identified and therefore again no modelling was needed. 
The binding pockets identified from receptor cavities using Fpocket 2.0165 are shown in Figure 
4.11 and Figure 4.12 respectively, and the corresponding druggability scores170 in Table 4.2. 
Fpocket identified four pockets at the HAT domain, one of which exhibited a particularly high 
druggability score of 0.908, and another four at the bromodomain, two of which had associated 
druggability scores of 0.807 and 0.869, suggestive of highly druggable cavities.  
 
Figure 4.11. Structural Pockets of KAT2A Acetyltransferase Domain Identified by Fpocket 2.0.165 Rotated views of 
Homo sapiens GCN5 acetyltransferase domain (PDB ID: 1Z4R)241, with KAT2A in yellow and acetyl-CoA in green, with 
heteroatoms highlighted. Structural pockets shown as spheres. Red pocket corresponds to binding site of acetyl-CoA. 
Unsurprisingly the most druggable cavity identified at the HAT domain was found to coincide 
with the binding site of acetyl-CoA. This is useful as the small molecule can be utilised in 
designing potential pharmacophores for drug development, and a tool inhibitor successfully 
targeted at this site would doubtlessly disrupt enzymatic function. However, given that all HATs 
are able to bind acetyl-CoA, selectively targeting this site may be challenging. 
3D7C238 is an apo structure, depicting the unbound KAT2A bromodomain. However, as discussed 
above, bromodomains are known to interact with acetylated lysine residues. To ascertain 
whether the lysine binding site coincided with either of the pockets identified as druggable, 
3D7C238 was aligned with a crystal structure of S. cerevisiae GCN5 bromodomain complexed with 
H4 peptide acetylated at lysine 16 (PDB ID: 1E6I)239, Figure 4.13. It was discovered that the 
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acetylated peptide binds at the site that has an associated druggability score of 0.807. As above, 
the structure of the acetylated peptide ligand is useful in suggesting potential pharmacophores 
for use in tool inhibitor design. It also improves the likelihood that drugs targeted at this site 
should have a desirable therapeutic effect. It is proposed that preventing the bromodomain 
from successfully tethering the HAT at precise chromosomal sites should prevent the proper 
acetylation of histones. 
 
Figure 4.12. Structural Pockets of KAT2A Bromodomain Identified by Fpocket 2.0.165 Rotated views of Homo sapiens 
GCN5 bromodomain (PDB ID: 3D7C)238, with KAT2A shown in purple with the heteroatoms highlighted. Structural 
pockets shown as spheres. 
Table 4.2. Druggability Scores from Fpocket 2.0.170 Druggability scores for the pockets identified at the KAT2A HAT 
domain and bromodomain. 
 Pocket Colour Druggability Score 
KAT2A 
Acetyltransferase 
Domain 
1 Red 0.908 
2 Blue 0.171 
3 Pink 0.043 
4 Orange 0.045 
KAT2A 
Bromodomain 
1 Red 0.807 
2 Green 0.869 
3 Pink 0.031 
4 Orange 0.038 
  
Given the high similarity of the two mammalian GCN5 homologues, KAT2A and KAT2B, both in 
their structures and involvement in protein association networks, it was deemed important to 
test the effect of knocking down KAT2B in BAF180 deficient cells. Interestingly, in unpublished 
work (Hopkins, S. and Downs, J., Genome Damage and Stability Centre, University of Sussex), it 
was determined that KAT2B is not synthetically lethal with PBRM1, highlighting KAT2A as a 
particularly valuable target for tool inhibitor development. Despite inevitable challenges, from 
the information available, KAT2A therefore appears to be an interesting and promising target 
for tool inhibitor development at both the HAT domain and bromodomain. 
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Figure 4.13. Analysis of Druggable Pocket in KAT2A Bromodomain. Homo sapiens GCN5 bromodomain (PDB ID: 
3D7C)238, shown in purple with the heteroatoms highlighted, aligned with that of S. cerevisiae (PDB ID: 1E6I)239, to 
determine whether the binding site of acetylated lysine corresponds to one of the structural pockets identified. 
Histone H4 peptide acetylated at lysine 16 in yellow with the heteroatoms highlighted and structural cavity in red. 
4.3 Discussion 
Mutations in PBRM1 have been identified in a variety of human cancers377, but most recently 
the gene has been identified as a major player in clear cell renal cell carcinoma, with truncating 
mutations observed in 41% of samples of primary ccRCC.1 Such unique features of tumours can 
be exploited in targeted therapies and are currently the focus of many efforts in cancer research 
using synthetic lethality approaches. The prominent mutation of PBRM1 has been specifically 
highlighted as a promising opportunity to target ccRCC.2 The aim of this work was to assess the 
druggabilities of RNF4, ASF1A and GCN5, which have been identified as synthetic lethal partners 
of PBRM13, and therefore could represent interesting targets for tool inhibitor development. 
Such tools should improve biological investigation and could initiate drug discovery projects. 
A crystal structure of Rattus norvegicus RNF4 (PDB ID: 3NG2)234 was identified with 99% identity 
to the human orthologue. A search for structural pockets identified one of particular interest 
with an associated druggability score of 0.608, suggesting it would be druggable. However, a 
search for small molecules bound at this site, which could provide inspiration for a 
corresponding pharmacophore, was unsuccessful. With the information available, RNF4 did not 
therefore represent a promising drug target.  
A crystal structure was identified characterising Homo sapiens ASF1A complexed with histones 
H3 and H4 (PDB ID: 2IO5).236 One interesting pocket was identified with an associated 
druggability score of 0.963. This pocket was located not at the PPI interface with histones H3.1 
and H4, but at the ASF1A-HIRA interface. It was noted that inhibiting ASF1A and HIRA from 
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interacting may not confer the desired synthetic lethal response with PBRM1 mutation. In 
unpublished work (Hopkins S. and Downs J., Genome Damage and Stability Centre, University of 
Sussex), it was confirmed that HIRA and PBRM1 are not synthetic lethal, suggesting that a drug 
targeted at the ASF1A-HIRA interface is not likely to induce selective killing in combination with 
PBRM1 mutation. Given the absence of other druggable pockets, it was determined that ASF1A 
was not a promising drug target at this time. 
KAT2A contains both a HAT domain and a bromodomain. Crystal structures of the Homo sapiens 
GCN5 Acetyltransferase domain (PDB ID: 1Z4R)241, and the Homo sapiens GCN5 bromodomain, 
(PDB ID: 3D7C)238, were identified. One pocket at the HAT domain, with a particularly high 
druggability score of 0.908, was found to coincide with the binding site of acetyl-CoA, thereby 
suggesting potentially suitable pharmacophores which could be utilised in drug design. A pocket 
of interest was also identified at the bromodomain, which had an associated druggability score 
of 0.807. This pocket coincided with the binding site of acetylated lysine residues, which again 
should be useful in tool inhibitor design, towards identifying pharmacophores and developing 
assays. Because mammalian cells have two GCN5 homologues, KAT2A and KAT2B, which are 
implicated in similar pathways, it seemed important to test whether KAT2B knockdown effects 
BAF180 deficient cells. This was investigated in unpublished work (Hopkins S. and Downs J., 
Genome Damage and Stability Centre, University of Sussex), and it was confirmed that KAT2B 
and PBRM1 are not synthetic lethal. From the available information, KAT2A was established as 
a promising and interesting target for tool inhibitor development. 
In summary, at the time this work was completed, RNF4 and ASF1A did not represent druggable 
targets, within the restraints of accessible resources. They could be revisited in the future, if 
further data and biological resources become available. However, KAT2A was highlighted as a 
promising target for development of a tool inhibitor. 
4.3.1 KAT2A-BAF180 Synthetic Lethality 
The precise mechanism for KAT2A-BAF180 synthetic lethality has not been defined. However, 
the two proteins are engaged in a number of overlapping pathways. The relationship between 
histone acetylation and chromatin remodelling was first observed in yeast. Genetic experiments 
were used to demonstrate that mutations in GCN5 and SWI/SNF cause strikingly similar 
phenotypes; both are required for proper expression of the same genes, interact with the same 
chromatin components, and are synthetic lethal in yeast.448 Furthermore, chromatin 
immunoprecipitation studies indicate that GCN5 is involved in recruiting and maintaining 
SWI/SNF at promoters449,450, and that in eukaryotes histone acetylation occurs prior to SWI/SNF 
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recruitment.451,452 Finally, it has been observed that GCN5-dependent acetylation at H3K9, 
H3K14, H4K8 and H4K12 is required for recruitment of the SWI/SNF BRG1 subunit, via acetylated 
H4K8453, and transcription factor II D (TFIID) via TAF1, which interacts with all four acetylated 
lysines453–455, Figure 4.14. 
 
Figure 4.14. Examples of Mechanisms by which GCN5 Regulates Gene Expression. (a) The GCN5 bromodomain binds 
to acetylated histones and anchors SAGA at the nucleosome, enabling acetylation of neighbouring nucleosomes. (b) 
BRG1 subunit of SWI/SNF binds to acetylated H4K8, enabling SWI/SNF to remodel adjacent promoter region. (c) TAF1 
binds to acetylated nucleosome and recruits transcription factor TFIID. Figure adapted from Josling et al., 2012.456 
Similarly, histone acetylation by the SAGA complex has been observed to promote SWI/SNF 
recruitment in vitro. SWI/SNF exhibits a higher affinity for nucleosomes containing acetylated 
H3, such that it is retained at these nucleosomes even after dissociation of the participating 
transcriptional activator.457 This could suggest that recruitment by lysine acetylation occurs by 
slowing the off-rate rather than promoting initial association.434 In support of this hypothesis, 
removing the bromodomain from the BRG1-like subunit disrupts but does not abolish 
recruitment458, which is less severe than the effect of mutations obstructing interactions with 
transcriptional activators.459 These observations suggest that chromatin remodellers are 
recruited to regulatory regions via site-specific DNA binding factors and then interact via their 
bromodomains with acetylated histones to stabilise their association with the chromatin.434 
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Mutations affecting RSC, another SWI/SNF homologue, are also lethal in combination with GCN5 
knockout, and this complex interacts with acetylated H3 as well.460 GCN5 is actually implicated 
in both positive and negative regulation of RSC. It has been observed that GCN5 acetylates RSC4 
K45 to create an intramolecular binding site for one of the RSC4 bromodomains. The associated 
binding prevents a second RSC4 bromodomain from interacting with H3K14.461 Despite the 
strong influence on binding affinity, it is rare that histone acetylation dramatically impacts the 
ATPase or remodelling functional activities of SWI/SNF complexes.462  
GCN5-dependent histone acetylation has also been shown to recruit SWI/SNF complexes to DNA 
double-stranded breaks via the BRG1 bromodomain.46 In mammalian cells, recruitment of BAF 
is reliant on γH2AX, but these do not appear to interact directly.463 Lee et al. showed that γH2AX 
recruits GCN5, which acetylates H3 to promote BAF recruitment.46 The chromatin remodelling 
directed by BAF increases the accessibility of neighbouring nucleosomes, enabling further H2AX 
phosphorylation and thereby more acetylation by GCN5 and further increased BAF binding. This 
results in a cooperative activation loop to propagate γH2AX formation and induce chromatin 
remodelling at DSBs.46 The interaction of SAGA with promoters seems to depend on a similar 
feed forward loop regulated by histone modifications. SAGA interacts with acetylated H3 via the 
GCN5 bromodomain.458 Thus, it appears that SAGA writes the acetylation mark on histone H3, 
and subsequently reads it. In this way GCN5 could be proposed to walk along a length of 
chromatin, gradually acetylating histones so as to establish a transcriptionally competent 
structure.464 
In conclusion, while the mechanism for KAT2A-BAF180 synthetic lethality is not yet understood, 
it is clear that KAT2A has the potential to be an interesting drug target. To understand whether 
the druggability determined in this work translates to phenotypic activity against BAF180 
deficient cancer cells, KAT2A tool inhibitors are required. Work carried out towards developing 
tool inhibitors for the KAT2A HAT domain and bromodomain is described in Chapters 5 and 6 
respectively. It is hoped that these tools will enable detailed biological investigation to afford a 
better understanding of the dynamic regulation of gene expression by acetylation, and 
potentially initiate translational drug discovery projects towards treating ccRCC via a synthetic 
lethality approach. 
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5 Towards Development of KAT2A HAT Domain Tool Inhibitors 
KAT2A is synthetic lethal with BAF1803, the second most frequently mutated gene in clear cell 
renal cell carcinoma.376 This histone acetyltransferase is therefore an interesting target for tool 
inhibitor development, to enable biological investigation and potentially initiate translational 
drug discovery projects towards treating ccRCC. 
In Chapter 4.2, a highly druggable binding pocket was identified at the KAT2A HAT domain using 
computational techniques. HATs represent an exciting class of targets in drug discovery, with an 
array of potential applications in many diseases. They are commonly deemed interesting targets 
for development of tool inhibitors, even in the absence of specific disease association. However, 
existing KAT2A inhibitors are inadequate for biological investigation, disease validation and 
initiation of drug discovery efforts. 
In this chapter, computational techniques were used to determine that a selective dual inhibitor 
of the KAT2A and KAT2B HAT domains was achievable and to select a diverse set of compounds 
with reported activity against KAT2A. Unfortunately, attempts to establish a fluorescence based 
activity assay in house, which was previously employed in high-throughput screening, were 
unsuccessful as the assay proved prohibitively unreliable. With those hits from this screen 
discounted4,5, the inventory of small molecule inhibitors of KAT2A and KAT2B was quickly 
exhausted, thereby terminating attempts to develop a KAT2A HAT tool inhibitor. 
5.1 Introduction 
Based on the previous work, in which KAT2A was identified as a promising target for 
development of a tool inhibitor, this enzyme became the major focus of this research. As 
discussed, KAT2A contains a HAT domain and a bromodomain. The HAT domain is the catalytic 
domain responsible for transferring acetyl groups from acetyl-CoA to conserved lysine residues 
in the amino terminal domains of histones, to induce transcriptional activity.381 An inhibitor 
successfully designed to target this domain and disrupt the interaction with acetyl-CoA would 
therefore disrupt enzymatic function and afford the desired biological response. As a result, the 
HAT domain was prioritised as the preferred target for tool inhibitor development. 
5.1.1 Phylogeny, Structure and Function 
Protein acetylation was discovered in 1963, when Phillips identified acetyl groups in histones 
isolated from calf thymus.465 In 1964, Allfrey et al. showed that in isolated nuclei radiolabelled 
acetate was rapidly incorporated into histones, independent of translation.466 Furthermore, it 
had not long before been shown that histones inhibit RNA synthesis, and Allfrey et al. 
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demonstrated that histone acetylation decreased the effectiveness of this inhibition. They 
proposed that post-translational histone acetylation affords a ‘dynamic and reversible 
mechanism for "activation" as well as "repression" of RNA synthesis’.466 Unfortunately, after this 
development, acetylation was largely neglected from research efforts for 30 years467, with the 
notable exception that, in 1978, sodium butyrate was discovered to inhibit histone deacetylase 
activity, causing histone hyperacetylation.468,469 In 1988, the connection between histone 
acetylation and transcriptional activation was uncovered431 and there was growing recognition 
that histones acetylated at specific residues mediate unique effects on gene expression.467 This 
initiated a flood of research in the 1990s, affording many discoveries, including the pivotal 
revelations that GCN5 and RPD3 (reduced potassium dependency 3), both known transcription 
regulators, possess histone acetyltransferase470 and deacetylase471 activity respectively. This 
finally confirmed a causal link between histone acetylation and transcriptional regulation. 
It is now widely accepted that transcription can be regulated via acetylation of conserved lysine 
residues located in the amino terminal domains of histones. Acetylation results in charge 
neutralisation which is thought to weaken the interactions between the histones, DNA and 
regulatory proteins, which alters the nucleosome structure, producing the more open chromatin 
environment required for transcription.381 These acetylation marks are written by HATs, by 
transferral of an acetyl from acetyl-CoA, and erased by histone deacetylases (HDACs). 
 
Figure 5.1. Phylogenetic Tree of HAT Families. Schematic showing HATs subdivided into their respective families. 
Figure adapted from Arrowsmith et al., 2012.380 
During the following five years an array of additional HATs were identified467, including for 
example, TAF1472, p300 and CREBBP473. Phylogenetic trees have been devised by groups such as 
the Structural Genomics Consortium (SGC) to map the evolutionary and structural relationships 
134 
Chapter 5 
within gene families.219 One such tree for the HAT domains is shown in Figure 5.1.380 Common 
aliases of the HAT proteins are listed in Table 5.1. As shown, the domains can be separated into 
families. The MYST family (after yeast members MOZ, YBF2/SAS3, SAS2 and TIP60) is the largest. 
The p300/CBP family comprises of p300, CREBBP and ATAT1 (α-tubulin N-acetyltransferase 1), 
and KAT2A and KAT2B are in the GNAT (GCN5-related N-acetyltransferases) family. The other 
HATs are transcriptional co-activators or steroid receptor co-activators, which harbour 
acetyltransferase activity alongside their other functions.474 Interestingly, except from at the 
core region of the acetyl-CoA binding sites, there is little overall sequence conservation between 
these HAT families. This diversity should enable development of selective tool inhibitors. Within 
families conservation is higher. As discussed, KAT2A and KAT2B have 70% sequence identity.435 
Table 5.1. Alternative Names for Histone Acetyltransferases. HATs listed with families, subtypes and aliases.474 
Family Subtype Aliases 
Cytoplasmic KAT1 HAT1 
 HAT4 NAA60 
GNAT KAT2A GCN5 
 KAT2B PCAF 
 KAT9 ELP3 
p300/CREBBP KAT3A CREBBP, CBP 
 KAT3B p300, EP300 
 ATAT1 MEC17 
MYST KAT5 TIP60 
 KAT6A MYST3, MOZ 
 KAT6B MYST4, MORF 
 KAT7 MYST2, HBO1 
 KAT8 MYST1, MOF 
Transcriptional Co-activators KAT4 TAF1, TAFII250, TFIID1 
 KAT12 GTF3C4, TFIIIC90 
Steroid Receptor Co-activators KAT13A NCOA1, SRC1 
 KAT13B NCOA3, SRC3, AIB1, ACTR 
 KAT13C NCOA2, SRC2, P600 
 KAT13D CLOCK 
  
The first HAT X-ray crystal structures resolved were Saccharomyces cerevisiae HAT1 (PDB ID: 
1BOB)475, Saccharomyces cerevisiae KAT2A (PDB ID: 1YGH)476 and Homo sapiens KAT2B (PDB ID: 
1CM0).477 The KAT2A HAT domain structure, which is well conserved between yeast and 
humans, has a mixed α/β topology, comprising of five α-helices and six β-strands with a globular 
fold, Figure 5.2.241 Overall, the domain resembles a vice. The core, which forms the base of the 
vice, is composed of the three-stranded antiparallel β-sheet of β2, β3 and β4, the α-helix α3 and 
the strand-loop-helix containing β5 and α4. The N- and C-termini form the two sides of the vice. 
At the N-terminus, β1 contributes to the core β-sheet via hydrogen bonds with β2, while α1 and 
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α2 sit off to one side and above the core. At the C-terminus, the β6 strand of the loop-α5-loop-
β6 substructure is associated with the core by hydrogen bonding with β5. The positioning of the 
core and the N- and C-termini creates a pronounced cleft, approximately 10 x 10 x 20 Å, suitable 
for substrate binding. While the core domain is structurally conserved among HATs, the terminal 
regions show no sequence homology with other acetyltransferases.476  
 
Figure 5.2. KAT2A HAT Domain Topology. Structure of Homo sapiens GCN5 acetyltransferase domain (PDB ID: 
1Z4R).241 Protein chain coloured from blue at N-terminus to red at C-terminus and α-helices and β-strands labelled. 
HATs are bi-substrate enzymes, meaning that they bind and convert two substrates during 
catalysis. Theoretically, there are three catalytic mechanisms that bi-substrate enzymes can 
employ. Firstly, a random-order ternary complex mechanism, in which both substrates bind to 
the enzyme, in any order, to form a ternary complex and then the acetyl is transferred directly 
from the acetyl-CoA to the lysine. Secondly, a compulsory-order ternary complex mechanism, 
which again relies on formation of a ternary complex and direct transfer of the acetyl group, but 
the substrates must bind in a particular order. Finally, a ping-pong mechanism, in which acetyl-
CoA binds first and the acetyl is transferred to an amino acid at the enzyme catalytic site, then 
subsequently the lysine substrate binds and is acetylated. All three of these mechanisms require 
a general base at the HAT catalytic site, such as a glutamic acid residue, to facilitate nucleophilic 
attack at the acetyl-CoA by deprotonating the lysine residue. In addition, the ping-pong 
mechanism requires a residue capable of accepting the acetyl group, such as a cysteine.474 There 
is increasing evidence that GCN5 employs a compulsory-order ternary complex mechanism. A 
conserved glutamic acid residue (S. cerevisiae Glu173/Homo sapiens Glu582/Tetrahymena 
Glu122) located at the bottom of the cleft in the GCN5 catalytic site is implicated as the general 
base necessary for catalysis.476,478 Bi-substrate kinetic experiments indicated that both 
substrates are required to bind before catalysis, forming a ternary complex in a sequential 
manner, where acetyl-CoA binds first, followed by the lysine substrate.479  
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Also in accordance with this, Rojas et al. reported a crystal structure of the HAT domain of 
Tetrahymena GCN5 with coenzyme A and a histone H3 peptide bound in the cleft (PDB ID: 
1QSN).480 They showed that histone H3 binding is dependent on structural contributions from 
CoA, which reorients GCN5 upon binding. In addition, they propose that the conserved general 
base, Glu122, which is responsible for extracting the proton from the substrate lysine, acts via a 
mediating water that shuttles the proton from the lysine to the glutamic acid, Figure 5.3.480  
 
Figure 5.3. KAT2A HAT Domain Substrate Binding. Tetrahymena GCN5 acetyltransferase domain (PDB ID: 1QSN)480 
illustrated with and without protein surface. KAT2A shown in yellow, CoA in green and histone H3 peptide in white, 
with heteroatoms highlighted. Conserved general base Glu122, lysine residue and mediating water depicted. 
The diverse cellular and physiological implications of lysine acetylation do not result solely from 
the effect at histones. The number of non-histone proteins known to be subject to acetylation 
is growing rapidly. The first non-histone target discovered was tubulin481, followed some 10 
years later by p53482, HIV-1 transcriptional regulator Tat483,484 and nuclear factor-κB (NF-κB).485 
In 2006, Kim et al. conducted the first proteomic survey of protein acetylation. They used a 
screen combining immunoaffinity purification of the lysine-acetylated peptides with peptide 
identification by nano-HPLC/mass spectrometric analysis, to identify 388 acetylation sites in 195 
proteins.486 In 2009, Choudhary et al. elevated this approach, incorporating immunoaffinity 
purification, isoelectric focusing and high-resolution mass spectrometry. They identified 3600 
lysine-acetylation sites in 1750 proteins.487 With such an extensive list of acetylated proteins 
involved in an array of cellular processes, acetylation has finally been established as a globally 
important post-translational modification.467 This abundance of interacting species and 
associated cellular processes might increase the likelihood that therapeutics targeting KAT2A 
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would suffer from adverse effects. However, it is likely that these risks would be outweighed by 
the benefits and therefore tolerable, given that current approved cancer therapeutics leave 
considerable room for improvement.10 Irrespective of this, tool inhibitors of the KAT2A HAT 
domain will be invaluable in enabling mechanistic biological investigation and disease validation. 
5.1.2 Existing Inhibitors 
Analysis of protein acetylation and the enzymes involved in writing and erasing acetyl marks has 
highlighted many novel epigenetic drug targets and thereby provoked translational research. 
HDACs have been studied extensively, primarily regarding their roles in cancer. To date, four pan 
HDAC inhibitors, Vorinostat (SAHA), Romidepsin (Istodax), Belinostat (Beleodaq) and 
Panobinostat (Farydak), have been approved by the FDA for the treatment of cancers such as 
cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma.488 In contrast, 
no clinical applications have been described for HATs, despite their diverse roles in disease.474  
Research into the roles of HATs has hitherto depended on genetically modified mice and 
immortalised cell lines. These methodologies have specific limitations. Mouse models can be 
unachievable, as some HATs are essential and therefore knock-out is lethal489,490, and 
immortalised cell lines can behave quite differently to cells in vivo.474 There has therefore been 
a concerted effort in drug discovery efforts to identify small molecule tool inhibitors of HAT 
activity, to use as research tools and to explore the potential for therapeutic intervention.491 
Bi-substrate inhibitors 
Various different approaches have been utilised in developing tool inhibitors. The first class of 
HAT inhibitors developed were bi-substrate inhibitors, inspired by the ternary complex between 
the histone substrate, acetyl-CoA and HAT enzyme during the acetyl transfer. The inhibitors 
comprise of derivatives of CoA covalently linked to lysine substrate peptides of varying lengths. 
In 2000, Lau et al. described the design, synthesis, and application of peptide-CoA conjugates as 
inhibitors of p300 and PCAF.492 H3-CoA-20 achieved effective and selective inhibition of PCAF 
HAT activity, Figure 5.4. Unfortunately, due to their partial peptide structure, these inhibitors 
exhibit poor metabolic stability and poor cell permeability, limiting their potential applications. 
Natural Products 
Several natural products have been identified as HAT inhibitors, Figure 5.4. Anacardic acid, the 
major component of the liquid extracted from cashew nut shells, was identified as a non-
competitive HAT inhibitor in 2003.493 It exhibits inhibitory activity against PCAF (IC50 5 μM), but 
is limited by its poor permeability and poor selectivity both between HATs and with other 
protein families.494 Curcumin is the principal curcuminoid of turmeric and was published as a 
138 
Chapter 5 
HAT inhibitor in 2004. It demonstrates some selectivity between HATs, inhibiting the enzymatic 
activity of p300 and CREBBP activity but not that of PCAF.495 Garcinol is a polyisoprenylated 
benzophenone from the dried rind of kokum fruit, Garcinia indica. It exhibits good cell 
permeability and has been shown to inhibit PCAF (IC50 5 μM), but again is not selective and is 
therefore highly cytotoxic.496 Recently it has been demonstrated that garcinol inhibits TgGCN5b, 
the nuclear acetyltransferase required for replication of Toxoplasma tachyzoite. Treatment with 
garcinol resulted in reduced global lysine acetylation, particularly at histone H3, which induced 
aberrant expression of TgGCN5b dependent genes, and inhibited replication.497 Finally, embelin, 
a hydroxybenzoquinone isolated from powdered Embelia ribes berries, was reported as a non-
competitive PCAF inhibitor. It was demonstrated that embelin inhibited the HAT activity of PCAF 
with some selectivity over that of p300 and TIP60, by targeting the acetyl-CoA-PCAF 
interaction.498 Despite the limitations due to lack of selectivity within the HAT family and with 
other target families, these compounds are useful templates in developing HAT modulators.491  
Natural Product Analogues 
To date, modifying such natural product lead structures, with the aim of enhancing inhibitory 
properties, selectivity, and cell permeability, has proved one of the most successful approaches 
for developing small molecule HAT inhibitors, Figure 5.4.491 Using the crystal structure of Homo 
sapiens PCAF with CoA (PDB ID: 1CM0)477, Ghizzoni et al. proposed a binding model for PCAF 
inhibition by anacardic acid and thereby designed a series of derivatives as potential novel 
inhibitors. One compound afforded a twofold improvement in inhibitory potency for PCAF.499 A 
curcumin-derived, cinnamoyl analogue was identified which inhibits p300, PCAF and GCN5 
acetyltransferase activity in vitro. However, this was not selective between HATs and it exhibited 
poor cell permeability.500 In 2010, hydrazinocurcumin CTK7A, a water-soluble curcumin 
derivative, was demonstrated to inhibit p300, CREBBP and PCAF.501  
Synthetic Small Molecules 
Methods such as high-throughput and virtual screening have highlighted another handful of 
synthetic small molecules as HAT inhibitors, Figure 5.4. The α-methylene-γ-butyrolactone MB-3 
has been identified as a small, cell permeable KAT2A inhibitor.502 MB-3 was designed and 
synthesised in 2004, but it remains one of the most potent inhibitors reported for the KAT2A 
HAT domain (IC50 100 μM), with affinity comparable to histone H3. Unfortunately, MB-3 exhibits 
limited selectivity for KAT2A over other HAT domains, such as CREBBP (IC50 500 μM)502, and 
therefore does not represent a useful tool compound. MB-3 is expected to inhibit enzyme 
activity irreversibly, as a result of the α,β-unsaturated carbonyl moiety accessible for Michael 
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addition, which may also result in poor specificity against other protein families. However, Biel 
et al. report that a time dependence study of the inhibition mode suggests non-covalent 
binding.502 A recent study confirmed that MB-3 inhibits GCN5 HAT activity in Arabidopsis 
thaliana. Arabidopsis thaliana seedlings were germinated in the presence of MB-3. Three hours 
post-treatment H3K14 acetylation was reduced and GCN5 related genes were 
downregulated.503 MB-3 is often employed as a reference drug in testing new potential 
inhibitors. In one such example, quinoline derivatives were identified from a yeast phenotypic 
screen, which significantly reduced S. cerevisiae cell growth and induced histone H3 
hypoacetylation. Structural optimisation led to 4-hydroxy-2-pentylquinoline-3-carboxylic acid, 
which reduced the HAT catalytic activity to an extent comparable to MB-3.504 
 
Figure 5.4. Existing KAT2A and KAT2B HAT Inhibitors. 
A series of 35 isothiazolone-based p300 and PCAF inhibitors were identified using a high-
throughput screen. The most promising hits were confirmed to reduce cellular acetylation in 
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human colon tumour cell lines and total acetylation of histones H3 and H4 and α-tubulin.505 It 
was proposed that isothiazolones irreversibly inhibit enzyme activity, binding covalently to 
cysteines to form disulphides via cleavage of the nitrogen-sulphur bond. The high chemical 
reactivity of isothiazolones is the major limitation of this class of compounds, but unfortunately 
this reactivity is demonstrably linked to HAT inhibitory activity.506 A number of attempts have 
been made to identify analogues that offer reduced chemical reactivity while retaining effective 
HAT inhibition, and to elucidate the structure-activity relationship for isothiazolone-based 
inhibitors. 5-Chloroisothiazolones507, N-pyridylisothiazolones508 and pyridoisothiazolones509 
were found to be potent PCAF inhibitors. Unfortunately though, the high reactivity of 
isothiazolones towards thiolates510 has proved irrepressible, limiting their applicability in 
biological systems.474  
Ineffectual Inhibitors 
In 2009, Chimenti et al. reported a series of novel thiazole derivatives, Figure 5.5, which inhibit 
GCN5 HAT activity by modulating the network in which it is involved. Importantly, these 
compounds were selected for their ability to inhibit the growth of yeast with GCN5 deletions.511 
A number of studies have emanated from this research and unfortunately these thiazole 
derivatives have begun to be misinterpreted as GCN5 and PCAF inhibitors.512–514 A recent study 
describes the effect of one analogue, a ‘novel PCAF and GCN5 histone acetyltransferase 
inhibitor’, preferentially targeting lung cancer stem-like cells derived from non-small cell lung 
cancer patients.515 These compounds do not directly interact with KAT2A, but target the 
functional network via an undetermined interacting protein. 
 
Figure 5.5. Unsuitable HAT Inhibitors. Thiazole derivatives modulate GCN5 network, not GCN5 directly.511 
ZINC19217280 selective for Plasmodium falciparum GCN5 and do not inhibit Homo sapiens homologue.516  
In a recent study, 20 potential inhibitors of Plasmodium falciparum GCN5 were reported and it 
was experimentally validated that ZINC19217280 possesses antimalarial activity, Figure 5.5. 
While the in vitro parasite growth assay indicated an IC50 in the nanomolar range (~225 nM), no 
effect was observed in mammalian fibroblast cells. It was therefore resolved that ZINC19217280 
selectively inhibits Plasmodium falciparum GCN5 and not the Homo sapiens homologue.516 
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Overall, the development of HAT tool inhibitors has unfortunately proved very challenging. The 
current inhibitors are largely non-selective494,496 or have poor permeability492 and many are 
redox cyclers or covalent modifiers506. As a result there remains a crucial need for new potent 
and selective HAT inhibitors with improved therapeutic potential.474  
5.1.3 New Chemical Matter 
As well as the known HAT inhibitors, a ChEMBL159 search for small molecules bioactive against 
KAT2A yielded an array of hits from a high-throughput screen described in the PubChem 
BioAssay database (PubChem BioAssay AID: 504327).4 793 bioactive compounds were identified 
in this screen, completed by the NIH Chemical Genomics Center (NCGC). A corresponding hit 
confirmation assay was reported (PubChem BioAssay AID: 588347)5, again by the NCGC, which 
confirmed the activity of 96 of these compounds. In the activity assay, a pro-fluorescent 
maleimide derivative, ThioGlo-1, was used to measure the production of reduced CoA. ThioGlo-
1 fluoresces upon reaction with free thiols, such as that in reduced CoA. Inhibition of HAT activity 
by a small molecule prevents the reduction of acetyl-CoA to the thiol, and therefore ThioGlo-1 
will not fluoresce, Figure 5.6. When the screens were conducted, an initial read was carried out 
in attempt to identify compounds with fluorescence quenching properties, which would be likely 
to afford false positives. However, the authors anticipate that a large number of artefacts will 
remain and recommend counter-screens and further assay validation. 
 
Figure 5.6. ThioGlo-1 and Schematic of Associated Fluorescence Assay. Assay utilised in HTS reported in the 
PubChem BioAssay database (PubChem BioAssay AID: 504327).4 
5.2 Results 
5.2.1 Selectivity Potential 
In Chapter 4.2, a druggable structural pocket was identified at the KAT2A HAT domain using 
Fpocket 2.0165,170, which corresponds to the binding position of acetyl-CoA. EMBL-EBI Clustal 
Omega181,182 was used to compile pairwise and multiple sequence alignments in attempt to 
assess the potential for selectivity at this site, Figure Apx.5. Those amino acids which comprise 
the KAT2A HAT domain were selected and Scorecons220 was used to rate the conservation at 
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each associated site. Predictably, KAT2A and KAT2B exhibit extremely high homology, Figure 5.7 
(a), but fortuitously the residues are poorly conserved across other HAT families, Figure 5.7 (b). 
There is therefore a high chance of achieving tool inhibitors that are selective for the two GCN5 
homologues, but not that can distinguish between them. This was not discouraging. Small 
molecule dual inhibitors will nevertheless represent useful tools, which will enable biological 
exploration of the target proteins to further elucidate their biological roles and help in 
establishing functional assays. 
 
Figure 5.7. Assessing Residue Conservation at KAT2A Acetyl-CoA Binding Site. Homo sapiens GCN5 Acetyltransferase 
domain (PDB ID: 1Z4R)241 with acetyl-CoA in yellow and KAT2A coloured to indicate amino acid conservation 
determined by Scorecons220; red indicates the least conserved regions and bright green the most. (a) Results from 
pairwise alignment of KAT2A and KAT2B. (b) Results from multiple sequence alignment of GNAT and MYST families. 
5.2.2 Sifting the Existing Chemical Matter 
As discussed, a ChEMBL159 search for small molecules bioactive against KAT2A yielded (among 
other entries) a high-throughput screen, described in the PubChem BioAssay database 
(PubChem BioAssay AID: 504327)4 and corresponding hit confirmation assay (PubChem BioAssay 
AID: 588347)5 completed by the NCGC. KNIME242 was utilised in filtering the results of the 
confirmatory screen. KNIME, the Konstanz Information Miner, is a modular environment, which 
enables visual assembly and interactive execution of a data pipeline.242 A KNIME workflow was 
designed to filter the results and identify compounds that were defined as ‘active’, had 
acceptable curve descriptions, discarding any with efficacy >150 calculated from a partial curve, 
which did not reach the second asymptote, and were available from preferred suppliers, such 
that they could be purchased easily and at low cost. 47 compounds remained after filtering. 
Attempts to cluster these into 5-10 series of 3-5 compounds was unsuccessful due to the small 
size of the set. Instead, 11 compounds were manually selected that were drug-like and avoided 
undesirable motifs, such as pan-assay interference compounds (PAINS)517, Figure 5.8. 
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Figure 5.8. Prospective KAT2A HAT Inhibitors. From NCGC hit confirmation assay (PubChem BioAssay AID: 588347).5 
5.2.3 Fluorescence Based Activity Assay 
Having established that the KAT2A HAT domain represents a desirable target for specific tool 
inhibitor development and identified the HTS (PubChem BioAssay AID: 504327)4 reported by the 
NCGC, attempts to establish this assay in house and confirm these results were prioritised.  
Unfortunately, since the HTS was reported, ThioGlo-1 had been discontinued. Three alternative 
thiol reactive fluorescent probes were trialled in this work, fluorescein diacetate 5-maleimide, 
Thiol Fluorescent Probe IV and ThioGlo-5, Figure 5.9. 
 
Figure 5.9. Thiol Reactive Fluorescent Probes. Fluorescein diacetate 5-maleimide, Thiol Fluorescent Probe IV and 
ThioGlo-5. 
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Figure 5.10. Common Reducing Agents. Reducing agents used in assay buffers to stabilise the protein and prevent 
formation of undesirable disulphide bonds. 
To begin with, the sensitivity of fluorescein diacetate 5-maleimide was assessed. 50 μM 
fluorescent probe was added to solutions of dithiothreitol (DTT), Figure 5.10, at a range of 
concentrations, and the developing fluorescence was measured over time, Figure 5.11 (a). It was 
determined that the fluorescein diacetate 5-maleimide was slow acting, which was not ideal but 
could be tolerated, requiring a delay between indicator addition and plate reading, but also that 
it may not be sufficiently sensitive to measure the necessary thiol concentrations. The 
experiment was repeated with increased fluorescent probe and decreased DTT, to mimic the 
amount of reduced CoA expected in the final assay conditions, Figure 5.11 (b). The maximum 
expected concentration of reduced CoA was calculated at 70 μM, assuming that the protocol 
used in the HTS (PubChem BioAssay AID: 504327)4 would be mimicked and that the acetyl-CoA 
would be completely converted to reduced CoA. There was no assay window at these thiol 
concentrations, confirming that the fluorescein diacetate 5-maleimide was not sufficiently 
sensitive to use in this assay. 
 
Figure 5.11. Sensitivity of Fluorescein Diacetate 5-Maleimide. (a) Fluorescence of 50 μM probe with 0-5000 μM DTT, 
40 μL well volume, measured for three hours. (b) Fluorescence of 127 μM probe with 0-320 μM DTT, 40 μL well 
volume, measured after three hour incubation. Graphs represent mean ± 1 SD of three experiments. 
With fluorescein diacetate 5-maleimide proving unsuitable, attention turned to Thiol 
Fluorescent Probe IV. Favourably, this was much faster acting, with the reaction complete as 
soon as the plate was read, simplifying and accelerating experiments. The sensitivity of Thiol 
Fluorescent Probe IV was assessed at varying concentrations of the indicator and of DTT. This 
probe exhibited much improved sensitivity at concentrations as low as 10 μM, Figure 5.12 (a). 
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Figure 5.12. Preliminary Tests with Thiol Fluorescent Probe IV. (a) Fluorescence of 10 μM probe with 0-320 μM DTT, 
40 μL well volume. (b) Fluorescence of 70 μM acetyl-CoA with or without 10 μM probe, 40 μL well volume. (c) 
Fluorescence of 10 μM probe with 70 μM DTT or 70 μM acetyl-CoA and 75 μM histone H3 peptide (1-21) with or 
without 20 nM KAT2A, 40 μL well volume, measured for 30 minutes. Graphs represent mean ± 1 SD of three 
experiments. 
In another preliminary test, Thiol Fluorescent Probe IV was added to a mix of acetyl-CoA and 
histone H3 peptide (1-21), with and without KAT2A, and the developing fluorescence was 
measured for 30 minutes, Figure 5.12 (c). Compared with the 70 μM DTT controls, it appeared 
that acetyl-CoA and the H3 peptide resulted in significant fluorescence. It was confirmed that 
acetyl-CoA induces fluorescence, Figure 5.12 (b). This could suggest either that a percentage of 
free thiol is permanently present in the acetyl-CoA solution, or that the fluorescent probe also 
interacts with unmodified acetyl-CoA. There was also an observed increase in fluorescence upon 
KAT2A addition, which might be attributable to protein activity. However, the KAT2A storage 
buffer incorporated both DTT and glutathione, Figure 5.10, and the protein contains cysteine 
residues, all of which contain thiols that could interact with the probe to induce fluorescence.  
An attempt to measure enzyme progression at varying KAT2A concentrations over the course of 
two hours showed an unexpected decrease in fluorescence over time, Figure 5.13 (a). However, 
a slight increase was observed over the first 5-10 minutes, which could theoretically be indicative 
of activity, although it is more likely that the solutions were proceeding to equilibrium. 
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Figure 5.13. KAT2A Activity Tests. (a) Fluorescence of 10 μM Thiol Fluorescent Probe IV, 70 μM acetyl-CoA, 75 μM 
histone H3 peptide (1-21) and 0-20 nm KAT2A, 40 μL well volume, measured for two hours. (b) Fluorescence of 10 μM 
probe with 0-800 pm KAT2A with stepwise addition of: (i) 70 μM acetyl-CoA at 5 minutes and (ii) 75 μM histone H3 
peptide (1-21) at 15 minutes; 40 μL well volume, measured for two hours. (c) Fluorescence of 40 μM probe with 0-
800 pm KAT2A with stepwise addition of: (i) 75 μM histone H3 peptide (1-21) at 5 minutes and (ii) 70 μM acetyl-CoA 
at 10 minutes; 40 μL well volume, measured for 2.5 hours. Graphs represent mean ± 1 SD of three experiments. 
To improve understanding, the activity test was repeated at lower KAT2A concentrations with 
stepwise addition of each assay component, Figure 5.13 (b). Initially the Thiol Fluorescent Probe 
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IV was added to KAT2A alone. The fluorescence was higher at increased protein concentrations, 
likely due to the presence of cysteine residues, or DTT and glutathione in the storage buffer. 
Addition of acetyl-CoA at 5 minutes resulted in a sharp increase in fluorescence at all enzyme 
concentrations, as expected from the previous result. Introduction of the histone H3 peptide (1-
21) at 15 minutes also resulted in a similar increase in fluorescence. This was surprising, as the 
peptide solution contained no reducing agents. However, it was discovered that whilst the 
histone H3 peptide (1-21) sequence contains no cysteine residues, the commercial peptide 
incorporates a tag containing a cysteine. This cysteine can be expected to interact with the thiol 
probe. Importantly, in the 10 minutes directly following peptide addition, there was no time 
dependent increase in fluorescence, implying an absence of enzyme activity. 
In light of the unexpectedly high thiol concentrations, it was proposed that the thiol probe was 
limiting the reaction. A second activity test was conducted at higher probe concentration, again 
with stepwise addition of the assay components, Figure 5.13 (c). This appeared to avert the 
decrease in fluorescence with time. Conceivably, if thiols are present in large excess, Thiol 
Fluorescent Probe IV could react more than once. If this final product is not fluorescent at the 
same wavelength as the product of the single 1,4-addition to the Michael acceptor, this could 
result in transitory fluorescence. However, still no enzyme activity was observed. 
 
Figure 5.14. Thiol Fluorescent Probe IV with TCEP. Fluorescence of 0-200 μM TCEP with or without 500 μM Thiol 
Fluorescent Probe IV, 40 μL well volume. Graph represents mean ± 1 SD of three experiments. 
Whilst the probe had likely been rate limiting at the higher KAT2A concentrations, this did not 
explain the lack of observable protein activity throughout. Considering that DTT and glutathione 
are present in the buffer to stabilise the protein and prevent formation of undesirable disulphide 
bonds, it was proposed that if these reducing agents react with the probe, this could leave KAT2A 
vulnerable to denaturation. Tris(2-carboxyethyl)phosphine (TCEP), Figure 5.10, can be utilised 
as an alternative reducing agent. TCEP does not contain a thiol and therefore should not react 
with the fluorescence indicator and could be substituted for the DTT and glutathione, to reduce 
background fluorescence and maintain the stability of the protein. However, unfortunately it 
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was discovered that TCEP also interacts with Thiol Fluorescent Probe IV, Figure 5.14. Thiol 
Fluorescent Probe IV was therefore determined unsuitable for use in the assay. 
After this lack of success with Thiol Fluorescent Probe IV, attention turned to a third fluorescence 
indicator, ThioGlo-5. To ensure that sufficient ThioGlo-5 was used so as not to be limiting, the 
capacity of the probe was tested. ThioGlo-5 was added to solutions of DTT and glutathione 
intended to mimic the background thiol concentrations associated with 0-20 nM KAT2A in 
buffer, Figure 5.15 (a). Above 250 μM ThioGlo-5 the probe did not significantly limit the 
fluorescence.  A second preparatory experiment confirmed that ThioGlo-5 is slower acting than 
Thiol Fluorescent Probe IV, reacting gradually over 1.5 hours, and that like Thiol Fluorescent 
Probe IV, it fluoresces in the presence of TCEP, Figure 5.15 (b).  
 
Figure 5.15. Preliminary Tests with ThiGlo-5. (a) Fluorescence of 62.5-500 μM ThioGlo-5 with DTT and glutathione to 
mimic background thiol concentrations in 0-20 nM KAT2A, 40 μL well volume, measured after 20 minute incubation. 
(b) Fluorescence of 250 μM ThioGlo-5, with or without 192 μM glutathione or 192 μM TCEP, 40 μL well volume, 
measured over 1.5 hours. Graphs represent mean ± 1 SD of three experiments. 
An attempt to measure enzyme progression at 5 nM and 20 nM KAT2A, showed an increase in 
fluorescence upon protein addition, Figure 5.16. However, there was substantial error in the 
measurements and it was judged that the increase could plausibly be attributed to KAT2A 
cysteine residues. It was therefore concluded that there was no indication of enzyme activity. 
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Figure 5.16. KAT2A Activity Test. 250 μM ThioGlo-5, 70 μM acetyl-CoA and 75 μM histone H3 peptide (1-21) with 0-
20 nm KAT2A, employing DTT and glutathione as necessary to imitate protein storage buffer, 40 μL well volume, 
measured over one hour. Graph represents mean ± 1 SD of three experiments. 
A troubleshooting experiment was conducted in which every assay component was tested with 
ThioGlo-5, individually and in combination with every other, Figure 5.17, in the hope of 
identifying the most problematic elements. As expected, the DTT- and glutathione-containing 
protein buffer and the H3 peptide demonstrated significant fluorescence. However, introducing 
additional acetyl-CoA to either of these or combining the two resulted in a decrease in overall 
fluorescence. This was highly surprising, as it had been anticipated that any increase in thiol 
concentration would provoke an increase in fluorescence. This may result from ThioGlo-5 
becoming limiting, or the various thiols might interact with one another. Irrespective of the 
explanation, it was clear that the assay was unreliable and there were many complex component 
interactions and factors that would impede assay optimisation. As such, the fluorescence based 
activity assay was abandoned. 
 
Figure 5.17. Troubleshooting Experiment. Fluorescence of 250 μM ThioGlo-5 with all assay components: 70 μM 
acetyl-CoA, 75 μM histone H3 peptide (1-21), and protein storage buffer; in every combination, 40 μL well volume, 
measured over one hour. Graph represents mean ± 1 SD of three experiments. 
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Shortly after reaching this decision, the authors of the HTS shared with us that despite their 
initial publication they were also unable to establish a robust assay and they planned to 
investigate alternative radioligand binding techniques. 
5.2.4 EpiQuik™ HAT Activity Assay 
Having abandoned attempts to establish the fluorescence based HAT activity assay in house, 
and with a desire to avoid other assays dependent on production of reduced CoA, the EpiQuik™ 
HAT activity assay (Epigentek, UK) was identified. In this assay, the histone substrate is first 
stably captured in the wells. GCN5L2 and acetyl-CoA are then added to acetylate the substrate. 
After incubation GCN5L2 and acetyl-CoA are washed away, preventing further acetylation. A 
high affinity anti-acetylated histone antibody is added, the ‘capture’ antibody, which specifically 
recognises and binds the acetylated substrate. Any excess after incubating is washed away. A 
second, ‘detection’ antibody is then added, and again the excess is washed away after 
incubating. Finally, developing and stop solutions are applied sequentially, to afford absorbance 
at 450 nm. In this way, the amount of acetylated histone, which is directly proportional to the 
enzyme activity, is colourimetrically quantified via an enzyme-linked immunosorbent assay 
(ELISA)-like reaction.  
 
Figure 5.18. GCN5L2 Activity Measured by EpiQuik™ HAT Assay. HAT activity proportional to absorbance measured 
at 450 nm using commercially available colourimetric assay kit (Epigentek, UK). (a) Absorbance measured at 0-24 nM 
GCN5L2. Graph represents single experiment. (b) Absorbance measured at 0-16 nM GCN5L2. Graph represents mean 
± 1 SD of three experiments. 
The first trial of the assay looked promising, with absorbance increasing and finally plateauing 
with increased GCN5L2, indicating that acetylation increases with GCN5L2 concentration until a 
saturation point at which the peptide is fully converted within the period of incubation, Figure 
5.18 (a). However, attempts to repeat this experiment in triplicate highlighted a high margin of 
error, such that the standard deviation was often significantly larger than the assay window, 
Figure 5.18 (b). It is anticipated that by using a higher concentration of the histone substrate, 
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and thereby increasing the final absorbance, the assay window could be expanded, although 
care should be taken not to exceed the binding limit of the strip wells. 
5.2.5 Isothiazolones as Potential HAT Inhibitors 
Meanwhile, having determined that the hits from the HTS were unlikely to represent true KAT2A 
inhibitors, it was necessary to identify other relevant published chemical matter. The list of small 
molecules reportedly active against KAT2A had been exhausted, but given the extremely high 
homology of KAT2A and KAT2B, inhibitors of KAT2B should also exhibit activity against KAT2A. 
The majority of relevant compounds identified in a ChEMBL159 search for KAT2B inhibitors were 
isothiazolones.505–509 
Compounds can be docked into protein crystal structures in attempt to ascertain their binding 
pose and improve understanding of their activity. The Homo sapiens KAT2A HAT domain (PDB 
ID: 1Z4R)241 was prepared for docking in MOE.187 Firstly, it was protonated, corrected and 
minimised, Figure 5.19 (a). Then the Site Finder functionality was used to identify the site 
available for ligand binding, dummies were created at the alpha sphere centres, and a molecular 
surface was generated within 4.5 Å of these dummies, Figure 5.19 (b). Finally, a pharmacophore 
was generated to exclude a volume of radius 1 around all receptor atoms, Figure 5.19 (c). 
 
Figure 5.19. Preparatory Work for Docking at KAT2A HAT Domain. Homo sapiens KAT2A HAT domain acetyl-CoA 
binding site (PDB ID: 1Z4R).241 (a) Prepared structure in complex with acetyl-CoA. (b) Ligand binding site depicted by 
dummy atoms with associated surface coloured by lipophilicity. (c) Pharmacophore excluding volume around all 
receptor atoms. (d) Acetyl-CoA inspired pharmacophore with thiol donor and donor projection towards cysteine. 
Images produced in MOE.187 
The library of isothiazolones reported as KAT2B inhibitors were loaded into MOE187, prepared, 
protonated and minimised. The compounds were then docked into the prepared structure of 
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the KAT2A HAT domain using the induced fit protocol and employing the pharmacophore as a 
guide. Unfortunately, this conventional approach of docking the inhibitors into the structure of 
the KAT2A HAT domain was unsuccessful. 
As discussed, the isothiazolones inhibit KAT2B irreversibly via covalent thiol interactions505 with 
cysteine residues.509 Therefore, in an attempt to improve the results, a KNIME242 workflow was 
designed to use before docking, employing a JChem reactor node, JChem 6.1.0, 2013, ChemAxon 
(http://www.chemaxon.com), to convert the isothiazolones to 3-mercaptoacrylamides, as they 
will eventually reside at the active site, Figure 5.20. Additionally, the pharmacophore was 
elaborated to also include the acetyl-CoA thiol donor with radius 1.2 and a donor projection with 
radius 1.2 towards the cysteine residue at the ligand binding site, Figure 5.19 (d). 
The library of mercaptoacrylamides were loaded into MOE187, prepared, protonated and 
minimised and then docked into the prepared structure of the KAT2A HAT domain using the 
induced fit protocol and employing the improved pharmacophore as a guide. A greater number 
of the compounds were docked into the structure using this method but there remained a lack 
of confidence in the results. 
 
Figure 5.20. Converting Isothiazolones to Mercaptoacrylamides. Compounds converted using reactor node, JChem 
6.1.0, 2013, ChemAxon (www.chemaxon.com) in KNIME.242  
With perseverance and guidance from the CCG (Chemical Computing Group), this challenge 
could be surmounted and the series of isothiazolones could be docked into KAT2A. However, 
the isothiazolones are well known PAINS.517 They are frequently identified as artefactual hits 
because they are highly reactive, which causes false positive signals across a variety of assays. 
In this particular instance the isothiazolones might represent true KAT2B inhibitors, which inhibit 
activity via a specific covalent interaction with the protein. However, this is unlikely and was not 
deemed to be worth the risk. Furthermore, the authors responsible for first identifying the 
isothiazolones as KAT2B inhibitors505,508 confirmed that they had also found these compounds 
to be highly reactive and non-specific. As such, it was decided that the isothiazolones were not 
worth pursuing. This left no suitable chemical matter available for the KAT2A/B HAT domains. 
5.3 Discussion 
As discussed in Chapter 4.1, KAT2A is synthetic lethal with BAF1803, which is frequently mutated 
in clear cell renal cell carcinoma.376 This protein therefore represents an interesting target for 
tool inhibitor development, to enable biological investigation and potentially initiate drug 
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discovery projects towards treating ccRCC. KAT2A contains a HAT domain and a bromodomain. 
In Chapter 4.2, druggable pockets were identified in both of these structural domains. As the 
catalytically active domain, the HAT domain was prioritised as the preferred target.  
HATs represent exciting targets in drug discovery, with many potential disease applications, and 
are therefore interesting targets for tool inhibitor development, especially as existing HAT 
inhibitors are largely non-selective494,496, have poor permeability492 or are covalent modifiers506, 
and are therefore inadequate for biological investigation. 
Initially, sequence alignments were used to assess the potential for selectivity. It was found that 
KAT2A shows extremely high homology with its closest relative, KAT2B, but that overall the 
residue conservation across the HAT families is poor. This should afford good selectivity in 
general, but it is anticipated that any small molecule inhibitor will act at both KAT2A and KAT2B. 
Attempts to establish a fluorescence based activity assay, previously utilised in HTS for KAT2A 
HAT inhibitors (PubChem BioAssay AID: 504327)4, were unsuccessful, despite trialling three 
different fluorescence indicators and many assay conditions. The assay proved unreliable and 
many complex component interactions and factors were encountered that would impede assay 
optimisation to establish robust activity, making continued efforts unattractive. Initial attempts 
to establish an alternative EpiQuik™ HAT activity assay were promising and potentially seemed 
to indicate enzyme activity but there was high associated error. 
With hits from the fluorescence based HTS4,5 likely representing false positives, these were 
discounted and the available chemical matter for the KAT2A and KAT2B HAT domains was 
reinvestigated. The only series identified was the isothiazolones, which are well known PAINS 
and were therefore also disregarded. Unfortunately, this exhausted the inventory of reported 
small molecule inhibitors of KAT2A and KAT2B and thereby concluded attempts to develop a 
KAT2A HAT tool inhibitor. 
Unfortunately, while HATs represent interesting targets for tool inhibitor development, as 
understanding of these enzymes improves, numerous challenges are being recognised in how 
to target them. For example, the HATs have an abundance of cellular substrates and their 
acetyltransferase activity and specificity for these is often influenced by other proteins. KAT2A 
is incorporated into multiprotein complexes, which influence the specificity and the catalytic 
activity towards its histone and non-histone targets.518 This affect must be addressed in the 
development of small molecule HAT inhibitors, as the activities of recombinant HAT enzymes 
may not reflect their in vivo activity. This may limit the translation from in vitro assays to in vivo 
disease models. 
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These challenges are not insurmountable. C646 has been reported as a potent and selective 
active-site directed small molecule inhibitor of p300, Figure 5.21.519 Structure-based, in silico 
screening was used to identify this commercially available inhibitor. C646 is a competitive p300 
inhibitor, with a Ki of 400 nM and was shown to inhibit histone acetylation and cell growth.519 
Since it was discovered, therapeutic benefits of C646 have been reported in many cancers. For 
example, it inhibits the growth of human melanoma520 and induces apoptosis in prostate cancer 
cells.521  
 
Figure 5.21. Existing p300 HAT Inhibitor C646. Best validated HAT inhibitor, selective for p300 and CBP.519 
Despite the associated challenges, novel HAT inhibitors are necessary and highly desirable. The 
existing KAT2A inhibitors are particularly poorly suited for biological investigation, disease 
validation and initiating drug discovery efforts. An alternative assay format with robust activity 
must be identified and a high-throughput screen should be conducted to identify new, reliable 
chemical matter. Regrettably, this was beyond the scope of this work. 
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6 Design and Characterisation of KAT2A Bromodomain Tool 
Inhibitors 
Despite complications in developing a tool inhibitor for the KAT2A HAT domain, this histone 
acetyltransferase remained an interesting protein target. KAT2A is synthetic lethal with 
BAF1803, which is frequently mutated in clear cell renal cell carcinoma376, and is therefore a 
compelling target for tool inhibitor development. 
In Chapter 4.2, a druggable binding pocket was also identified at the KAT2A bromodomain. 
Bromodomains are currently a hot topic in research, with many potential applications in 
diseases, particularly cancers522, and therefore represent highly interesting targets for the 
development of small molecule tool inhibitors. When this work was initiated there were no 
existing KAT2A or KAT2B inhibitors with sufficient affinity or selectivity to enable biological 
investigation, disease validation and initiation of drug discovery efforts. 
In this chapter, available KAT2A and KAT2B crystal structures were utilised in a computational 
drug design effort, and Tm shift, TR-FRET, ITC and X-ray crystallography assay techniques were 
optimised and established in-house to enable characterisation of prospective tool inhibitors of 
the KAT2A bromodomain. The assays were employed in screening over 3000 small molecules 
and fragments to assess their affinity for KAT2A, and an assortment of novel KAT2A 
bromodomain binders were identified. The optimised assays, novel chemical matter and 
collection of ligand-bound crystal structures provide an exciting opportunity for further study 
and should enable development of potent and selective KAT2A bromodomain tool inhibitors. 
6.1 Introduction 
Having encountered a variety of setbacks in developing a tool inhibitor for the KAT2A HAT 
domain, including exhausting the inventory of small molecule HAT inhibitors of KAT2A and 
KAT2B, further efforts in developing a HAT tool inhibitor were terminated. Focus was instead 
redirected to the KAT2A bromodomain. Bromodomains (BRDs) are evolutionarily conserved 
protein-protein interaction domains, which selectively recognise and bind to acetylated lysine 
residues, thereby directing protein function.522 Inhibitors designed to target this domain should 
disrupt interactions with the acetylated protein targets, which are commonly histones. This will 
not impede the catalytic activity of KAT2A but should disrupt its function by preventing it from 
properly localising to target sites. It is hoped that this will afford the desired biological response, 
to selectively kill BAF180 deficient cells. 
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6.1.1 Function and Phylogeny 
Lysine acetylation has emerged as a prevalent regulatory post-translational modification (PTM) 
in proteins and, as discussed in Chapter 5.1, it is important in transcriptional activation and gene 
expression. The acetylation of conserved lysine residues located in the amino terminal domains 
of histones serves to loosen the chromatin structure.  Acetylation results in neutralisation of the 
positive charge of the basic lysines. This weakens the interaction of the histone with the DNA, 
producing the more open chromatin required for transcription, and establishes binding sites for 
other proteins and complexes.433 Deregulation of histone acetylation can induce aberrant 
expression of critical genes implicated in cell growth, differentiation and apoptosis, and thereby 
enable proliferation and tumourigenesis.523 Histone acetyltransferases, such as KAT2A, are 
responsible for acetylating lysine side chains on histones, by transferring acetyl from acetyl-CoA. 
These acetyl groups are erased by histone deacetylases. Recognition of acetylated lysine 
residues is principally mediated by bromodomains, Figure 6.1. 
 
Figure 6.1. The Mechanism of Histone Acetylation. Lysine residues are acetylated by HATs, utilising acetyl-CoA, and 
this is erased by HDACs. BRDs recognise acetylated lysine. Figure adapted from Shortt et al., 2017.524 
The first BRD was identified in the Drosophila melanogaster protein brahma.525 As this structural 
motif was conserved in drosophila FSH, yeast SNF2 and SPT7 and human CCG1 and RING3, it was 
suggested that it may be characteristic of a new family of regulatory proteins.525,526 Four of these 
proteins were known to function in activation of other genes, and therefore it was hypothesised 
that the bromodomain in some way mediates interactions with other proteins that are 
necessary for transcriptional activation.525 Secondary structure prediction methods identified 
amphipathic α-helices that were nominated as sites of intramolecular or intermolecular protein-
protein interaction, which could influence the assembly of multicomponent complexes.526 
It is now well established that bromodomains selectively recognise and bind to acetylated lysine 
residues, primarily on histones522, thereby acting as epigenetic reader domains.527 It is therefore 
perhaps unsurprising that these evolutionarily conserved protein modules are found in many 
chromatin-associated proteins and the majority of known nuclear HATs.446 In total, 61 unique 
BRDs are encoded by the human proteome, in 46 different proteins.238 As for the HAT domains, 
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phylogenetic trees have been devised to map the evolutionary and structural relationships of 
the BRDs, Figure 6.2.219,380 Common aliases of some of the proteins are listed in Table 6.1. 
 
Figure 6.2. Phylogenetic Tree of Bromodomains. Schematic showing bromodomains subdivided into families. Figure 
adapted from Shortt et al., 2017.524 
These bromodomains commonly occur in multidomain proteins, in which they are linked via 
flexible amino acid chains to diverse catalytic domains, such as the HAT domain in KAT2A, or 
additional epigenetic reader domains, such as methyl-lysine reader PHD (plant homeodomain) 
fingers, BAH domains or other bromodomains.238 The linker chain affords conformational 
flexibility, which enables the protein to interact with diverse motifs. The combining of multiple 
protein-protein interaction domains is illustrative of a combinatorial recognition process, which 
further complicates interpretation of the histone code.522 
Bromodomain-containing proteins have diverse physiological functions and regulate gene 
expression by modulating transcription via a range of mechanisms. They can function directly as 
components of chromatin remodelling complexes, perform catalytic functions to modify 
histones, act as histone-recognising scaffolds to facilitate the assembly of larger protein 
complexes, or serve as transcriptional co-regulators, Figure 6.3.522  
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Table 6.1. Bromodomains. List of common aliases of subset of the bromodomains. 
Given Name Alias Given Name Alias 
KAT2A GCN5 BAZ2A TIP5 
KAT2B PCAF TRIM24 TIF1α 
BPTF FALZ, FAC1 TRIM28 TIF1β, KAP1 
BRD2 RING3 TRIM33 TIF1γ 
BRWD1 WDR9 SP140L LOC93349 
PHIP WDR11 SMARCA2 BRM, BAF190B, SNF2A 
BRD1 BRPF2 SMARCA4 BRG1, BAF190A, SNF2B 
ATAD2B KIAA1240 PB1 PBRM1, BAF180 
CREBBP CBP, KAT3A ASH1L KMT2H 
P300 KAT3B, EP300 TAF1 KAT4, TAFII250, TFIID1, CCG1 
MLL KMT2A ZMYND8 PRKCBP1, PKCB1 
BAZ1B WSTF   
 
The multisubunit BAF and PBAF complexes, which have key roles in cell differentiation and 
proliferation393,397 and DNA repair399, contain multiple BRD-containing proteins. The central 
ATPases, BRG1 and BRM, are responsible for ATP-dependent alteration of chromatin structure, 
and contain carboxy-terminal BRD modules.238 Closely related proteins BRD9 and BRD7, specific 
to BAF and PBAF respectively, contain individual bromodomains.  Additionally, PBAF contains a 
third bromodomain-containing protein, PBRM1, which contains six tandem BRDs, two bromo-
adjacent homology (BAH) domains, and a high-mobility group (HMG).376 
Catalytic activity is observed in several bromodomain-containing proteins, including PCAF, 
GCN5, CREBBP, ASH1L (absent, small and homeotic disks protein 1 homologue) and MLL (mixed-
lineage leukaemia). These proteins modify chromatin structure by introducing PTMs on 
histones. The bromodomains bestow specificity by tethering the proteins to particular 
chromosomal sites, and thereby modulate transcriptional programs and drive phenotypic 
changes.446 PCAF, GCN5 and CREBBP have catalytic acetyltransferase activity and thereby 
regulate transcriptional activation.437,528 ASH1L and MLL have catalytic methyltransferase 
activity, which can cause relaxation or compaction of chromatin. ASH1L contains BRD, PHD 
finger and BAH domains as well as the SET (Su(var)3-9, Enhancer-of-zeste and Trithorax) domain, 
which is responsible for its methyltransferase activity.529 MLL contains BRD and SET domains and 
three PHD fingers.530  
All bromodomain-containing proteins are able to recognise acetylated lysine residues, but for 
some, which serve to recruit transcriptional regulators or machinery to specific loci, this is their 
primary function. The most prominent example is the BET proteins, BRD2, BRD3, BRD4 and 
testis-specific BRDT. These proteins harbour tandem, amino-terminal bromodomains, which 
bind to acetylated lysines, and an extra-terminal (ET) protein-protein interaction domain, which 
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interacts with specific transcriptional effectors.531 Utilising these interaction domains, the BET 
proteins act as scaffolds to recruit transcriptional machinery components to conserved loci and 
thereby regulate transcriptional activity. A second example is TAF1, which is the largest 
component of the TFIID transcription factor complex. TAF1 also contains tandem bromodomains 
that bind selectively to multiply acetylated histone H4 peptides.532 It modulates transcriptional 
initiation by binding at the promoter region and recruiting other transcriptional regulators.533  
 
Figure 6.3. Roles of BRD-Containing Proteins in Regulating Gene Expression. Schematic detailing range of 
mechanisms by which bromodomain-containing proteins can modulate transcription. (a) BRG1, BRM, BRD7, BRD9 
and PBRM1 are components of SWI/SNF chromatin remodelling complexes. (b) GCN5, PCAF and CREBBP exhibit 
catalytic histone acetyltransferase activity and thus regulate transcriptional activation. ASH1L and MLL exhibit 
catalytic histone methyltransferase activity, which can relax or compact chromatin. (c) The BET proteins and TAF1 act 
as histone-recognising scaffolds, which recruit transcriptional effectors. (d) The TRIM family proteins function as co-
regulators to modulate transcriptional activity. Figure adapted from Fujisawa & Filippakopoulos, 2017.522 
Finally, some BRD-containing proteins, such as the TRIM family members, act as transcriptional 
co-regulators. TRIM24 is a co-activator of oestrogen receptor α, a ligand-activated transcription 
factor.534 TRIM28 has roles in transcriptional repression by modulating chromatin structure via 
interaction with heterochromatin protein 1 (HP1)535, and mediating intramolecular 
SUMOylation, which provokes gene silencing via recruitment of the NuRD (nucleosome 
remodelling and deacetylase) complex.536 TRIM33 exhibits E3 ubiquitin ligase activity and 
regulates the TGF-β signalling pathway, which induces transcription of a variety of integral 
genes.537  
Large-scale studies have identified mutations in various bromodomain-containing proteins that 
lead to cancer. For example, an analysis of 21 paediatric cancer subtypes identified recurrent 
mutations in 21 BRD-containing proteins.538 No systematic studies have yet determined the 
mutation load within the BRD modules however, and therefore it is not clear what contribution 
acetyl-lysine readout makes towards these phenotypes.522 This is a common obstacle in the 
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study of multidomain proteins. Specific bromodomain tool inhibitors will aid in elucidating the 
functions of these modules in physiology and disease. 
6.1.2 Structure and Interactions 
High-resolution X-ray or NMR structures are now available for 53 of the 61 BRDs219, thanks in 
large part to the Structural Genomics Consortium. This abundance of structural information has 
enabled the comprehensive structural analysis of bromodomains, to establish the sequence and 
structural conservation of the modules.539 Bromodomains are small modules of approximately 
110 amino acids540, which despite a low degree of overall sequence homology, share a conserved 
architecture. The globular fold, which was first characterised almost twenty years ago541, 
comprises of a left-handed bundle of four α-helices (αZ, αA, αB and αC), linked by two variable 
loop regions (ZA and BC loops), Figure 6.4.238 The loop regions form the binding site for 
acetylated lysine residues.446 
 
Figure 6.4. Conserved Structure of Bromodomain Modules. Crystal structure of Saccharomyces cerevisiae GCN5 
bromodomain (PDB ID: 1E6I)239, with protein chain coloured from blue at N-terminus to red at C-terminus. 
The four helices form a deep cavity, flanked by the ZA and BC loops, to create a surface-
accessible hydrophobic binding pocket, which accommodates the neutralised acetyl-lysine.238 
This pocket is surrounded by a charged surface that interacts with the backbone of the bound 
peptide.522 In contrast to the conserved fold, these protein-interaction surfaces are highly 
diverse, exhibiting electrostatic potentials ranging from strongly positively to strongly negatively 
charged.238 This indicates that different bromodomains recognise distinct peptide sequences. 
The BRDs with highly positively charged interaction surfaces are intriguing as histone peptides 
are typically rich in positively charged lysine and arginine residues and will therefore interact 
poorly with these. Given the numerous bromodomain-containing proteins, it is plausible that an 
array of other acetylated protein targets might exist besides the histones.522 So far however, 
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only a few examples are known, such as the interaction of PCAF with HIV-1 protein Tat 
acetylated at lysine 50542, or CREBBP with p53 acetylated at C-terminal lysine 382.543  
In 2012, Filippakopoulos et al. conducted a comprehensive study of BRD structure and peptide 
binding properties, in attempt to better understand acetylation-mediated signalling, as 
interpreted by bromodomains.238 They crystallised and determined the structures of 29 BRDs, 
including 25 novel structures, and performed a SPOT blot analysis to assess the ability of 33 
representative human bromodomains to recognise acetylated histone peptides spanning known 
acetyl-lysine sites.544 In general, they found that the binding of bromodomains to acetylated 
histone peptides is relatively weak, indicative of additional interaction domains in vivo, and that 
peptide recognition is typically dependent on patterns of multiple PTMs rather than single 
acetylation marks. They also uncovered that of the acetyl-lysine sites within the histone tails, 
H2AK15ac, H2AK36ac, H3K14ac and H4K5ac were the most commonly recognised by BRDs.238  
The study provides a powerful resource to enable future functional studies of these epigenetic 
reader domains. 
Despite their divergence, the bromodomains contain several highly conserved residues and 
motifs, Figure 6.4. Two residues understood to facilitate the interaction with acetyl-lysine are 
observed in the majority of BRDs. An asparagine within the BC loop forms a direct hydrogen 
bond with the acetyl group, while a tyrosine in a conserved PxY motif in the ZA loop interacts 
with the lysine residue via a water-mediated hydrogen bond, Figure 6.5. Other conserved motifs 
are believed to stabilise the structural fold. For example, a tyrosine residue in the AB loop forms 
a charge-assisted hydrogen bond with an aspartic acid residue in αB, Figure 6.4. 
 
Figure 6.5. Interaction of Bromodomains with Acetylated Peptides. Crystal structure of Saccharomyces cerevisiae 
GCN5 bromodomain complexed with acetylated H4 peptide (PDB ID: 1E6I).239 Protein chain coloured from blue at N-
terminus to red at C-terminus and conserved structural elements annotated.  
As discussed, there are now many bromodomain crystal structures available, many of which 
depict them in complex with acetylated histone peptides. The structures confirm the mode of 
binding of acetyl-lysine. As well as the conserved asparagine and tyrosine, an array of water 
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molecules is invariably observed at the bottom of the binding cavity, which interact in a 
consistent manner with histone peptides and other ligands, Figure 6.5.545 It is important that 
these conserved waters are considered in BRD drug design and virtual screening efforts.539 
Some BRD-containing proteins are able to interact with multiple acetyl-lysines. Predictably, 
proteins with tandem bromodomains joined by a flexible linker, such as the BET proteins and 
TAF1, are able to simultaneously recognise two distinct acetylated lysine residues that exist on 
the same or on different proteins.546 This increases their specificity for multiply acetylated 
histone tails.532 Furthermore, some single bromodomains are able to recognise diacetylated 
peptides. For example, murine BRDT interacts with histone H4 acetylated at K5 and K8. Both 
acetyl-lysine residues are accommodated in the same hydrophobic binding cavity.547 It seems 
that this ability to recognise diacetylated histone peptides is a common feature of the BET 
bromodomains, which exhibit enlarged binding pockets.238 
In Chapter 4.2, a druggable binding pocket was identified in the KAT2A bromodomain, which 
coincides with the binding site of acetylated histone peptides, composed of the hydrophobic 
acetyl-lysine binding pocket and the surrounding charged surface. This indicates that this binding 
site could be susceptible to targeting with a small molecule inhibitor. The high sequential and 
structural variability at the comprising ZA and BC loop regions should enable discrimination of 
different bromodomain targets548 and thereby afford selectivity potential, making this an 
attractive target site for inhibitor development. 
6.1.3 Existing Inhibitors 
Bromodomains have emerged as interesting targets for the development of protein interaction 
inhibitors and currently represent a particularly lively area of research. This is in part enabled by 
scientists at the SGC, who aim to develop chemical probes and optimise therapeutic leads to 
encourage translation of small-molecule modulators of epigenetic targets to therapeutics. An 
illustrative subset of the BRD inhibitors reported to date is reviewed below.  
The first small molecule BRD inhibitors were reported by the Zhou laboratory. Firstly, in 2005, 
using a combination of NMR-based chemical screening and an ELISA assay, N1-aryl-propane-1,3-
diamine compounds were identified as a novel class of PCAF BRD inhibitors, capable of displacing 
acetylated HIV-1 transactivator Tat peptide (Tat-AcK50) from KAT2B.548 In 2007, structure-
guided optimisation was used to determine a related small molecule chemical inhibitor, Figure 
6.6, which exhibited an EC50 of ~1 μM on inhibiting Tat-mediated transcription of the viral 
promoter in a HIV-1 long terminal repeat-luciferase reporter gene assay.549 These ligands 
purportedly bind the KAT2B BRD selectively over structurally similar CREBBP and TRIM28 BRDs, 
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capitalising on the aforementioned sequence variations in the ZA and BC loops to discriminate 
between binding targets.548 Secondly, in 2006, a similar NMR-based approach was used to 
identify small molecules that block lysine 382-acetylated p53 from interacting with CREBBP, 
from a focused chemical library generated based on structural knowledge of the CREBBP BRD-
p53-AcK382 interaction.550 Hits were confirmed using structure-based characterisation, an in 
vitro protein-peptide binding assay, cell-based functional assays and fluorescence spectroscopy, 
in which the most potent inhibitor, MS7972, Figure 6.6, exhibited a Kd of ~20 μM.550  
2010 saw the landmark discoveries of potent BET BRD inhibitors, JQ1 and I-BET762, Figure 6.6, 
which bind competitively with histones at the acetyl-lysine recognition motif, Figure 6.7.217,218 
These triazolodiazepines are selective for the BET family but not individual members. Developing 
inhibitors specific for a single BET bromodomain will aid in elucidating the functional roles of the 
proteins and remains an important challenge for the field.545 JQ1 exhibited Kds of ~50 nM for 
BRD4(1), ~90 nM for BRD4(2) and 60-190 nM for the other family members, and showed 
preclinical efficacy as a NUT (nuclear protein in testis) midline carcinoma therapeutic, targeting 
the BRD4-NUT fusion oncoprotein.217 The triazole moiety mimics the acetyl-lysine, forming 
hydrogen bonds with the signature asparagine and conserved waters. I-BET762 was developed 
and investigated independently but simultaneously. It presents interactions, binding affinities 
and selectivity profile with BET bromodomains similar to JQ1.218,551 The publication of these 
potent BET inhibitors with translational potential markedly elevated interest in BRD inhibitors. 
As discussed, although all bromodomains contain the hydrophobic acetyl-lysine binding pocket, 
the variable residues at the ZA and BC loop region result in diversity in the environments around 
that small cavity. As such, druggability varies considerably for different bromodomains, Figure 
6.8.552 Currently, the majority of existing BRD inhibitors target the highly druggable BET proteins. 
Like JQ1 and I-BET762, many of these BRD inhibitors have rigid aromatic scaffolds and present 
hydrogen bond acceptors to mimic the acetyl-lysine, Figure 6.7.553 Triazolodiazepine, OTX015554, 
Figure 6.6, derived from JQ1, is currently in clinical trials for various malignancies including 
lymphoma and leukaemia.555,556 The structural rigidity and hydrophobicity of these diazepines 
confers good shape complementarity and specificity for the BET bromodomains but limits 
bioavailability and chemical diversity.545 The more adaptable dimethylisoxazole scaffold was 
discovered fortuitously by Hewings et al.557 following the identification of DMSO (dimethyl 
sulfoxide) and NMP (N-Methyl-2-pyrrolidone) as BRD ligands.558 A number of dimethylisoxazole 
BET inhibitors have now been developed, including I-BET151, Figure 6.6, which exhibits efficacy 
against human and murine MLL-fusion leukaemic cell lines.559 I-BET151 retains the potency and 
selectivity of I-BET762 while affording improved pharmacokinetics and half-life. 
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Figure 6.6. Existing Bromodomain Inhibitors. 
As well as the diazepines and dimethylisoxazoles, a number of other scaffolds have been 
successfully employed in BET inhibitors. Quinazolinones were identified as effective inhibitor 
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scaffolds via fragment-based screening and optimised to afford the potent, BET-selective 
inhibitor, PFI-1, Figure 6.6.560 PFI-1 has antiproliferative effects on leukaemic cell lines exhibiting 
MLL rearrangements.561 RVX-208, Figure 6.6, a quinazolinone derivative of resveratrol, was 
discovered as a BET BRD inhibitor in 2013, and is currently the sole BET inhibitor that offers any 
selectivity for one of the tandem BRDs (BRD3(2) Kd = 195 nM, BRD3(1) Kd = 4.1 μM).562 
 
Figure 6.7. Interaction of BRD4 with JQ1. Crystal structure of Homo sapiens BRD4 bromodomain in complex with 
inhibitor JQ1 in pink (PDB ID: 3MXF).217 Protein chain coloured from blue at N-terminus to red at C-terminus.  
Closely related CREBBP and p300 are theoretically less druggable than the BET proteins, Figure 
6.8.552 Nevertheless, likely inspired by the success of MS7972550, a number of research groups 
have ventured to develop potent and selective CREBBP/p300 inhibitors. Ischemin, Figure 6.6, 
was developed using a structure-guided approach from hits from an NMR-based screen of 3000 
compounds.563 Ischemin inhibited CREBBP, exhibiting a Kd of 19 μM, and was observed to down-
regulate p53-induced apoptosis. The dimethylisoxazole scaffold was also discovered to be 
effective for CREBBP inhibition. A structure-guided approach was utilised to develop a potent 
and selective inhibitor of CREBBP and p300. CBP30, Figure 6.6, exhibits Kds of 21 nM and 32 nM 
for CREBBP and p300 respectively, and 40-fold selectivity over the BET bromodomains.564  
Despite them being classified among the least druggable bromodomains due to their shallow 
binding pockets552, inhibitors have also been reported for the bromodomain adjacent to zinc 
finger domain (BAZ) proteins, BAZ2A and BAZ2B. In 2015, the SGC utilised virtual screening and 
structure-guided design to develop methylpyrazole BAZ2-ICR, Figure 6.6.565 BAZ2-ICR binds to 
BAZ2A and BAZ2B with Kds of 109 nM and 170 nM respectively, and is selective against all other 
BRDs with the exception of CECR2 (Cat Eye syndrome chromosome region, candidate 2), which 
it binds with a Kd of 1.55 μM. In collaboration with GlaxoSmithKline, the SGC also developed 
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acetylindolizine GSK2801, Figure 6.6, as a potent and reasonably selective inhibitor of BAZ2A 
and BAZ2B.566 GSK2801 offers Kds of 257 nM and 136 nM for BAZ2A and BAZ2B respectively, but 
also binds to TAF1L (Kd = 3.2 μM) and BRD9 (Kd = 1.1 μM), albeit more weakly. 
 
Figure 6.8. Box Plots Showing Range and Distribution of BRD Druggability Assessed by SiteMap. Domains ranked by 
median Dscore and coloured to indicate druggability classification: red, druggable; yellow, intermediate; white, 
difficult. Figure from Vidler et al. (2012).552  
Dual inhibitors of BRPF1 (bromodomain and PHD finger containing 1) and TRIM24 have also 
been developed. For example, in 2015, benzimidazolone IACS-9571, Figure 6.6, was reported as 
a potent inhibitor with Kds of 31 nM and 14 nM for TRIM24 and BRPF1 respectively.567 IACS-9571 
has yet to be validated in cell or animal disease models.545 
Finally, in 2015, the quinolinone-fused lactam LP99, Figure 6.6, was reported as the first potent, 
selective and cell-active inhibitor of the BRD7 and BRD9 bromodomains.568 LP99 was developed 
from a fragment hit via an approach that combined structure-based inhibitor design and 
biophysical characterisation with tractable chemical synthesis. 
Potent and selective inhibitors afford new therapeutic strategies and are crucial for biological 
exploration of the target protein.527 As a result, publication of a new chemical probe often 
provokes an increased level of research in the area. The past five years have therefore seen an 
explosion in research into the therapeutic application of BRD inhibitors, which has facilitated a 
recent deluge of BET inhibitors entering clinical trials as anticancer agents.569  
Despite the considerable efforts of the SGC and other academic groups, selective inhibitors are 
not yet described for every bromodomain target. As such, tool compounds with a wider 
specificity profile are also useful in research, for example in elucidating the universal roles of 
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bromodomains and in establishing functional in vitro and cellular assays. Bromosporine, Figure 
6.6, is a pan-BRD inhibitor described by the SGC with activity against the BET, CECR2, TAF1, BRD9 
and CREBBP bromodomains (http://www.thesgc.org/chemical-probes/bromosporine). 
6.1.4 Recent KAT2A/B Chemical Matter 
Despite the early report of N1-aryl-propane-1,3-diamine compounds as potential PCAF BRD 
inhibitors548, and GCN5 and PCAF representing two of the most highly druggable bromodomains, 
Figure 6.8552, when this work was initiated there were no potent and selective inhibitors 
reported for either of these closely related homologues. However, the SGC had utilised thermal 
stability shift assays, ITC and high-throughput X-ray crystallography to identify fragments with 
inhibitory activity against the PCAF bromodomain, Table 6.2, which they shared with us pre-
publication.240 
Table 6.2. Available Biophysical Data for Novel Fragment Inhibitors of KAT2B/PCAF Bromodomain.240 
 
 
Of these fragments, SL1126 represented the most promising start point for structure-based 
design, with reasonable affinity (Kd = 30 μM) and an available X-ray crystal structure (PDB ID: 
5FE8).240 Notably, the fragments showed no selectivity for the KAT2B BRD over the other 
bromodomains. In fact, many demonstrated higher affinity for other bromodomains, for 
example BR004 has a Kd of 5.0 μM for BRD9.568 With this in mind, strategies to develop a potent 
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and selective small molecule inhibitor of the KAT2A bromodomain, with low micromolar or 
nanomolar affinity, should incorporate both growth and diversification of the existing 
quinolinone scaffold and screening to identify other potential cores.  
6.2 Results 
6.2.1 Selectivity Potential 
In Chapter 4.2, a druggable structural pocket was identified at the KAT2A BRD using Fpocket 
2.0165,170, which corresponds to the binding position of acetyl-lysine. As at the HAT domain, 
EMBL-EBI Clustal Omega181,182 was used to compile pairwise and multiple sequence alignments 
to assess the potential for selectivity at this site, Figure Apx.6. Those amino acids which comprise 
the KAT2A BRD were identified and Scorecons220 was used to rate sequence conservation. As 
seen at the HAT domain, the KAT2A and KAT2B BRDs exhibit high homology, Figure 6.9 (a), but 
the residue conservation between bromodomain families is poorer, Figure 6.9 (b). It is therefore 
likely that dual inhibitors, which are selective for the two GCN5 homologues but not able to 
distinguish between them, can be achieved. This was deemed acceptable, especially considering 
the huge impact of JQ1, which targets all members of the BET BRD family.217 Small molecule dual 
inhibitors will serve as useful tools to enable biological exploration of KAT2A and KAT2B to 
further elucidate their biological roles, as well as aid in establishing assays. 
 
Figure 6.9. Assessing Residue Conservation at KAT2A Bromodomain. Homo sapiens GCN5 bromodomain (PDB ID: 
3D7C)238 aligned with that of S. cerevisiae (PDB ID: 1E6I)239, to show acetyl-lysine binding site. Histone H4 peptide 
shown in grey. KAT2A coloured to indicate amino acid conservation determined by Scorecons220; red indicates the 
least conserved regions and bright green the most. (a) Results from pairwise alignment of KAT2A and KAT2B. (b) 
Results from multiple sequence alignment of the type I and II bromodomains. 
6.2.2 Screening Cascade 
The KAT2A bromodomain therefore represents a desirable and promising target for 
development of a potent and specific tool inhibitor. A screening cascade was designed, 
incorporating the screening techniques routinely adopted by the SGC and other research groups 
in identifying bromodomain tool inhibitors, Figure 6.10.217,240,568  
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Figure 6.10. Schematic of Proposed KAT2A BRD Screening Cascade. 
It was proposed that a structure-based approach would be utilised to design a library of potential 
KAT2A BRD inhibitors based on the quinolinone scaffold of SL1126. This library of inhibitors 
would be screened using a thermal stability shift assay to identify those with affinity for KAT2A. 
In tandem, an NMR fragment screen would be conducted to identify novel scaffolds for inhibitor 
development. Hits from the thermal shift and NMR screens would be confirmed using ITC and 
crystallographic techniques. 
In addition, it was decided that once screening with thermal shift, NMR and ITC was underway, 
a time-resolved fluorescence resonance energy transfer (TR-FRET) assay would be developed in-
house for use in high-throughput screening. While thermal shift assays are straightforward to 
establish and offer the capacity for good throughput, they can be limited by poor sensitivity and 
high frequency of false positives. TR-FRET technology has not yet been used to screen for KAT2A 
BRD inhibitors, but has been utilised with other bromodomains, for example BRD4(1) and 
CREBBP and p300.570,571 
6.2.3 Structure-Based Design From SL1126 
As discussed, fragments had been identified by the SGC that exhibited micromolar affinity for 
the KAT2B bromodomain, and of these, SL1126 represented the most promising start point for 
a structure-based design approach.240 To commence this structure-based drug design, EMBL-EBI 
Clustal Omega181,182 was employed to compile a multiple amino acid sequence alignment of the 
61 unique human bromodomains, Figure Apx.7, with an aim to identify residues which differ 
throughout the bromodomains and therefore should enable selectivity towards KAT2A and 
KAT2B. Ten of the type V BRDs as well as MLL and ZMYND11 (Zinc finger Myeloid, Nervy, and 
DEAF-1 domain-containing protein 11), exhibited significant divergence from the other 
bromodomains and consequently aligned poorly. This substantial diversity should make it easy 
to select against these proteins and therefore they were excluded from subsequent analysis. 
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Table 6.3. Comparison of Bromodomain Binding Site Residues. Multiple sequence alignment generated by EMBL-
EBI Clustal Omega.181,182 Residues comprising druggable pocket at the acetyl-lysine binding site selected by consulting 
PDB structures of KAT2A (3D7C)238 and KAT2B (5FE8)240. Conservation scores determined using Scorecons220 and 
amino acid residues coloured accordingly; pink indicates the least conserved regions and dark green the most. 
 
 
The remaining 49 bromodomains were realigned, the conservation scores were determined 
using Scorecons220, and those residues comprising the druggable pocket at the acetyl-lysine 
binding site were selected for review by consulting KAT2A and KAT2B PDB structures 3D7C238 
BRD
Start
Position
1 2 3 4 5 6 7 8 11 12 13 14 15 54 57 58 64
KAT2A 751 W P F M E P V K E A P D Y C Y N Y
KAT2B 746 W P F M E P V K E A P G Y C Y N Y
BPTF 2950 W P F L E P V D D A P D Y C Y N F
BRDT(1) 50 W P F Q R P V D Q* L* P* D* Y* C* Y* N* I* *Pos+2
BRD4(1) 81 W P F Q Q P V D N* L* P* D* Y* C* Y* N* I* *Pos+2
BRD3(1) 57 W P F Y Q P V D N* L* P* D* Y* C* Y* N* I* *Pos+2
BRD2(1) 97 W P F R Q P V D G* L* P* D* Y* C* Y* N* I* *Pos+2
BRDT(2) 293 W P F Y N P V D G* L* H* N* Y* C* Y* N* V* *Pos+2
BRD4(2) 374 W P F Y K P V D G* L* H* D* Y* C* Y* N* V* *Pos+2
BRD3(2) 332 W P F Y K P V D E* L* H* D* Y* C* Y* N* V* *Pos+2
BRD2(2) 370 W P F Y K P V D G* L* H* D* Y* C* Y* N* V* *Pos+2
PHIP(1) 1182 S A F V A P V D A Y P M Y T F N I
BRWD1(1) 1183 A A F A G P V D T Y P K Y A F N I
BRWD3(1) 1164 S P F A V P V D A Y P L Y A F N I
BRD8(1) 730 N V F L Q P V T I A P G Y A Y N V
BRD8(2) 1126 S P F L K P V S Q A P G Y A Y N V
BAZ1B 1362 W P F R E P V T E A E D Y A Y N V
BRWD3(2) 1323 E P F R Q P A D S Y P D* Y* S* Y* T* I** *Pos+25 **Pos+26
BRWD1(2) 1336 E P F R Q P V D E Y P D Y A Y T I
PHIP(2) 1339 E P F R Q P V D E Y P D Y S Y T I
CREBBP 1109 L P F R Q P V D G* I* P* D* Y* A* Y* N* V* *Pos+2
P300 1073 L P F R Q P V D G* I* P* D* Y* A* Y* N* V* *Pos+2
ATAD2 1007 R V F T K P V D E V P D Y A Y N I* *Pos+4
ATAD2B 981 N I F S K P V D E V S D Y A Y N I* *Pos+4
BRD9 159 G F F A F P V T I A P G Y A Y N Y
BRD7 154 A F F S F P V T I A P G Y A Y N Y
BRPF3 612 H I F A E P V N E V P D Y C Y N F
BRD1 585 R I F A Q P V S E V P D Y C Y N F
BRPF1-1 651 N I F S E P V P E V P D Y C Y N F
BRPF1-2 651 N I F S E P V P E* V* P* D* Y* C* Y* N* F* *Pos+6
BAZ1A 1452 W P F L K L V S Q V P D Y C Y N E
CECR2 457 W P F L E P V D Y A P N Y C Y N Y
BAZ2A 1816 W P F L E P V N L V S G Y C F N V
BAZ2B 2083 W P F L L P V N L V P G Y C F N I
TAF1(1) 1403 Y P F H T P V N V V K D Y S Y N L
TAF1L(1) 1422 H P F H T P V N V V K D Y S Y N L
TAF1(2) 1526 W P F H H P V N F V P D Y S Y N Y
TAF1L(2) 1545 W P F H H P V N F V P D Y S Y N Y
ZMYND8 171 D A F Q K P V P Q H P D Y C Y N L
PB1(1) 70 E L F I R A P K N Q P D Y A Y Y E
PB1(2) 206 E L F Q K L P S Q Y P D Y A Y N V
PB1(3) 406 E P F Y H L P S K Y P D Y A Y N I
PB1(4) 544 D L F M V K P S D Y P D Y A Y N V
PB1(5) 682 A I F L R L P S E L P D Y A Y N I
PB1(6) 798 R C Y S D S L A P A V D P A M N I
ASH1L 2469 A P L L N L P P K N A D Y A Y Y V
SMARCA2-1 1425 E V F I Q L P S E L P E Y A F N I
SMARCA2-2 1407 E V F I Q L P S E L P E Y A F N I
SMARCA4 1483 E V F I Q L P S E L P E Y A F N I
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and 5FE8240, Table 6.3. Three residues were identified within the ZA loop which are poorly 
conserved amongst bromodomains and therefore may enable selectivity towards KAT2A and 
KAT2B, Figure 6.11. The tryptophan, KAT2A W751, situated at the C-terminus of αZ, forms part 
of a lipophilic shelf, termed the WPF (Trp-Pro-Phe) shelf, which is conserved within a number of 
bromodomains including the type I and BET BRDs. This WPF shelf has previously been targeted 
to afford potent and selective BET BRD inhibitors.560 A tool inhibitor designed to interact with 
this tryptophan should select against many of the bromodomains lacking the WPF shelf, but not 
the BET BRDs. The methionine, KAT2A M754, exhibits significant diversity throughout the BRDs 
and therefore could afford good selectivity for KAT2A and KAT2B. Unfortunately, the residue is 
located a significant distance from the acetyl-lysine binding pocket, which may cause problems 
with ligand size. Finally, the glutamic acid, KAT2A E761, is poorly conserved throughout the 
BRDs, including, importantly, the BET family. This residue is located reasonably close to the 
acetyl-lysine binding pocket and may afford good selectivity for KAT2A and KAT2B. 
 
Figure 6.11. Poorly Conserved Residues at KAT2A and KAT2B BRD Binding Sites. KAT2A and KAT2B bromodomains 
with protein chains coloured from blue at N-terminus to red at C-terminus. Poorly conserved binding site residues 
highlighted. (a) Homo sapiens GCN5 bromodomain (PDB ID: 3D7C)238, aligned with that of S. cerevisiae (PDB ID: 
1E6I)239, to show acetyl-lysine binding site. Histone H4 peptide shown in grey. (b) Homo sapiens PCAF bromodomain 
in complex with SL1126, shown in pink (PDB ID: 5FE8).240 
Comparing PDB structures 3D7C238 and 5FE8240, it was clear that the glutamic acid, KAT2A E761, 
has the flexibility to move to accommodate small molecules at the binding site, Figure 6.11. This 
should be advantageous in attempts to grow SL1126 to interact with this residue. Fragment 
growth at the amide at the 7-position of SL1126 was expected to enable novel interactions with 
the methionine and glutamic acid residues, and thereby afford selectivity for KAT2A and KAT2B. 
Fortunately, ligand growth at this secondary amide is theoretically straightforward. Libraries of 
amides and sulphonamides can be synthesised from SL1121, the primary amide analogue of 
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SL1126, using carboxylic acids or sulphonyl chlorides respectively, Figure 6.12. This afforded the 
potential to use automated synthesis to generate compound libraries for screening. 
 
Figure 6.12. Synthesis of Amide and Sulphonamide Libraries from SL1126. 
Towards the structure-based design of suitable libraries, quinolinone amides and 
sulphonamides were identified, which could be synthesised from acids available in-house, or 
acids and sulphonyl chlorides available commercially. A KNIME242 workflow was designed to 
generate six conformers of every compound, give each a unique identifier and output an SDF 
file, which would subsequently be used in docking. 
It was decided that the structure of the Homo sapiens PCAF BRD in complex with SL1126 (PDB 
ID: 5FE8)240 would be utilised in structure-based design. The KAT2A and KAT2B bromodomains 
are essentially identical and the PCAF structure was preferred as in the apo structure of Homo 
sapiens GCN5 BRD (PDB ID: 3D7C)238, K758, which is positioned close to the acetyl-lysine binding 
pocket, is truncated due to poor resolution. In addition, using the original structure of the 
complex negated any potential errors induced by docking SL1126 into the GCN5 structure. 
The PCAF BRD (PDB ID: 5FE8)240 was prepared for docking in MOE.187 Initially it was protonated, 
corrected and minimised. Following this, the Site Finder functionality was utilised to identify the 
site available for ligand binding, dummies were created at the alpha sphere centres, and a 
molecular surface was generated within 4.5 Å of these dummies, Figure 6.13 (a). A set of 
conserved waters, located at the active site, were selected that would be incorporated in 
docking and the remaining solvent was removed, Figure 6.13 (b). Finally, a pharmacophore was 
generated comprising of the carbonyl acceptor and two aromatic markers at the quinolinone 
bicycle, Figure 6.13 (c). 
 
Figure 6.13. Preparatory Work for Docking at PCAF BRD. Homo sapiens PCAF bromodomain in complex with SL1126, 
shown in grey (PDB ID: 5FE8).240 (a) Ligand binding site depicted by dummy atoms with associated surface coloured 
by lipophilicity. (b) Conserved water at the binding site depicted as sticks. (c) SL1126 inspired pharmacophore with 
carbonyl acceptor and two aromatic markers at the quinolinone. Images produced in MOE.187 
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The three libraries of conformers of the amides and sulphonamides were loaded into MOE187, 
prepared, protonated and minimised. The compounds were then docked into the prepared 
structure of the PCAF BRD using the rigid receptor protocol and employing the pharmacophore 
as a guide and SL1126 as a template. The results were saved both as MOE molecular database 
files and SDF files for analysis. 
To analyse the results, initially a KNIME242 workflow was used to group the multiple conformers 
and associated poses, retaining only the highest scoring pose for each species, sort these by 
docking score and retrieve the top scoring 40%. These ‘top 40%’ compounds were analysed by 
eye in MOE187 and those which were either interesting because they made new interactions with 
PCAF, Figure 6.14 (a), or uninteresting because the compound extended completely into the 
solvent, were marked as such. Following this, another KNIME242 workflow was designed to split 
the compounds accordingly. Those compounds that instigated new interactions were combined 
with the top 20% of compounds that did not instigate new interactions but were reasonable, as 
they did not protrude completely into the solvent, Figure 6.14 (b), to create the final hit list.  
 
Figure 6.14. Example Docking Hits. Homo sapiens PCAF bromodomain (PDB ID: 5FE8)240, with proposed ligand binding 
site demonstrated as surface coloured by lipophilicity. (a) Example docking hit exhibiting additional interactions with 
PCAF BRD. (b) Example docking hit exhibiting no additional electrostatic interactions but also not extending 
unreasonably into solvent. Images produced in MOE.187 
From these compound hits, a diverse set were selected for synthesis, comprising of 25 amides 
from acids available in-house, Figure Apx.8, 100 amides from commercially available acids, 
Figure Apx.9, and 25 sulphonamides from commercially available sulphonyl chlorides, Figure 
Apx.10. These libraries were provided to David Pearce (Automated High-Throughput Medicinal 
Chemistry and Synthesis Lab, University of Sussex) for synthesis.  
Unfortunately, synthesis of the amides and sulphonamides proved unexpectedly challenging 
due to solubility problems. Of the 150 compounds, only 72 were successfully synthesised, 13 
amides from acids available in-house, Figure Apx.8, 42 amides from commercially available 
acids, Figure Apx.9, and 17 sulphonamides from commercially available sulphonyl chlorides, 
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Figure Apx.10. Disappointingly, a significant number of the compounds that could not be 
synthesised were those with the lowest molecular weight, which represented the smallest 
changes from the SL1126 quinolinone starting fragment. These posed less of a challenge to the 
model than the larger compounds and were most likely to maintain a favourable interaction 
with the BRD. Regardless, a library of 72 amides and sulphonamides had been successfully 
designed and synthesised ready for screening against the KAT2A bromodomain. 
As an aside, comparing the structure of Homo sapiens PCAF BRD (PDB ID: 5FE8)240 with the S. 
cerevisiae GCN5 BRD in complex with acetylated H4 peptide (PDB ID: 1E6I)239, it is evident that 
that there is also space available at the SL1126 4-position, where the acetylated peptide typically 
interacts with the bromodomain. It is possible that this vector could be exploited, as an 
alternative to growth at the amide at the 7-position, to improve affinity and specificity, Figure 
6.15. No attempts have yet been made to explore SAR at this position and it is believed that this 
could be valuable. 
 
Figure 6.15. Alternative Position for SL1126 Fragment Growing. Homo sapiens PCAF bromodomain with protein 
chain coloured from blue at N-terminus to red at C-terminus in complex with SL1126 in pink (PDB ID: 5FE8)240, aligned 
to S. cerevisiae bromodomain (PDB ID: 1E6I)239 to show acetyl-lysine binding site. Histone H4 peptide in grey. 
6.2.4 Tm Shift Optimisation and Screening 
With a library of potential KAT2A and KAT2B BRD inhibitors ready for testing, a suitable assay 
was required in-house to begin screening efforts. The thermal stability shift assay was prioritised 
due to relative ease of assay set up and capacity for high throughput. Thermal stability shift is 
intended to identify ligands that bind and stabilise proteins. The thermal denaturation 
temperature at which a protein unfolds is characterised by an increase in fluorescence of an 
applied dye (SYPRO orange) with affinity for hydrophobic regions that are exposed only upon 
protein unfolding. An increase in melting temperature (Tm) upon addition of a ligand is 
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interpreted as a binding event, as the small molecule has increased the energy required to 
disrupt the protein structure, indicative of a constructive interaction. 
Histidine-tagged KAT2A bromodomain protein was required for use in thermal shift screening. 
The 16 kDa protein was successfully expressed and purified, using immobilised metal affinity 
chromatography and size exclusion chromatography, from a construct generously provided by 
Dr Antony Oliver (Genome Damage and Stability Centre, University of Sussex), Figure 6.16.  
 
Figure 6.16. His-Tagged KAT2A BRD Purification. (a) Chromatogram from SEC purification of His6-KAT2A BRD. (b) 
SDS-PAGE gel of fractions obtained by SEC, numbered to correspond to the chromatogram. Concentrated protein 
band at 16 kDa corresponds to His6-KAT2A BRD protein. 
After preparation of the His6-KAT2A BRD protein, efforts in Tm shift assay optimisation were 
initiated. To begin with, it was necessary to confirm that the thermal denaturation of the KAT2A 
BRD protein could be successfully measured, Figure 6.17. 2 μM KAT2A BRD was added to 5x 
SYPRO orange dye and the fluorescence was measured whilst ramping the temperature 
between 20 °C and 85 °C. A melting temperature of ~50 °C was observed. 
 
Figure 6.17. Thermal Denaturation of KAT2A BRD. Fluorescence of 5x SYPRO orange dye with or without 2 μM KAT2A, 
20 μL well volume, measured over temperature ramp 20-85 °C. Graph represents mean ± 1 SD of three experiments. 
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Figure 6.18. KAT2A BRD Thermal Stability Shift Assay Optimisation. Fluorescence of SYPRO orange dye with KAT2A 
and 2% DMSO, 20 μL well volume, measured over temperature ramp 20-85 °C. (a) 5x SYPRO orange dye with 0 μM, 
1 μM or 2 μM KAT2A, to measure effect of protein concentration. (b) 5x SYPRO orange dye with 2 μM KAT2A in buffer 
with varied concentrations of sodium chloride, to measure effect of salt concentration. (c) 1.25x, 2.5x or 5x SYPRO 
orange dye with 2 μM KAT2A, to measure effect of SYPRO orange concentration. Graphs represent mean ± 1 SD of 
three experiments. 
Following this, a number of optimisation experiments were conducted. Firstly, the effect of 
protein concentration was assessed. 0 μM, 1 μM or 2 μM KAT2A BRD was added to 5x SYPRO 
orange dye, and the fluorescence was measured whilst increasing the temperature from 20 °C 
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to 85 °C, Figure 6.18 (a). Whilst significant, the fluorescence at 1 μM KAT2A was considerably 
less than the signal at 2 μM. Given the ease of protein preparation for this target, it was decided 
that 2 μM KAT2A should be used in the assay as standard. In the absence of protein, minimal 
fluorescence was observed and there was no significant change with temperature. 
Secondly, the effect of buffer composition was assessed. The thermal denaturation of 2 μM 
KAT2A BRD protein was measured in a buffer containing 100 mM, 300 mM, 500 mM or 700 mM 
sodium chloride, Figure 6.18 (b). The KAT2A BRD showed a stable melting curve at NaCl 
concentrations of 300 mM or above, but showed destabilisation at 100 mM. It was decided that 
500 mM salt should be used as standard, consistent with a protocol provided by the SGC. 
 
Figure 6.19. DMSO Tolerance of Thermal Stability Shift Assay. Fluorescence of 5x SYPRO orange dye with 2 μM KAT2A 
and 0-20% DMSO, 20 μL well volume, measured over temperature ramp 20-85 °C. (a) Melting curves. (b) Melting 
peaks, calculated as the derivative of the melting curve. Minima correspond to Tm. Graphs represent mean ± 1 SD of 
three experiments. 
Thirdly, the effect of the concentration of the SYPRO orange dye was assessed. 2 μM KAT2A BRD 
was added to 1.25x, 2.5x or 5x SYPRO orange dye and the fluorescence was measured whilst 
increasing the temperature between 20 °C and 85 °C, Figure 6.18 (c). Decreasing the 
concentration of SYPRO orange significantly reduced the fluorescence signal and therefore the 
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sensitivity of the assay. It was determined that the dye should be used at 5x concentration as 
standard, again consistent with the protocol provided by the SGC. 
Finally, the impact of addition of DMSO was assessed. The small molecules tested in assays are 
rarely water soluble and therefore must be dissolved in a suitable solvent prior to addition. 
DMSO is popular as it able to dissolve both polar and nonpolar compounds and is miscible with 
many organic solvents as well as water. Consequently, most compound libraries, including all 
those available in-house are dissolved in DMSO, so it is necessary to test the DMSO tolerance of 
protein assays. Thermal denaturation of the KAT2A BRD protein was measured in the presence 
of 0-20% DMSO, Figure 6.19 (a). Stable melting curves were observed for the KAT2A BRD with 
up to 5% DMSO. At 20% DMSO the protein appeared to be completely denatured. Notably, it 
was also observed that addition of any concentration of DMSO induced a shift in melting 
temperature, e.g. from 50 °C at 0% DMSO to 53 °C at 5%, Figure 6.19 (b). This was expected, as 
DMSO is a known BRD ligand and will thereby affect protein stability.558 Accordingly, any 
comparisons in Tm should be made only between samples of equivalent DMSO concentration. 
 
Figure 6.20. KAT2A BRD Tm Shift with SL1126 and SL1132. Fluorescence of 5x SYPRO orange dye with 2 μM KAT2A 
and 2% DMSO, with or without 1 mM SL1126 or SL1132, 20 μL well volume, measured over temperature ramp 20-
85 °C. (a) Melting curves. (b) Melting peaks, calculated as the derivative of the melting curve. Minima correspond to 
Tm. Graphs represent mean ± 1 SD of three experiments. 
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Having optimised the thermal shift assay conditions, an attempt was made to reproduce some 
of the results provided by the SGC. The thermal denaturation of 2 μM KAT2A BRD protein was 
measured in the presence and absence of 1 mM SL1126 or SL1132 with 2% DMSO, Figure 6.20, 
and the melting temperatures, determined using the Roche Protein Melting Analysis Software, 
were compared to calculate the Tm shift. Frustratingly, the Tm shifts were measured as just 
1.0 °C and 0.5 °C for SL1126 and SL1132 respectively, considerably lower than the 5.7 °C and 
4.2 °C shifts observed of KAT2B by the SGC. 
To investigate the cause of this discrepancy, isothermal titration calorimetry was employed to 
measure the heats of binding of SL1126 and SL1132 with the KAT2A BRD. The results of 
experiments conducted at 800 μM compound and 60 μM protein are shown in Figure 6.21. 
SL1126 exhibited a Kd of 199 μM and SL1132 a Kd of 231 μM, Table 6.4. These values were again 
considerably higher than those reported with KAT2B by the SGC, 30 μM and 35 μM respectively.  
 
Figure 6.21. ITC Binding Data for Interaction Between KAT2A BRD and SL1126 or SL1132. Isotherms of raw titration 
heat above. Normalised binding heats below, with solid line representing nonlinear least squares fit using single-site 
binding model. Error calculated from deviation to least squares fit. (a) 800 μM SL1126 titrated into 60 μM KAT2A BRD. 
(b) 800 μM SL1132 titrated into 60 μM KAT2A BRD. 
Based on the thermal shift and ITC data it appeared that SL1126 and SL1132 were significantly 
less potent inhibitors of the KAT2A BRD than expected. It was rationalised that this observation 
could be explained in two ways. Either the compounds were less potent inhibitors of the KAT2B 
bromodomain than reported, or the compounds exhibited a considerable, unexpected 
selectivity for KAT2B over KAT2A. To test this, the thermal denaturation of 2 μM KAT2B BRD 
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protein, generously provided by the SGC, was measured in the presence and absence of 1 mM 
SL1126 or SL1132 with 2% DMSO, Figure 6.22, and the melting temperatures, determined using 
the Roche Protein Melting Analysis Software, were compared to calculate the Tm shift. The Tm 
shifts were measured as 2.5 °C and 2.1 °C for SL1126 and SL1132 respectively, higher than 
observed for the KAT2A BRD but still lower than originally reported by the SGC. It was therefore 
concluded that the inhibitors might exhibit some selectivity for KAT2B compared to KAT2A, but 
fundamentally, they were not as potent as previously believed. Correspondingly, when it was 
ultimately published that SL1126 inhibits PCAF, a thermal shift of 2.6 °C was reported and no ITC 
data was included.240  
 
Figure 6.22. KAT2B BRD Tm Shift with SL1126 and SL1132. Fluorescence of 5x SYPRO orange dye with 2 μM KAT2B 
and 2% DMSO, with or without 1 mM SL1126 or SL1132, 20 μL well volume, measured over temperature ramp 20-
85 °C. (a) Melting curves. (b) Melting peaks, calculated as the derivative of the melting curve. Minima correspond to 
Tm. Graphs represent mean ± 1 SD of three experiments. 
This result served to bolster confidence that the thermal stability shift assay had been 
appropriately optimised for use in screening. However, SL1126 no longer represented such a 
desirable lead compound for structure-based design, which boded poorly for the libraries of 
amides and sulphonamides inspired by this scaffold. 
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Despite these concerns, the libraries of amides and sulphonamides, along with a handful of 
other quinolinone homologues generously prepared by Kamlesh Bala (Sussex Drug Discovery 
Centre, University of Sussex), were screened against the KAT2A BRD using the optimised Tm 
shift assay. The thermal denaturation of 2 μM KAT2A BRD was measured in the presence and 
absence of 1 mM inhibitor with 2% DMSO, and the melting temperatures, determined using the 
Roche Protein Melting Analysis Software, were compared to calculate the Tm shifts. Those 
compounds which induced a significant shift in Tm, calculated as greater than three times the 
standard deviation in the controls, which equated to approximately 2.5 °C, are displayed in 
Figure 6.23. It is notable that within these constraints, the binding of SL1126 and SL1132 would 
not have been detected. This is illustrative of the poor sensitivity of this thermal shift assay.  
 
Figure 6.23. KAT2A BRD Tm Shift Screening Results. Tm shift values calculated by comparing Tm of protein with and 
without compound, as determined by Roche Protein Melting Analysis Software. Fluorescence of 5x SYPRO orange dye 
with 2 μM KAT2A, 2% DMSO and 1 mM compound, 20 μL well volume, measured over temperature ramp 20-85 °C. 
Graph represents mean ± 1 SD of two experiments. 
Nine compounds induced a significant positive Tm shift and were of interest. The positive shift 
indicated an increase in the stability of the KAT2A BRD upon compound addition, which it was 
hoped corresponded to protein binding. Twelve compounds exhibited a significant negative Tm 
shift, apparently decreasing the stability of the protein. These compounds may interact 
favourably with the denatured protein and thereby shift the equilibrium toward the unfolded 
state. These were not of interest in this work. 
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6.2.5 NMR Preparation and Screening 
Whilst growing and diversifying the SL1126 fragment would enable exploration of SAR, as 
previously discussed, the quinolinone fragments show no selectivity for the type I BRDs over 
other bromodomain families. As such, development of a selective small molecule inhibitor of 
the KAT2A bromodomain required screening to identify other suitable cores. NMR fragment 
screening was selected as a suitable technique for identification of novel scaffolds for inhibitor 
development. 
 
Figure 6.24. KAT2A BRD Purification. (a) SDS-PAGE gel showing His6-KAT2A BRD (16 kDa) and KAT2A BRD (13.5 kDa) 
indicating successful cleavage by TEV protease. (b) Chromatogram from SEC purification of KAT2A BRD in sodium 
phosphate buffer. (c) SDS-PAGE gel of fractions obtained by SEC, numbered to correspond to the chromatogram. 
Concentrated protein band at 13.5 kDa corresponds to KAT2A BRD protein. 
The NMR fragment screen was conducted externally but some preparatory work was conducted 
in-house. The assay required untagged KAT2A bromodomain protein, purified in a sodium 
phosphate buffer. Accordingly, the His6-KAT2A bromodomain protein was expressed and 
purified and the histidine tag was cleaved using TEV (tobacco etch virus) protease to afford the 
13.5 kDa KAT2A BRD protein, Figure 6.24. 
 
Figure 6.25. KAT2A BRD Protein Stability Test. Thermal denaturation of KAT2A BRD stored at 4 °C in 20 mM sodium 
phosphate buffer with 200 mM NaCl, measured over four days. Fluorescence of 5x SYPRO orange dye with 2 μM 
KAT2A BRD, 20 μL well volume, measured over temperature ramp 20-85 °C. Graph represents mean ± 1 SD of 
triplicate repeats. 
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It was necessary to confirm that the protein would be stable at 4 °C for the duration of the NMR 
assay, which runs over four days, ideally in a buffer with lower than the standard 500 mM 
sodium chloride. A solution of 2 μM KAT2A BRD in sodium phosphate buffer with 200 mM NaCl 
was stored for four days in the fridge. Every 24 hours a sample of the protein was taken and the 
thermal denaturation was measured. The protein was stable over this period, Figure 6.25. 
The NMR fragment screening was conducted externally utilising Water-Ligand Observed via 
Gradient Spectroscopy (WaterLOGSY) and Saturation Transfer Difference (STD) NMR 
techniques. 32 fragments were identified that exhibited affinity for the KAT2A BRD, Figure 
Apx.11. These compounds were purchased for confirmation in-house. 
6.2.6 ITC Hit Confirmation 
Hit confirmation was conducted using isothermal titration calorimetry. ITC is a powerful and 
sensitive technique for characterisation of the thermodynamics of molecular interactions in 
solution. Typically, a test compound is titrated, via a series of small injections, into the protein 
sample. Any interaction between the compound and the protein will cause a small release or 
uptake of heat within the sample cell, which is measured relative to a reference cell, Figure 6.26. 
Monitoring of the relationship between the dose of the compound added and the magnitude of 
the heat changes enables calculation of the equilibrium dissociation constant (Kd), which 
corresponds to the free ligand concentration when 50% of the protein binding sites are 
occupied.572 This ability to directly monitor binding means that ITC can be used to characterise 
protein fragments which lack native biochemical activity, such as bromodomains. 
 
Figure 6.26. Schematic of Isothermal Titration Calorimetry Instrumentation. 
Consulting with the SGC it was discovered that untagged BRD protein is utilised as standard in 
ITC experiments, with the histidine tag cleaved from the protein during purification. Reportedly, 
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the tag can be problematic at the high protein concentrations required in ITC, impacting protein 
stability and causing aggregation. Accordingly, KAT2A bromodomain protein was expressed and 
purified with the histidine tag cleaved, affording the 13.5 kDa protein, Figure 6.27. 
 
Figure 6.27. KAT2A BRD Purification. (a) SDS-PAGE gel showing His6-KAT2A BRD (16 kDa) and KAT2A BRD (13.5 kDa) 
indicating successful cleavage by TEV protease. (b) Chromatogram from SEC purification of KAT2A BRD. (c) SDS-PAGE 
gel of fractions obtained by SEC, numbered to correspond to the chromatogram. Concentrated protein band at 
13.5 kDa corresponds to KAT2A BRD protein. 
ITC requires no specialised reagents or labelling of reactants and the same detection method is 
used for all protein targets. As a result, assay development is minimal. In addition, interpretation 
of measured binding affinities is straightforward as there are no complicating effects, for 
example from substrates, intermediates, products or reporter ligands.572  
Initial attempts to confirm the affinity of the amides identified in the thermal shift screen were 
hindered by solubility difficulties. The compounds were not soluble at the necessary 
concentration (≥600 μM) to enable injection into the test protein. Fortunately, however, it was 
discovered that the KAT2A BRD protein was soluble at this concentration. It was therefore 
determined that the compound-protein addition should be reversed, such that KAT2A BRD was 
injected into a solution of the small molecule. Fortuitously, this also aided in improving the 
throughput of the assay. A single heat of dilution, of protein into buffer, could be conducted as 
the control experiment for titration of that sample of KAT2A BRD into a series of compounds. 
Unfortunately, UOS-26687, UOS-26702 and UOS-26619 remained insoluble at 60 μM and 
therefore could not be tested. However, the heats of binding of the other amides with the KAT2A 
BRD were measured. Only compounds UOS-21430 and UOS-26660 exhibited binding with the 
target protein, Table 6.4. UOS-21430 exhibited a Kd of 29 μM and UOS-26660 a Kd of 170 μM. 
The results of the experiments conducted at 613 μM KAT2A BRD and 60 μM compound are 
shown in Figure 6.28. UOS-21430 represented an interesting hit as it represented only a minor 
change from SL1126, with addition of a methyl, and therefore retained good ligand efficiency. 
Overall, this was a disappointing result, exposing a high frequency of false positives from the Tm 
shift screen. Of the compounds that exhibited a positive Tm shift and could be tested by ITC, 
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only 33% confirmed as active. With the poor sensitivity and high rate of false positives, it was 
concluded that the Tm shift assay did not represent a useful screening technique for KAT2A BRD. 
Table 6.4. Tm Shift and ITC Kd Data From Experiments with KAT2A BRD and Amides Designed as KAT2A/KAT2B 
Binders. Error for ITC data calculated from deviation to least squares fit. 
 
 
Additionally, the result represented a low hit rate from the libraries of compounds designed 
from the SL1126 lead. This was somewhat anticipated when the true affinity of SL1126 for the 
KAT2A BRD was determined. Futhermore, the poor solubility associated with the quinolinones 
was highly detrimental to fragment growth efforts and ultimately defined which compounds 
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could be tested effectively. It was critically important that a novel scaffold be identified, which 
offered improved scope for growth and optimisation. 
 
Figure 6.28. ITC Binding Data for Interaction Between KAT2A BRD and UOS-21430 or UOS-26660. Isotherms of raw 
titration heat above. Normalised binding heats below, with solid line representing nonlinear least squares fit using 
single-site binding model. Error calculated from deviation to least squares fit. (a) 613 μM KAT2A BRD titrated into 
60 μM UOS-21430. (b) 613 μM KAT2A BRD titrated into 60 μM UOS-26660. 
Towards this aim, ITC was used as a secondary assay to confirm the hits from the NMR fragment 
screen. Fragment libraries consist of small molecules of molecular weight lower than 300 Da. 
Because of this small size, fragment space is smaller than chemical space and therefore can be 
more effectively probed using a smaller library. The drawback of this low molecular weight is 
that fragments are typically less potent than larger compounds, thus requiring highly sensitive 
assay techniques to detect binding. 
The heats of KAT2A BRD binding of the 32 fragments identified by NMR were measured, again 
by titrating protein into a solution of the small molecule, to maximise throughput. Seven of the 
fragments exhibited binding, Table 6.5. The results of the experiments conducted at 600 μM 
KAT2A BRD with 60 μM UOS-18715 and UOS-28671 are shown in Figure 6.29. 
Although dissociation constants were calculated, these were associated with high error, and 
there is a lack of confidence in the values. The low affinity of the fragments had two effects. 
Firstly, the measured heats of binding were small. As well as increasing the error due to 
background noise, this permitted the small perturbations resulting from binding of DMSO, a 
known BRD ligand558, to impact the data. This results in a poor fit between the experimental 
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data and the nonlinear least squares fit using a single-site binding model. Secondly, the titrations 
did not represent full binding curves. In a full curve, at low molar ratios, 100% of the ligand will 
bind to the available protein and eventually, when the protein becomes saturated, 0% of the 
ligand will bind. Commonly, for compounds of low affinity, only a section of this binding curve is 
observed, for example from 90% binding to 10% binding, and therefore the data must be 
extrapolated to calculate the dissociation constant, inducing error in the result. It is likely that in 
the case of these fragments the titrations represent only a small section of the binding curve, 
affording significant error. When a ligand with low micromolar affinity, for which a full binding 
curve can be obtained, becomes available, competition assays could be employed to more 
accurately calculate Kds for these weakly binding ligands. 
Table 6.5. Kd Data from ITC Experiments with KAT2A BRD and Fragments Identified as KAT2A Binders by NMR. Error 
calculated from deviation to least squares fit. 
 
 
6.2.7 ITC Screening 
Having concluded that the thermal stability shift assay exhibited prohibitively poor sensitivity 
and high rate of false positives, ITC was instead adopted as the primary screening assay. The 
principal limitation of ITC is the high quantity of test protein required.572 Fortunately, 
preparation of the KAT2A BRD was straightforward and sufficient protein could be generated. 
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ITC is also not a high-throughput technique, with each titration taking at least 30 minutes. To 
maximise throughput, KAT2A BRD protein was titrated into compound as standard. 
 
Figure 6.29. ITC Binding Data for Interaction Between KAT2A BRD and UOS-18715 or UOS-28671. Isotherms of raw 
titration heat above. Normalised binding heats below, with solid line representing nonlinear least squares fit using 
single-site binding model. Error calculated from deviation to least squares fit. (a) 600 μM KAT2A BRD titrated into 
60 μM UOS-18715. (b) 600 μM KAT2A BRD titrated into 60 μM UOS-28671. 
A series of quinolinones inspired by SL1126 and UOS-21430, prepared by Dr Darren Le Grand 
and Kamlesh Bala (Sussex Drug Discovery Centre, University of Sussex) were screened by ITC. 
Seven of the compounds exhibited binding, Table 6.6. Apart from UOS-28438, which exhibited 
a Kd of 18 μM, none of the compounds showed a significant increase in potency compared to 
UOS-21430 (Kd = 29 μM). The results of the experiments with ~600 μM KAT2A BRD and 60 μM 
of the two most potent compounds, UOS-28438 and UOS-26378, are shown in Figure 6.30. This 
data fits poorly with the binding model, as was observed with fragments UOS-18715 and UOS-
28671. This is likely a result of DMSO binding effects. 
UOS-28438 was an interesting hit. Considering the crystal structure of SL1126 in complex with 
PCAF (PDB ID: 5FE8)240, the ethyl group at the 1-position is expected to extend towards the 
conserved waters at the back of the binding cavity, Figure 6.13 (b). There are limited examples 
in the literature in which any of these waters are displaced.573 It was therefore surprising that 
binding was retained with ligand growth at this position. It was speculated that the binding 
position of the ligand may be adjusted to accommodate the ethyl group. UOS-28438 was 
therefore highlighted as an interesting target for crystallographic study. 
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Table 6.6. Kd Data from ITC Experiments with KAT2A BRD and Quinolinone Derivatives. Error calculated from 
deviation to least squares fit. 
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Figure 6.30. ITC Binding Data for Interaction Between KAT2A BRD and UOS-28438 or UOS-26378. Isotherms of raw 
titration heat above. Normalised binding heats below, with solid line representing nonlinear least squares fit using 
single-site binding model. Error calculated from deviation to least squares fit. (a) 580 μM KAT2A BRD titrated into 
60 μM UOS-28438. (b) 600 μM KAT2A BRD titrated into 60 μM UOS-26378. 
 
 
Figure 6.31. ITC Binding Data for Interaction Between KAT2A BRD and UOS-28514 or UOS-28646. Isotherms of raw 
titration heat above. Normalised binding heats below, with solid line representing nonlinear least squares fit using 
single-site binding model. Error calculated from deviation to least squares fit. (a) 580 μM KAT2A BRD titrated into 
60 μM UOS-28514. (b) 600 μM KAT2A BRD titrated into 60 μM UOS-28646. 
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Compounds UOS-28514 and UOS-28646 were also of interest. The results of experiments 
conducted at ~600 μM KAT2A BRD with 60 μM of these compounds are shown in Figure 6.31. 
Reportedly, UOS-28514 exhibited reasonable potency for the PCAF BRD, with an associated Kd 
of 21 μM.240 However, no binding was observed by ITC in-house with the KAT2A BRD. 
Table 6.7. Kd Data from ITC Experiments with KAT2A BRD and Phenylpyridinone Derivatives. Error calculated from 
deviation to least squares fit. 
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Inspired by the experience with SL1126 and UOS-21430, UOS-28646 was designed, with addition 
of a methyl group at the sulphonamide at the 7-position. UOS-28646 exhibited significantly 
improved binding with the KAT2A BRD, with a Kd of 49 μM. 
Unfortunately, despite evidence from the crystal structure of SL1126 with PCAF (PDB ID: 5FE8)240 
that space is available at the quinolinone 4-position, ligand growth at this vector was not 
tolerated. No binding was measured for compounds UOS-28527, UOS-28573 or UOS-28519. 
Following this, a series of phenylpyridinones, generously prepared by Dr Irina Chuckowree, 
Kamlesh Bala and Dr Tristan Reuillon (Sussex Drug Discovery Centre, University of Sussex), which 
were hoped to offer improved solubility compared to the quinolinones, were screened by ITC. 
Ten of the compounds exhibited binding, Table 6.7. UOS-28625 showed a small improvement in 
potency compared to UOS-21430 (Kd = 29 μM), with a Kd of 20 μM, but all other compounds 
exhibited affinity similar to or poorer than UOS-21430. The results of experiments conducted at 
600 μM KAT2A BRD with 60 μM UOS-28625 and UOS-28734, are shown in Figure 6.32. Again, 
the UOS-28625 data fits poorly with the binding model, as observed with fragments UOS-18715 
and UOS-28671, likely as a result of DMSO binding effects. Nonetheless, as examples of a novel 
scaffold, these compounds also represented interesting targets for crystallographic study. 
 
Figure 6.32. ITC Binding Data for Interaction Between KAT2A BRD and UOS-28625 or UOS-28734. Isotherms of raw 
titration heat above. Normalised binding heats below, with solid line representing nonlinear least squares fit using 
single-site binding model. Error calculated from deviation to least squares fit. (a) 600 μM KAT2A BRD titrated into 
60 μM UOS-28625. (b) 600 μM KAT2A BRD titrated into 60 μM UOS-28734. 
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Table 6.8. Kd Data from ITC Experiments with KAT2A BRD and Pyridylpyridinone Derivatives. Error calculated from 
deviation to least squares fit. 
 
 
Figure 6.33. ITC Binding Data for Interaction Between KAT2A BRD and UOS-31235 or UOS-31126. Isotherms of raw 
titration heat above. Normalised binding heats below, with solid line representing nonlinear least squares fit using 
single-site binding model. Error calculated from deviation to least squares fit. (a) 600 μM KAT2A BRD titrated into 
60 μM UOS-31235. (b) 600 μM KAT2A BRD titrated into 60 μM UOS-31126. 
A final series of pyridylpyridinones, prepared by Dr Lewis Pennicott (Sussex Drug Discovery 
Centre, University of Sussex), were also screened by ITC. All five of these compounds exhibited 
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binding, Table 6.8. UOS-31235 and UOS-31126 exhibited enhanced binding compared to UOS-
21430. The results of the ITC experiments with these compounds are shown in Figure 6.33. 
In addition, 33 novel fragments, generously prepared by Dr Lewis Pennicott (Sussex Drug 
Discovery Centre, University of Sussex), were screened. KAT2A BRD binding was successfully 
observed for fragment UOS-27986, Figure 6.34 (a), which exhibited a Kd of 154 μM. The result 
of the experiment conducted at ~600 μM KAT2A BRD with 60 μM UOS-27986 is shown in Figure 
6.34 (b). As another novel scaffold, UOS-27986 was also highlighted as an interesting target for 
crystallographic study. 
 
Figure 6.34. UOS-27986 as a Novel Binder of the KAT2A BRD. (a) Chemical structure of UOS-27986. (b) ITC binding 
data for interaction between KAT2A BRD and UOS-27986. 621 μM KAT2A BRD titrated into 60 μM UOS-27986. 
Isotherm of raw titration heat above. Normalised binding heat below, with solid line representing nonlinear least 
squares fit using single-site binding model. Error calculated from deviation to least squares fit. 
6.2.8 X-Ray Crystallography 
Alongside ITC screening, crystallographic studies were initiated. It was hoped that if ligand-
bound structures of the KAT2A BRD with small molecule micromolar inhibitors could be 
obtained, these would enable improved structure-based drug design. 
The crystals used to obtain the apo structure of the Homo sapiens GCN5 bromodomain (PDB ID: 
3D7C)238 reported previously, were grown in 0.1 M Tris (Tris(hydroxymethyl)aminomethane), pH 
8.5, with 25% PEG (polyethylene glycol) 3350. Fortunately, these conditions were effective, and 
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the His6-KAT2A bromodomain protein, used in the Tm shift assay, was successfully crystallised 
in hanging drops, with 0.1 M Tris, pH 8.5 and 16% PEG 3350 at 5 mg/mL protein at 4 °C. 
The resulting crystals were robust and crystal soaking, at 10 mM compound in 10% DMSO as 
standard, was successfully used to obtain crystals of ligand-bound KAT2A BRD, with compounds 
UOS-21430, UOS-18715, UOS-28438, UOS-28625, UOS-28734 and UOS-27986. 
X-ray diffraction data was kindly collected using a rotating anode X-ray source (Rigaku 
MicroMax™-007 HF generator and Saturn 944+ CCD detector), or using synchrotron radiation at 
the Diamond Light Source, and the structures solved and refined by Dr Mark Roe (X-Ray 
Crystallography Collaborative Research Facility, University of Sussex). 
The apo structure, which was determined at a resolution of 1.53 Å, was in good agreement with 
the published structure of the Homo sapiens GCN5 bromodomain (PDB ID: 3D7C).238 The 
druggable site, comprised of the hydrophobic acetyl-lysine binding cavity and surrounding 
charged surface, is depicted in Figure 6.35. The conserved asparagine N808, which interacts via 
hydrogen bonding with the carbonyl on acetyl-lysine residues, sits at the back of the pocket, 
alongside four conserved water molecules, common to BRDs. The three residues previously 
identified that may afford selectivity towards the KAT2A and KAT2B BRDs were of particular 
interest. Tryptophan W751 forms part of a lipophilic WPF shelf above the druggable pocket. 
Methionine M754 sits at the far right of the druggable site, distant from the hydrophobic acetyl-
lysine binding cavity. Finally, glutamic acid E761 forms a hydrogen bonding interaction with 
tyrosine Y814, which bridges across the front of the binding site.  
 
Figure 6.35. Crystal Structure of Apo KAT2A BRD. Homo sapiens KAT2A bromodomain. Residues either highly 
conserved in bromodomains or unique to KAT2A and KAT2B are displayed and annotated. Conserved waters at the 
back of the binding cavity and others within the pocket are displayed as red spheres. 
The first ligand-bound crystal structure solved was that of the KAT2A BRD in complex with UOS-
21430, shown in Figure 6.36 (a). As expected, considering the structure of the PCAF BRD with 
SL1126 (PDB ID: 5FE8)240, the quinolinone carbonyl at the 2-position formed a hydrogen bonding 
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interaction with N808 at the back of the hydrophobic acetyl-lysine binding cavity. The flat 
quinolinone scaffold fits neatly into the narrow BRD binding site and E761, which in the apo 
structure bridges across the small molecule binding site, rotates clockwise to accommodate the 
ligand. The increased activity of UOS-21430 compared to SL1126 appears to result from the N-
methyl group causing the amide to twist relative to the quinolinone. This relieves some clashing 
with E761 and positions the carbonyl to interact with the solvent. 
 
Figure 6.36. Crystal Structures of KAT2A BRD in Complex with Small Molecules. Homo sapiens KAT2A bromodomain 
with (a) UOS-21430, (b) UOS-18715, (c) UOS-28438, (d) UOS-28625, (e) UOS-28734 and (f) UOS-27986 bound at the 
acetyl-lysine binding site. Residues either highly conserved in BRDs or unique to KAT2A and KAT2B are highlighted. 
Conserved waters at the back of the binding cavity and others within the binding pocket are displayed as red spheres. 
Hydrogen bonding interactions highlighted as yellow dashed lines. 2D structures included for reference.  
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Attempts to generate a crystal structure of UOS-18715 in complex with the KAT2A BRD were 
complicated by the lower affinity of the fragment. With the standard crystal soaking protocol, 
using 10 mM compound in 10% DMSO, no ligand was observed at the KAT2A acetyl-lysine 
binding site. As DMSO is a known BRD ligand558, it was likely that at this concentration the DMSO 
was outcompeting the compound for KAT2A binding. Crystal soaking was therefore repeated at 
100 mM compound in 20% methanol, to successfully produce a structure of the KAT2A BRD in 
complex with UOS-18715, Figure 6.36 (b). The bicyclic rings were rotated by 90° compared to 
the quinolinone UOS-21430, enabling the ester carbonyl to interact with N808 at the back of the 
acetyl-lysine binding pocket via a hydrogen bond, whilst avoiding clashing with E761. Again, 
E761 twisted away from Y814 to accommodate the ligand. 
UOS-28438 was highlighted as an interesting target for crystallographic study as the ethyl group 
at the 1-position was expected to extend towards the conserved waters at the back of the 
binding cavity. As there are few reported examples in which any of these waters are displaced573, 
it was assumed that the binding of the ligand must be adjusted to accommodate the ethyl group. 
However, the crystal structure of the KAT2A BRD in complex with UOS-28438, Figure 6.36 (c), 
confirmed that the ethyl group can simply extend up into the hydrophobic binding pocket, 
pointing away from the conserved waters. The space available at this position could be tested 
using a series of quinolinones with propyl, isopropyl or butyl groups introduced at the 1-position. 
UOS-28625 was an interesting target for crystallographic analysis as it was slightly more potent 
than UOS-21430 and represented a novel scaffold. The binding of UOS-28625 with KAT2A BRD, 
shown in Figure 6.36 (d), showed some notable differences to that of the quinolinones. As 
expected, the pyridinone carbonyl formed a hydrogen bonding interaction with N808 at the back 
of the acetyl-lysine binding site. The separation of the aromatic rings, compared to the bicyclic 
quinolinone scaffold, alleviated clashing with E761 and therefore the glutamic acid assumed a 
position more similar to that observed in the apo structure, with the carboxyl group turned to 
be directed away from the binding pocket. The sulphonamide moiety was then effectively placed 
to form hydrogen bonding interactions with E761 and with Y814 via a bridging water. 
As expected, phenylpyridinone UOS-28734 interacted with the KAT2A BRD in a similar manner 
to UOS-28625, as shown in Figure 6.36 (e). The pyridinone carbonyl formed a hydrogen bond 
with N808 at the back of the hydrophobic acetyl-lysine binding cavity, and E761 assumed a 
position similar to that in the apo structure. The ether protruded into the pocket rather than 
towards the E761 carboxyl as the UOS-28625 sulphonamide did. It should be noted that for 
compounds UOS-28625 and UOS-28734, from the electron density maps it was not possible to 
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assign the orientation of the pyridinone ring regarding whether the N-methyl or C-methyl is 
directed towards the conserved waters at the back of the binding pocket. 
Finally, the crystal structure of the KAT2A BRD in complex with UOS-27986 is shown in Figure 
6.36 (f). As for UOS-18715, the low affinity of UOS-27986 meant it was more difficult to generate 
a ligand-bound structure. No ligand was observed at the KAT2A acetyl-lysine binding site using 
the standard crystal soaking protocol. Crystal soaking was repeated at 100 mM compound in 
20% DMSO to successfully obtain a structure of the KAT2A BRD in complex with UOS-27986. The 
UOS-27986 bicycle bound in the same orientation as the quinolinone UOS-21430, the 
benzimidazolone carbonyl interacted with N808 at the back of the acetyl-lysine binding pocket 
and E761 rotated away from Y814 to enable ligand binding. 
6.2.9 TR-FRET Assay Design 
Although ITC had been utilised to generate many useful results, it was undoubtedly not well 
suited as a primary screening assay. ITC is time consuming, low throughput and the requirement 
for protein supply was unsustainably high. It was therefore essential that a new KAT2A BRD 
assay be developed in-house, which was better suited to high-throughput screening. Time-
resolved fluorescence resonance energy transfer technology had been used to characterise 
inhibitors of other bromodomains such as BRD4(1) and CREBBP and p300570,571, and was 
therefore highlighted as a promising alternative assay. 
 
Figure 6.37. Schematic of Generic HTRF® Assay Design Using EPIgeneous™ Binding Domain Kit. 
Cisbio sell an assay kit, the EPIgeneous™ Binding Domain Kit, which is designed to measure the 
interaction between bromodomains and acetylated histone peptides, to enable characterisation 
of inhibitors. As shown in Figure 6.37, the interaction between Glutathione S-transferase (GST)-
tagged protein and a suitable biotinylated peptide is detected using an anti-GST antibody 
coupled to a donor and an acceptor-labelled streptavidin (SA). When the peptide is bound to 
the BRD and therefore the dyes are in close proximity, the excitation of the donor triggers a FRET 
towards the acceptor, which then fluoresces. The HTRF® (homogeneous time resolved 
fluorescence) technology, refined by Cisbio, utilises cryptate donors that are excited at 337 nm 
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and emit at 620 nm, and red acceptors that emit at 667 nm. The signal modulates positively in 
proportion to the protein-peptide interaction, such that when an unlabelled small molecule 
inhibitor competes with the peptide for BRD binding, the fluorescence at 665 nm is reduced. 
Unfortunately, KAT2A is not one of the sixteen bromodomains for which the Cisbio assay kit has 
been optimised. As such, there was not a recommended peptide which could be utilised in the 
assay. Furthermore, in peptide array screens, while the histone binding partners of several other 
BRDs were successfully identified, no peptides exhibited significant binding affinity for KAT2A558, 
and any weak binding appeared to be largely independent of peptide sequence.574 However, 
eight peptides were identified that reportedly exhibit some affinity for the KAT2A 
bromodomain, including three variant HIV-1 Tat peptides acetylated at lysine 50542,575, three 
histone H3 peptides acetylated at lysine 14238,576, and two histone H4 peptides acetylated at 
lysines 12 or 16.239 These peptides were purchased, along with a tetra-acetylated H4 peptide 
frequently employed with other BRDs in the EPIgeneous™ binding assay. 
ITC was employed to measure the heats of binding of the nine peptides with the KAT2A BRD. 
Only peptides 35329 and 36685 showed any indication of binding with the bromodomain, Table 
6.9. 35329 bound with a Kd of 67 μM and 36685 a Kd of 282 μM. The results of the ITC 
experiments conducted with KAT2A BRD and peptides 35329 and 36685 are shown in Figure 
6.38. Despite representing the most potent peptide, 35329 exhibited poorer affinity than many 
of the small molecule inhibitors already identified and was not optimal for use in the 
EPIgeneous™ competition assay. 
Table 6.9. Kd Data from ITC Experiments with KAT2A BRD and Acetylated Peptides. Error calculated from deviation 
to least squares fit. 
 
 
At this time, a slew of PCAF and GCN5 inhibitors were reported in quick succession in patents 
and in the literature, Figure 6.39. First, the SGC reported several new classes of acetyl-lysine 
mimetic ligands with micromolar affinity for PCAF, including SL1126 as well as CPD3, which were 
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identified using thermal shift, ITC and X-ray crystallography.240 Following this, a surface plasmon 
resonance (SPR) screen delivered fragments CPD-D and CPD-E, which exhibit 73 μM and 250 μM 
affinity for PCAF respectively.577 Genentech and Constellation Pharmaceuticals then disclosed, 
in three patent applications, highly potent inhibitors of PCAF and GCN5, which demonstrated 
significant improvements in potency compared to anything reported previously. The patents 
covered three chemotypes, phthalazines578, 6-azauracil derivatives579 and pyridazinones580. 
Moustakim et al. utilised thermal shift, ITC and X-ray crystallography data in the rational design 
of triazolopthalazine L-Moses, which exhibited a Kd of 126 nM for PCAF.581 Finally, in January 
2017, Humphreys et al. from GlaxoSmithKline reported GSK4027 as a dual PCAF/GCN5 chemical 
probe, with low nanomolar potency and ≥70-fold selectivity over all other bromodomains.582  
 
Figure 6.38. ITC Binding Data for Interaction Between KAT2A BRD and Peptides 35329 and 36685. Isotherms of raw 
titration heat above. Normalised binding heats below, with solid line representing nonlinear least squares fit using 
single-site binding model. Error calculated from deviation to least squares fit. (a) 588 μM KAT2A BRD titrated into 
60 μM 35329. (b) 497 μM KAT2A BRD titrated into 50 μM 36685. 
That the first tool inhibitors of KAT2A and KAT2B were published elsewhere was disappointing. 
However, the publications were highly useful. Firstly, in optimising SPR as a fragment screening 
tool for BRDs, Navratilova et al. demonstrated that DMSO interferes with BRD-inhibitor 
binding577, as previously noted in this work. The binding affinities of CPD-D and CPD-E for PCAF 
were measured at DMSO concentrations between 0% and 3%. The best results were obtained 
at 0% DMSO, with the apparent affinity of the compounds decreasing approximately 2.5 fold at 
1% DMSO and 5 fold at 3% DMSO. As the majority of fragment screening campaigns use DMSO 
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as the standard solvent for preparing fragment libraries, as a compromise it was recommended 
that 1% DMSO should be utilised in fragment screening.577 Additionally, these novel inhibitors 
afforded the opportunity to develop an effective KAT2A TR-FRET assay in-house. 
 
Figure 6.39. Recently Published KAT2A and KAT2B Binders. 
Seven inhibitors and associated enantiomers were kindly prepared by Dr Tristan Reuillon and Dr 
Lewis Pennicott (Sussex Drug Discovery Centre, University of Sussex), or provided by the SGC, 
for screening by ITC. All of the compounds except the inactive enantiomer of L-Moses (D-Moses) 
exhibited binding with the KAT2A bromodomain, Table 6.10. The results of the ITC experiments 
with the two most potent inhibitors, UOS-31388 and UOS-31181 are shown in Figure 6.40. UOS-
31388 exhibited a Kd of 0.94 μM and UOS-31181 a Kd of 1.5 μM. 
In attempt to obtain X-ray crystal structures of compounds UOS-31388 and UOS-31181 in 
complex with the KAT2A BRD, His6-KAT2A bromodomain protein was crystallised using 0.1 M 
Tris, pH 8.5 and 16% PEG 3350, in hanging drops, at 5 mg/mL protein at 4 °C. Crystals of UOS-
31388 complexed with the KAT2A BRD were successfully generated using crystal soaking at 
10 mM compound in 10% DMSO. 
Unfortunately, crystals of UOS-31181-bound KAT2A BRD could not be obtained using the 
standard crystal soaking protocol. It was hypothesised that the larger UOS-31181 could not 
successfully access the binding site by diffusing through the solvent channels. Instead, UOS-
31181 was co-crystallised with the His6-KAT2A BRD. Four 96-condition crystallisation screens 
were conducted with the JCSG-plus™ HT-96, ProPlex HT-96, Morpheus™ and PACT premier™ HT-
96 commercial libraries, to identify suitable crystallisation conditions. Ligand-bound His6-KAT2A 
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BRD was successfully crystallised in sitting drops, with 0.1 M sodium acetate, pH 5.0 and 1.5 M 
ammonium sulphate at 10 mg/mL protein at 20 °C.  
Table 6.10. Kd Data from ITC Experiments with KAT2A BRD and Published Binders. Error calculated from deviation 
to least squares fit. 
 
 
 
X-ray diffraction data was collected using a rotating anode X-ray source (Rigaku MicroMax™-007 
HF generator and Saturn 944+ CCD detector) and the structures solved and refined by Dr Mark 
Roe (X-Ray Crystallography Collaborative Research Facility, University of Sussex). 
The crystal structure of UOS-31388 in complex with the KAT2A BRD was determined at a 
resolution of 2.20 Å. UOS-31388 exhibits remarkable shape and structural complementarity with 
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the BRD binding site, as shown in Figure 6.41 (a). The pyridazinone carbonyl forms a hydrogen 
bonding interaction with N808 at the back of the hydrophobic acetyl-lysine binding site. The 
amine spacer between the two rings not only alleviates clashing with E761 but also engages in 
a hydrogen bond with the protein backbone at proline P752. Finally, the glutamic acid E761 is 
drawn in, towards the small molecule, to form hydrogen bonding interactions with the 
piperidine nitrogen. 
 
Figure 6.40. ITC Binding Data for Interaction Between KAT2A BRD and UOS-31388 or UOS-31181. Isotherms of raw 
titration heat above. Normalised binding heats below, with solid line representing nonlinear least squares fit using 
single-site binding model. Error calculated from deviation to least squares fit. (a) 600 μM KAT2A BRD titrated into 
60 μM UOS-31388. (b) 500 μM KAT2A BRD titrated into 50 μM UOS-31181. 
 
Figure 6.41. Crystal Structures of KAT2A BRD in Complex with Published Binders. Homo sapiens KAT2A BRD with (a) 
UOS-31388580 and (b) UOS-31181578 bound at the acetyl-lysine binding site. Residues either highly conserved in BRDs 
or unique to KAT2A and KAT2B are highlighted. Conserved waters at the back of the binding cavity and others within 
the binding pocket are displayed as red spheres. Hydrogen bonding interactions highlighted as yellow dashed lines. 
2D structures included for reference. 
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The structure of UOS-31181 with KAT2A BRD was determined at a resolution of 1.80 Å. Like UOS-
31388, UOS-31181 is well adapted to interact at the KAT2A BRD, Figure 6.41 (b). The 
phthalazinone carbonyl interacts with N808 at the back of the acetyl-lysine binding pocket via 
hydrogen bonding. The bicycle is rotated 90° compared to the quinolinone scaffold analysed 
previously, as observed for UOS-18715. The spacer between the two rings again alleviates 
clashing with E761, while the two amines engage in hydrogen bonding interactions with this 
glutamic acid. Finally, the aromatic ring sits beneath the lipophilic WPF shelf. 
As the more synthetically straightforward of the two compounds, UOS-31388 was selected for 
use in developing an HTRF® assay in-house. It was anticipated that this small molecule inhibitor 
could substitute the peptide required in the competition assay. Dr Lewis Pennicott (Sussex Drug 
Discovery Centre, University of Sussex) kindly synthesised compound UOS-31490, Table 6.11, an 
analogue of UOS-31388 joined via a PEG linker to biotin, at the solvent accessible N-methyl 
position. ITC was employed to measure the heat of binding of UOS-31490 with KAT2A. The result 
of the experiment at 600 μM protein and 60 μM compound is shown in Figure 6.42 (a). Despite 
the significant increase in size, UOS-31490 retained good affinity, exhibiting a Kd of 4.9 μM. 
Table 6.11. Kd Data from ITC Experiments with KAT2A BRD and Prospective Ligand-Biotin Peptide Substitutes. Error 
calculated from deviation to least squares fit. 
 
 
Having finally attained a biotinylated ligand with low micromolar affinity for the KAT2A BRD, 
efforts began to establish a TR-FRET assay in-house. N-terminal GST-tagged human KAT2A 
bromodomain and the EPIgeneous™ Binding Domain Discovery Kit were purchased from Cisbio. 
This kit is designed to determine the combination of donor and acceptor dyes best suited to 
measuring the interaction between the target protein and biotinylated ligand. 
Firstly, ligand-biotin titrations were conducted with 0.1 nM to 30000 nM UOS-31490, at fixed 
concentrations of 5 nM GST-KAT2A and anti-GST-donor cryptate, with a constant ligand-biotin : 
streptavidin-acceptor ratio of 8:1, as recommended. Negative controls, lacking GST-KAT2A, were 
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included to assess the non-specific signal at each concentration of UOS-31490. These were used 
to calculate the assay window (= HTRF® ratio positive / HTRF® ratio negative). The fluorescence 
emission was read at wavelengths 665 nm and 620 nm and the results expressed in HTRF® ratio 
(= (665 nm/620 nm) x 104). Three detector reagent pairings were assessed, anti-GST-Eu3+ with 
SA-d2, anti-GST-Eu3+ with SA-XL665 and anti-GST-Tb2+ with SA-XL665. The resulting assay 
windows are shown in Figure 6.43 (a). 
 
Figure 6.42. ITC Binding Data for Interaction Between KAT2A BRD and UOS-31490 or UOS-31670. Isotherms of raw 
titration heat above. Normalised binding heats below, with solid line representing nonlinear least squares fit using 
single-site binding model. Error calculated from deviation to least squares fit. (a) 600 μM KAT2A BRD titrated into 
60 μM UOS-31490. (b) 585 μM KAT2A BRD titrated into 60 μM UOS-31670. 
Unfortunately, no assay window was observed with any detector reagent pair at any 
concentration of UOS-31490. It was hypothesised that the linker between the UOS-31388 and 
biotin moieties may not enable sufficient flexibility, such that the biotin is shrouded by the 
protein and unable to interact with the streptavidin-acceptor. It was anticipated that use of a 
longer linker chain, comprised of multiple PEGs, would liberate the biotin moiety. 
Dr Lewis Pennicott (Sussex Drug Discovery Centre, University of Sussex) synthesised two UOS-
31490 analogues with increased linker length. ITC was employed to measure the heats of binding 
of these compounds, UOS-31669 and UOS-31670, with the KAT2A BRD. Both UOS-31669 and 
UOS-31670 retained good affinity, with Kds of 7.7 μM and 7.2 μM respectively, Table 6.11. UOS-
31670, which offered the longest linker, was selected for use in the TR-FRET assay. The result of 
the experiment conducted at 600 μM protein and 60 μM UOS-31670 is shown in Figure 6.42 (b).  
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Figure 6.43. KAT2A BRD TR-FRET Assay Design Using EPIgeneous™ Binding Domain Discovery Kit. Titrations of 
0.11 nM to 30000 nM ligand-biotin and SA-acceptor (SA-d2 or SA-XL665) at a ligand-biotin : streptavidin-acceptor 
ratio of 8:1, added to 5 nM GST-KAT2A BRD with 1x anti-GST-donor cryptate (Eu3+ or Tb2+), 20 μL well volume, and 
incubated for three hours. HTRF® ratios calculated and compared with negative controls without GST-KAT2A to 
determine assay windows. Optimised with ligand-biotin species (a) UOS-31490 and (b) UOS-31670. Graphs represent 
mean ± 1 SD of duplicate repeats. 
The ligand-biotin titrations were repeated with UOS-31670, again utilising 0.1 nM to 30000 nM 
ligand-biotin, fixed concentrations of 5 nM GST-KAT2A and anti-GST-donor cryptate, a constant 
UOS-31670 : streptavidin-acceptor ratio of 8:1, and including negative controls without GST-
KAT2A. The fluorescence emission was read at wavelengths 665 nm and 620 nm to attain the 
HTRF® ratio and the assay windows were calculated. The same three detector reagent pairings 
were assessed. The derived assay windows are shown in Figure 6.43 (b). 
Gratifyingly, greatly increased assay windows were observed. The best HTRF® conjugate 
combination was anti-GST-Eu3+ with SA-XL665, which gave the largest assay windows and would 
therefore afford the most robust assay. This detector reagent pair was therefore selected for 
assay optimisation and the corresponding reagents and buffers were purchased as appropriate. 
6.2.10 TR-FRET Optimisation and Screening 
These results fundamentally defined the design for the in-house TR-FRET assay. As discussed, 
Cisbio EPIgeneous™ Binding Domain assays are designed to measure the interaction between 
bromodomains and suitable peptides, to enable characterisation of inhibitors. In this assay 
however, UOS-31670 was used in lieu of a suitable peptide. The interaction between GST-KAT2A 
BRD and UOS-31670 was detected using an anti-GST antibody coupled to an Eu3+ cryptate donor 
and an XL665 acceptor-labelled streptavidin, Figure 6.44. The Eu3+ cryptate is excited at 337 nm 
and emits at 620 nm. If UOS-31670 is bound to the GST-KAT2A BRD, the dyes are close and the 
excitation of the cryptate triggers a FRET towards XL665, which fluoresces at 665 nm. The 
specific signal, HTRF® Δ ratio (= HTRF® positive - HTRF® negative), modulates in proportion with 
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the KAT2A BRD-UOS-31670 interaction. Binding of unlabelled small molecules is measured via 
competition with the ligand-biotin, UOS-31670.  
 
Figure 6.44. Schematic of In-House HTRF® Assay Design Using EPIgeneous™ Binding Domain Kit. 
It was anticipated that post-optimisation this TR-FRET assay would be utilised to conduct a 
fragment screen in-house. Accordingly, it was decided that 1% DMSO should be utilised as 
standard in the assay, as recommended by Navratilova et al. in 2016.577 As a known BRD 
inhibitor, DMSO was expected to influence the HTRF® signal.558 As such, all optimisation 
experiments were conducted in the presence of 1% DMSO. 
 
Figure 6.45. KAT2A BRD TR-FRET Assay Anti-GST-Eu3+ Optimisation. Titrations of 0.156 ng to 5 ng anti-GST-Eu3+ and 
0.49 nM to 2000 nM UOS-31670 with SA-XL665 at a ligand-biotin : streptavidin-acceptor ratio of 8:1, added to 5 nM 
GST-KAT2A BRD, 20 μL well volume, and incubated for two hours. HTRF® ratios calculated and compared with 
negative controls without GST-KAT2A to determine assay windows. Graph represents mean ± 1 SD of two 
experiments. 
In the EPIgeneous™ Binding Domain Discovery Kit the anti-GST-Eu3+ reagent was supplied at 50x  
working concentration. However, when purchased at higher quantities for assay optimisation 
and screening it was provided as a powder. As a result, assay optimisation necessarily began 
with establishing the approximate required concentration of the Eu3+ cryptate. 5 nM GST-KAT2A 
was incubated for two hours with 0.156 ng to 5 ng anti-GST-donor cryptate and 0.49 nM to 
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2000 nM ligand-biotin with a constant UOS-31670 : streptavidin-acceptor ratio of 8:1. Negative 
controls without GST-KAT2A were included. The fluorescence emission was read at wavelengths 
665 nm and 620 nm to attain the HTRF® ratio and the assay windows were calculated, Figure 
6.45. At every concentration of anti-GST-Eu3+, assay windows of greater than 20x were observed 
with appropriate concentrations of UOS-31670. 0.313 ng to 1.25 ng anti-GST-Eu3+ afforded good 
assay windows with small associated error. Under these conditions, UOS-31670 concentrations 
of between 7.8 nM and 500 nM were optimal. 
During the aforementioned primary experiments it was noticed that the fluorescence signal 
attributed to the GST-KAT2A BRD interacting with UOS-31670 exhibits some variation over time. 
To determine the impact of this fluctuation on the specific signal it was necessary to monitor 
the fluorescence over a series of incubation periods. 5 nM GST-KAT2A was incubated for 
between 1 and 24 hours with 0.313 ng to 1.25 ng anti-GST-donor cryptate and 125 nM UOS-
31670 with 8:1 ligand-biotin : streptavidin-acceptor, with negative controls. The fluorescence 
emission was read at 665 nm and 620 nm to attain the HTRF® ratios and the specific signals were 
calculated, Figure 6.46. The specific signal developed gradually during early incubation but after 
two hours exhibited no further significant increase with time. It was therefore concluded that 
assay plates should be incubated for at least two hours to ensure that the specific signal is 
maximised and to achieve consistency between plates. 
 
Figure 6.46. KAT2A BRD TR-FRET Assay Incubation Period Optimisation. Titration of 0.313 ng to 1.25 ng anti-GST-
Eu3+ added to 125 nM UOS-31670 with 15.6 nM SA-XL665 and 5 nM GST-KAT2A BRD, 20 μL well volume, and 
incubated for 1-24 hours. HTRF® ratios calculated and the background signal, deduced from negative controls lacking 
GST-KAT2A, subtracted to determine the specific signal. Graph represents mean ± 1 SD of two experiments. 
As the N-terminal GST-tagged human KAT2A bromodomain protein was purchased from Cisbio, 
there was a financial incentive to employ a low protein concentration in the assay. 1.25 nM to 
5 nM GST-KAT2A was incubated for two hours with 0.313 ng to 1.25 ng anti-GST-Eu3+ and 
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200 nM UOS-31670 with 8:1 ligand-biotin : streptavidin-acceptor, including negative controls. 
The fluorescence emission was read at wavelengths 665 nm and 620 nm to attain the HTRF® 
ratio and the assay windows were calculated, Figure 6.47. There was no significant reduction in 
assay window using 2.5 nM GST-KAT2A BRD compared to 5 nM. 
 
Figure 6.47. KAT2A BRD TR-FRET Assay Protein Concentration Optimisation. Titration of 0.313 ng to 1.25 ng anti-
GST-Eu3+ added to 200 nM UOS-31670 with 25 nM SA-XL665 and 1.25 nM to 5 nM GST-KAT2A BRD, 20 μL well volume, 
and incubated for two hours. HTRF® ratios calculated and compared with negative controls without GST-KAT2A to 
determine assay windows. Graph represents mean ± 1 SD of two experiments. 
Following this, it was necessary to determine the most appropriate combination of 
concentrations of the HTRF® conjugates. A fixed concentration of 2.5 nM GST-KAT2A was 
incubated with 0.313 ng to 1.25 ng anti-GST-donor cryptate and 12.5 nM to 800 nM UOS-31670 
with 8:1 ligand-biotin : streptavidin-acceptor, including negative controls as standard. The 
fluorescence emission was measured at 665 nm and 620 nm to calculate the HTRF® ratio and 
the assay windows were calculated, Figure 6.48. Again, all concentrations of anti-GST-Eu3+ 
afforded assay windows of greater than 20x when combined with appropriate UOS-31670 
concentrations. With 0.313 ng anti-GST-Eu3+ the largest assay window was observed at between 
50 nM and 100 nM UOS-31670, with 0.625 ng anti-GST-Eu3+ at roughly 100 nM and with 1.25 ng 
at between 100 nM and 200 nM UOS-31670. 
Similarly to the GST-KAT2A BRD protein, anti-GST-Eu3+ and SA-XL665 are commercial reagents, 
and therefore there is an economic incentive to use lower concentrations. Plate tests were 
conducted, in which 384 well assay plates were filled with 192 low and 192 high controls, to test 
the reliability of automation and expose any edge effects. 2.5 nM GST-KAT2A was incubated 
with 0.313 ng anti-GST-Eu3+ and 80 nM UOS-31670, or 0.625 ng or 1.25 ng anti-GST-Eu3+ and 
120 nM UOS-31670, with 8:1 UOS-31670 : streptavidin-acceptor. The fluorescence emission was 
read at wavelengths 665 nm and 620 nm to attain the HTRF® ratios and the Z-factor was 
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calculated for each of the three plates as a measure of statistical effect size, Table 6.12. All three 
HTRF® conjugate concentration pairings exhibited good Z’. It was therefore concluded that 
although higher anti-GST-donor cryptate concentrations might afford a slightly increased assay 
window, Figure 6.48, to reduce the cost of the assay and therefore optimise for HTS, 0.313 ng 
anti-GST-Eu3+, 80 nM UOS-31670 and 10 nM SA-XL665 would be employed as standard. 
 
Figure 6.48. KAT2A BRD TR-FRET Assay UOS-31670 and Anti-GST-Eu3+ Optimisation. Titrations of 0.313 ng to 1.25 ng 
anti-GST-Eu3+ and 12.5 nM to 800 nM UOS-31670 with SA-XL665 at a ligand-biotin : streptavidin-acceptor ratio of 8:1, 
added to 2.5 nM GST-KAT2A BRD, 20 μL well volume, and incubated for two hours. HTRF® ratios calculated and 
compared with negative controls lacking GST-KAT2A to determine assay windows. Graph represents mean ± 1 SD of 
two experiments. 
Table 6.12. Assessing Reliability of TR-FRET Assay with Automation. 384 well assay plates filled with 50% high and 
50% low controls. Anti-GST-Eu3+, UOS-31670 and SA-XL665 incubated for two hours with or without 2.5 nM GST-
KAT2A. HTRF® ratios calculated and Z’ determined to measure statistical effect size. 
[Anti-GST-Eu3+] (ng) [UOS-31670] (nM) [SA-XL665] (nM) Z-Prime 
1.25 120 15 0.789 
0.625 120 15 0.838 
0.313 80 10 0.865 
 
To test these assay conditions, IC50s were determined for a series of ten known KAT2A BRD 
inhibitors, previously assessed in-house using ITC. The IC50 is defined as the concentration of a 
competitive inhibitor that displaces 50% of the labelled ligand. The compounds were serially 
diluted at 1/3 to achieve a ten point dilution curve and incubated with 2.5 nM GST-KAT2A, 
0.313 ng anti-GST-Eu3+, 80 nM UOS-31670 and 10 nM SA-XL665 for two hours. High (positive) 
and low (negative) controls without inhibitor and with or without GST-KAT2A respectively, were 
included to determine the maximum and minimum signal. The fluorescence emission was read 
at 665 nm and 620 nm to attain the HTRF® ratios, and the specific signals were calculated and 
converted into percentage inhibition (= 100 - ((HTRF® Δ ratio)sample / (HTRF® Δ ratio)pos ctrl) x 100). 
The percentage inhibition was plotted against log[inhibitor], Figure 6.49, and the IC50s were 
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determined using the nonlinear regression, log[inhibitor] vs. normalised response – variable 
slope equation in GraphPad Prism 7.02.243 
 
Figure 6.49. Dose-Response Curves Showing Percentage Inhibition of KAT2A BRD-UOS-31670 Binding. Serial dilution 
of small molecule added to 0.313 ng anti-GST-Eu3+, 80 nM UOS-31670, 10 nM SA-XL665 and 2.5 nM GST-KAT2A BRD, 
20 μL well volume, and incubated for two hours. HTRF® ratios calculated and background signal, deduced from low 
controls lacking GST-KAT2A, subtracted to determine specific signal. Specific signal converted to percentage inhibition 
dependent on high controls. (a) Ten-point dilutions of UOS-31181 and UOS-31388 serially diluted 1/3 with top 
concentration 100 μM. (b) Ten-point dilutions of UOS-28625, UOS-28734, UOS-31235 and UOS-31126 serially diluted 
1/3 with top concentration 1 mM. (c) Ten-point dilutions of UOS-21430, UOS-18715, UOS-28671 and UOS-27986 
serially diluted 1/3 with top concentration 1 mM. Graph represents mean ± 1 SD of two experiments. 
The Cheng-Prusoff equation defines the theoretical relationship between the IC50 measured for 
a competitive inhibitor with given Ki, the concentration of the labelled ligand, [L], and the Kd of 
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the labelled ligand-receptor interaction. The inhibition constant, Ki, of the unlabelled ligand, 
defined as the equilibrium concentration of the inhibitor that would occupy 50% of the receptor 
sites in the absence of competing labelled ligand, is calculated as Ki = IC50 / (1 + ([L]/Kd)). In this 
HTRF® assay, [L] is small compared to Kd. The UOS-31670-KAT2A BRD interaction has an 
associated Kd of 7.2 μM and UOS-31670 is utilised at a concentration of just 80 nM. As a result, 
under these assay conditions Ki ≈ IC50 and therefore the calculated IC50 values can be compared 
directly with the dissociation constants determined by ITC, Table 6.13. Encouragingly the IC50s 
determined by TR-FRET compared very well with those observed by ITC. For the majority of the 
compounds the calculated values differed by less than two-fold and all were of the same order 
of magnitude, with the exception of UOS-18715. As discussed previously, there was a lack of 
confidence in the Kd calculated by ITC for the interaction of UOS-18715 and the KAT2A BRD, due 
to the low affinity of the fragment. The measured heats of binding were small, which permitted 
DMSO binding effects to impact the data, increasing the error in the value, and it was expected 
that the titration represented only a small section of the binding curve, obligating extensive data 
extrapolation. This could explain the considerable variation between the HTRF® IC50 and ITC Kd. 
Table 6.13. Comparison of Kd and IC50 Values determined by ITC and HTRF® Assays. 
Compound ITC Kd (μM) HTRF® IC50 (μM) 
UOS-31181 1.5 1.07 
UOS-31388 0.94 0.656 
UOS-28625 20 30.0 
UOS-28734 34 8.30 
UOS-31235 12 41.8 
UOS-31126 14 6.36 
UOS-21430 29 42.0 
UOS-18715 42 819 
UOS-28671 117 107 
UOS-27986 154 165 
 
Having demonstrated that the IC50s calculated using the TR-FRET assay compare well with the 
Kds determined by ITC, a small single point screen was conducted in duplicate, to test 80 
compounds available in-house, generously prepared by Dr Lewis Pennicott (Sussex Drug 
Discovery Centre, University of Sussex). 1 mM of each compound was incubated with 2.5 nM 
GST-KAT2A, 0.313 ng anti-GST-Eu3+, 80 nM UOS-31670 and 10 nM SA-XL665 for two hours. High 
and low controls were included to determine the maximum and minimum signal. The 
fluorescence emission was read at 665 nm and 620 nm and the HTRF® ratios were calculated. 
The specific signals were determined and converted into percentage inhibition using the Studies 
package from Dotmatics.244 
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The data was analysed using the Vortex package from Dotmatics.244 The results from the first 
repeat are illustrated in Figure 6.50 (a). Reassuringly, the controls were tightly distributed, with 
the positive controls presenting standard deviations of 5.20 and 4.75 for the first and second 
repeats respectively. The correlation between the two repeats is displayed in Figure 6.51 (a). 
The repeats correlated strongly, with a Pearson correlation coefficient of 0.84, computed using 
GraphPad Prism 7.02243, indicative of good reproducibility of data. 
 
Figure 6.50. Distribution of Percentage Inhibition Observed in Single Point Screens. 1 mM small molecule added to 
0.313 ng anti-GST-Eu3+, 80 nM UOS-31670, 10 nM SA-XL665 and 2.5 nM GST-KAT2A BRD, 20 μL well volume, and 
incubated for two hours. HTRF® ratios calculated and background signal, deduced from low controls without GST-
KAT2A (shown in black), subtracted to determine specific signal. Specific signal converted to percentage inhibition 
dependent on high controls (shown in red). (a) Screen of 80 small molecules available in-house. (b) Screen of 3140 
fragments from Maybridge Ro3 2500 Diversity Fragment Library and Life Chemicals 3D Fragments Library. Graphs 
represent first of the two repeats. 
60 compounds induced significant inhibition (over 15%) of GST-KAT2A-UOS-31670 binding, 
calculated as greater than three times the standard deviation in the controls, and were 
progressed to IC50 screening, which was again conducted in duplicate. The compounds were 
serially diluted at 1/3 to obtain ten point dilution curves with a top concentration of 1 mM. The 
compound dilutions were incubated with 2.5 nM GST-KAT2A, 0.313 ng anti-GST-Eu3+, 80 nM 
UOS-31670 and 10 nM SA-XL665 for two hours. High and low controls were included as 
standard. The fluorescence emission was read at 665 nm and 620 nm and the HTRF® ratios were 
calculated. The specific signals were calculated and converted into percentage inhibition and the 
resulting IC50s were determined using the Studies package from Dotmatics.244  
For 18 of the 60 compounds tested, the IC50 could not be calculated, indicative of a value greater 
than 1 mM. However, the remaining 42 compounds exhibited average IC50s ranging from 29 nM 
to 979 μM. Again the two repeats correlated strongly, Figure 6.52 (a), with a Pearson correlation 
coefficient of 0.93, computed using GraphPad Prism 7.02243, indicative of reproducible data. 
Apart from the known inhibitors discussed previously, the most potent compounds identified 
were UOS-32585, L-Moses and UOS-31608, which exhibited IC50s of 29 nM, 499 nM and 3.64 μM 
respectively, Figure 6.53. L-Moses, identified as a PCAF BRD inhibitor by Moustakim et al. in 
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2017581, was previously tested by ITC and exhibited a Kd of 2 μM for the KAT2A BRD. UOS-32585 
and UOS-31608 are pyridazinone derivatives, similar to UOS-31388. 
 
Figure 6.51. Correlation Between Percentage Inhibition Observed in Two Repeats of Single Point Screens. 1 mM 
small molecule added to 0.313 ng anti-GST-Eu3+, 80 nM UOS-31670, 10 nM SA-XL665 and 2.5 nM GST-KAT2A BRD, 
20 μL well volume, and incubated for two hours. HTRF® ratios calculated and background signal, deduced from low 
controls without GST-KAT2A, subtracted to determine specific signal. Specific signal converted to percentage 
inhibition dependent on high controls. (a) Screen of 80 small molecules available in-house. (b) Screen of 3140 
fragments from Maybridge Ro3 2500 Diversity Fragment Library and Life Chemicals 3D Fragments Library. Graphs 
compare two repeats. 
Following the success of this small compound screen the optimised TR-FRET assay was used to 
screen the in-house fragment library of 3140 compounds, which is comprised of the Maybridge 
Ro3 2500 Diversity Fragment Library and the Life Chemicals 3D Fragments Library. The initial 
single point screen was again conducted in duplicate. 1 mM of each fragment was incubated 
with 2.5 nM GST-KAT2A, 0.313 ng anti-GST-Eu3+, 80 nM UOS-31670 and 10 nM SA-XL665 for two 
hours. High and low controls were incorporated to determine the maximum and background 
signals. The fluorescence emission was read at 665 nm and 620 nm wavelengths to attain the 
HTRF® ratios. The specific signals were determined and converted to percentage inhibition using 
the Studies package from Dotmatics.244 
 
Figure 6.52. Correlation Between IC50 Values Determined in Two Repeats of Dose-Response Screens. Ten-point 
serial dilutions of small molecules diluted 1/3 with top concentration 1 mM, added to 0.313 ng anti-GST-Eu3+, 80 nM 
UOS-31670, 10 nM SA-XL665 and 2.5 nM GST-KAT2A BRD, 20 μL well volume, and incubated for two hours. HTRF® 
ratios calculated and background signal, deduced from low controls without GST-KAT2A, subtracted to determine 
specific signal. Specific signal converted to percentage inhibition dependent on high controls. (a) Screen of 60 small 
molecules sourced in-house. (b) Screen of 300 fragments from Maybridge Ro3 2500 Diversity Fragment Library and 
Life Chemicals 3D Fragments Library. Graphs compare two repeats. 
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Figure 6.53. KAT2A BRD Binders Assessed Using TR-FRET Assay. 
The Vortex package from Dotmatics was utilised for data analysis.244 The results from the first 
repeat are displayed in Figure 6.50 (b). As observed in the previous smaller screen, the controls 
were tightly distributed. In the first and second repeats the positive controls presented standard 
deviations of just 5.04 and 6.94 respectively. Additionally, the two repeats again correlated 
strongly, Figure 6.51 (b), with a Pearson correlation coefficient of 0.83, computed using 
GraphPad Prism 7.02243, indicating that the data was reproducible. 
As a result of the tight distribution of the controls, inhibition of greater than 18% was deemed 
significant, calculated as three times the standard deviation in the controls. However, too many 
fragments inhibited the GST-KAT2A-UOS-31670 binding by more than 18% to progress them all 
to IC50 analysis. The ten point dilution curves utilised to measure IC50 in this TR-FRET assay 
employ a top concentration of 1 mM compound. As such, IC50s greater than 1 mM cannot be 
determined. Those fragments that inhibit the protein-labelled ligand binding by 50% at 1 mM in 
the single point screen should exhibit IC50s of approximately 1 mM. It was therefore decided that 
any fragments which afforded less than 50% inhibition in the single point screen would be 
disregarded. 
A more manageable set of 300 fragments afforded at least 50% inhibition of GST-KAT2A-UOS-
31670 binding in both repeats of the single point screen, equating to 40 dilution plates and 20 
assay plates. These fragments were serially diluted at 1/3 to obtain ten point dilution curves 
with top concentrations of 1 mM. The titrations were incubated with 2.5 nM GST-KAT2A, 
0.313 ng anti-GST-Eu3+, 80 nM UOS-31670 and 10 nM SA-XL665 for two hours, alongside high 
and low controls. The fluorescence emission was measured at 665 nm and 620 nm and the 
HTRF® ratios were calculated. The specific signals were calculated and converted into 
percentage inhibition and the IC50s determined using the Studies package from Dotmatics.244 
IC50 values could not be determined for 31 of the 300 fragments tested, indicating a value greater 
than 1 mM. The remaining 269 compounds exhibited average IC50s ranging from 263 nM to 
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863 μM. Once again the two repeats correlated well, Figure 6.52 (b), with a Pearson correlation 
coefficient of 0.81, computed using GraphPad Prism 7.02243, indicative of good data 
reproducibility. The 12 most potent fragments are illustrated in Figure 6.54. 
 
Figure 6.54. KAT2A BRD Fragment Binders Identified Using TR-FRET Assay. 
Unfortunately, the three most potent hits, UOS-19245, UOS-19030 and UOS-18981 were 
isothiazolones, which are PAINS.517 As discussed previously in Chapter 5.2, these compounds are 
frequently identified as artefactual hits due to subversive reactivity that affords false positive 
signals in a variety of assays, and should therefore be rejected. However, in fragment drug 
discovery programs it is prudent to also consider ligand efficiency. In addition to the potency, LE 
takes into account the size of the fragment, determined as the number of non-hydrogen atoms 
(NHA), and thereby quantifies how effectively a molecule uses its structural features in binding 
to the target. It is calculated as LE = ΔG/NHA = 1.4(-logIC50)/NHA. The LEs of the fragments were 
determined using the Studies package from Dotmatics.244 Figure 6.55 shows a plot of LE vs. mean 
IC50. 
Many of the fragments identified in the screen have good LE values of >0.45 and could make 
interesting starting points for development in drug discovery projects. It is hoped that a selection 
of the fragments will represent legitimate and novel hits with affinity for the Homo sapiens 
KAT2A BRD. Unfortunately, due to time constraints, no attempt was made to confirm the hits 
using any second assay format. 
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Figure 6.55. Comparison of Ligand Efficiency and IC50 Values Determined in Dose-Response Screens. Mean LEs and 
IC50s calculated from two repeats of ten-point serial dilutions of 300 fragments from Maybridge Ro3 2500 Diversity 
Fragment Library and Life Chemicals 3D Fragments Library. 
6.3 Discussion 
BRDs represent particularly compelling targets in drug discovery, with many potential disease 
applications, especially in cancers.522 They are therefore interesting targets for development of 
small molecule tool inhibitors, as evidenced by the myriad of BRD inhibitors published in recent 
years. The focus of this chapter was the KAT2A bromodomain, which was identified in Chapter 
4 as an interesting and promising target for tool inhibitor development. 
Initially, as at the HAT domain, sequence alignments were used to assess the potential for 
selectivity. It was again observed that KAT2A is highly homologous with KAT2B, but the residue 
conservation between the bromodomain families is poorer. This should afford good potential 
for selectivity except from between KAT2A and KAT2B. A screening cascade was proposed, 
incorporating Tm shift, NMR, TR-FRET, ITC and X-ray crystallographic techniques, which are 
routinely adopted by other research groups in identifying bromodomain tool inhibitors. 
A structure-based approach was used to design a library of potential KAT2A BRD binders inspired 
by the quinolinone scaffold of SL1126, reported as a KAT2B inhibitor by the SGC.240 Sequence 
alignments were used to identify residues unique to KAT2A and KAT2B, and libraries of amides 
and sulphonamides were docked into the PCAF BRD (PDB ID: 5FE8)240 to assess which might offer 
improved potency. A Tm shift assay was established in-house and used to screen this library to 
identify KAT2A binders. Nine compounds exhibited a significant positive Tm shift, indicative of 
an increase in stability of the KAT2A BRD. Only six of these compounds were sufficiently soluble 
to be investigated using ITC. Of these, two were confirmed as KAT2A binders, including UOS-
21430, which exhibited a Kd of 29 μM.  
Simultaneously, an NMR fragment screen was conducted externally to identify novel scaffolds 
for inhibitor development. 32 fragments were identified that interact with KAT2A. These hit 
fragments were screened in-house using ITC and seven were confirmed as KAT2A binders. 
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Due to poor sensitivity and high rate of false positives, the Tm shift assay was abandoned and 
ITC was adopted as the primary screen. Three series of quinolinone, phenylpyridinone and 
pyridylpyridinone derivatives, as well as a collection of fragments were screened. Four 
compounds were identified which afforded a slight improvement in affinity compared to UOS-
21430. The most potent, UOS-31235, exhibited a Kd of 12 μM. 
Seven crystal structures were successfully obtained in-house, depicting the KAT2A BRD apo and 
with small molecules bound. The ligand-bound structures depicted the binding of micromolar 
KAT2A BRD inhibitors and enhanced understanding of the KAT2A BRD acetyl-lysine binding site. 
It is hoped that these structures will facilitate improved structure-based drug design. 
ITC did not represent an optimal primary screen. It was time consuming, due to low throughput 
and required a large quantity of protein. As such, a TR-FRET assay was designed and established 
in-house, which was better suited to high-throughput screening. Attempts to identify a suitable 
peptide to employ in this competitive binding assay were unproductive. However, at this time, 
Genentech and Constellation Pharmaceuticals disclosed highly potent dual inhibitors of PCAF 
and GCN5 in three patent applications, encompassing phthalazine578, 6-azauracil579 and 
pyridazinone580 derivatives. Several of the reported inhibitors were tested in-house using ITC, 
and crystal structures were successfully obtained of two of these, UOS-31388 and UOS-31181, 
in complex with the KAT2A BRD. UOS-31388, which exhibited a Kd of 940 nM, was used to 
develop a ligand-biotin species for use in the TR-FRET competition assay. 
The TR-FRET assay was optimised and used to assess known KAT2A BRD binders. The calculated 
IC50s were in good agreement with Kds previously determined by ITC. Following this, two single 
point screens were conducted, the first with 80 compounds available in-house and the second 
with 3140 fragments from the Maybridge Ro3 2500 Diversity Fragment Library and the Life 
Chemicals 3D Fragments Library. Hits from the single point screens were progressed to ten-point 
dose-response screens, used to determine IC50. The assay proved reliable, the data was 
reproducible and many novel KAT2A BRD binders were identified. Unfortunately, due to time 
constraints, it was not possible to confirm these hits using a second assay format, and attempts 
to develop a KAT2A BRD tool inhibitor were concluded. 
Overall, more than 3000 small molecules and fragments were screened in this work, to assess 
their affinity for KAT2A, and many novel KAT2A BRD inhibitors were discovered. The optimised 
assays, novel chemical matter and ligand-bound crystal structures afford an exciting opportunity 
for the development of potent and selective KAT2A BRD tool inhibitors. 
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As discussed, bromodomains are protein-protein interaction domains, which recognise and bind 
to acetylated lysine residues and thereby direct protein function.522 It is hoped that KAT2A BRD 
inhibitors will disrupt interactions with the acetylated protein targets and thereby disrupt KAT2A 
function by preventing the protein from properly localising to target sites. However, BRD 
inhibitors will not impede the catalytic activity of KAT2A and therefore may not afford the 
desired biological response and selectively kill BAF180 deficient cells. To navigate this obstacle 
it is proposed that proteolysis targeting chimera (PROTAC) technology could be employed.583 
A number of PROTACs have been developed, which target BET bromodomain proteins for 
degradation, Figure 6.56. These chimeric molecules comprise of BET inhibitors tethered to E3 
ubiquitin ligase modulators via a flexible linker. Upon binding the PROTAC, the BET BRD protein 
is selectively ubiquitinated and degraded via a proteasome-mediated mechanism.545 As such, it 
is possible to inhibit the catalytic activity of the target BRD protein using compounds which bind 
at the bromodomain. PROTACs MZ1584 and ARV-771585 were designed from BET inhibitor JQ1217 
tethered to VHL ligase modulators. dBET1586 and ARV-825587 were derived from BET inhibitors 
JQ1217 and OTX015554 coupled with thalidomide and pomalidomide respectively, which are 
modulators of cereblon, a component of the cullin-RING ubiquitin ligase complex. Finally, BETd-
260 was designed from an azocarbazole-based BET inhibitor588, with lenalidomide, another 
cereblon modulator.589 These BET degraders have been demonstrated to efficiently induce BET 
protein degradation and are more potent in inhibiting cancer cell growth and inducing apoptosis 
than the associated BET inhibitors.589 Small molecule BRD protein degraders therefore represent 
promising therapeutics for treatment of cancers and other human diseases, and KAT2A protein 
degraders may enable selective killing of BAF180 deficient cells even if bromodomain tool 
inhibitors do not. 
 
Figure 6.56. Chemical Structures of Reported BET BRD PROTACs. Chimeric molecules composed of BET inhibitors 
(red) conjugated to E3 ubiquitin ligase modulators (green) via flexible linkers, which induce proteasome-mediated 
degradation of BET proteins.  
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7 Discussion 
As a result of the high cost of drug discovery and poor productivity of research and 
development10, it is imperative that more effort is expended to identify and validate the best 
targets with the strongest disease association before embarking on the costly molecule 
discovery and development phases. Good quality tool inhibitors provide an excellent mechanism 
to test therapeutic hypotheses. A non-toxic, therapeutic phenotype in cellular or in vivo models 
in response to a probe is fundamental in target validation.216 Additionally, chemical probes are 
remarkably powerful in unveiling and accessing novel biology and potential targets.214 
Consequently, publication of a new tool inhibitor often provokes increased research in the area. 
This project was initiated with the aim of designing and characterising tool inhibitors of proteins 
involved in DNA damage response. The areas of primary focus were the structural maintenance 
of chromosomes proteins and lysine acetyltransferase 2-A. It was hoped that such probes would 
enable detailed mechanistic biological investigation, disease validation and ultimately initiation 
of translational drug discovery projects. 
7.1 SMC Complexes 
The SMC complexes are critically important in regulating chromosome condensation, sister 
chromatid cohesion, DNA repair, homologous recombination and transcription. They represent 
interesting targets for tool inhibitor development, particularly as these roles in regulating 
chromosome architecture and organisation are well known, but not well understood. 
In this work, the initial focus was SMC5/6, which has a prominent role in DNA repair254–256 and 
the ALT pathway361, and represents a potential opportunity for novel cancer therapeutics 
dependent on synthetic lethality. The SMC5/6 hinge domain and head domain and the non-SMC 
elements were modelled and analysed to identify whether they represent druggable targets, 
suited to tool inhibitor development. 
Unfortunately, the SMC5/6 hinge domain was deemed undruggable as there were no discernible 
structural pockets and therefore no potential for rational inhibitor design. Potential binding 
pockets were identified at the SMC5 N-terminal ATP binding site. Although the druggability 
scores170 suggested that these pockets were not druggable, it was reasoned that this could result 
from the significant solvent exposure or the polar environment at the site. However, in ITC 
binding studies, the SMC5 head domain was not observed to interact with ATP derivatives, 
indicating that the pocket is not suitable for small molecule binding, and therefore the SMC5/6 
head domain was also deemed undruggable. In the models of the NSEs, cavities were identified 
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at the NSE1-NSE3 and NSE2-SMC5 PPI interfaces, but neither represented desirable target sites 
for tool inhibitor development. 
Following this, the human cohesin hinge and head domains were modelled and analysed. A 
pocket was identified in the SMC3 subunit at the hinge domain, which corresponded to a helix 
in SMC1, but the fpocket druggability score170 indicated that this cavity was not druggable. 
In conclusion, at the time this work was completed, the SMC5/6 and cohesin complexes did not 
represent desirable targets for design and characterisation of tool inhibitors. 
7.2 BAF180 Synthetic Lethal Targets 
BAF180 has been identified as a major clear cell renal cell carcinoma cancer gene, with 
truncating mutations observed in 41% of samples of primary ccRCC1, and has therefore been 
highlighted as a promising opportunity to target ccRCC using a synthetic lethality approach.2 
RNF4, ASF1A and GCN5/KAT2A have been identified as synthetic lethal partners of PBRM13, and 
therefore may represent interesting targets for tool inhibitor development. 
In this work, RNF4, ASF1A and GCN5 were analysed to identify any potentially druggable binding 
pockets. Rattus norvegicus RNF4 (PDB ID: 3NG2)234 exhibited one interesting druggable pocket, 
but no molecules could be identified which bound at this site to indicate any corresponding 
pharmacophore, so it was concluded that RNF4 did not represent a promising target. Homo 
sapiens ASF1A (PDB ID: 2IO5)236 similarly exhibited one interesting druggable pocket, but this 
was located at the ASF1A-HIRA interface. In unpublished work (Hopkins S. and Downs J., 
Genome Damage and Stability Centre, University of Sussex), it has been shown that HIRA and 
BAF180 are not synthetic lethal. It was therefore concluded that ASF1A also did not represent a 
good target. 
KAT2A contains a HAT domain and a bromodomain. Both Homo sapiens GCN5 Acetyltransferase 
domain (PDB ID: 1Z4R)241 and Homo sapiens GCN5 bromodomain, (PDB ID: 3D7C)238, exhibited 
druggable pockets, which coincided with the acetyl-CoA and acetyl-lysine binding sites 
respectively. KAT2A was therefore established as a promising and interesting target for tool 
inhibitor development. 
7.3 KAT2A HAT Domain 
Based on these results, KAT2A became the focus of this project. With druggable pockets 
identified in both the HAT and BRD structural domains, the catalytically active HAT domain was 
prioritised as the preferred target. HATs currently represent exciting targets in drug discovery, 
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with many potential disease applications, and are therefore interesting targets for tool inhibitor 
development, especially as existing HAT inhibitors are not suitable for biological investigation. 
In this work, sequence alignments were used to assess the potential for selectivity between 
KAT2A and other HAT-containing proteins. KAT2A shows extremely high homology with KAT2B, 
but overall the residue conservation throughout HATs is poor, which should afford good 
selectivity except from between KAT2A and KAT2B. 
Attempts to establish a fluorescence based activity assay in-house, which had previously been 
used in HTS for KAT2A HAT inhibitors (PubChem BioAssay AID: 504327)4, were unsuccessful. The 
assay proved unreliable and robust activity could not be achieved. Initial attempts to establish 
an alternative EpiQuik™ HAT activity assay were promising but associated with high error. 
The hits from the HTS4,5 were discounted as likely false positives, which significantly diminished 
the inventory of reported small molecule inhibitors of KAT2A and KAT2B. The only remaining 
series was the isothiazolones, which are well known PAINS and were therefore also disregarded.  
Unfortunately, while HATs represent interesting targets for tool inhibitor development, in 
general they have proved very challenging to work on. However, novel HAT inhibitors remain 
necessary and highly desirable. It is vital that an alternative KAT2A HAT assay format is 
developed, such as radioligand binding, which offers robust activity, and that a high-throughput 
screen is conducted to identify new reliable chemical matter. This was regrettably beyond the 
scope of this work and attempts to develop a KAT2A HAT tool inhibitor were concluded. 
7.4 KAT2A Bromodomain 
Despite the difficulties encountered in developing a tool inhibitor for the HAT domain, KAT2A 
remained an interesting protein target. As such, focus was redirected to the KAT2A BRD, which 
was also identified as a druggable target in Chapter 4.2. Bromodomains are a hot topic in 
research, with many disease applications, particularly in cancers522, and represent particularly 
compelling targets for tool inhibitor development. 
Initially, sequence alignments were used to assess the potential for selectivity between KAT2A 
and other BRD-containing proteins. KAT2A is highly homologous with KAT2B, but the 
conservation between BRD families is poor. This should afford good selectivity in general, but 
again it is anticipated that inhibitors will target both KAT2A and KAT2B. 
A structure-based design approach was used to generate a library of potential KAT2A BRD 
binders, utilising the ligand-bound structure of quinolinone SL1126 with the PCAF BRD, (PDB ID: 
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5FE8).240 The library of compounds was screened in-house using Tm shift and ITC. Two 
compounds were confirmed as KAT2A binders, including UOS-21430, with a Kd of 29 μM.  
An NMR fragment screen was conducted externally to identify novel scaffolds for inhibitor 
development. The 32 hit fragments were screened in-house using ITC and seven were confirmed 
as KAT2A binders. 
The Tm shift assay was abandoned due to poor sensitivity and high rate of false positives and 
ITC was adopted as the primary screen to assess three series of quinolinone, phenylpyridinone 
and pyridylpyridinone derivatives, as well as a number of fragments. Four of the compounds 
afforded a slight improvement in affinity compared to UOS-21430. The most potent was UOS-
31235, with a Kd of 12 μM. 
ITC did not represent an optimal primary screen. It was time consuming, low throughput and 
required a large supply of protein. As such, a TR-FRET assay was designed and established in-
house, which was better suited to high-throughput screening. Typically, these competitive 
binding assays employ biotin-labelled peptides, however, in this case, a ligand-biotin species was 
utilised, inspired by the pyridazinone derivatives disclosed as potent dual inhibitors of PCAF and 
GCN5 in the patent application from Genentech and Constellation Pharmaceuticals.580 
The TR-FRET assay was optimised and used to assess known KAT2A BRD binders. The calculated 
IC50s were in good agreement with Kds determined by ITC. Subsequently, two single point 
screens were conducted, the first with 80 compounds and the second with 3140 fragments. Hits 
from the single point screens were progressed to ten-point dose-response screens, which were 
used to determine IC50s. The assay format was reliable, the data was reproducible and many 
novel KAT2A BRD binders were identified. Unfortunately, it was not possible to confirm the hits 
using a second assay format, due to time constraints. 
Alongside screening, nine crystal structures were successfully obtained in-house, depicting the 
apo and ligand-bound KAT2A BRD. It is hoped that these structures will facilitate improved 
structure-based drug design. 
Overall, in this work, more than 3000 small molecules and fragments were screened using a 
combination of assay formats, and many novel KAT2A BRD inhibitors were discovered. The 
optimised assays, novel chemical matter and ligand-bound crystal structures afford an exciting 
opportunity to develop potent and selective KAT2A BRD tool inhibitors. 
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VII Appendix 
VII.I. SMC Multiple Sequence Alignments 
 
SMC1A_HUMAN - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0
SMC1B_HUMAN - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0
SMC2_HUMAN - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0
SMC3_HUMAN - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0
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Appendix 
 
Figure Apx.1. Multiple Sequence Alignment of SMC5, SMC6 and Human Homologues. Multiple sequence alignment 
generated by EMBL-EBI Clustal Omega.181,182 Positions with single, fully conserved residue coloured green. Where 
aligned residues have strongly similar or weakly similar properties, residues coloured purple or orange respectively. 
ATPase head domain highlighted with red border, and hinge domain with blue border. 
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SMC5_HUMAN - K E L L E R K T K K R Q L E Q K I S S K L G S L K L M E Q D T C N L E E E E R K A S T K I K E I N V Q K A K - - - - - - - 748
SMC5_MOUSE - K E L L E R K T R K R Q L E Q K I S S K L A S I R L M E Q D T C N L E E E E R K A S T K I K E I N V Q K A K - - - - - - - 748
SMC5_YEAST - H L L S K M A S S M K S L K N C Q K E L I S T Q I L Q F E A Q N M D V S M N D V I G F F N E R - - - - - - - - - - - - - - 806
SMC5_SCHPO - - F - E - - - A L M N S V L K V K E N S I K A T N N - F - E K M L G S R L N V I E A K Y K L E K H E M D A N Q V N A R L - 790
SMC5_TAKRU - - I V K - - - A F I A S I K L K A T L T M E K V Y L S L E M M G L S A E K T K L E H D F R E G A S L L R S - - M D Q R C - 793
SMC5_CHICK - - L V T - - - E L M C H I K N Y V S L N I C K A D L I L Q S T A V D A E K N R L E A E Y K A A S V E L R A - - S E Q R F - 781
SMC5_XENLA - - L V K - - - D L L E L M K E C T S L S I E K V E L A L Q S T A I S S E K N K I E S D Y K S A T S Q L R E - - L K N Q Y - 782
SMC5_HUMAN - - L V T - - - E L T N L I K I C T S L H I Q K V D L I L Q N T T V I S E K N K L E S D Y M A A S S Q L R L - - T E Q H F - 802
SMC5_MOUSE - - L V T - - - E L T G L V K I C T S F Q I Q K V D L I L Q N T T V I S E K N K L E A D Y M A S S S Q L R V - - T E Q Q F - 802
SMC5_YEAST - - - - E A D L K S Q Y E D K K K F V K E M R D T - - - P E F Q S W M R E I R S Y D Q D T K E K L N K V A E K Y E E E G N - 860
SMC5_SCHPO - T E V Q D R L K D I T D K L - - - - A S A R E - D A M S L Y G S V V D S L Q T Q S S - - - - - - - - - - - - - - - - - D - 828
SMC5_TAKRU - S Q L E Q R K V Q L T E Q G K G Q M K R A K S I C N M Q P N D S L S E E L R N V R V - - - - - - - Y V I P P Y L C V P S - 846
SMC5_CHICK - L E L D E R K R I L T E N C K E L L K K A R Q M C N M N L D Q H L P K E F Q T - - - - - - - - - - - - - - - - - - - - - - 820
SMC5_XENLA - D G I E A K K L H L L E N C K G L L R K A R Q A C N L G P N Q A V P Q D F Q T - - - - - - - - - - - - - - - - - - - - - - 821
SMC5_HUMAN - I E L D E N R Q R L L Q K C K E L M K R A R Q V C N L G A E Q T L P Q E Y Q T Q V P - - - - - - - - T - I P N G H N S S - 853
SMC5_MOUSE - I E L D D N R Q R L L Q K C K E L M K K A R Q V C N L S A D Q A V P Q E F Q T Q V P - - - - - - - - T - I P N G H S S S - 853
SMC5_YEAST - F - - N L S F V Q D V L D K L E S E I A M V N H - - - - - - - - - - - D E S A V T I L D Q V T A E L R E L E H T V P Q Q - 907
SMC5_SCHPO - R Q T A I T E L N E E F A T S S E V D N K I S I E E - T K L K F M N V N S Y V M E Q Y D A R K K E I E E L E S K M S D F - 887
SMC5_TAKRU - P L M A F A K L P - - - D T P D D I D S M L N E E R S R S E C F T G L S E N V V D E Y N R S D Q E I K E L E N E L E E K - 903
SMC5_CHICK - - - - A F Q T L P - - - D T L E E I D A F L N E E R S R V S C F T G L S A S V V E E C S K Q M E E I Q K L M E S I E E N - 874
SMC5_XENLA - - - - A F Q S L P - - - E S L D E I D A M L N E E R S R A S C F T G L T A S V V D D Y N K R T K E I Q E V T E E L N R K - 875
SMC5_HUMAN - L P M V F Q D L P - - - N T L D E I D A L L T E E R S R A S C F T G L N P T I V Q E Y T K R E E E I E Q L T E E L K G K - 910
SMC5_MOUSE - P P M A F Q D L P - - - N T L D E I D A L L T E E R S R A S C F T G L N P S V V E E Y S K R E V E I Q Q L T E E L Q G K - 910
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Appendix 
 
Figure Apx.2. Multiple Sequence Alignment of SMC5 Orthologues. Multiple sequence alignment generated by EMBL-
EBI Clustal Omega.181,182 Positions with single, fully conserved residue coloured green. Where aligned residues have 
strongly similar or weakly similar properties, residues coloured purple or orange respectively. ATPase head domain 
highlighted with red border, and hinge domain with blue border. 
 
 
SMC5_YEAST - S K D L E T I K A K L K E D H A V L E P K L D D I V S K I S A R F A R L F N N V G S A G A V R L E - - K P K D Y A E W K - 965
SMC5_SCHPO - D Q S V E E L Q D E M N S I K E D W V S K L E E N V Q C I S D R F S K G M S G M G Y A G E V R L G - - K S D D Y D K W Y - 945
SMC5_TAKRU - K N A L E S Y R Q N I S E A K E R W L N P L K Q L V E Q I N E K F T A F F R S M N C A G E V D L H S E K E E D Y D K Y G - 963
SMC5_CHICK - K K E L D D Y K Q S I S K I K E R W L N P L K K M I E S I N E K F S G F F S S M E S V G E V D L H V E N E E E Y D K Y G - 934
SMC5_XENLA - K L E L E D Y R K N I S Q V K E K W L N P L K Q L I E K I N D Q F S S F F S S M Q C V G E V D L H T E K E E E Y D K Y G - 935
SMC5_HUMAN - K V E L D Q Y R E N I S Q V K E R W L N P L K E L V E K I N E K F S N F F S S M Q C A G E V D L H T E N E E D Y D K Y G - 970
SMC5_MOUSE - K V E L D E Y R E N I S Q V K E R W L N P L K E L V E K I N E K F S N F F S S M Q C A G E V D L H T E N E E D Y D K Y G - 970
SMC5_YEAST - I E I M V K F R D N A P L K K L D S H T Q S G G E R A V S T V L Y M I A L Q E F T S A P F R V V D E I N Q G M D S R N E - 1025
SMC5_SCHPO - I D I L V Q F R E E E G L Q K L T G Q R Q S G G E R S V S T I M Y L L S L Q G L A I A P F R I V D E I N Q G M D P R N E - 1005
SMC5_TAKRU - I R I R V K F H S N T Q L H E L T P F H Q S G G E R S V S T M L Y L M S L Q E L N R C P F R V V D E I N Q G M D P I N E - 1023
SMC5_CHICK - I R I R V K F H N F T D L H E L T P Y H Q S G G E K S V S T V L Y L M A L Q E L N R C P F R V V D E I N Q G M D P V N E - 994
SMC5_XENLA - I R I R V K F R S S T Q L H E L T P H H Q S G G E R S V S T M L Y L M A L Q E L N R C P F R V V D E I N Q G M D P V N E - 995
SMC5_HUMAN - I R I R V K F R S S T Q L H E L T P H H Q S G G E R S V S T M L Y L M A L Q E L N R C P F R V V D E I N Q G M D P I N E - 1030
SMC5_MOUSE - I R I R V K F R S S T Q L H E L T P H H Q S G G E R S V S T M L Y L M A L Q E L N R C P F R V V D E I N Q G M D P I N E - 1030
SMC5_YEAST - R I V H K A M V E N A C A E N T S Q Y F L I T P K L L T G L H Y H E K M R I H C V M A G S W I P N P S E D P K M I H F G - 1085
SMC5_SCHPO - R V V H R H I V N S V C D N A V S Q Y F L V T P K L L P D L T Y H R N L K V L C I C N G A W L P A T F R T S L S T Y F E - 1065
SMC5_TAKRU - R R V F D I V V G T A C K E R T S Q Y F F I T P K L L Q N L K Y A E E M T V L C V H N G A Y M L P P N Q W D D K A F L R - 1083
SMC5_CHICK - R R V F E M F V K T A C K E S T S Q Y F L I T P K L L Q N L T Y N E K M T L L F V Y N G P F M L E A N K W N L K S F C R - 1054
SMC5_XENLA - R R V F E M V V K T A C K E N T S Q Y F F I T P K L L Q N L T Y A E K M T V L F V Y N G P F M L E P T K W N L K A F H R - 1055
SMC5_HUMAN - R R V F E M V V N T A C K E N T S Q Y F F I T P K L L Q N L P Y S E K M T V L F V Y N G P H M L E P N T W N L K A F Q R - 1090
SMC5_MOUSE - R R V F E M V V N T A C K E N T S Q Y F F I T P K L L Q N L P Y S E K M T V L F V Y N G P H M L E P N R W N L K A F Q R - 1090
SMC5_YEAST - E T S N Y S F D - - - - 1093
SMC5_SCHPO - K L K K S A L I S S S - 1076
SMC5_TAKRU - R C L Q R K A K A - - - 1092
SMC5_CHICK - R R R R L G R M D E Q - 1065
SMC5_XENLA - R R R R V A A V D Q - - 1065
SMC5_HUMAN - R R R R I T F T Q P S - 1101
SMC5_MOUSE - R R R R I T F T Q P Q - 1101
SMC6_YEAST - M I - - - - - - - - - - - - S - - T T I S G K R P I - E Q V D D - - - - E L L S L - - - - - - T A Q Q E N E E Q Q Q Q R - 35
SMC6_SCHPO - M T T E L T N V S L E E A I T E K T S E N - R R K R D S D V L Q T - E E V D L S N V K R I R A S R N Q D N R P E R Q S R - 58
SMC6_TAKRU - M S - - - - - - - K R K S I S T H D K S T K R A R - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - P V - 20
SMC6_XENLA - M G - - - - - - - K R K D G S P I A P S S Q R K K Q R Q E V D D P Y D E E D Y G - - - Q A G P S V S N D Y G Q R K K Q R - 50
SMC6_HUMAN - M A - - - - - - - K R K E E N F S S P K N A K R P R Q E E L - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 23
SMC6_MOUSE - M A - - - - - - - K R K E E N F C S P E N A K R P R Q E E L - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 23
SMC6_YEAST - K R R R H Q F A P M T Q F N S N T L D E D S G F R S S S D V A T A D Q D N F L E E S P S G Y I K K V I L R N F M C H E H - 95
SMC6_SCHPO - L Q R S S - - S L I E Q V R G N - - - E D G E N - - - D V L N Q T R E T N S N F D N R V G V I E C I H L V N F M C H D S - 110
SMC6_TAKRU - E - - - - - - - E E E D S E D A - - - D D R D Q D V E R L S - - P Q V L P S G D V S D V G I V K S I T L N N F M C H A N - 68
SMC6_XENLA - K - - - - - - - E A D N S H T D - - - S D Y E N S V S C A S S Q R V S A S Q S G T G D V G I I E S I F L R N F M C H S M - 100
SMC6_HUMAN - - - - - - - - - - - E D F D K D - - - - - - G D E D E C K G - - - - - - T T L T A A E V G I I E S I H L K N F M C H S M - 61
SMC6_MOUSE - - - - - - - - - - - E D F D K D - - - - - - G D E D E C T I S F T N G T S T L T A A E V G I I E S I Q L R N F M C H S M - 67
SMC6_YEAST - F E - L E L G S R L N F I V G N N G S G K S A I L T A I T I G L G A K A S E T N R G S S L K D L I R E G C Y S A K I I L - 154
SMC6_SCHPO - L K - I N F G P R I N F V I G H N G S G K S A I L T G L T I C L G A K A S N T N R A P N M K S L V K Q G K N Y A R I S V - 169
SMC6_TAKRU - L G P F A F G S N V N F I V G K N G S G K S A I L T G L I V A L G G N A Q A T N R G S S L K G F V K E G E S F A V V S I - 128
SMC6_XENLA - L G P F R F G P N V N F V I G N N G S G K S A V L T A L I V G L G G K A A I T N R G S S I K G F V K E G Q T F A E I S I - 160
SMC6_HUMAN - L G P F K F G S N V N F V V G N N G S G K S A V L T A L I V G L G G R A V A T N R G S S L K G F V K D G Q N S A D I S I - 121
SMC6_MOUSE - L G P F K F G S N V N F V V G N N G S G K S A V L T A L I V G L G G K A V A T N R G S S L K G F V K A G Q N S A D I S I - 127
SMC6_YEAST - H L D N S K Y G A Y Q Q G I F G N E I I V E R I I K R D G P A S F S L R S E N G K E I S N K K K D I Q T V V D Y F S V P - 214
SMC6_SCHPO - T I S N R G F E A Y Q P E I Y G K S I T I E R T I R R E G S S E Y R L R S F N G T V I S T K R D E L D N I C D H M G L Q - 229
SMC6_TAKRU - T L N N I G K D A Y K P E V Y G Q A I V I D Q K I T R E G I R T Y K L K S Q S G H I I S T K K E D L V T I L D Y Y N I Q - 188
SMC6_XENLA - T L R N R G Q D A Y K P D V F G N S I T V Q Q R L T T D G S R T Y K L K S A T G A V V S N K K E E L T A I L D H F N I Q - 220
SMC6_HUMAN - T L R N R G D D A F K A S V Y G N S I L I Q Q H I S I D G S R S Y K L K S A T G S V V S T R K E E L I A I L D H F N I Q - 181
SMC6_MOUSE - T L R N R G D D A F R A N V Y G D S I V V Q Q H I S V D G S R S Y K L K S E K G T V V S T R K E E L I A I L D H F N I Q - 187
SMC6_YEAST - V S N P M C F L S Q D A A R S F L T A S T S Q D K Y S H F M K G T L L Q E I T E N L L Y A S A I H D S A Q E N M A L H L - 274
SMC6_SCHPO - I D N P M N I L T Q D T A R Q F L G N S S P K E K Y Q L F M K G I Q L K Q L E E N Y S L I E Q S L I N T K N V L G N K K - 289
SMC6_TAKRU - V N N P V T I L T Q E M S K Y F L H S K G G A E K Y K F F M K A T Q L E Q M K D D F V H I K S T K S V T V D K V E Q H S - 248
SMC6_XENLA - V D N P V S V L T Q E M S K H F L Q S K N E S D K Y K F F M K A T Q L E Q M K E D Y S Y I M E T K S R T H D Q V E N G G - 280
SMC6_HUMAN - V D N P V S V L T Q E M S K Q F L Q S K N E G D K Y K F F M K A T Q L E Q M K E D Y S Y I M E T K E R T K E Q I H Q G E - 241
SMC6_MOUSE - V D N P V S V L T Q E M S K Q F L Q S K N E G D K Y K F F M K A T Q L E Q M K E D Y S Y I M E T K E R T K E Q I N Q G E - 247
SMC6_YEAST - E N L K S L K A E Y E D A K K L L R E L N - - - - Q T S D L N E R K M L L Q A K S L W I D V A H N T D A C K N L E N E - - 329
SMC6_SCHPO - T G V S Y L A - - - - K K E E E Y K L L W E Q S R E T E N L H N L L E Q K K G E M V W A Q V V E V E K E L L L A E K E F - 345
SMC6_TAKRU - E C L K D L K R D Y L E K E D R Y K S L A - - - - S V N E M Y T K L E E L K K Q M A W A L V G E V E K E F E P M K E K L - 304
SMC6_XENLA - E R L R D L R Q E C I Q K E E R F K S I A - - - - S L G E M K E K L E D L K N K M A W A L V T E S E K Q I K P F I E Q I - 336
SMC6_HUMAN - E R L T E L K R Q C V E K E E R F Q S I A - - - - G L S T M K T N L E S L K H E M A W A V V N E I E K Q L N A I R D N I - 297
SMC6_MOUSE - E R L T E L K R Q C L E K E E R F Q N I A - - - - G L S T M K T N L E Y L K H E M A W A V V N E I E K Q L N A I R D N I - 303
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SMC6_YEAST - - - - - - - - - - - - - - I S G I Q Q K V D E V T E K I R N R Q E K I E R Y T S D G T T I E A Q I D A K V I Y V N E K D - 376
SMC6_SCHPO - Q H A E V K L S E A K E N L E S I V T N Q S D I D G K I S S K E E V I G R A K G E T D T T K S K F E D I V K T F D G Y R - 405
SMC6_TAKRU - E S D R C A T N K F N E K V D E W K K K V E V A E G K Q K Q S - - - - - - - - - - - - - - H E Q L E E I T Q Q V S E L Q - 350
SMC6_XENLA - S T E E G R T V K Y E Q K I E E C Q G K V I N A E E K F R A K - - - - - - - - - - - - - - Q E E L D K I T Q E A V A L K - 382
SMC6_HUMAN - K I G E D R A A R L D R K M E E Q Q V R L N E A E Q K Y K D I - - - - - - - - - - - - - - Q D K L E K I S E E T N A R A - 343
SMC6_MOUSE - K I G E E R A A K L D R K M E E Q Q V R L N D A E K K Y K D I - - - - - - - - - - - - - - Q D K L E K I S E E T N A R A - 349
SMC6_YEAST - S E H Q N A R E L L R D V K S R F E K E K S N Q A E A - - Q S N I D Q G R K - - - K V D A L N K T I A H L E E E L T K E - 431
SMC6_SCHPO - S E M N D V D I Q K R D I Q N S I N A A K S C L D V Y R E Q L N T E R A R E N N L G G S Q I E K R - - - - - - - - - - - - 454
SMC6_TAKRU - S K C T - - - E F K T E V Q R R N A D L K S C E V T V H R H K A I L R D L E K - - D K A Q L S S K I N D L S L S I S Q A - 405
SMC6_XENLA - P Q G I - - - G L K E D V Q K K R K S Y N E S E V L Y N R H R M E L K R L E R - - D A E Q L H K R I E E L K K S A D N D - 437
SMC6_HUMAN - P E C M - - - A L K A D V V A K K R A Y N E A E V L Y N R S L N E Y K A L K K - - D D E Q L C K R I E E L K K S T D Q S - 398
SMC6_MOUSE - P E C M - - - A L K T D V I A R T R A F N D A E V L Y N R S L N E Y K A L K K - - D G E Q L C K R I E E L K K S T D Q S - 404
SMC6_YEAST - M G G D K D Q M R Q E L E Q L E K A N E K L R E V N N S L V V S L Q D V K N - - - E E R D I Q H E R E S E L R T I S R S - 488
SMC6_SCHPO - - A N E S N N L Q R E I A D L S E Q I V E L E S K R N D L H S A L L E M G G - - - - - - - N L T S L L T K K D S I A N K - 506
SMC6_TAKRU - T G A E S Q A R M E R I A Q I E A A L E D L T H H T S T L G Q Q I E Q Y Q H S Y R H A I E G Q G K M K R E L E G L Q K S - 465
SMC6_XENLA - S E S E K M A R Q K E I N Q I R E R M K A L H D K D I T T N Q Q I H Q F Q Q A I E K Y K E E R A R I G N E E R N I K Q R - 497
SMC6_HUMAN - L E P E R L E R Q K K I S W L K E R V K A F Q N Q E N S V N Q E I E Q F Q Q A I E K D K E E H G K I K R E E L D V K H A - 458
SMC6_MOUSE - L E P E R L E R Q K R I C W L K E K V K A L Q D Q E H T V N Q E A E Q F E Q A I E K D K Q E H G R V R K E D I E V R H A - 464
SMC6_YEAST - I Q N K K V E L Q N I A K G N D T F L M N F D R N M D R L L R T I E - - Q R K N E F E T P A I G P L G S L V T I R K G F - 546
SMC6_SCHPO - I S D Q S E H L K V L E D V Q R D K V S A F G K N M P Q L L K L I T - - - R E T R F Q H P P K G P M G K Y M T V K E - - - 561
SMC6_TAKRU - I D A N R R Q L Q S M E S S R S N R L Q R F G D Q M P A L L A A I D E A H K K G Q F K H R P R G P L G Y L I S L K D - - - 523
SMC6_XENLA - L E Q H K R Q L K E L H E S K T D R L K R F G Q N M P A L L A A I D E A D K L G R F R K K P V G P L G A C I H L K D - - - 555
SMC6_HUMAN - L S Y N Q R Q L K E L K D S K T D R L K R F G P N V P A L L E A I D D A Y R Q G H F T Y K P V G P L G A C I H L R D - - - 516
SMC6_MOUSE - L N Y N Q R Q L K E L K D S K T D R L K R F G P H V P A L L E A I D D A Y R R R Q F T H K P I G P L G A C I H L R D - - - 522
SMC6_YEAST - E K W T R S I Q R A I S S S L N A F V V S N P K D N R L F R D I M R S C G I R S - - N I P I V T Y C L S Q F D Y S K - - - 602
SMC6_SCHPO - Q K W H L I I E R I L G N V I N G F I V R S H H D Q L I L K E L M R Q S N C H A - - - - T V V V G K Y D P F D Y S S - - - 615
SMC6_TAKRU - P E L A L S I E I C L K N L V Q A F T C D N Y D D E R V L K S L M T K V L Q H G - R R P A I I T S R F F P K V H D V S V - 582
SMC6_XENLA - Q E L A L A V E S C L K G L M F A F C C D N H Q D E R M L Q N I M S R E Y P R G - R R P Q I I V N E F I D H V Y D V R Q - 614
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Appendix 
 
Figure Apx.3. Multiple Sequence Alignment of SMC6 Orthologues. Multiple sequence alignment generated by EMBL-
EBI Clustal Omega.181,182 Positions with single, fully conserved residue coloured green. Where aligned residues have 
strongly similar or weakly similar properties, residues coloured purple or orange respectively. ATPase head domain 
highlighted with red border, and hinge domain with blue border. 
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Appendix 
 
Figure Apx.4. Multiple Sequence Alignment of SMC Human Homologues with Template Structure (PDB ID: 1XEX).224 
Multiple sequence alignment generated by EMBL-EBI Clustal Omega.181,182 Positions with single, fully conserved 
residue coloured green. Where aligned residues have strongly similar or weakly similar properties, residues coloured 
purple or orange respectively. ATPase head domain highlighted with red border, and hinge domain with blue border. 
 
1XEX|B - - - - - E K E K K N V F M R T F E A I S R N - - - - F S E I F A K L S P G G S A R L I - - L E N P E D P F S - - - - - - - 44
SMC1A_HUMAN - F E Q I K K E R F D R F N A C F E S V A T N - - - - I D E I Y K A L S R N S S A Q A F L G P E N P E E P Y L - - - - - - - 1108
SMC1B_HUMAN - F E Q V K K R R Y D L F T Q C F E H V S I S - - - - I D Q I Y K K L C R N N S A Q A F L S P E N P E E P Y L - - - - - - - 1104
SMC2_HUMAN - I E D L D Q K K N Q A L N I A W Q K V N K D - - - - F G S I F S T L L P G A N A M L A - - P P E G Q T V - - - - - - - - - 1064
SMC3_HUMAN - M N V L E L R K Y E A I Q L T F K Q V S K N - - - - F S E V F Q K L V P G G K A T L V - - M K K G D V E G S Q S Q D E G - 1071
SMC4_HUMAN - Y E D L R K Q R L N E F M A G F Y I I T N K - - - - L K E N Y Q M L T L G G D A E L E - - L V D S L D P F S - - - - - - - 1171
SMC5_HUMAN - I S Q V K E R W L N P L K E L V E K I N E K - - - - F S N F F S S M Q C A G E V D L H - - T E N E E D Y D - - - - - - - - 967
SMC6_HUMAN - L G E I M E H R F K T Y Q Q F R R C L T L R C K L Y F D N L L S Q R A Y C G K M N F D - - H K N E - - - - - - - - - - - - 965
RAD50_HUMAN - Y K T L D Q A I M K F H S M K M E E I N K I - - - - I R D L W R S T Y R G Q D I E Y I E I R S D A D E N V S - - - - - - - 1174
1XEX|B - - - - - - - - - - - - - - - - - - - - - - - - - G G L E I E A K P A G K - - - D V K R I E A M S G G E K A L T A L A F V - 77
SMC1A_HUMAN - - - - - - - - - - - - - - - - - - - - - - - - - D G I N Y N C V A P G K - - - R F R P M D N L S G G E K T V A A L A L L - 1141
SMC1B_HUMAN - - - - - - - - - - - - - - - - - - - - - - - - - E G I S Y N C V A P G K - - - R F M P M D N L S G G E K C V A A L A L L - 1137
SMC2_HUMAN - - - - - - - - - - - - - - - - - - - - - - - - L D G L E F K V A L G N T - - - W K E N L T E L S G G Q R S L V A L S L I - 1098
SMC3_HUMAN - E G S G E S E R G S G S Q S S V P S V D Q F T G V G I R V S F T G K Q G - - - E M R E M Q Q L S G G Q K S L V A L A L I - 1128
SMC4_HUMAN - - - - - - - - - - - - - - - - - - - - - - - - - E G I M F S V R P P K K - - - S W K K I F N L S G G E K T L S S L A L V - 1204
SMC5_HUMAN - - - - - - - - - - - - - - - - - - - - - - - - K Y G I R I R V K F R S S T Q L H E L T P H H Q S G G E R S V S T M L Y L - 1004
SMC6_HUMAN - - - - - - - - - - - - - - - - - - - - - - - - - - T L S I S V Q P G E G N K A A F N D M R A L S G G E R S F S T V C F I - 1000
RAD50_HUMAN - - - - - - - - - - - - - - - - - - A S D K R R N Y N Y R V V M L K G D T - - - A L D M R G R C S A G Q K V L A S L I I R - 1214
1XEX|B - F A - - I Q K F K P A P F Y L F D Q I D A H L D D A N V K R V A D L I K E S S K - - - - - - E S Q F I V I T L R D V M M - 129
SMC1A_HUMAN - F A - - I H S Y K P A P F F V L D E I D A A L D N T N I G K V A N Y I K E Q S T - - - - - C N F Q A I V I S L K E E F Y - 1194
SMC1B_HUMAN - F A - - V H S F R P A P F F V L D E V D A A L D N T N I G K V S S Y I K E Q T Q - - - - - D Q F Q M I V I S L K E E F Y - 1190
SMC2_HUMAN - L S - - M L L F K P A P I Y I L D E V D A A L D L S H T Q N I G Q M L R T H F T - - - - - - H S Q F I V V S L K E G M F - 1150
SMC3_HUMAN - F A - - I Q K C D P A P F Y L F D E I D Q A L D A Q H R K A V S D M I M E L A V - - - - - - H A Q F I T T T F R P E L L - 1180
SMC4_HUMAN - F A - - L H H Y K P T P L Y F M D E I D A A L D F K N V S I V A F Y I Y E Q T K - - - - - - N A Q F I I I S L R N N M F - 1256
SMC5_HUMAN - M A - - L Q E L N R C P F R V V D E I N Q G M D P I N E R R V F E M V V N T A C - - - K E N T S Q Y F F I T P K - - L L - 1057
SMC6_HUMAN - L S - - L W S I A E S P F R C L D E F D V Y M D M V N R R I A M D L I L K M A D - - - S Q R F R Q F I L L T P Q - - S M - 1053
RAD50_HUMAN - L A L A E T F C L N C G I I A L D E P T T N L D R E N I E S L A H A L V E I I K S R S Q Q R N F Q L L V I T H D E D F V - 1274
1XEX|B - A N A - - - - - - D K I I G V S M R D G V S K V V S L S L - E K A M K I L E E I R K K Q G W E H G N - - - - - - - - - - - 172
SMC1A_HUMAN - T K A - - - - - - E S L I G V Y P E Q G D C V I S K V L T F D L T - K Y P D A N P N P N E Q - - - - - - - - - - - - - - - 1233
SMC1B_HUMAN - S R A - - - - - - D A L I G I Y P E Y D D C M F S R V L T L D L S - Q Y P D T E G Q E S S K R H G E S R - - - - - - - - - 1235
SMC2_HUMAN - N N A - - - - - - N V L F K T K F V D G V S T V A R F T Q C Q N G K - I S K E A K S K A K P P K G A H V E V - - - - - - - 1197
SMC3_HUMAN - E S A - - - - - - D K F Y G V K F R N K V S H I D V I T A - E M A K D F V E D D T T - - - - - H G - - - - - - - - - - - - 1217
SMC4_HUMAN - E I S - - - - - - D R L I G I Y K T Y N I T K S V A V N P K E I A S K G L C - - - - - - - - - - - - - - - - - - - - - - - 1288
SMC5_HUMAN - Q N L P Y - - - - S E K M T V L F V Y N G P H M L E P N T - - - - - - - - - - - - W N L K A F Q R R R R R I T F T Q P S - 1101
SMC6_HUMAN - S S L P S - - - - S K L I R I L R M S D P - - - - - - E R - - - - - - - - - - - - G Q T T L P F R P V T Q E E D D D Q R - 1091
RAD50_HUMAN - E L L G R S E Y V E K F Y R I K K N I D Q C S - - E I V K C S V S S L G F N V H - - - - - - - - - - - - - - - - - - - - - 1312
264 
Appendix 
VII.II. Histone Acetyltransferase Domain Multiple Sequence Alignment 
 
Figure Apx.5. Multiple Sequence Alignment of GNAT and MYST Family HAT Domains. Multiple sequence alignment 
generated by EMBL-EBI Clustal Omega.181,182 Positions with single, fully conserved residue coloured green. Where 
aligned residues have strongly similar or weakly similar properties, residues coloured purple or orange respectively. 
HAT domain highlighted with red border. 
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Appendix 
VII.III. Bromodomain Multiple Sequence Alignments 
 
Figure Apx.6. Multiple Sequence Alignment of Type I and Type II Bromodomains. Multiple sequence alignment 
generated by EMBL-EBI Clustal Omega.181,182 Positions with single, fully conserved residue coloured green. Where 
aligned residues have strongly similar or weakly similar properties, residues coloured purple or orange respectively. 
Bromodomain highlighted with blue border. 
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Appendix 
 
Figure Apx.7. Multiple Sequence Alignment of 61 Unique Bromodomains. Multiple sequence alignment generated 
by EMBL-EBI Clustal Omega.181,182 Conservation scores determined using Scorecons220 and amino acid residues 
coloured accordingly; red indicates the least conserved regions and dark green the most. Bromodomain highlighted 
with blue border. 
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Appendix 
VII.IV. Quinolinone Screening Libraries 
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Figure Apx.8. Amides from Acids Available In-House Selected for Synthesis. 25 amides selected via docking studies 
as potential KAT2A and KAT2B inhibitors. Those successfully synthesised labelled with identification codes. 
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Figure Apx.9. Amides from Commercially Available Acids Selected for Synthesis. 100 amides selected via docking 
studies as potential KAT2A and KAT2B inhibitors. Those successfully synthesised labelled with identification codes. 
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Figure Apx.10. Sulphonamides from Commercially Available Sulphonyl Chlorides Selected for Synthesis. 25 
sulphonamides selected via docking studies as potential KAT2A and KAT2B inhibitors. Those successfully synthesised 
labelled with identification codes. 
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VII.V. NMR Fragment Screening 
 
Figure Apx.11. KAT2A BRD Fragment Binders Identified Using NMR Assay. 
 
